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ABSTRACT  
 
Investigations on the effect of fasting on liver function and the response to 
acetaminophen overdose in two mouse models 
 
Hamid NF1,2,3, Williams D2, Antoine D2, Benson C2, Webb H2, Starkey-Lewis P2, Kipar A1,2,3 
1Department of Infection Biology, Institute of Infection and Global Health, 2Department of 
Pharmacology and Therapeutics, Institute of Translational Medicine, and 3School of 
Veterinary Science, University of Liverpool, UK 
 
Laboratory mice are widely used in biomedical research as models for human diseases 
and also to provide insight into the toxicity of various xenobiotics. Fasting of mice prior 
to dosing is common practise in toxicological studies to ensure uniform drug 
absorption. However, many studies ignore the potential effect of fasting on parameters 
that are affected by the circadian rhythm. Model hepatotoxicants like acetaminophen 
(APAP) are commonly used to provide better insight into, for example, chemical 
structure, drug metabolism and the response of cells to toxicants. The APAP mouse 
model has been extensively used for studies on pathogenesis and intervention of drug 
induced liver injury (DILI) based on the CYP450 mediated formation of N-acetyl-p-
benzo-quinoneimine (NAPQI). More recently, it also served for the identification of new 
biomarkers for liver injury. In addition, it can also serve to gain further insight into liver 
regeneration, the mechanisms of which need to be further elucidated. So far, liver 
regeneration has mainly been studied in partial hepatectomy (PHx) models, which 
could have a different mechanism than regeneration after DILI. The work presented in 
this thesis has used two mouse models, out-bred CD-1 and in-bred C57BL/6J mice to 
investigate the differences in their response to APAP overdose and the effect of fasting 
prior to dosing. This was done over a time course expected to cover both acute liver 
injury and regeneration.  
The results on saline dosed control mice show that fasting alone significantly reduces 
the body weight (up to 12%) with onset of the fasting period during day time (16:00 to 
18:45). Interestingly, C57BL/6J mice have higher basic hepatic GSH levels than CD-1 
mice. While the hepatic GSH content followed a circadian rhythm in fed mice, it 
overshot in animals refed after fasting. In contrast, the restitution of ATP after feeding 
was slow in CD-1 mice where even after 24 hours of refeeding the ATP levels were still 
lower than in fed mice. In fasted C57BL/6J mice, however, they returned to control 
animal levels within 20 hours of refeeding. Surprisingly, after 10 hours of refeeding, the 
GSH levels showed a significantly higher fold increase than the ATP levels in both 
strains. Fasting did not induce any histopathological changes, however there was 
evidence of complete hepatocellular glycogen depletion after fasting and full glycogen 
restitution within 1 hour of refeeding in C57BL/6J mice but 4 hours in CD-1 mice. 
Fasting neither had an effect on the transcription of cytokines TNF-α, IL-6, and IL-10 nor 
on hepatocellular proliferation, assessed on the basis of NF-kB and cyclin-D1 
transcription and in situ PCNA expression. 
The determination of the hepatic GSH and ATP content, serum ALT levels and the 
histopathological changes with an established scoring system served to assess the 
extent of liver injury following APAP overdose. A reduction of the GSH content was 
observed as early as 1 hour post dosing (hpd) in CD-1 mice and at 3 hpd in C57BL/6J 
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mice; after that  the levels increased gradually again until the end of the study period. 
In fasted CD-1 mice, GSH levels returned to control levels with delay; this was variable 
in C57BL/6J mice until the levels were similar to those of control animals at 36 hpd. ATP 
levels remained lower in fasted mice of both strains over the entire time course. In both 
strains, APAP overdose resulted in a progressive increase in serum ALT activity with 
significantly higher levels in fasted mice at the later time points. This was matched by 
the histological findings, i.e. centrilobular hepatocyte loss. In fed mice, cell death via 
apoptosis was initially seen and most abundant at 3 and 5 hpd in CD-1 mice. However, 
in C57BL/6J, only a few individual apoptotic hepatocytes were seen in the affected 
centrilobular areas at 5 hpd, whereas they were abundant in the same location at 24 
hpd. The first sign of liver damage was the centrilobular loss of hepatocellular glycogen, 
a feature that remained obvious until the pathological changes resolved. Fasting of 
mice prior to APAP overdose led to similar, though more severe changes, whereby cell 
death was almost exclusively via necrosis with a variably intense centrilobular 
neutrophil infiltration. At 15 hpd, histology showed that the damage had subsided in 
fed CD-1 mice, in association with increased proliferation and evidence of full 
regeneration including complete glycogen reconstitution at 24 hpd. In C57BL/6J mice, 
there was prolonged evidence of centrilobular hepatocyte degeneration and death, by 
both apoptosis and coagulative necrosis, which declined but was still present at 36 hpd. 
In fasted mice of both strains, there was evidence of substantial ongoing hepatocyte 
death and neutrophil recruitment until the end of the study at 24 and 36 hpd, 
respectively, together with delayed hepatocyte proliferation.  
The extent of the inflammatory response after APAP-induced DILI and the regenerative 
capacity of the liver were assessed via the quantitative assessment of the transcription 
of the cytokines TNF-α, IL-6 and IL-10, and the transcription factor NF-kB and cell cycle 
protein, cyclin-D1 in the liver and, for TNF-α and IL-6, the spleen, using RT-qPCR. Fed 
animals showed early upregulation of hepatic TNF-α, obvious at 5 hpd in CD-1 and at 10 
hpd in C57BL/6J mice, with levels dropping thereafter. In fasted mice, a further increase 
was seen after these time points, correlating also with the more pronounced neutrophil 
influx. Splenic TNF-α transcription seemed to follow the hepatic transcription alongside 
serum protein levels that were continuously elevated at the later time points, 
suggesting systemic effect. Fed mice, and in particular CD-1 mice, showed higher 
hepatic and splenic IL-6, IL-10, NF-kB and cyclin-D1 mRNA levels than fasted mice, 
correlating with effective liver regeneration. In fasted mice of both strains, the 
transcription of these markers started to increase only towards the end of the study 
period. The quantitative assessment of hepatocyte proliferation, based on the in situ 
expression of PCNA, confirmed the earlier onset and faster liver regeneration in fed 
animals, with an earlier onset also in fed CD-1 mice than in fed C57BL/6J mice.  
In conclusion, the results of the present study confirm circadian rhythms for body 
weight and hepatic GSH and ATP content, features that could interfere with study 
outcomes. They also provide definite evidence that fasting prior to APAP overdose does 
not only modulate the resulting liver injury, but has further effects, i.e. the induction of 
an inflammatory response and a delay in the subsequent liver regeneration. Finally, 
they confirm that the inbred C57BL/6J mice are more susceptible to APAP-induced DILI 
when fed prior to dosing, but show that both strains react in a similar way when dosed 
after a period of fasting.   
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1.1 THE LABORATORY MOUSE AS AN ANIMAL MODEL FOR HUMAN LIVER 
DISEASES 
1.1.1   The use of the laboratory mouse as an animal model  
Animal models are important tools in biomedical research since the 16th century, for 
scientific discovery including genetics, medicine and other disciplines (Hedrich Hans, 
2012). The laboratory mouse, species Mus musculus, is most commonly used in 
human-oriented research as the animals are easy to handle, inexpensive to raise 
and maintain, and due to the fact that 99% of mouse genes have human 
counterparts. Basically, by examining the physiology, anatomy and metabolism of a 
mouse, scientists can gain valuable insight into how humans function. Mice 
reproduce in a short time period, therefore enable researchers to study generations 
of offspring within a reasonable period of time at minimal cost. In drug safety 
development, the laboratory mouse is an important human model to understand 
the effectiveness and the toxicities of various xenobiotics (Jacksons, 2010).  
 
1.1.2 The laboratory mouse as a model for APAP-induced acute liver injury 
Previous studies have shown that the mouse is both a clinically relevant and 
experimentally convenient species for the study of APAP hepatotoxicity. Similar to 
humans, it can exhibit mitochondrial damage and nuclear DNA fragmentation in 
response to APAP overdose, different from rats which are resistant to APAP toxicity 
due to reduced mitochondrial protein adducts and dysfunction, which prevents the 
oxidative stress (McGill et al., 2012b; Mitchell et al., 1973). Furthermore, other 
studies have shown that the mechanisms of APAP toxicity in humans are similar to 
those in mice which render the laboratory mouse the preferred species for 
mechanistic studies (Knight et al., 2001; McGill et al., 2012b; Muldrew et al., 2002). 
Although the basic mechanism of APAP toxicity is similar, hepatotoxic responses are 
variable in different animal models, including dog (Francavilla et al., 1989; Gazzard 
et al., 1975) and pig (Miller et al., 1976). The incidence of sudden death due to 
methaemoglobinaemia is a notable recurrent problem when using these models 
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(Gazzard et al., 1975; Henne-Bruns et al., 1988). Although the large animal models 
are useful to determine the haemodynamic parameters including intracranial 
pressure, cardiac output, systemic vascular disturbance and many more, the 
laboratory mouse is still a good candidate to understand the pathogenic outcome of 
hepatocellular damage and the immune response due to widely available 
antibodies and immune markers in this species that provide better understanding of 
mechanism for APAP-induced liver injury (Mossanen and Tacke, 2015).         
Laboratory mice are bred and maintained in a tightly controlled environmental 
setting, without the confounding influence of any other factors. CD-1 and C57BL/6J 
mice are commonly used in toxicity studies. CD-1 mice are the most common out-
bred mice used when the inter-individual genetic variability that mimics the genetic 
variation in humans is supposed to be considered and where this may be beneficial 
in toxicology research (Chia et al., 2005). They are therefore widely used in 
toxicology and pharmacology studies, particularly for product safety testing (Chia et 
al., 2005). They also serve as models in acetaminophen toxicity studies (Antoine et 
al., 2010; Goldring et al., 2004; Hart et al., 1994). However, C57BL/6J are mostly 
used in studies of APAP hepatotoxicity and the mechanism of toxicity in these 
animals is well understood (McGill et al., 2012c). C57BL/6J mice are an in-bred 
strain that is considered as genetically homogeneous or identical (Beck et al., 2000). 
They are used as physiological and pathological models for in vivo experiments that 
aim to obtain consistent data; this allows reproducible studies especially to 
establish novel drugs (Festing, 2010). The use of C57BL/6J mice as a model of APAP 
hepatotoxicity is well documented and proven to produce results significant to 
humans (Festing, 2010). Meanwhile, other relevant and susceptible strains have 
been used in APAP toxicity studies, like ICR mice (Jaeschke, 1990), C3Heb/FeJ mice 
(Cover et al., 2005), and B6C3F1 mice (Agarwal et al., 2011). All these studies 
consistently reported mitochondrial dysfunction, oxidative stress and peroxynitrite 
formation after APAP insult.  
APAP toxicity studies frequently use male C57BL/6J mice because they are more 
susceptible to APAP hepatotoxicity than females (Botta et al., 2006; Dai et al., 2006; 
McConnachie et al., 2007). This is also evident by the higher levels of serum ALT and 
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hepatocellular damage in male compared  to female CD-1 mice following APAP 
overdose (Botta et al., 2006).  
Different mouse strains with their specific genetic backgrounds can potentially 
show different degrees of immune cell activation after APAP administration. Due to 
different genetic profiles, liver injury induced by APAP may require dose 
adjustments to achieve a similar response (Mossanen and Tacke, 2015). A previous 
study has shown more intense liver damage in C57BL/6J mice, together with higher 
TNF-α expression, compared to BALB/c mice (Masubuchi et al., 2009). This was 
considered a consequence of a more intense innate immune response, due to a 
more intense specific Th1-dominant response of T-helper cells in C57BL/6J mice 
(Masubuchi et al., 2009). Although numerous published studies have explored APAP 
toxicity in mouse models, comparative studies to assess APAP toxicity in different 
mice, such as out-bred CD-1 vs. in-bred C57BL/6 mice, as a means to allow the 
choice of the optimal mouse model, have not been performed.   
 
1.1.3 Effect of food restriction on the laboratory mouse 
Food availability affects the basal metabolism and therefore the function of the liver 
as the major metabolic organ. Fasting of mice changes several physiological 
parameters and moreover, these changes are depending on a variety of 
environmental factors (Jensen et al., 2013). In experimental settings, fasting is 
primarily used as a way to ensure uniform drug absorption and minimise the 
variability in basal blood glucose levels. Both is helpful in toxicology tests and 
pharmacokinetics studies in general and helps to reduce the number of animals per 
dosing group to achieve statistical significance (Ellacott et al., 2010; Kim et al., 2006; 
Kinoshita et al., 2000; Strubelt et al., 1981b).  
Mice lost significantly more weight after 18 hours of fasting compared to 5 hours, 
16% and 5% respectively, with significantly lower gastrointestinal tract weights than 
in fed mice (Ayala et al., 2006; Heijboer et al., 2005). Fasting can also lead to a 
reduction of the basal metabolic rate, which can even persist after food re-
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introduction, while the body weight is returning to a value within the normal range 
as in pre-fasting state (Bj et al., 1982; Penicaud and Le Magnen, 1980). The 
metabolic state of fasting mice can be described as catabolic or post-absorptive, 
and it is characterised by mobilisation of glycogen to maintain the necessary blood 
glucose levels (Ayala et al., 2006). A study has reported that the amount of hepatic 
glycogen is significantly reduced after a 18 hours fasting period compared to 5 
hours of fasting (Ayala et al., 2006). Furthermore, in mice fasted for 24 hours, 
muscle glycogen was reduced to half the level of fed mice (Gavrilova et al., 1999).  
In the liver, glutathione (GSH) acts as an antioxidant in hepatocytes to detoxify free 
radicals and oxygen species (Pompella et al., 2003). After a 16 or 24 hour fasting 
period, the amount of GSH in the liver is significantly decreased, which reduces the 
detoxification capacity of hepatocytes (Brooks and Pong, 1981; Strubelt et al., 
1981b). No significant difference in the CYP450 level was seen after 12 hours of 
fasting, but it was significantly lower (about 33%) after 24 hours of fasting in mice 
(Walker et al., 1982). This is interesting since a lack in CYP450 can minimise the 
toxification of acetaminophen (Strubelt et al., 1981b). Several factors, such as food 
intake, overnight fasting and disease conditions, affect the function of hepatic 
phase II enzymes and are thus able to influence the formation of reactive 
metabolites (Howell and Klaassen, 1991; Walker et al., 1982). During the feeding 
period of mice, peak GSH levels were noted at the end of dark period or in the early 
morning (i.e. when mice are most active) while the GSH levels were lowest when 
the mice were normally asleep (i.e. at the end of a prolonged period of light) 
(Schnell et al., 1984). Also, the susceptibility of mice to APAP toxicity has shown to 
follow a circadian rhythm in hepatic glutathione levels (Howell and Klaassen, 1991; 
Schnell et al., 1984). Therefore, the importance of feeding regime and circadian 
variations in hepatic GSH levels needs to be considered when animal models are 
used to investigate the relationship between drug metabolism and toxicity.  
In C57BL/6J mice, the histological examination of the liver did not reveal any 
evidence of a reduction in the number of liver cells, and the zonal architecture 
including periportal and pericentral regions of the lobules remained unaffected 
after 12 and 24 hours of fasting (Sokolovi et al., 2008). Staining for active caspase-3, 
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a marker of apoptosis, did not indicate an increase in apoptotic cell death even after 
72 hours of fasting. In agreement with this, the microarray data for apoptosis genes 
showed no significant expression in fasted and fed mice (Sokolovi et al., 2008).  
Fasting can be expected to cause stress, aggressive behaviour and reduction in body 
weight (Ayala et al., 2006; Strubelt et al., 1981b), body temperature (Webb et al., 
1982) and glucose levels  (Tsuneki et al., 2002) as well as enhance sympathetic 
nervous system activity (Jensen et al., 2013). However, the association of all these 
changes between strains is still poorly defined, and the study on the metabolic 
response of mice upon food re-introduction after fasting is limited (Jensen et al., 
2013). Figure 1.1 illustrates in a schematic diagramme of the changes in the feeding 
pattern which influence various responses including  body weight (%), and the level 
of hepatic GSH and ATP contents (Froy and Miskin, 2010; Jensen et al., 2013). 
 
                          
 
Body weight (%) 
Glutathione level 
Hepatic ATP level 
Hepatic CYP450 activity 
Plasma glucose level  
Body temperature 
Sympathetic activity 
 
 
Figure 1.1. Schematic diagramme of the effect of food restriction in the laboratory mouse.  
The effects of ad libitum feeding and fasting on body weight, hepatic glutathione, ATP, 
CYP450, plasma glucose level,  body temperature and sympathetic activity in mice are 
shown (Jensen et al., 2013).  
FEEDING  
PATTERN FED AD LIBITUM FOOD RESTRICTION 
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The effect of food deprivation is greatest in the scotophase, when the animals are 
most active. A study has argued that overnight fasting of mice is not comparable 
with the overnight fasting of humans as mice have a nocturnal circadian rhythm and 
a higher metabolic rate compared to man. Fasting of mice for 5-6 hours instead of 
overnight (16-18 hours) might offer a better comparison to humans, who are 
usually fasted overnight for toxicology testing (Jensen et al., 2013). 
 
1.1.4 Hepatic regenerative capacity in mice  
The process of liver regeneration is complicated and relies on various factors 
including the type, aetiology and severity of liver injury, and the clinical conditions 
(Kvittingen et al., 1994). Hepatocytes are capable of regeneration and to fully 
reconstitute damaged livers multiple times (Kvittingen et al., 1994). Previous studies 
in rats have suggested that new hepatocytes are formed in the periportal region 
and then slowly migrate towards the centrilobular area (Friedman and Kaestner, 
2011; Zajicek et al., 1985). During normal liver turnover or in response to mild 
injury, the liver mass is maintained by self-duplicating hepatocytes (Malato et al., 
2011). However, when an injury is severe or the proliferative capability of 
hepatocytes is impaired, liver progenitor cells (LPCs) located in the periportal areas 
provide a backup system for hepatocyte regeneration (Malato et al., 2011). During 
liver regeneration, hepatocyte clusters are formed, followed by proliferation of 
hepatic stellate cells and fenestrated sinusoidal endothelial cells; this process also 
re-establishes the normal vascularisation (Martinez-Hernandez and Amenta, 1995). 
In the healthy liver, hepatocytes are in the G0 phase of the cell cycle (i.e. the 
quiescent state) and respond only minimally to growth factors (Fausto, 2000). 
Briefly, the kinetics of liver regeneration can be divided into three closely related 
phases, initiation, progression and termination. During initiation, quiescent 
hepatocytes are primed to enter the cell cycle also through cytokine-mediated 
signalling. Once primed, hepatocytes respond more intensely to mitogens, such as 
growth factors (Apte et al., 2015). During progression, they then undergo several 
Chapter 1 
10 
 
cell cycle rounds to improve liver structure and restore its function. Termination of 
liver regeneration takes place once cell proliferation stops.  
Evidence of liver regeneration as a compensatory response and final outcome of 
hepatotoxicity has been provided in various hepatotoxicant mouse models, such as 
acetaminophen (APAP), carbon tetrachloride (CCl4), chloroform, thioacetamide 
(TA), trichloroethylene (TCE) and allyl alcohol (AA); this provides relevant 
information for the risk assessment of toxic exposure (Mangipudy et al., 1995; 
Mehendale, 2005). Analysis of cell proliferation after prolonged exposure to various 
toxic insults has shown that high doses inhibit cell cycle progression by suppression 
of cytokine or growth factor-mediated signalling followed by cyclin-D1 reduction 
(Shankar et al., 2003). 
 
1.2 DRUG INDUCED LIVER INJURY (DILI) 
DILI can affect parenchymal or non-parenchymal cells within the liver, leading to a 
variety of pathological conditions which include acute or chronic hepatitis, hepatic 
vascular damage and cirrhosis (Larrey, 2000; Martinez-Hernandez and Amenta, 
1995). Acute hepatitis and cholestasis are two predominant forms of DILI which is 
characterised by a pronounced increase in alanine aminotransferase (ALT) activities 
and liver necrosis that could be seen histologically (Gunawan et al., 2004). DILI is a 
major contribution towards patient mortality and morbidity (Lee et al., 2005). A 
main concern for the pharmaceutical industry and regulatory authorities are DILI, 
causing a significant issue for withdrawal of an approved drug (Jaeschke et al., 
2002). In the United States, approximately 50% of drug-induced liver toxicity 
contributes to the cause of acute liver failure, with over 800 drugs associated with 
hepatotoxicity (Dossing and Sonne, 1993; Ostapowicz et al., 2002). Liver is the main 
organ to metabolise endogenous and exogenous compounds and thereby is a major 
target for toxic insults. It plays an indispensable role to metabolise xenobiotics into 
hydrophilic metabolites to assist their excretion via urine or bile. Although the 
actual mechanisms are still being studied, it is well accepted that the formation of 
reactive metabolites contributes to cellular damage as an outcome of oxidative 
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stress. In order to examine the mechanism of hepatotoxicity, acetaminophen 
(paracetamol, APAP) serves as one of the classically studied drugs, is also 
characterised as an ideal hepatotoxicant (Ostapowicz et al., 2002).   
 
1.2.1 Mechanism of DILI 
Drug metabolism is the complex process by which a drug was chemically 
biotransformed by several enzymatic reactions into more hydrophilic metabolites to 
ease their excretion. Principally, liver is the main organ and most important site of 
drug metabolism. Most xenobiotics have characteristic of non-polar and lipophilic 
chemical compounds that are readily absorbed in the gastrointestinal tract. 
Xenobiotics need to be metabolised to increase their hydrophilicity and facilitate 
their excretion in the urine or bile. Drug metabolism can be divided into three 
different phases; phase I (functionalization/bioactivation), phase II 
(conjugation/detoxification), and phase III (transport/excretion) (Pachkoria et al., 
2007). Phase I reactions involve the exposure or incorporation of a functional group. 
Then, it serves as a target for phase II conjugation reactions to form a highly polar 
conjugate (Guengerich and Shimada, 1991). It should also be noted that a drug can 
be metabolised by phase II metabolism without having previously been involved in 
phase I metabolism, provided the parent compound carries a suitable functional 
group. Meanwhile, drug conjugates that are transported across the membranes are 
involved in phase III metabolism (Pachkoria et al., 2007). Metabolism does not only 
result in detoxifying process, however, some drugs are bioactivated to reactive and 
potentially toxic metabolites (Grillo et al., 2003). An imbalance of these three 
different phases could also promote an accumulation of reactive metabolites, 
resulting in liver injury (Pachkoria et al., 2007).  
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1.2.1.1  Phase I drug metabolism  
Phase I metabolic reactions are also known as functionalization reactions and 
involve functional groups, such as hydroxyl groups (-OH), primary amines (-NH2), 
sulphydryl (-SH) and carboxylic acids (-COOH) by oxidation, reduction, hydrolysis or 
hydration reactions to facilitate phase II reactions (Gibson, 2001). Phase I drug 
metabolism enzymes include CYP450, an enzyme that is highly expressed at the 
innermost layer of the mitochondrial membrane or in the endoplasmic reticulum of 
hepatocytes are able to catalyse the majority of phase I oxidation reactions 
(Guengerich, 2003; Meyer and Meyer, 1996). CYP450 is known to have a mixed 
functional role, with the predominant role to detoxify the metabolites from 
endogenous and exogenous compounds. However, there is a chance that the newly 
generated metabolite catalysed by CYP450 is more active than the parent 
compound in some ways, resulting in hepatocellular damage. Basically, the 
metabolism of drugs can potentially produce free radicals and reactive oxygen 
species (ROS), resulting in oxidative stress to cellular macromolecules such as 
proteins, DNA and RNA, by covalent interactions. The functional modification of 
these cellular macromolecules has the potential to cause a variety of toxic changes, 
such as necrosis, apoptosis, chemical carcinogenesis and hypersensitivity (Hinson et 
al., 1981; Park et al., 2005).  
 
1.2.1.2  Phase II drug metabolism  
A second hepatic drug metabolism pathway is represented by the processing of 
electrophilic metabolites initially formed by phase I reactions in order to raise 
polarity and water solubility to facilitate excretion (Timbrell, 2000).  The phase II 
drug-metabolising enzymes include uridine 5’ diphosphate-glucuronyltransferases 
(UGTs), N-acetyltransferases (NATs), sulfotransferases (SULTs), glutathione S-
transferases (GSTs) and several methyltransferases (McCarver and Hines, 2002). 
These are responsible for the detoxification of reactive metabolites generated 
during phase I, enabling their excretion via urine or bile. Phase II reactions are 
generally considered detoxification reactions which include glucuronidation, 
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sulphation, acethylation, acetylation, methylation, amino acid conjugation and GSH 
conjugation (Zamek-Gliszczynski et al., 2006). In the liver, ROS and free radicals can 
be detoxified by GSH conjugation. GSH is an endogenous tripeptide (y-
glutamylcycteinylglycine) consisting of glutamate, cysteine and glycine amino acids, 
plays an indispensable role as antioxidant and scavenger within the cells (Hayes et 
al., 1999). Basically, GSH exists in an oxidised (GSSG) and a reduced (GSH) form. GSH 
is able to conjugate with a reactive electrophilic species, or by facilitation through 
GST, an enzyme located in the cytosol and microsomes, to form a thioether bond 
between the cysteine residue of GSH and electrophiles (Coles et al., 1988). If highly 
reactive metabolites are exposed and exceed the amount of GSH available, other 
thiol groups and especially critical proteins such as γ-glutamyl cysteine ligase 
catalytic subunit (GCLC), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
Ca2+/Mg2+ ATPase, undergo subsequent oxidation, cross-linking and formation of 
covalent adducts. It is well known that depletion of GSH is a prerequisite for the 
onset of toxicity (Mitchell et al., 1973). For example, newly generated GSH is unable 
to replace GSH used by GSSG conjugation or oxidation during APAP hepatotoxicity 
(Mitchell et al., 1973). There is still a potential for bioactivation to occur, although 
phase II metabolism is principally a detoxification pathway (Zhou et al., 2005).  
 
1.2.1.3  Phase III drug metabolism  
Phase III involves a series of hepatic drug transporter proteins (Ishikawa, 1992). A 
study characterised plasma membrane-bound hepatocyte transporters and 
illustrated that drugs enter and exit hepatocytes by using energy dependent 
transporters (Mizuno et al., 2003), which are responsible to transport and remove 
endogenous as well as exogenous compounds (Borst et al., 2002). The predominant 
solute carrier (SLC) transporter superfamily that is responsible for drug uptake or 
efflux is found on the basolateral (sinusoidal) membrane that lies between 
hepatocytes (Jose, 2012). The hepatic sinusoidal plasma membrane plays a role to 
transport organic/inorganic cations and/or anions for the efflux from cell into 
circulation (Yabuuchi et al., 1998). Examples of these transporters are organic amine 
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transporters (OAT), organic cation transporters (OCT) (Zhang et al., 1998) and 
sodium taurocholate cotransporting polypeptide (NTCP) (Hagenbuch and Meier, 
1994). The excretion of drugs and their metabolites involve the ATP binding 
cassette (ABC) transporter superfamily which mediates the excretion of drugs into 
the bile or the sinusoidal membrane and also mediates the efflux back into the 
bloodstream (Dean et al., 2001; Kerb et al., 2001).  
 
1.2.2  Adverse drug reactions (ADRs) 
Adverse drug reactions (ADRs) are a major concern for patient health. In 1994, it 
was estimated that over 100,000 patients died from ADRs in the United States alone 
(Lazarou et al., 1998). Three out of five drugs were removed from the market within 
two years, between 1997 and 1998 (Lasser et al., 2002). ADRs have been 
responsible for the post-market withdrawal of more than 75 drugs/drug products in 
the USA between 1969 and 2002 and have also become a major reason for attrition 
in the drug development (Lasser et al., 2002). A 6 month prospective study from 
two hospitals in Merseyside, UK revealed that 6.5% (1,225 out of 18,820) patients 
were admitted during 2001-2002 for the case of ADRs, and 2.3% died due to the 
reaction (Pirmohamed et al., 2004).  
ADRs can be classified as ‘on target’ or ‘off target’ reactions. On target reactions can 
be predicted from the known compound of the drug, and the pharmacological side 
effect of the drug can usually be avoided by dose reduction without life-threatening 
outcome (Park et al., 2005). In contrast, off target ADRs are often dose-independent 
due to lack of toxicological knowledge; accordingly, the response in patients is 
unpredictable as it follows their levels of tolerance. Off-target ADRs, also known as 
idiosyncratic ADRs, can therefore be severe and life-threatening (Park et al., 2005; 
Uetrecht, 2003). ADRs are known to affect every organ system, but particularly liver 
and kidney (McNaughton et al., 2014). DILI represents a major proportion of the 
ADRs observed in drug development as a consequence of poor predictive models in 
understanding of the mechanism responsible for cell death (Roberts et al., 2004). 
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1.2.3 Sterile inflammation and damage-associated molecular pattern molecules 
(DAMP) induced by ADRs 
 
First response of an organism upon cellular injury is inflammation. It is characterised 
by increasing blood flow, with extravasation of both nucleated blood cells and fluid 
from vessels into the affected tissue. Neutrophils are recruited to damaged areas, 
as a response to intruding microorganisms or with sterile inflammation induced by 
necrotic cells, and to clear the debris, they are later followed by macrophages 
(Raucci et al., 2007). Inflammation has a dual and contradictory role, one that can 
repair and another that can produce damage. It is a part of the physiological 
processes to repair tissue after damage, however, when this process is not 
controllable and inflammation spreads, it may cause severe damage (Aller et al., 
2006; Kumar and Robbins, 2007; Nathan et al., 2002).  
In liver inflammation, molecules that are initially generated to kill microbes, such as 
ROS and proteases, leak from dying hepatocytes or leukocytes and subsequently kill 
surrounding healthy cells (Rock et al., 2008). Dying cells trigger inflammation also in 
the absence of pathogens (Dumitriu et al., 2005; Rock and Kono, 2008). Such a 
sterile inflammation occurs in response to intracellular proteins released by necrotic 
cells, known as damage-associated molecular patterns (DAMPs) which attract 
neutrophils. Following cellular injury, DAMPs are recruited to initiate an 
inflammatory response (Ishida et al., 2006; Jaeschke, 2006a; Laskin et al., 1986). 
They include heat-shock proteins (HSPs) (Quintana and Cohen, 2005; Vabulas et al., 
2001), DNA fragments (Jahr et al., 2001), ATP (Mariathasan et al., 2006) and high 
mobility group box-1 (HMGB-1) (Hori et al., 1995; Tian et al., 2007; Yu et al., 2006). 
Meanwhile, under physiological circumstances, DAMPs commonly remain 
intracellularly and undetectable by innate immune cells. However, in acute 
hepatotoxicity, DAMPs (i.e. HMGB-1) are released from necrotic cells and trigger an 
inflammatory and an immune response (Miller et al., 1976; Rubartelli et al., 2007).  
The role played by inflammatory response and the innate immune system in the 
modulation of liver injury remains disputed (Adams et al., 2010). DILI can be 
initiated by bioactivation of drugs to chemically reactive metabolites, which allows 
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them to interact with cellular macromolecules, leading to cellular dysfunction. The 
impairment of hepatocellular function can lead to cell death and ultimately liver 
failure. Hepatocellular dysfunction and death after mitochondrial peroxidation due 
to oxidative stress can initiate an immunological response and trigger both an 
innate and adaptive immune response. Hepatocyte damage results in the release of 
signals that stimulate the activation of particularly innate immune cells, including 
Kupffer cells (KCs), natural killer cells (NKs) and natural killer T (NKT) cells (Jaeschke, 
2006b; Liu et al., 2006). These can all contribute to the progression or regression of 
liver injury as they can produce pro-inflammatory or anti-inflammatory mediators 
and chemokines to inhibit or recruit inflammatory cells, like neutrophils, to the liver 
(Ishida et al., 2006; Jaeschke, 2006a; Laskin et al., 1986; Liu et al., 2004; Luster et al., 
2001). Moreover, a balance between pro- and anti-inflammatory mediators 
produced after activation of the innate immune response could determine the 
susceptibility towards liver injury after a toxic insult (Gardner et al., 2003). 
Therefore, in hepatotoxicity studies, knock-out (KO) animals with depletion of 
specific cell types are widely used to highlight their critical role in innate immune 
response (B. Yee et al., 2007; Bourdi et al., 2002; Masubuchi et al., 2003b). 
 
1.3  ACETAMINOPHEN INDUCED LIVER INJURY      
APAP is a commonly used as an analgesic and anti-pyretic drug that is safe at 
therapeutic doses of 4 g/day in healthy patients (Evans and Evans, 1993) but with 
overdosing can induce acute liver failure (ALF) due to massive centrilobular cell loss. 
It continues to be a major contributing factor to acute liver failure in the United 
Kingdom and United States (Larson et al., 2005; Ostapowicz et al., 2002). 
Intriguingly, APAP-induced hepatotoxicity has been widely studied as it provides a 
clinically relevant tool to study toxicological consequences of drug metabolism in 
vitro and in vivo models. Over the last 4 decades, rodent models have been widely 
used in order to understand the mechanism of APAP hepatotoxicity in toxicological 
studies (McGill et al., 2012a). 
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APAP hepatotoxicity is well-characterised in animal models. Toxicity is initiated 
through the formation of a reactive metabolite called N-acetyl-p-benzoquinonimine 
(NAPQI) (Mitchell et al., 1973; Raucy et al., 1989), which depletes hepatic GSH, an 
antioxidant and scavenger within hepatocytes (Knight et al., 2001). NAPQI initiates 
covalent binding to cellular macromolecules, leading to mitochondrial dysfunction 
and oxidative stress which results in hepatocellular damage and, ultimately, death 
(Jaeschke et al., 2003). Previous studies provided evidence that different laboratory 
mouse strains respond differently to APAP overdose, with some in-bred strains 
showing a higher susceptibility than others (i.e. B6C3F1/J > DBA/2J > C57BL/6J > 
SM/J > CAST/EiJ). These also suggested that genetic factors could independently 
influence APAP-induced liver damage and ALT release into the serum, and indicated 
that CD44 is involved in the modulation of susceptibility (Harrill et al., 2009). 
Although no strain difference has been identified with regards to the 
metabolism of APAP, C57BL/6J mice tend to be more susceptible than those of 
Balb/c (Masubuchi et al., 2009) and SW mice (Williams et al., 2011).  
For the assessment of liver damage, the measurement of serum liver enzymes, 
released once the reactive metabolites inhibit the functions of various critical 
proteins within hepatocytes and lead to hepatocyte cell death, is used. Alanine 
aminotransferase (ALT) activity has long been established as a reliable tool for the 
detection of hepatotoxicity. ALT is released during severe liver damage, when levels 
exceeding 1000 U/L can be reached (Becketta et al., 1985). Serum ALT is an 
important marker and used in a plethora of studies ranging from preclinical animal 
studies until patient monitoring (Amacher, 1998). However, a major limitation of 
this enzyme as a marker of liver toxicity is that it is not an early indicator, as it is 
only elevated once liver necrosis and toxicity has occurred. It then slowly returns to 
baseline levels which it may only reach when the damage has already been resolved 
(Kim et al., 2008a). Subsequently, the cellular damage can trigger the activation of 
other cells, which can initiate an inflammatory response as shown in Figure 1.2. This 
event may overwhelm the capacity of the liver to regenerate, thereby contributing 
to the pathogenesis of hepatic injury (Bhushan et al., 2014; James et al., 2003b). 
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Figure 1.2. Acetaminophen induced hepatocellular injury. 
In APAP overdose, released DAMPs into extracellular space and blood, are recognised by KC 
and then become activated. Upon activation, KCs secrete cytokines and chemokines to 
attract monocytes and neutrophils, which induce inflammation and sensitize hepatocytes 
to undergo apoptosis and/or necrosis, and further enhancing inflammation. Neutrophils 
also secrete cytokines to phagocytose apoptotic bodies and cell debris. Activation of innate 
immune cells (KCs, neutrophils and NK/NKT cells) modulate an overall pathogenesis of AILI. 
DAMPs – damage-associated-molecular patterns; KCs – Kupffer cells; NK – Natural killer 
cell; NKT – natural killer T cell.  
 
1.3.1 Role of drug metabolism in APAP-induced liver injury  
APAP is extensively metabolised in the liver (Lee et al., 1996; Mitchell et al., 1973). 
Around 55% and 30% of APAP at therapeutic doses is bioactivated to glucuronide 
and sulphate conjugates, by UDP-glucuronosyltransferase (UGT) and 
sulfotransferase (SULT), respectively (Howie et al., 1977). However, these 
metabolites are rapidly excreted in the urine (Nelson, 1990). At therapeutic doses, 
only a small proportion of APAP (5-10%) is bioactivated to the reactive metabolite, 
NAPQI, by some CYP450s, including CYP2E1, CYP1A2, CYP3A4, and CYP2D6 yields 
the generation of NAPQI (Raucy et al., 1989; Thummel et al., 1993). NAPQI, which is 
react either spontenously or via catalysis by GST with GSH, leading to detoxification 
process, and subsequently excreted as cysteine and mercapturate conjugates in the 
urine (Mitchell et al., 1973).  
Saturation of the glucuronidation and sulphation pathways in APAP overdose forces 
a larger amount of APAP to become metabolised via the oxidative pathway. 
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Consequently, it promotes the production and accumulation of NAPQI, exceeding 
the hepatic GSH storage and the amount of newly synthesised GSH, leading to 
subsequent GSH depletion (Dahlin et al., 1984; Davies, 1986; Jollow et al., 1973; Lee 
et al., 1996; Mitchell et al., 1973). Hepatic GSH depletion enables NAPQI to 
covalently modify and suppress the function of various hepatocytes cellular 
proteins, leading to cellular dysfunction and ultimately cell death. The covalent 
modification or functional suppression of critical proteins such as glutamyl cysteine 
ligase catalytic subunit (GCLC) (Kitteringham et al., 2000), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Dietze et al., 1997) and Ca2+/Mg2+ ATPase 
(Tsokos-Kuhn et al., 1988) can severely impair hepatocyte function. NAPQI is 
responsible to modify these proteins that has been hypothesised to lead to 
mitochondrial dysfunction and disturbance of ATP and Ca2+ homeostasis (Jaeschke 
et al., 2003).  Therefore, NAPQI was believed to be a crucial step in cell death 
development after APAP overdose. NAPQI has been shown to be capable of binding 
to cellular proteins (Guengerich et al., 1985). In APAP hepatotoxicity, the covalent 
modification of proteins is mentioned to correspond with the oxidation of protein 
thiols (Bartolone et al., 1988; Davis et al., 1974; Roberts et al., 1987).  
When NAPQI covalently binds to mitochondrial proteins, mitochondrial respiration 
can be inhibited, thereby promoting oxidative stress and peroxynitritrite formation. 
This causes opening of the mitochondrial membrane permeability transition (MPT) 
pore, lysis of the outer membrane and swelling of the matrix. Consequently, the 
mitochondrial membrane potential and thereby the synthesis of ATP is suppressed, 
which further increases ROS production and cellular damage (James et al., 2003, 
Jaeschke et al., 2003). ROS inhibits the pro-survival transcription factor NF-kB and 
subsequently initiates autophosphorylation and activation of c-Jun N-terminal 
kinase (JNK). JNK activation will lead to the production of more ROS and, 
subsequently, to mitochondrial permeability, dysfunction, which ultimately causes 
hepatocyte necrosis, followed by the release of DAMPs. HMGB-1 is one of the most 
notable DAMPs recognised by KCs and dendritic cells (DCs), subsequently leading to 
further activation of immune cells. N-acethylcysteine (NAC) is known as a standard 
treatment for APAP intoxication. In fact, NAC is responsible to replace intracellular 
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stores of GSH, which allows the  detoxification of NAPQI (Hazelton et al., 1986). 
Without NAC, NAPQI would not only contribute to more tissue injury (David Josephy 
et al., 2005) but it also activates the cellular defence response (Park et al., 2005). 
NAC is most beneficial if administered within 16 hours after APAP overdose (Bari 
and Fontana, 2014) and is less effective for delayed cases (Kerr et al., 2005; Whyte 
et al., 2007). The mechanism of APAP-induced liver injury is presented in Figure 1.3.  
 
1.3.2 Mode of cell death after APAP intoxication   
Reactive metabolites resulting from APAP contribute to cell damage in a variety of 
ways which result in reversible or irreversible injury; the latter consequently leads 
to cell death. The reactive metabolite can irreversibly attach to cellular 
macromolecules and generate oxidative stress after massive depletion of hepatic 
GSH stores. Ultimately, the macromolecule binding contributes to damage and 
dysfunction of mitochondria, the cell organelles that are mainly responsible for ATP 
synthesis through metabolic conversion by glycolysis and oxidative phosphorylation 
(Boelsterli and Lim, 2007). Damage to mitochondria results in uncoupling of 
oxidative phosphorylation, suppressed ATP synthesis and opening of mitochondrial 
permeability transition (MPT) pore due to compromise of membrane potential, and 
subsequently cell death through generation of ROS and the disruption of electron 
transport systems and ATP production (Bossy-Wetzel and Green, 1999; Gross et al., 
1999). These changes are mediated either via apoptosis or necrosis, or a 
combination of both. However, the actual mechanisms leading to drug-induced cell 
death are still being investigated. Some studies believed that evidence of apoptosis 
or necrosis is dependent on ATP levels within the cell (Leist et al., 1997; Nicotera et 
al., 1998). If MPT occurs as a result of damage to a few mitochondria within the cells 
or without severe ATP depletion, apoptosis occurs, but if marked ATP depletion 
takes place during this process then necrosis will intervene (Leist et al., 1997; 
Lemasters, 1999; Lemasters et al., 1999). Mitochondrial injury can gradually 
accumulate while being silent, which eventually leads to liver dysfunction and 
explains the delay of liver recovery by weeks or months (Boelsterli and Lim, 2007).  
Chapter 1 
21 
 
                                                                 
 
        
       
Figure 1.3. Metabolism of APAP-induced hepatotoxicity. 
Generally, APAP is detoxified to glucuronide and sulphate metabolites in hepatocytes. 
CYP450 converts APAP to the chemically reactive metabolite NAPQI which is then 
conjugated by GSH stored in the liver, and detoxified. With APAP overdose, glucuronide and 
sulphate metabolites will saturate which promotes NAPQI production. When intracellular 
GSH is depleted, NAPQI is oxidised and can covalently bind to cellular macromolecules 
resulting in toxicity (James et al., 2003b). APAP - Acetaminophen; SULT - sulfotransferase; 
UGT - UDP-glucuronyltransferases; GST - Glutathione-S-transferase; GSH - reduced 
glutathione; NAPQI - N-acetyl-p-benzoquinoneimine. 
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1.3.2.1     APAP-induced hepatocellular apoptosis   
Apoptosis is a mechanism of programmed cell death that is executed during the 
normal, i.e. physiological regulation of cell numbers (Kerr et al., 1972). It takes place 
if hepatocytes are injured beyond repair to avoid the spread of damaged DNA to 
other healthy cells and stop the damaged or abnormal DNA from dividing (Kerr et 
al., 1972). Apoptosis is characterised by membrane blebbing, cell shrinkage, 
chromatin condensation and DNA fragmentation (Robertson et al., 2000). Apoptotic 
bodies which represent cell fragments surrounded by an intact cell membrane are 
phagocytosed by adjacent cells and macrophages, for lysosomal degradation. This 
minimises the leakage of cellular components into the extracellular space and 
prevents the initiation of subsequent inflammatory responses (Savill et al., 2003). 
Many stimuli can initiate apoptosis. Among these are tumour necrosis factor alpha 
(TNF-α) and Fas ligand (FasL) which engage with death receptors on the cell surface 
(Ashkenazi et al., 1998; Latta et al., 2000). These stimuli can activate a cascade of 
cysteine-aspartate proteases (caspases) that are commonly expressed in most cells 
and once activated can usually release other procaspases, allowing initiation of a 
protease cascade. Some of the procaspases are able to aggregate and autoactivate 
(Elmore, 2007). Moreover, activation of other caspases are capable to amplify the 
apoptotic signalling pathway, they cleave cellular proteins after an aspartate 
residue, thereby leading to rapid cell death (Cohen, 1997; Elmore, 2007).  
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1.3.2.2   APAP-induced hepatocellular necrosis  
Necrosis is another form of cell death that occurs as a consequence of acute cellular 
injury. It is characterised by mitochondrial swelling, loss of plasma membrane 
integrity and random nuclear DNA cleavage as a consequence of cellular 
degradation. This results in damage of the cell membrane and subsequent release 
of intracellular contents into the surrounding tissue. This release can trigger an 
inflammatory response, leading to exacerbation of injury and further damage 
(Robertson et al., 2000). Many studies had reported that necrotic hepatocyte cell 
death is a result of APAP overdose (Gujral et al., 2002; Jaeschke et al., 2003; Malhi 
et al., 2006).  
Generally, it has been accepted that necrosis is the final and ultimate form of 
hepatocyte death in APAP-induced hepatotoxicity in animals as well as man 
(Jaeschke et al., 2003). However, some studies claimed that intracellular events 
following APAP insult may result in hepatocyte apoptosis (Ferret et al., 2001; 
Henderson et al., 2007; Kon et al., 2007). These mechanisms are largely dependent 
upon mitochondrial pathways, such as the induction of the MPT and the release of 
cytochrome C after mitochondrial rupture (Buki et al., 2000). Other reports support 
the role of apoptosis in the modulation of APAP-induced liver damage (El-Hassan et 
al., 2003; Ray et al., 1996). However, the role played by apoptosis following APAP in 
man and in experimental animals is so far not clear. Some reports suggest that 
apoptosis may not be a feature of APAP hepatotoxicity due to overwhelming 
oxidative stress and rapid depletion of hepatocyte ATP, conditions not favourable 
for caspase activation (Gujral et al., 2002; Gunawan et al., 2006). Antoine et al. have 
reported that fasting of mice for 24 hours prior to APAP dosing can inhibit APAP-
induced caspase activation through depletion of basal ATP, thereby switching the 
mode of cell death to necrosis, which promotes the induction of an inflammatory 
response (Antoine et al., 2010). The process of apoptosis and necrosis during liver 
damage forms a mixture of events associated with cell death that can occur in 
parallel or sequentially (Raffray and Cohen, 1997).  
 
Chapter 1 
24 
 
1.3.3 Liver regenerative response after APAP insult  
Hepatic regeneration following APAP intoxication plays an indispensable role in 
determining the outcome of liver injury (Bhushan et al., 2014). Other studies also 
suggested that liver regeneration is stimulated in a timely manner leading to 
improved survival after stimulation by stem cell factor (Hu and Colletti, 2008) and 
vascular endothelial growth factor (Donahower et al., 2010). Although models of 
partial hepatectomy (PHx) have been extensively studied in the past in order to 
understand the mechanism of liver regeneration, the link from PHx to APAP 
overdose is still questionable because PHx is not associated with tissue injury and 
inflammation. After PHx, hepatocytes enter the cell cycle phases simultaneously 
and undergo mitosis together whereas the cell cycle is not synchronised following 
chemical injury as the time, duration and signals required for cell proliferation may 
differ (Apte, 2009; Bhushan et al., 2014). While the mechanism of APAP induced 
liver injury has been studied widely over the last three decades, the mechanisms 
underlying the subsequent liver regeneration are still poorly understood (Pritchard 
and Apte, 2015). In hepatotoxicity studies, it has been suggested that the extent of 
liver regeneration is associated with the dose response until a threshold level is 
reached (Bhushan et al., 2014). When a threshold dose is exceeded, liver 
regeneration would be impaired due to inhibition of the pro-regenerative signalling 
pathway, resulting in enhanced liver damage (Anand et al., 2003; Mangipudy et al., 
1995; Mehendale, 2005). Each increment of a toxic dose corresponds to a delay in 
the onset of liver recovery (Mangipudy et al., 1995). Due to dose dependency of the 
response, it is important to carry out preliminary toxicity studies in order to gather 
the information the optimal dose and thef time course of liver regeneration in an 
animal model (Pritchard and Apte, 2015).  
 
 
  
Chapter 1 
25 
 
1.4 EFFECT OF FASTING ON APAP-INDUCED LIVER INJURY 
1.4.1 Effects of fasting on mouse hepatotoxicity 
The effects of food availability or deprivation on liver damage and function after 
APAP administration are yet to be further elucidated. A recent study suggested a 
standard operating protocol (SOP) for APAP toxicity studies, which included fasting 
a mice for 12 to 16 hours prior to APAP administration, with an adjustment for the 
different mouse strains, sex, age and dosage (Mossanen and Tacke, 2015). 
Furthermore, an overview of many studies that reveal the effects of fasting on the 
examined parameters in pharmacological research has been given in the past 
(Claassen, 1994). Fasting of animals prior to APAP dosing can profoundly affect the 
toxicological response to the drug by decreasing hepatic GSH (Shimizu et al., 1992) 
and ATP (Lee et al., 1988), altering CYP450 expression (Hu et al., 1995) and 
downregulating gene expression related to apoptosis (Matthias et al., 2004). 
Theoretically, GSH depletion is known to be a prerequisite for the onset of toxicity 
as it is required to detoxify the reactive metabolite (Jollow et al., 1973). A reduction 
of intracellular hepatic GSH levels due to fasting results in a markedly increased 
susceptibility to the toxic effects of APAP  (Pessayre et al., 1979). A reduction of 
hepatic GSH has been documented in chronic alcoholic patients following 
therapeutic doses of APAP (Jewell et al., 1986; McClain et al., 1980; Seeff et al., 
1986). Hence, malnourished individuals have a compromised detoxification capacity 
due to reduced hepatic GSH levels, and thereby become more susceptible to APAP-
induced liver injury (Larson, 2007; Price et al., 1987).  
A 6 hour duration of study showed that mice fasted for 12 hours overnight had a 
higher prevalence of hepatic centrilobular necrosis and a mortality rate of up to 
20% compared to 4-6 hours fasting mice prior to APAP administration. Also, the 
fasted mice developed a significantly increased liver weight/body weight ratio after 
APAP treatment compared to non-fasted mice (Walker et al., 1982). A recent study 
has histologically confirmed the depletion of hepatocellular glycogen in fasted mice, 
coupled with significantly decreased basal hepatic ATP and GSH levels in these 
animals (Antoine et al., 2010). Overnight fasting of mice prior to APAP 
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administration can cause hypothermia, more intense liver necrosis and hepatic 
congestion, with significantly higher covalent binding of APAP or its reactive 
metabolite, thereby enhancing the mortality rate (Walker et al., 1982).  
 
1.4.2 Effects of fasting on liver regeneration after APAP overdose  
Mice that have been treated with 300 mg/kg APAP underwent liver regeneration 
similar to that observed in the PHx model (James et al., 2003a). A recent study 
revealed that liver regeneration is inhibited and sustained injury up to 96 hours at 
high doses of APAP (600 mg/kg) in C57BL/6J mice because of active restriction of 
cell progression and/or reduced pro-regenerative signal pathways compared to 300 
mg/kg treated animals that underwent complete recovery at 48 hours, as evidenced 
by reduced serum ALT and lack of necrosis (Bhushan et al., 2014). This study also 
revealed a significantly higher amount of total PCNA positive cells and cyclin-D1 in 
low dose than high dose APAP treatment. It also demonstrated that liver 
regeneration involves Wnt/β-catenin and NF-kB mediated signalling (Bhushan et al., 
2014). However, these studies have all been performed in mice that had been 
fasted for 12 hours prior to APAP dosing, and there is no information on animals 
that have been fed ad libitum. Overnight fasting of mice is known to generate 
hepatic CYP2E1 levels which potentially have an effect on liver injury or/and 
regeneration (Pritchard and Apte, 2015). A study in CD-1 mice showed liver 
regeneration had taken place within 24-48 hours after APAP-induced liver injury 
subsided. Regenerating hepatocytes were estimated by percentage of S-phase in 
PCNA analysis, but it did not mentioned the condition (fed or fasted) of animals 
prior to dosing (Apte et al., 2009b).     
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1.5 CYTOKINES INVOLVED IN ASSOCIATION WITH APAP-INDUCED LIVER 
TOXICITY AND LIVER REGENERATION  
The innate immune system acts as the first line defence mechanism against any 
invading pathogens. The liver is also an immune organ and plays a pivotal role in the 
innate immune response, as non-parenchymal cells including KCs, NK cells, NKT cells 
and DCs show their own specific responses towards invading pathogens (Mackay, 
2002). The immune response can also contribute to severity and progression of 
APAP-induced hepatotoxicity, through recruitment of inflammatory cells into the 
liver and production of cytokines downstream of bioactivation (Blazka et al., 1995; 
Laskin et al., 2001; Liu et al., 2004). The production of inflammatory mediators 
including cytokines released by KCs and macrophages have been implicated in APAP 
hepatotoxicity by exacerbating cell damage as a result of an aggressive 
inflammatory response (Liu et al., 2004; Luster et al., 2001). Cytokines are soluble 
protein mediators produced by almost all cell types in response to various stimuli. 
There are many cytokines including IL-1, TNF-α and IL-6 which play a role as key 
mediators of APAP hepatotoxicity (Blazka et al., 1995). An understanding of the 
cytokine response is beneficial to the future development of novel therapies for 
APAP-induced liver injury (Galun and Axelrod, 2002).  
Tissue repair is an important determinant of the final outcome of toxicant-induced 
liver injury. Since hepatocytes are mostly in a quiescent state (G0 phase of the cell 
cycle), pro-inflammatory mediators such as TNF-α and IL-6 are needed for their 
priming (Fausto, 2000). This renders the cells more responsive to growth factors 
which results in the expression of cell cycle proteins (Michalopoulos, 2013). 
Meanwhile, the gene expression is widely studied during liver regeneration because 
the changes are rapid and transcribe within minutes after PHx or DILI and the 
production of gene transcription continues throughout the time course of liver 
regeneration (Michalopoulos, 2013; Taub, 1996, 2004). Many factors including 
nutrition and metabolic status may influence liver regeneration. After the loss of a 
large number of parenchymal cells, the metabolic response of surviving hepatocytes 
is increased to generate more ATP for both maintenance of homeostasis and 
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regeneration in APAP overdose (Yang et al., 2009b). Figure 1.4 illustrates the 
pathogenesis of APAP hepatotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1.4. Pathogenesis of APAP hepatotoxicity.  
A. APAP is metabolised by CYP450 to the toxic metabolite NAPQI, but GSH detoxifies NAPQI 
with the aid of Nrf2, which protects against toxicity. Intracellular injury initiated at this 
stage activates simultaneously pro and anti-inflammatory cascades and the balance 
between them determines the outcome of toxicity. B. With GSH depletion, NAPQI triggers 
cellular oxidative stress that activates JNK and thereby activates more NK/NKT cells to 
release IFN-γ to stimulate FasL expression, and promotes production of pro-inflammatory 
cytokines and chemokines leading to severe APAP hepatotoxicity.  APAP - acetaminophen; 
FasL - Fas ligand; GSH - glutathione; JNK - c-Jun-N-terminal; NAPQI - N-acethyl-p-
benzoquinone-Imine; NK - natural killer cells: NKT - natural killer T cells; Nrf2 - NF-E2-
related factor 2; PMN - polymorphonuclear cells (Liu and Kaplowitz, 2006). 
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1.5.1 Role of Kupffer cells (KCs) 
KCs are the liver macrophages and constitute up to 90% of tissue macrophages in 
the body; they are localised in the periportal and centrilobular regions (Mackay, 
2002). Upon activation, KCs can functionally differentiate into M1 and M2 
macrophage subsets (Yang et al., 2012a). Release of type 1 cytokines including TNF-
α, IL-6 and IFN-γ is associated with M1 macrophage activation which contributes to 
the induction of pro-inflammatory cytokines that further promote a T helper cell 
response. However, activation of M2 macrophages is responsible for the excretion 
of IL-4, IL-10 and IL-13; these inhibit the inflammatory response and stimulate liver 
regeneration. Some studies have reported that activated KCs release cytokines and 
thereby contribute to APAP-induced hepatotoxicity (Ito et al., 2003; Laskin et al., 
1986). In contrast, another experiment demonstrated the hepatoprotective role of 
KCs (Ju et al., 2002). These contradictory reports highlight the complexity of the 
Kupffer cell function to either inhibit or promote liver damage following APAP 
overdose which depends on types or doses of agents used (Ju et al., 2002).   
 
1.5.2  Role of natural killer (NK) and natural killer T (NKT) cells  
Natural killer (NK) and natural killer T (NKT) cells, which account for 20-50% of 
isolated liver leukocytes, produce a variety of immunoregulatory mediators after 
the cells have been infected, transformed or stressed (Liu et al., 2000). Infected cells 
trigger NK/NKT cells to kill the cells directly or generate cytokines and chemokines 
which then stimulate immune system components (Biron et al., 1999). NK and NKT 
cells were shown to become activated and play a crucial role in the progression of 
hepatotoxicity following APAP overdose. Meanwhile, neutralisation of NK and NKT 
cells by anti-NK1.1 was discovered to downregulate the expression of IFN-γ and 
monocyte chemoattractant protein-1 (MCP-1) mRNA (Liu et al., 2004). It 
subsequently minimises the susceptibility of mice in APAP toxicity as evidenced by 
low serum ALT levels, reduced hepatic necrosis and increased survival rate (Liu et 
al., 2004). In contrast, APAP solubilisation by dimethyl sulfoxide (DMSO) enhanced 
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the NK and NKT cell response and further increased the sensitivity to APAP-induced 
cell damage (Masson et al., 2008). Activated Kupffer cells release cytokines TNF-α, 
IL-12 and IL-18 which may activate NK/NKT cells (Gao et al., 2009). Activated 
NK/NKT cells increase the production of IFN-γ, which in turns promote further 
activation of macrophages, stimulates Fas ligand (FasL) expression and increases the 
production of chemokines and cytokines that could further stimulate the 
recruitment of neutrophils into the liver (Gunawan et al., 2006; Yuko et al., 2002). 
Innate immune cells like KCs, NK/NKT cells and neutrophils that express the FasL 
effector on their surface can induce the death of Fas-expressing hepatocytes via 
apoptosis (Gunawan et al., 2006; Imamura et al., 2004). Depletion of NK/NKT cells 
resulted in the inhibition of APAP-promoted upregulation of hepatic FasL expression 
at both mRNA and protein levels (Liu et al., 2004). It should be noted that FasL also 
plays a inflammatory role as it induces inflammatory cytokines/ chemokines that 
are responsible for progression of APAP-induced liver injury (Faouzi et al., 2001; 
Imamura et al., 2004; Liu and Kaplowitz, 2006; Park et al., 2003).      
 
1.5.3 Role of cytokines in APAP-induced liver injury and regeneration  
1.5.3.1  Role of TNF-α  
TNF-α is the mainly produced by KCs after inflammatory stimulation and is also 
known as cachectin (Decker et al., 1990). Currently, the role of TNF-α in APAP 
toxicity appears to be controversial because it is considered to have diverse effects 
in different phases. It has been shown that TNF-α production during early events of 
hepatic injury triggers the release of a cascade of cytokines, therefore recruiting and 
activating inflammatory cells (Bradham et al., 1998). However, continuous 
production of TNF-α induces necrosis of hepatocytes and can increase the 
infiltration of inflammatory cells, by promoting recruitment and adhesion of 
neutrophils to endothelial cells (Fiers, 1991). The effect of TNF-α is mediated by two 
receptors, TNFR1 and TNFR2, which are involved in different distinct signalling 
pathways (Tartaglia et al., 1993; Tartaglia et al., 1991). TNF-α signalling via TNF-α 
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receptor 1 (TNFR1) which is heavily released and expressed by Kupffer cells is the 
main signalling pathway leading to an inflammatory response (Douni et al., 1998; 
Peschon et al., 1998). TNF-α can act directly on hepatocytes via both receptors 
TNFR1 and TNFR2 to induce direct toxicity, leading to hepatocyte apoptosis and 
necrosis (Bour et al., 1996; Wang et al., 1995). Several previous studies reported 
that TNF-α plays a role in the exacerbation of liver damage and it has been shown 
that its secretion contributes to the hepatotoxicity in APAP overdose (Blazka et al., 
1996a; Blazka et al., 1995; Goldin et al., 1996). A recent study demonstrated 
significantly higher serum TNF-α levels in fasted mice treated with APAP than in fed 
mice (Antoine et al., 2010). Blazka and co-authors have demonstrated the secretion 
of TNF-α between 4 and 24 hours after APAP overdose; the APAP-induced liver 
injury was attenuated after administration of antibodies targeted against TNF-α 
(Blazka et al., 1995). However, another study showed that antibody-mediated 
neutralisation of TNF-α had no effect on APAP hepatotoxicity (Simpson et al., 2000). 
Likewise, TNF-α KO mice and wild-type mice showed similar response in APAP 
hepatotoxicity (Boess et al., 1998).  
It has also been reported that TNF-α plays a role in liver regeneration after PHx 
(Diehl, 1995) and APAP-induced liver injury (Bhushan et al., 2014). In addition, 
deletion of TNF-α receptor (TNFR1) also showed delayed liver proliferation (Yamada 
et al., 1997). Therefore, TNF-α has been implicated to play a dual role in tissue 
repair and tissue damage in hepatotoxicity after APAP challenge, depending on the 
balance and kinetics of TNF-α production as well as other mediators in the liver 
(Gardner et al., 2003). Gardner et al. also suggested that the contradictory results 
regarding the role of TNF-α are due to the variability in the APAP doses and the 
sensitivity of the different mouse strains to APAP (Gardner et al., 2003). 
Michalopoulos concluded that TNF-α should not be viewed as initiator of liver 
regeneration, but as one contributor signal during the early response because TNF-
α has no direct mitogenic effects on hepatocytes. This study also showed that TNF-α 
is unable to induce DNA synthesis both in cell culture and in vivo (Michalopoulos, 
2013). Although the major source of TNF-α are KCs, production by other cells 
cannot not been ruled out; i.e increased TNF-α levels in the plasma after PHx may 
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be induced by another stimulus like endotoxin, produced by bacteria from gut 
(Michalopoulos and DeFrances, 1997).  
 
1.5.3.2  Role of IL-6  
IL-6 is mainly produced by macrophages and T cells and has both pro- and anti-
inflammatory properties that regulate acute phase immune responses and 
inflammation (Heinrich et al., 2003; Hirano, 1998). IL-6 also plays a role in liver 
regeneration (Cressman et al., 1996; Trautwein et al., 1996). It has been calculated 
that almost 40% of the immediate early genes expressed in the regenerating liver 
may be IL-6 dependent, suggesting that the role of IL-6 in this process is complex 
(Fausto, 2000). A role of IL-6 is probably in proliferation, as IL-6 KO mice showed a 
significant reduction of liver regeneration due to delayed STAT-3 activation, a major 
signal transduction factor that is important for the activation of a large number of 
genes in hepatocyte regeneration (Cressman et al., 1996). Likewise, IL-6 deficient 
mice showed a reduced capacity of liver regeneration compared to wild-type mice 
following PHx and 30 minute ischaemia; hepatocyte proliferation improved when 
the animals were pre-treated with recombinant IL-6 (Selzner et al., 1999). In animal 
models of autoimmune diseases such as insulin-dependent diabetes mellitus 
(Rabinovitch, 1998), inflammatory bowel disease (Mudter and Neurath, 2007) and 
rheumatoid arthritis (Srirangan and Choy, 2010), IL-6 has a pathogenic pro-
inflammatory effect. In contrast, it is protective and anti-inflammatory in liver 
damage caused by ethanol (Hong et al., 2002), carbon tetrachloride (CCl4) 
(Kovalovich et al., 2000), and APAP (James et al., 2003a; Masubuchi et al., 2003c). A 
few studies have reported an increase in IL-6 production after APAP-induced liver 
damage in mice (Bourdi et al., 2002; James et al., 2003a). In addition, it has been 
suggested that IL-6 is relevant for hepatocyte regeneration and that liver damage 
following APAP overdose is pronounced in the absence of IL-6 due to lack of 
cytoprotective hepatic heat-shock protein expression compared to wild-type mice 
(James et al., 2003a; Masubuchi et al., 2003c).  
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Significantly elevated IL-6 serum levels together with evidence of hepatic 
regeneration were seen in APAP treated fed mice (Antoine et al., 2010).  IL-6 was 
claimed to play a pathogenic role when overexpressed in a model of APAP-induced 
liver injury which indicates that the dual, pro- and anti-inflammatory role of IL-6 
may be determined by its level of expression (Bourdi et al., 2002). The same study 
also showed that even though the level of IL-6 is high in IL-10/IL-4 KO mice, these 
animals were highly sensitive to APAP. Administration of an anti-IL-6 antibody 
reduced the degree of APAP-induced liver damage and was followed by decreasing 
IL-6 levels. Based on this, the authors concluded that although the production of IL-
6 was high in the absence of IL-10 and IL-4, mice were still susceptible to 
hepatotoxicity following APAP overdose because IL-6 alone is unable to stimulate 
hepatocyte regeneration in vivo (Bourdi et al., 2002).  
 
1.5.3.3  Role of IL-10  
Similar to IL-6, IL-10 plays a protective role in APAP hepatotoxicity (Bourdi et al., 
2002).  It has been reported that IL-10 KO mice are more susceptible to APAP liver 
injury due to suppression of monocytes activation by downregulating NF-kB, and 
also increased the release of pro-inflammatory cytokine production (TNF-α, IL-1 and 
IFN-γ) (Bourdi et al., 2002). However, a study has demonstrated that liver 
regeneration in PHx model is also enhanced in IL-10 deficient mice, due to 
capabilility of IL-10-/- mice to increase inflammatory response-associated STAT-3 
activation (Yin et al., 2011). It is strongly believed that the anti-inflammatory role of 
IL-10 is mediated by activation of STAT-3 signaling pathway in macrophages or 
neutrophils (Bazzoni et al., 2010), as deletion of STAT-3 in IL-10-/- mice inhibited 
liver regeneration (Yin et al., 2011).   
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1.5.3.4  Role of NF-kB  
NF-kB is a transcription factor that is strongly activated by TNF-α (Guicciardi and 
Gores, 2009) and has pleiotropic effects in various events, including inflammation 
and injury, cell survival, proliferation, and apoptosis (Karin et al., 2002). Under 
normal conditions, NF-kB remains in the cytoplasm through the influence of the 
inhibitor kB (IkB) (Wajant et al., 2003). When IkB undergoes phosphorylation, 
ubiquination and degradation, the NF-kB pathway is activated. IkB kinases (IKKs) are 
the enzymes important for IkB phosphorylation (Tacke et al., 2009). Once the IkB 
complex has lost various subunits after phosphorylation through the IKKs, NF-kB is 
released and translocates to the nucleus (Perkins, 2000). A study demonstrated that 
in mice after PHx, the primary activation of NF-kB in the liver occurs in KCs rather 
than in hepatocytes (Yang et al., 2005). Depletion of KCs resulted in reduced NF-kB 
activation and reduced regeneration of the liver in PHx model (Abshagen et al., 
2007). NF-kB provides signals to the cells, resulting in transcription of inflammatory 
cytokines, such as TNF-α and IL-6 (Karin et al., 2002; Yamada et al., 1997). It also 
acts as a regulator of inflammation; its activation can induce the expression of 
survival genes, including BCLXL and A1, that are strongly linked to liver regeneration 
after cell injury (Fausto, 2000; Malhi et al., 2006). Some studies provide evidence 
that NF-kB induces the inflammatory response that is involved in the progression of 
hepatotoxicity (Tsung et al., 2005; Ulloa et al., 2002). Others concluded that NF-kB is 
not critical in the process of liver regeneration after PHx (Laurent et al., 2005). 
Another study has shown that inhibition of NF-kB results in pronounced hepatocyte 
cell death and thereby worsens liver injury and increases the mortality in a PHx 
model (Malato et al., 2012). It has also been demonstrated that enhanced NF-kB 
activation diverts intracellular pathways involved in inflammation and cell death to 
other mechanisms that activate a pro-regenerative response (Sun and Karin, 2008). 
This is supported by another study which suggests that enhanced NF-kB binding is 
associated with improved liver regeneration during the late phase of APAP 
hepatotoxicity (Yang et al., 2012b; Yang et al., 2011), and decreased NF-kB binding 
is associated with impaired liver regeneration (Yang et al., 2009a). A more recent 
study also demonstrated the production of NF-kB during liver regeneration 
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(Bhushan et al., 2014). Although NF-kB was shown to be activated both during 
hepatic regeneration after PHx and in the APAP toxicity model, its overall 
contribution to hepatocyte proliferation is yet to be determined (Robinson and 
Mann, 2010). Therefore, NF-kB activation during liver regeneration can have an 
upregulating or downregulating effect or none at all on regeneration and/or 
apoptosis, it is influenced by many factors including various specific target of cell 
types which induced by different agent or model used (Nejak-Bowen and Monga, 
2015). The role of NF-kB played in liver regeneration as it is known so far is 
illustrated in Figure 1.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. The role of NF-kB in liver regeneration.  
(A) NF-kB is activated in hepatocytes to drive regeneration, (B) Activation of NF-kB cell in 
Kupffer cells that are capable to secrete cytokines that trigger the proliferation of 
hepatocytes. Activation of TNF-α, LPS or other cytokines on KCs surface are able to induce 
NF-kB production, thereby further release of IL-6 and TNF-α. Subsequently, these cytokines 
can stimulate adjacent hepatocytes to proliferate via activation of signal transducer and 
activator of STAT-3 transcription (Nejak-Bowen and Monga, 2015). 
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1.5.3.5  Role of cytokine networks in hepatic regeneration 
The process of liver regeneration involves activation of two distinct pathways, a 
growth factor and a cytokine-regulated pathway (Fausto, 2000). The importance of 
cytokines for liver regeneration is due to the fact that certain cytokines can prime 
resting hepatocytes for cell division (Fausto, 2000). Before hepatocytes fully 
respond to growth factors, such as hepatocyte growth factor (HGF), transforming 
growth factor alpha (TGF-α) and epidermal growth factor (EGF), they need to be 
primed by cytokines like TNF-α and IL-6. Also, transcription factors including NF-kB, 
STAT-3, AP1 and C/EBPβ which are proteins responsible for binding to specific 
recognition sites in target genes are crucial for the initiation of liver proliferation. 
The precise role played by these individual cytokines and transcription factors is still 
needs further clarification. In PHx and CCl4-induced liver injury, the TNF-α signal 
transduction pathway plays an important role, with the following sequence: TNF-α - 
TNFR1 - NF-kB - IL-6 - gp130 – STAT-3 (Fausto, 2000).  
The cytokine network is initiated by binding of TNF-α to TNFR1, leading to activation 
of NF-kB by removal of the inhibitory IkB through phosphorylation, mediated by the 
kinase IKK, and the subsequent proliferative response by preventing further cell 
death (Yamada and Fausto, 1998; Yamada et al., 1997). TNF-R1 KO mice show a lack 
of NF-kB activation due to blockage of cell cycle progression at the G1 and S phase, 
and are ultimately depleted of IL-6 serum levels and show impaired DNA synthesis 
in the liver (Yamada et al., 1997). Induction of NF-kB by TNF-α can promote 
production of IL-6 and its release from hepatocytes, which activates the Jak/STAT 
pathway, an important stimulator in the early phase of liver regeneration 
(Libermann and Baltimore, 1990). Binding of IL-6 to a soluble circulating receptor, 
which then binds to the cell-surface receptor gp130 will initiate the signals for STAT-
3 activation (Cressman et al., 1996; Wuestefeld et al., 2003). An important STAT-3 
target is Suppressor of cytokine signalling-3 (Socs3), which acts in a feedback loop 
by preventing ongoing activation of IL-6 signalling through inhibiting STAT-3 
phosphorylation (Riehle et al., 2008). The activation of IL-6/STAT-3 signalling is a 
pivotal mediator of pro-survival factors for liver regeneration (Kovalovich et al., 
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2001). STAT-3 activation acts together with transcription factors C/EBPβ and AP1 to 
increase expression of other additional factors such as NF-IL-6.c-myc, c-fos, IRF-1, to 
enable cell progression from G1 to S phase (Galun and Axelrod, 2002).     
Taking together, this indicates that the induction of cytokine signalling activates 
pro-survival factors that are important in protecting the liver against further 
damage and promote liver recovery (Kovalovich et al., 2001). However, the balance 
between pro-inflammatory and anti-inflammatory cytokines produced by the liver is 
important to determine the development towards toxicity or regeneration of the 
liver (Galun and Axelrod, 2002). Deletion of certain cell gene or types in KO animals 
has been substantially used to highlight the role played by the innate immune cells 
in APAP hepatotoxicity and regenerative response (listed in Table 1.1). 
 
Table 1.1. Experimental models of APAP-induced liver toxicity and regenerative response. 
 
Experimental model References 
Increased susceptibility  
IL-6 (-/-) mice (Masubuchi et al., 2003c) 
TNFR1(-/-) mice (Yamada et al., 1997) 
IL-10 (-/-) mice (Bourdi et al., 2002) 
Kupffer cell depletion (Ju et al., 2002) 
GSH depletion (Jollow et al., 1973) 
Decreased susceptibility   
IL-6 administration (Masubuchi et al., 2003c) 
NK and NKT cell depletion (Liu et al., 2004) 
Neutrophil depletion  (Liu and Kaplowitz, 2006) 
FasL-deficient mice  (Liu et al., 2004) 
Increased regeneration  
HMGB-1 blockade (Yang et al., 2012b) 
IL-6 administration  (Masubuchi et al., 2003b) 
Decreased regeneration   
IL-6 (-/-) mice (Cressman et al., 1996) 
TNFR1 (-/-) mice (Chiu et al., 2003) 
STAT-3 deletion in IL-10(-/-) mice (Yin et al., 2011) 
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1.5.4 Liver regeneration after APAP overdose: markers and mediators 
1.5.4.1  Role of cyclin-D1  
Cyclin-D1 is cell cycle protein that believed to be a reliable marker of proliferating 
hepatocytes in the G1 phase. Hepatocytes express cyclin-D1 once they have passed 
the G1 restriction point and started DNA replication (Fausto, 2000). A few recent 
studies revealed that after Ringer’s lactate solution and anti-HMGB1 treatment, 
cyclin-D1 was highly expressed during liver recovery, at the late phase of APAP 
hepatotoxicity (Yang et al., 2012b; Yang et al., 2011). In addition, other previous 
studies have demonstrated that EP therapy and prolonged treatment with NAC 
reduce cyclin-D1 expression after liver regeneration is inhibited (Yang et al., 2009a; 
Yang et al., 2012c). Based on these reports, cyclin-D1 is concluded to be a reliable 
marker to detect liver regeneration after APAP induced hepatotoxicity (Yang et al., 
2009b; Yang et al., 2012c).   
 
1.5.4.2  Proliferating cell nuclear antigen (PCNA) and HE staining  
Proliferating cell nuclear antigen, commonly known as PCNA, is a 36-kDa auxiliary 
protein that acts as a processivity factor that measures the average number of 
nucleotides added by a DNA polymerase enzyme in eukaryotic cells (Bravo et al., 
1987). It is an example of a DNA clamp since it achieves this processivity by 
encircling the DNA, thus creating a topological link to the genome. PCNA is found in 
the nucleus and is a cofactor of DNA polymerase delta that is involved in the 
coordination of cell cycle progression. Since DNA polymerase delta is involved in the 
resynthesis of excised damaged DNA strands during DNA repair, PCNA is important 
for both DNA synthesis and DNA replication (Bravo et al., 1987). Many proteins are 
involved in the process of cell cycle replication, including cyclins and cyclin-
dependent kinases that are important in the regulation of cell transition at different 
phases; G1, where cells increase in size and become ready to divide; S, where 
genome duplication occurs; G2 where cells check for completion of DNA replication; 
and M where the mitosis takes place (Pritchard and Apte, 2015). Under normal 
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circumstance, the majority of hepatocytes are in a quiescent state, i.e. in the G0 
phase and not within the cell cycle (Kurki et al., 1986). However, DNA damage 
induced by chemicals, disease or aging leads to the production of p21 protein that 
blocks the transition from the G1 to the S phase, by inhibiting the activity of cyclin-
dependent kinases. PCNA expression is induced in the late G1 phase, peaks in the S 
phase and stops thereafter (Kurki et al., 1986).  
The in situ demonstration of PCNA by immunohistology is a well-known method to 
assess hepatic regeneration and the clone the most commonly used is PC10, as it 
can detect PCNA in formalin-fixed tissues (Hall and Woods, 1990). By this method, 
individual hepatocytes at each time point when the liver was removed can be 
assessed to determine which phase of cell cycle is dominant during liver 
regeneration (Eldrige et al., 1993; Greenwell et al., 1991). Figure 1.6 provides 
detailed information on how the cell-cycle phase can be evaluated using PCNA 
immunostaining. However, some authors claimed that PCNA is an unreliable 
indicator for the quantitative assessment of hepatocyte regeneration during APAP 
hepatotoxicity in C57BL/6J mice, because the specificity of the first antibody used 
markedly influence the results (Yang et al., 2012b; Yang et al., 2011; Yang et al., 
2014). The studies indicate that PCNA is expressed in the liver at 24 hours post 
APAP administration, but without positive PCNA immunostaining. Also, after 48 
hours, PCNA staining was seen extensively in areas of marked liver damage, with 
larger areas of necrosis exhibiting larger numbers of PCNA positive cells, while 
improved liver damage with smaller areas of necrosis exhibited a lower number of 
PCNA positive cells; this was considered as a potential false result (Yang et al., 2011; 
Yang et al., 2014). A conclusion comes from the finding that the pattern of 
hepatocyte regeneration as indicated in HE stained slides does not match the 
pattern of liver proliferation suggested by the distribution of PCNA-positive cells 
(Yang et al., 2012b; Yang et al., 2011; Yang et al., 2014). Although HE staining is not 
widely used for the assessment of early hepatocyte regeneration, it can be a 
reliable method in determining late recovery of hepatocytes in C57BL/6J mice 
during APAP-induced liver injury as it confirms the improvement of the hepatic 
architecture, the lower numbers of necrotic cell death and the reduced recruitment 
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of inflammatory cells (Bhushan et al., 2014). Although these studies suggested that 
the immunohistological demonstration of PCNA does not provide reliable results for 
the assessment of liver regeneration after APAP toxicity, a most recent study 
demonstrated that PCNA immunostaining is indeed an effective tool for the 
quantification of cell proliferation in cancer risk assessment (Wood et al., 2015).  
 
 
Figure 1.6. PCNA cell-cycle phases.  
G0 or quiescent cells; no brown staining. Cells in the G1 phase exhibit a light brown nuclear 
staining, while cells in the S phase exhibit dark to nearly black nuclear staining; cells in both 
G1 and S cells do not show cytoplasmic staining. When cells enter the G2 phase, a reaction 
is seen both in nucleus and cytoplasm, while mitotic cells exhibit a light brown cytoplasmic 
reaction and a negative nucleus (Pritchard and Apte, 2015). 
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1.6  AIMS OF THESIS  
1.6.1 Effects of fasting on the liver of untreated (i.e. saline dosed, control) mice 
Despite the extensive use of fasting in toxicity studies, and in particular also in acute 
drug induced liver injury (DILI) studies, only limited information is available on the 
effect of fasting on a range of relevant liver parameters that could potentially also 
affect the outcome of DILI studies. Furthermore, the effect of refeeding on the liver 
has not been examined, and this has not been looked at in the context of the 
circadian rhythms. The hypothesis was that both fed and fasted control CD-1 and 
C57BL/6J mice have similar basic levels after a certain time period prior to and after 
the onset of refeeding. 
 
 The aims of this part of the thesis are therefore: 
 To gather reliable baseline data that allow better interpretation of the 
results from DILI studies in mice; 
 To understand the effect of fasting on hepatocyte function, by assessing 
hepatic GSH content, serum ALT levels, hepatic ATP levels, cytokine levels, 
and the extent of hepatocyte proliferation as well as the morphological 
features of the liver including the hepatocellular glycogen content. 
 
For this purpose, male CD-1 and C57BL/6J mice that had been consistently fed ad 
libitum or had been fasted for 16 or 24 hours and then refed for different time 
spans thereafter were used.  
Answers to the following questions were sought:  
 What is the effect of fasting in untreated mice?  
 Do CD-1 and C57BL/6J mice show the same type and degree of fasting 
effects? 
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1.6.2 Effects of fasting on the development and extent of APAP-induced DILI and 
the regeneration thereafter 
Despite intensive research, inconsistencies and conflicting reports remain on the 
extent of the role of innate immune, inflammatory and regenerative response in 
APAP-induced hepatotoxicity. The aim of the thesis was to assess the influence of 
fasting on hepatocyte regeneration after the toxic insult and on the inflammatory 
response that contributes to either progression or regression of APAP-induced liver 
injury. The hypothesis was that fasting of mice prior to APAP overdose results in 
higher susceptibility to APAP hepatotoxicity and subsequent delayed capability of 
hepatocytes to regenerate after the damage has subsided. 
The aims of this thesis were to answer the following questions:   
 To investigate the influence of fasting on the outcome of APAP-induced liver 
damage which include serum ALT, hepatic ATP and hepatic GSH content.  
o What effect has fasting animals on the extent of hepatocyte damage 
(serum ALT level) and the detoxifying capacity of hepatocytes (GSH 
level)? 
o Does fasting influence the type and extent of drug induced cell death 
(hepatic ATP content)?  
 
 To assess the degree of hepatocellular injury and the glycogen content 
microscopically to identify any effect of fasting on APAP-induced liver injury.  
o Does fasting exacerbate liver damage and delayed regeneration 
following APAP overdose?  
 
 To further explore the signalling cascade triggered by DILI by investigating 
the degree of expression of inflammatory cytokines, such as TNF-α, IL-6 and 
IL10 transcription in liver and spleen, and TNF-α and IL-6 in the serum.  
o Does fasting affect the expression and secretion of cytokines?  
o When after DILI are these cytokines expressed most intensely? 
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 To further evaluate the effect of fasting on the degree and speed of 
hepatocyte regeneration, as indicated by the hepatocellular expression of 
PCNA and the transcription of NF-kB and cyclin-D1 in the liver following 
APAP-induced liver damage.   
o Does DILI induce NF-kB and cyclin-D1 expression? 
o Does DILI induce hepatocellular proliferation, and when after injury? 
o Can a quantification of NF-kB and cyclin-D1 transcription and/or 
PCNA expression be used as indicators for the extent of hepatic 
regeneration following APAP overdose? 
 
1.6.3 Differences between C57BL/6J and CD-1 mice in their response to fasting 
and APAP overdose.  
 
 Due to conflicting data obtained in toxicological studies, we wanted to 
explore the effect of fasting on acute APAP toxicity and the subsequent liver 
regeneration, comparing the two strains, CD1 and C57BL/6J mice, using the 
same APAP dose (530 mg/kg). 
o Do the two strains respond differently to an APAP overdose of 530 
mg/kg? If yes, what are the differences? It is postulated that the 
extent of APAP-induced liver injury and/or regeneration differs 
between fed and fasted groups, however, both strains are expected 
to respond in a similar fashion to APAP treatment. 
 
The studies in this thesis have been undertaken in an attempt to provide more 
information on the effect of fasting on the response of mice to APAP induced acute 
hepatotoxicity. The overall objective was to provide information on baseline data of 
liver parameter after fasting, since these appear to be often ignored. Furthermore, 
this study also wants to raise the awareness on how important it is to carefully 
choose the mouse strain and the experimental protocol during the planning of 
toxicity studies in vivo. This study also provides data that might allow researchers to 
optimise their experimental settling to maximise the scientific outcome and secure 
better scientific data without compromised animal welfare. 
Chapter 2 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
45 
 
CONTENTS 
2.1 Experimental animals       46 
2.2 Experimental and sampling protocols     46 
2.3 Assessment of serum alanine transaminase (ALT) levels    47 
2.4 Determination of hepatic glutathione (GSH) levels    48 
2.4.1  Glutathione assay        49 
2.4.2 Lowry assay         50 
2.4.3  Quantification of glutathione levels      50 
2.5 Determination of hepatic ATP content      51 
2.6 Histology and immunohistochemistry for the assessment of 
hepatotoxicity and regeneration in the liver 52 
2.6.1 Preparation of specimens for histological and immunohistological 
examinations 52 
2.6.2 Histological examinations        52 
2.6.3 Immunohistological examinations       54 
2.6.3.1  Quantitative analysis of immunohistological stains     56 
2.7 Assessment of cytokine expression in serum, liver and spleen  57 
2.7.1  Measurement of serum cytokine levels by ELISA    57 
2.7.2 Determination of cytokine transcription levels in liver and  
spleen            58 
2.7.2.1 RNA extraction       58 
2.7.2.2 DNase treatment        59 
2.7.2.3 Reverse transcription (RT)      59 
2.7.2.4 Conventional PCR        60 
2.7.2.5 Quantitative Real time PCR (qPCR)     61 
2.8 Statistical analysis        63 
  
Chapter 2 
46 
 
2.1 Experimental animals 
All protocols described were undertaken in accordance with criteria outlined in a 
licence granted under the Animals (Scientific Procedures) Act 1986 and approved by 
the University of Liverpool Animal Welfare Committee. All CD-1 and C57BL/6J mice 
were obtained from Charles River Laboratories (Canterbury, England), were housed 
at the Biomedical Service Unit (BSU), University of Liverpool, UK, and had a 7 day 
acclimatisation period prior to experimentation. They were maintained in a 12 
hours light/dark cycle with free access to a commercial diet (Source: Special diet 
services (SDS) - carbohydrate 77%, amino acids 11.5%, fatty acids 2.7%) and drink. 
 
2.2 Experimental and sampling protocols 
The study was performed on male CD-1 and C57BL/6J mice (body weight: 25-35 g) 
that had been grouped randomly for each strains which either had free access to 
food and water throughout the entire experiment or were fasted for 16 or 24 hours 
with free access to water prior to dosing. The body weight of individual animals was 
determined before and upon completion (i.e. immediately prior to dosing) of the 
fasting period in the fasted group and immediately before dosing in the fed group 
for both CD-1 and C57BL/6J mice.  
Acetaminophen (APAP) solution (Sigma, St Louis, MO, 30 mg/ml) was freshly 
prepared with 0.9% saline (9 g NaCl / 1 L dH2O) and incubated at 42
°C for 15 min 
with intermittent agitated using a vortex machine. In groups of 4 or 6 animals, mice 
were intraperitoneally administered 530 mg/kg of acetaminophen in 0.9% saline. 
Food was returned immediately after APAP administration in the fasted mouse 
groups. Control animals received 0.9% saline intraperitoneally instead. 
Animals were euthanized at different time points; 0, 0.5, 1, 2, 4, 5, 10, 15, 20, 24, 30 
and/or 36 hours post APAP and saline administration, respectively. Animals were 
euthanised by CO2 inhalation followed by exsanguination. Blood was collected by 
cardiac puncture. Blood samples were stored at 4◦C and allowed to clot overnight to 
obtain serum. 
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Subsequently, animals were dissected and livers removed, rinsed in ice cold saline 
and fixed in 4% paraformaldehyde (PFA) [4 g paraformaldehyde in 100 ml PBS] for 
histology processing, or snap frozen at -80°C until further analysis.  
Animals originated from 3-5 experiments undertaken either specifically for the 
current PhD project or as part of other PhD and/or postdoctoral research projects at 
the MRC CDSS, Institute of Translational Medicine (ITM), University of Liverpool, UK. 
In all experiments, the same mouse strains (CD-1 or/and C57BL/6J mice) from the 
same source (Charles River) were used, the same APAP dose (530 mg/kg APAP in 
0.9% saline) and the same application protocol was applied (Appendix Table 6.1), 
using a minimum of 4 animals per group. The same procedure was performed on 
each individual mouse, including the euthanasia technique and the procedures for 
blood and tissue sample collection. This approach served to keep animal numbers 
at a minimum and avoid unnecessary repetitive experimentation. The time of 
fasting, dosing and endpoint as well as the tests carried out on the different groups 
of mice from the different studies are listed in Appendix (Tables 6.2 to 6.5).  
 
2.3 Assessment of serum alanine transaminase (ALT) levels 
Serum alanine transaminase (ALT) levels were determined and served as a 
measurement of hepatotoxicity using Infinity ALT liquid kits (Sigma-Aldrich, Poole, 
UK). Serum samples were diluted with 0.9% saline in microtubes according to Table 
2.1 and two sets of serum dilution, i.e. either 1:2 and 1:5 or 1:5 and 1:10 were 
needed for each sample. The dilution of serum sample required for individual 
sample was depends on degree of hepatotoxicity. If liver is severely damaged, the 
serum is needed to be more diluted and vice versa. After pre-warming of the ALT 
solution and the chamber of the plate reader to 37°C (an optimal temperature for 
liver enzyme activities), 30 µl of diluted sample was added to each well, this was 
done in duplicate. After placing the well into the plate reader, 300 µl of ALT solution 
was added using multichannel pipette and the plate was read immediately. 
The mean velocity of the plate was read at every 30 sec for 5 min at 340 nm with a 
Dynex Magellan Bioscience MRXe reader (Dynex Technologies Inc, Sussex, UK). The 
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kinetic curve obtained was evaluated and recorded for each individual sample. If no 
or a very low kinetic curve was obtained, the sample was examined again, using a 
lower dilution, while with too high readings within short interval, the samples were 
examined again, using a higher dilution. Then, the value was corrected by substract 
it to blank and the actual ALT level was calculated by multiply the obtained value to 
dilution factor.       
 
Table 2.1. Serum ALT dilution measurement 
Ratio 
Volume of 
serum (µl) 
Volume of 0.9% 
saline (µl) 
Neat 30 0 
1:2 15 15 
1:5 6 24 
1:10 3 27 
1:50 5 245 
  µl – microlitre. 
 
2.4 Determination of hepatic glutathione (GSH) levels  
Thawed liver samples (30-50 mg) were prepared and homogenised with a Retsch 
MM400 homogeniser (ThermoFisher Scientific, Loughborough, UK) in 800 µl GSH 
stock buffer (143 mM Na2HPO4, 6.3 mM EDTA, pH 7.4) with 200 µl of 6.5% SSA (5-
sulfosalicyclic acid). The protein was allowed to precipitate on ice for 10 min prior to 
centrifugation at 14,000 rpm for 5 min. Subsequently, the supernatant was 
removed, placed into a new tube and subjected to the GSH assay protocol for 
glutathione determination. Meanwhile, the protein pellet left at the bottom of the 
tube was dissolved in 1 ml 1 M NaOH at 50-60°C for at least 1 hour and then 
subjected to the Lowry assay protocol for Lowry-protein correction. The 
supernatants containing GSH and dissolved protein were stored at -80°C until 
analysis. Both the GSH and the Lowry assay were performed in 96-well plates. 
Chapter 2 
49 
 
2.4.1  Glutathione assay 
GSH stock buffer was prepared by adding 125 mM NaH2PO4.2H2O and 12.5 mM 
EDTA (99% pure) and 500 ml sterile water. After that, the pH was adjusted to 7.4 by 
gradual addition of 5 M NaOH. Subsequently, 1 mM GSH stock solution was 
prepared by adding 3.07 mg GSH reduced to 10 ml GSH stock buffer. The 1 mM GSH 
solution was then diluted 1:10 to obtain a 0.1 mM GSH solution. For the preparation 
of GSH reductase, 154 µl of GSH reductase reagent was added to 10 ml of GSH stock 
buffer. After that, 20 µl of GSH standards (Table 2.2) or diluted samples (1:20 and 
1:50) were added to the wells in duplicates. Then, 20 µl of GSH stock buffer solution 
were pipetted to each well to neutralise the pH. Daily Assay Reagent was prepared 
immediately before use by mixing 9.9 mg DTNB, 7.08 mg NADPH and 25 ml GSH 
stock buffer. Once done, 200 µl of Daily Assay Reagent was added to each individual 
well and the plate was incubated at room temperature. After a 5 min incubating 
period, the plate was placed on the plate reader and 50 µl of GSH reductase was 
added to each well immediately with a multichannel pipette, at the same time 
removing all bubbles with a needle to avoid interference with the results. Finally, 
the results were obtained at 415 nm at 1 min interval for 5 min with Revelation 
software on a Dynex Magellan Bioscience MRXe reader (Dynex Technologies Inc, 
Sussex, UK).  
         Table 2.2. Standards for the glutathione assay.  
 
Standard 
(Std) 
Concentration 
(nmoles/ml) 
Volume of 0.1 mM 
stock solution (µl) 
Volume of GSH 
stock buffer (µl) 
Std 1 0 0 1000 
Std 2 1 10 990 
Std 3 2 20 980 
Std 4 5 50 950 
Std 5 10 100 900 
Std 6 20 200 800 
Std 7 30 300 700 
Std 8 40 400 600 
Std – standard; nmoles/ml – nanomoles per millilitre; mM – miliMolar; µl – 
microlitre. 
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2.4.2  Lowry assay  
A standard of the assay was prepared using a stock solution of 1 mg/ml BSA that 
was diluted in 0.5 M NaOH (5 ml of 0.2 mg/ml solution). Meanwhile, the Lowry 
reagent was prepared by adding 0.5 ml of 1% CuSO4.5H2O, 0.5 ml of 2% NaK tartrate 
(2 g NaK tartrate/100 ml dH2O) and 10 ml 10% Na2CO3 in 0.5 M NaOH. 1 ml of 
Folin’s Reagent (yellow phenol reagent, serving as sample indicator to measure 
levels of amines and amino acids) was added to 9 ml of dH2O (1:10 ratio) and kept 
in the dark. After all the reagents were prepared, the standard was diluted (Table 
2.3) and each sample diluted 1:100 (10 µl sample with 990 µl 0.5 M NaOH) and 
1:200 (5 µl sample with 995 µl of 0.5 M NaOH). After that, 50 µl of either standard 
or sample were added to wells in duplicate for each standard and individual sample, 
followed by 50 µl of Lowry reagent. Wells were incubated at room temperature for 
15 min. Subsequently, 150 µl Folin’s reagent was added to each well and the plate 
further incubated at room temperature for 30 min, followed by reading on the plate 
reader at 540 or 570 nm, using Revelation software on a Dynex Magellan Bioscience 
MRXe reader (Dynex Technologies Inc, Sussex, UK).  
Table 2.3. Standard of Lowry assay  
Standard (Std) Protein (g/ml) 0.2mg/ml BSA (µl) 0.5 M NaOH (µl) 
Std 1 0 0 1000 
Std 2 20 100 900 
Std 3 40 200 800 
Std 4 80 400 600 
Std 5 100 500 500 
Std 6 200 1000 0 
     g/ml - gram per millilitre; mg/ml – milligram per millilitre; M – Molar; µl – microlitre. 
 
2.4.3  Quantification of glutathione levels  
Data obtained from GSH and Lowry assay were calculated from their respective 
standard curve graph. Finally, total hepatic glutathione (GSH + oxidized glutathione) 
levels were quantified by normalisation of GSH levels to the hepatic protein content 
derived from Lowry assay. 
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2.5 Determination of the hepatic ATP content  
Protein free lysates generated for measurement of the hepatic GSH content were 
also utilised for the determination of the hepatic ATP content with the Sigma ATP 
bioluminescence kit (Sigma-Aldrich, Poole, UK) that comes with 3 reagents, ATP 
stock solution, ATP dilution buffer and ATP standard. ATP stock solution was 
dissolved in 5 ml dH2O to generate a stock solution with pH 7.8. After gentle mixing, 
the solution was kept on ice for at least 1 hour to ensure complete dissolution. 
Then, the ATP assay dilution buffer was prepared by dissolving the buffer solution 
(ready made in kit) in 50 ml dH2O. After that, one vial of ATP was dissolved with 1.8 
ml sterile water to 1 mM. Then, serial dilutions of ATP standard were prepared 
(Table 2.4). Subsequently, from each liver sample generated from GSH assay, a 1:10 
and 1:20 dilution was prepared. 100 µl of ATP stock solution was put to 96-well 
plate and allowed to stand for 3 min before rapidly adding 100 µl of either standard 
or diluted samples to each well. For each sample, duplicates were prepared. Finally, 
the samples were swirled briskly in order to mix well, followed by measuring the 
amount of light with a luminometer, Dynex Magellan Bioscience MRXe reader 
(Dynex Technologies Inc., Sussex, UK). The hepatic ATP content was recorded as 
nmol and quantified using ATP standard curve.  
 
  Table 2.4. Standard of ATP assay 
Standard (Std) Protein (nM) ATP standard (1mM) dH2O (µl) 
Std 1 0 0 1000 
Std 2 1 100 µl of std 3 900 
Std 3 10 100 µl of std 4 900 
Std 4 100 100 µl of std 8 900 
Std 5 300 3 µl of ATP std 997 
Std 6 600 6 µl of ATP std 994 
Std 7 800 8 µl of ATP std 992 
Std 8 1000 10 µl of ATP std 990 
  Std – standard; nM – nanoMolar; mM – miliMolar; µl – microlitre. 
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2.6 Histology and immunohistochemistry for the assessment of hepatotoxicity 
and regeneration in the liver 
2.6.1 Preparation of specimens for histological and immunohistological 
examinations 
Histological specimens from the livers were prepared in the Histology Laboratory, 
Veterinary Laboratory Services, School of Veterinary Science, University of 
Liverpool, UK. Samples from the left lateral lobe were fixed in 4% PFA for 24 to 48 
hours. Transverse sections were prepared from the fixed samples and placed (cut 
surface down) into a pre-labelled histology cassette, then routinely paraffin wax 
embedded using a tissue processor (Tissue-TEK Vacuum Infiltration Processor). 
Briefly, the tissue was dehydrated with a series of increasing concentrations of 
ethanol to remove free and bound water. It was then submersed and washed in 
xylene to remove the ethanol (EtOH). The tissue specimens were then removed 
from the cassette and embedded into a mould of molten paraffin wax with the 
trimmed side down. The cassette was then placed on the top of the mould, topped 
up with wax and allowed to solidify. Sections (3-5 µm) were cut on a microtome, 
floated onto a clean water bath (45°C) to remove creases, then retrieved and placed 
on a charged microscope slide and allowed to dry in an oven (60-70°C).  
 
2.6.2 Histological examinations  
For the histological assessment, sections were routinely stained with haematoxylin 
and eosin (HE). The hepatocellular carbohydrate (glycogen) content was assessed 
on sections routinely stained with the Periodic Acid Schiff (PAS) reaction (Vaquero 
et al., 2007). All stains were performed by the technical staff in the Histology 
Laboratory, Veterinary Laboratory Services, School of Veterinary Science, University 
of Liverpool. For routine histological examination, the liver sections were mounted 
on plain glass slides (ColorSlides, Solmedia Laboratory Supplies). Slides were then 
deparaffinized in xylene and dehydrated in graded alcohol. After that, the slides 
were stained for 5 min with Haematoxylin (VWR International), blueing in running 
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tap water for 6 min and another 2 min staining with eosin (VWR International). 
Then, sections were dehydrated again with 95% and 100% EtOH for 1 min before 
clearing in xylene and mounting with DPX (VWR International).  
HE stained sections were examined for any histopathological features and for the 
identification of apoptotic, necrotic and mitotic hepatocytes. The degree of 
(predominantly centrilobular) hepatocyte loss was scored (0-5), where 0 indicated 
no evidence of cell loss (unaltered liver) and 5 extensive cell losses  according to the 
criteria outlined in Table 2.5 (Antoine et al., 2009a). Leukocyte recruitment and 
infiltration was also assessed and recorded. The histological assessment and scoring 
was undertaken blindly and independently by Fazila Hamid and Prof Anja Kipar.  
 
Table 2.5. Grading score of histological changes in murine livers. 
Grading 
score 
Descriptions 
0 Normal – no evidence of hepatocyte necrosis 
1 Hepatocyte loss and necrosis – minimal to mild 
Focal, Limited to centrilobular region 
Less than ¼ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
2 Hepatocye loss and necrosis – mild to moderate 
Focal and multifocal 
Extends from central to midzonal lobular region 
½ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
3 Hepatocye loss and necrosis – moderate to severe 
Multifocal, May extends from centrilobular to portal region 
More than ½ to ¾ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
4 Hepatocye loss and necrosis – severe 
Multifocal, More than ¾ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
5 Massive hepatocye loss and necrosis – severe, involving entire lobules 
Hepatocytes loss extends from central vein to portal area 
Hepatocytes loss extends to adjacent lobules (multilobular necrosis) 
Associated with vacuolar degeneration or haemorrhages 
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2.6.3 Immunohistological examinations  
Immunohistology was applied for the demonstration of cleaved caspase-3 
(apoptotic cells) and proliferating cell nuclear antigen (PCNA; proliferating cells) on 
selected cases, as summarised in Appendix (Table 6.2: CD-1 and Table 6.3: C57BL/6J 
mice). The staining was performed by Valerie Tilston and Julie Dunn, technical staff 
in the Histology Laboratory, Veterinary Laboratory Services, School of Veterinary 
Science, University of Liverpool, UK. Consecutive sections, prepared from the 
formalin-fixed, paraffin-embedded liver specimens, following those stained with HE 
and PAS reaction, were used. Sections were deparaffinised in xylene for 10 min 
followed by rehydration in graded alcohols through each 2 min, twice in 100% EtOH 
and once in 96% EtOH to remove free and bound water. Then, inactivation of 
endogenous peroxidase was performed to avoid non-specific background staining, 
by 30 min incubation in freshly prepared methanol with 0.5% (v/v) H2O2 (Perhydrol 
30% H2O2 P-a, ThermoFisher Scientific) at room temperature, followed by washing 
twice in dH2O. Subsequently, antigen retrieval was performed (Table 2.6). For this 
purpose, sections were incubated at 96-98°C in pre-warmed citrate buffer for 30 
min, then cooled at room temperature for 20 min, followed by 5 min washing in 
TBST (TBS buffer with 0.05% Tween 20). 1xTBST (TBS buffer with 0.05% Tween 20) 
was prepared by mixing 10xTRIS Stock [60.57 g TRIS, 610 ml dH2O + 390 ml 1M HCl], 
900 ml dH2O, 7.2 g NaCl and 500 µl Tween 20 and stored in fridge. Citrate buffer pH 
4.0/6.0 was prepared by adding 9 ml Stock Solution A [Citric Acid 10.505 g and 500 
ml dH2O] and 41 ml Stock Solution B [Tri-Sodium Citrate 14.705 g and 500 ml dH2O] 
and dH2O with final total volume 500 ml at respective pH 4 or pH 6 and stored in 
fridge.  
Table 2.6. Antigen retrieval methods.  
Antigen 
detection 
Antigen retrieval Retrieval details  
Cleaved 
caspase-3 
Citrate buffer,  
pH 6.0 
Incubation at 96-98oC in pre-warmed citrate buffer for 
30 min, then cooling at room temperature for 20 min, 
followed by 5 min  TBST wash 
PCNA Citrate buffer,  
pH 4.0 
Incubation at 96-98oC in pre-warmed citrate buffer for 
15 min, followed by 20 min cooling at room 
temperature, followed by 5 min TBST wash 
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The individual slides were placed into coverplates and Sequenza racks (Thermo 
Shandon) and washed for 5 min in TBST, followed by blocking of non-specific 
binding of the antiserum by incubation for 30 min in undiluted goat serum (G9023; 
Sigma Aldrich, Poole, UK). Then, a further 5 min TBST wash was performed.  
Sections were then incubated with the primary antibodies at approximately 4°C in 
fridge) for 15-18 hours, followed by a 5 min TBST wash and incubation with the 
secondary antibody at room temperature, followed by a further TBST wash. 
Antibodies and detection systems are listed in Table 2.7.  
 
Table 2.7. Summary of antibodies used, antigen retrieval methods, detection systems and 
the staining result.  
 Cleaved caspase-3 PCNA 
Antigen 
retrieval 
method 
Citrate buffer, pH 6.0 Citrate buffer, pH 4.0 
Primary 
antibody 
Rabbit anti-cleaved caspase-3a 
monoclonal antibody (Asp 1756) 
(5A1E) 1:50 in TBST at 4oC for 
overnight 
Mouse anti-PCNAc, clone PC10, DAKO 
(M0879); 
1:100 in TBST for 30 min at room 
temperature, followed by TBST wash 
Secondary 
antibody 
Goat anti-rabbit biotinylated IgGb 
(BA-1000); 1:100 in TBST for 30 
min, followed by 5 min TBST 
wash 
Goat anti mouse Biotin-SP-conjugated 
Affinipure Fab Fragment IgGc; 
(115.067.003) 1:500 in PBS for 20 min at 
room temperature; and again wash with 
TBST for 5 min 
Detection 
system 
Vectastain ABC kit standard, 
polyclonal rabbitb (PK-4000); 1µl 
A +1µl B in 100µl TBST for 30 min, 
followed by TBST wash for 5 min 
and 4 times dH2O wash 
HRP: Horseradish Peroxidase-
Streptavidinb (SA-5014); 1:500 in PBS for 
20 min at room temperature; and last 
wash with TBST for 5 min 
Specificity Apoptotic cells  
(Gjorret et al., 2007) 
Nuclear expression: 
Proliferating in early phase G1 and S 
phases (Kurki et al., 1986) 
Cytoplasmic expression: 
Proliferating cells in S phase, late G1 and 
early G2 phases  
(Kubben et al., 1994) 
 
a Obtained from DAKO, Glostrup, Denmark; b Obtained from Vector Laboratories Ltd, 
Peterborough, UK; c Obtained from Jackson Immunoresearch Laboratories, Suffolk, UK; 
TBST- Tris-buffered saline tween; PBS- Phosphate buffered saline. 
*PBS- 1 liter (L) of 1XPBS was prepared by adding 8 g of NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 
0.24 g of KH2PO4 to 800 ml of dH2O and the pH has been adjusted to 7.4 with HCl. Lastly, 
more dH2O was added until the total volume is 1000 ml. The solution was dispensed and 
sterilised by autoclaving at 121ºC for 20 min before stored at room temperature.   
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After removal from the sequenza clips, antibody binding was visualised with 
diaminobenzidine-tetrahydrochloride (DAB, Fluka Chemie AG, Buchs, Switzerland) 
with 0.01% H2O2 (Perhydrol 30% H2O2 P-a, Fisher Scientific) in 0.1 M imidazole 
buffer (pH 7.1, Fluka Chemie AG) in a 10 min incubation at room temperature, 
followed by 3 washes with distilled water for each 5 min. After that, slides were 
counterstained with Papanicolaou’s haematoxylin (Merck) for 1 min and then blued 
in running tap water for 5 min. This was followed by dehydration with ascending 
EtOH (1 min 96%, 2 min 100% and 3 min 100%), clearing in xylene (2 min 100% and 
2 x 3 min 100%) and mounting of cover slips with DPX (BDH brand, VWR 
International).  
 
2.6.3.1 Quantitative analysis of immunohistological stains   
The amount of cleaved caspase 3-positive cells (cytoplasmic staining) was 
semiquantitatively assessed, based on an estimation of the amount of cells with the 
morphology of apoptotic cells and showing a specific cytoplasmic reaction (− no 
positive cells; + scattered positive cells; ++ moderate number of positive cells, and 
+++ numerous positive cells).  
PCNA expression was seen as a nuclear reaction in late G1 phase (faint, stippled) 
and S phase (intense, uniform) and/or as a cytoplasmic reaction in the G2 phase 
(stippled, with or without nuclear reaction) and M phase (diffuse reaction, 
combined with mitotic figures), as previously described (Eldrige et al., 1993). For the 
quantification of PCNA positive, proliferating cells, ten random fields (at 200x 
magnification), i.e. non-overlapping areas comprising a minimum of 1,000 
hepatocytes, were analysed for each liver. A photomicrograph was taken for each of 
the 10 random areas for each individual mouse liver, using a Zeiss Axio Imager M2 
microscope (Carl Zeiss Ltd, Gottingen, Germany). The total number of hepatocytes, 
the number of hepatocytes with cytoplasmic PCNA expression, and the total 
number of PCNA positive hepatocytes (nuclear and/or cytoplasmic reaction) were 
counted. The mean percentage and standard deviation were calculated for the cells 
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expressing overall (nuclear and cytoplasmic) PCNA, and the cells showing a 
cytoplasmic PCNA expression. 
 
2.7 Assessment of cytokine expression in serum, liver and spleen 
2.7.1  Measurement of serum cytokine levels by ELISA 
For the determination of TNF-α and IL-6 levels in the serum, commercial mouse 
TNF-α (MTA00B) and IL-6 (M6000B) ELISA assay kits (R&D Laboratories Systems Inc., 
Abingdon, UK) were used. Mouse kit control, wash buffer and standard solution 
were prepared according to the manufacturer’s protocol. The standard was added 
with calibrator diluent to prepare serial dilutions and the diluent calibrator served 
as 0 pg/ml for blank. Assay diluent (50 µl) provided with the kit was added to each 
well, followed by 50 µl of the standard, control or serum sample. Plates were 
vortexed gently on a shaker to avoid protein degradation. The plate was covered 
with a sheet of sealing tape to prevent liquid escaping from the wells and was then 
incubated for 2 hours at room temperature. Subsequently, the sealing tape was 
removed and discarded. Wash buffer (100 µl) was added to each well with a squirt 
bottle for 5 times, inverting the plate and blotting excess liquid in between on a 
clean paper towel. Subsequently, 100 µl of conjugate was added to each well which 
was then covered with a new adhesive strip and incubated at room temperature for 
2 hours. During the incubation period, the substrate solution was prepared within 
15 min of use to minimise light exposure. After careful removal of the sealing tape 
and further washing with wash buffer for 5 times, 100 µl substrate solution was 
added and the plate incubated for 30 min while covered with clean paper towel to 
avoid light exposure. Finally, stop solution (100 µl) was added to each well and the 
plate gently tapped to ensure thorough mixing. The optical density of each well was 
determined within 30 min using a microreader Luminex 100 System set to set to 
540 nm or 570 nm. The lowest protein concentration of the assay that can be 
detected is 7.21 pg/mL for TNF-α and 1.8 pg/mL for IL-6 (obtained from 
manufacturer guideline). Levels below these were assigned a value of zero. 
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2.7.2 Determination of cytokine transcription levels in liver and spleen 
2.7.2.1  RNA extraction  
For RNA extraction, frozen liver and spleen specimens with a weight of 
approximately 50-100 mg were placed in an RNAse-free microtube (1.5 ml). 200 µl 
of Trizol reagent (Sigma-Aldrich) was added and the tissue was homogenised 
thoroughly with a homogeniser (Retsch® MM400, ThermoFisher Scientific, 
Loughborough, UK) with frequency of 30/sec for 1 min. A further 800 µl of Trizol 
reagent was added after full homogenisation was achieved by passing the lysate 
through a pipette tip. The samples were then incubated at room temperature for 5 
min to permit dissociation of nucleoprotein complexes. Each tube was vigorously 
shaken by hand for 15 sec and then 200 µl of chloroform added to each tube. The 
tubes were left to incubate for 2 min at room temperature and then spun for 15 
min (12,000 x g, 4°C) to separate the solution into an RNA-containing aqueous 
phase and an organic phase containing DNA and protein. The aqueous phase was 
then placed into a new 1.5 ml microtube and the other phase discarded. 
Subsequently, 500 µl of 100% isopropyl alcohol (IPA) was added and the solution 
incubated for 10 min at room temperature until a white top layer had formed. After 
that, samples were spun for 10 min (12,000 x g, 4°C). The supernatant was discarded 
after which the RNA precipitated in a gel-like pellet on the side and bottom of the 
tube. Pre-chilled (-20°C) 75% EtOH [75 ml EtOH and 25 ml nuclease-free H2O) was 
added to each tube which was then agitated for 15 sec and spun for 5 min (7,500 x 
g, 4°C). The supernatant was again discarded thoroughly and the pellet was allowed 
to air dry for a minimum of 5-10 min. Finally, the dried pellet was dissolved in 
approximately 50 µl to 100 µl of nuclease-free H2O, the amount is depending on the 
size of the pellet obtained. The RNA was stored at -80°C until DNase treatment was 
performed later.  
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2.7.2.2 DNase treatment  
An Ambion DNA-free kit (Life Technologies, Paisley, UK) was used to eliminate DNA 
contamination in the RNA extracts and to obtain pure RNA. To each tube containing 
44 µl RNA solution, 5 µl of 10x DNase buffer and 1 µl of 2U rDNase I were added. 
The tubes were spun at 3,000 rpm (500 g) for 10 sec to remove any bubbles and 
then placed on a heating block at 37°C for 30 min. After that, 5 µl of DNase 
inactivation reagent was added to each tube which was then agitated gently to mix. 
The tubes were incubated at room temperature for 2 min, followed by 
centrifugation for 1 min (14,000 rpm or 11,000 g) at room temperature. The 
resultant supernatant was transferred into new RNase-free tubes (2 ml) and stored 
at -80°C until reverse transcription (RT) was performed. From each RNA sample, an 
aliquot of supernatant was used to quantify the RNA with a ND 1000 
spectrophotometer (Nanodrop; ThermoFisher Scientific). Samples with good quality 
RNA values (A260/280 ratio of 1.8-2.1 only) were reverse transcribed later. Samples 
with low quality RNA were not used because it may contain contaminants such as 
proteins that interfere with the RNA purity. Therefore, RNA was re-extracted from 
the liver samples until good RNA quality was achieved.  
 
2.7.2.3 Reverse transcription (RT)  
The ImProm-II reverse transcriptase kit and Oligo(dT)16 (Promega, Southampton, 
UK) were used to synthesise cDNA from the total DNA-free RNA. 2.5 µg of DNA-free 
RNA was incubated with 1 µl of 0.5 µg/µl Oligo(dT)16 and nuclease-free H2O (total 
volume of 25 µl) at 70°C for 5 min. The samples were put on ice and the remaining 
RT components were added: 10 µl of 5x RT buffer, 8 µl 25 mM MgCl2, 1 µl of 10 mM 
dNTPs, 2.5 µl of 10x reverse transcriptase and 3.5 µl nuclease-free H2O (final volume 
of 50 µl). For each sample, “no RT” reactions (without RT and dNTPs) were included 
as negative control. The samples were then incubated in a GeneAmp PCR System 
9700 (ThermoFisher Scientific, Loughborough, UK) at 25°C for 5 min, followed by 1 
hour at 42°C, then 15 min at 70°C and holding at 4°C. After that, 200 µl of nuclease 
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free-H2O was added to each tube to achieve a cDNA concentration of 10 ng/µl and 
the cDNA was stored at -20°C until the PCR was performed. 
  
2.7.2.4 Conventional PCR  
Conventional PCR was performed for the detection of DNA amplification products in 
agarose gel electrophoresis on selected primers to ensure the PCR has worked. 
Primers were selected to detect TNF-α, IL-6, IL-10, cyclin-D1, NF-kB and GAPDH 
mRNA by both the conventional and the qPCR, as listed in Table 2.8. 
The gradient temperature was first run starting from 55 to 65oC (based on 
manufacturer’s datasheet) in order to obtain an optimal annealing temperature 
using the Opticon qPCR machine. After obtaining an optimal temperature (as Table 
2.8), these temperature were used both in the conventional PCR and the real-time 
PCRs.  
 
Table 2.8. Primer sequences for the detection of TNF-α, IL-6, IL-10, cyclin-D1, NF-kB and 
GAPDH by PCR and real-time PCR.  
Target 
Primer sequence 5’-3’ 
(F-forward, R-reverse) 
Reference of primer 
sequence 
Annealing 
temperature 
(oC) 
Product 
length 
(bp) 
TNF-α 
F:CCAGTGTGGGAAGCTGTCTT 
R:AAGCAAAAGAGGAGGCAACA 
(McKallip et al., 2013) 62 100 
IL-6 
F:TAGTCCTTCCTACCCCAATTTCC  
R:TTGGTCCTTAGCCACTCCTTC 
(Sebastian et al., 2011) 62 76 
IL-10 
F:GGTTGCCAAGCCTTATCGGA 
R:ACCTGCTCCACTGCCTTGCT 
(Yin et al., 2014) 60 191 
Cyclin-
D1 
F:CTACCGCACAACGCACTTTC 
R:TAGAAGGCACAGTCGAGG 
(Biliran et al., 2005) 56 960 
NF-kB 
F:CTTGGCAACAGCACAGACC 
R:GAGAAGTCCATGTCCGCAAT 
(Kim et al., 2008b) 65 128 
GAPDH 
F:GTATGACTCCACTCACGGCAAA 
R:GGTCTCGCTCCTGGAAGATG 
(Zhang et al., 2010) 56-62 101 
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Reactions were carried out in 0.2 ml thin walled tubes and with a total reaction 
volume of 50 µl, containing 10 µl of cDNA (see Chapter 2.7.2.3), 10 µl of 10x PCNA 
buffer, 4 µl of 1.5 mM MgCl2, 1 µl of 10 mM dNTP mixture (Invitrogen), 0.2 µl of 2U 
DNA Taq polymerase (Invitrogen), 1 µl of 40 ng each of sense and antisense primers 
and 22.8 µl of nuclease-free H2O. PCR reactions were performed in a Thermo-
Hybaid MBS thermocycler (Thermo Electron Corporation), applying the following 
cycling conditions: 15 min at 95°C, followed by 35 or 45 cycles of 2 min denaturation 
at 95°C, 1 min at the annealing temperature (see Table 2.9) and 2 min extension at 
72°C, and final extension for 5 min at 72°C. PCR products were electrophoresed 
through 2% (w/v) agarose gels (Invitrogen) with 2 µl ethidium bromide (Sigma 
Aldrich) in TAE Buffer [40 mM Tris-base, 20 mM glacial acetic acid, 1 mM EDTA] and 
mixed 5:1 with loading buffer [50% v/v glycerol, 100 mM Tris-HCl pH 7.4, 10 mM 
EDTA, 0.02% w/v orange G]. Electrophoresis was performed in a horizontal 
electrophoresis chamber (Biorad) filled with TAE buffer at 100 V for 30 min. The gel 
was examined under UV light (Ultraviolet Transilluminator, Biorad) and the height 
of the bands from PCR products compared with a 1 kb or 100 bp DNA ladder 
(Invitrogen) that had been loaded alongside the PCR products.  
 
 
2.7.2.5  Quantitative Real time PCR (qPCR) 
The qPCRs were performed with a final volume of 20 µl for each sample, containing 
5 µl cDNA of 10 ng/µl of reversed transcribed total RNA, 0.4 µl of 200 nM of each 
forward and reverse primers for each specific gene (see Table 2.9) and 14.2 µl of 
DNA fluorescent dye SYBR Green JumpStartTM (Sigma-Aldrich). An Opticon Monitor 
3.0 qPCR machine thermocycler (Bio-Rad) was used, with the cycling conditions 
provided in Table 2.9. TNF-α, IL-6, NF-kB and GAPDH were run for 35 cycles and 
cyclin-D1 and IL-10 were quantified at 45 cycles. 
  
Chapter 2 
62 
 
Table 2.9. Cycling condition, temperature and time used for qPCR analysis. 
Cycling condition Cycle temperature Time (min) 
Pre-denaturation 95°C 2 
Denaturation 95°C 1 
Annealing See Table 2.8 1 
Extension 72°C 2 
Final Extension 72°C 5 
Hold 4°C Infinity 
 
All reactions were performed in duplicates and run alongside reactions for the 
reference gene, GAPDH. The melting curve was created to analyse the specificity of 
the product by measuring the fluorescence at 0.2°C increments, from 65°C to 95°C; 
the amplification efficiency of the reactions provided together with mRNA 
transcription by the Opticon qPCR machine (Bio-Rad) were also taken into account. 
Efficiency (E) is the extent of target DNA or PCR product increase after each cycle 
where an ideal reaction reaches an efficiency of up to 100%, with acceptable values 
between 90 to 110% (1.9 to 2.1). Ct value of sample with low E was repeated. Low E 
indicates poor primer design, inappropriate reaction condition, pipetting errors or 
other factors. A negative control was included for each sample (“No RT”, see 
2.7.2.3) to determine if DNA contamination was present.  
Relative quantification was performed. This determines the ratio between the 
amount of target DNA and the reference amplicon, GAPDH. All values quantified 
were normalised to the reference gene, GAPDH, and then the calculations are made 
to obtain fold change by the delta-delta Ct (2-ΔΔCt) formula that also referred to 
comparative Ct value relative to control animals (reference sample) as calculations 
below (Schmittgen and Livak, 2008). The transcription values were also compared 
between fed and fasted animals.  
 
Delta Ct    = Ct (target gene) – Ct (reference gene, GAPDH) 
2^-delta Ct (2-ΔCt)    = 2-[Ct (target gene) – Ct (reference gene, GAPDH)] 
 
2^-(delta-delta Ct) [2-ΔΔCt]                 Comparative delta-Ct value (Fold change) 
= 2-(ΔCt (target sample) – ΔCt (reference sample))  =      Target sample 2-ΔCt 
                   Reference sample 2-ΔCt 
35 or 45 
cycles 
or 
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2.8 Statistical analysis 
For statistical analysis of the results, all quantitative values. i.e. values for 
glutathione (GSH) content, serum ALT level, histological grading score, numbers of 
PCNA positive cells, serum cytokine levels, relative cytokine mRNA levels, were 
expressed as mean±standard deviation (SD). Values were analysed for non-
normality using a Shapiro-Wilk test. The unpaired t-test was used when normality 
was indicated, the Mann-Whitney U test used for non-parametric data. Comparisons 
between multiple groups were performed with One-way ANOVA or Two-way 
ANOVA, followed by a post hoc Tukey’s test, but Dunnett’s test was applied to 
compare to controls. If non-normality was indicated, Kruskal-Wallis test was used. 
All calculations were performed using StatsDirect statistical software version 2.7.9, 
results were considered significant when P<0.05 (*P<0.05, **P<0.01, *** P<0.005). 
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3.1 Effect of fasting in saline dosed male CD-1 and C57BL/6J mice 
Mice that had been deprived of food for 16 or 24 hours and mice that had been fed 
ad libitum throughout (i.e. prior and post saline administration) were assessed over 
a 24 hour (CD-1 mice) and 36 hour (C57BL/6J mice) time period to gain information 
on the effect of fasting on liver function and morphology in two different types of 
mice commonly used in DILI studies, out-bred CD-1 and in-bred C57BL/6J mice. 
Several parameters were assessed, including the degree of weight loss, the hepatic 
glutathione (GSH) and ATP levels, the histological features of the liver, the serum 
alanine transaminase (ALT) levels and the expression of inflammatory mediators 
(i.e. cytokines) in liver, spleen and blood as well as the expression of proliferation 
markers (NF-kB and cyclin-D1 mRNA, proliferating cell nuclear antigen) in the liver 
to assess the hepatocellular turnover. These parameters were examined to obtain 
baseline information on features of potential relevance for the effect of hepatotoxic 
drugs. 
 
3.1.1 Effect of fasting on proportion of body weight   
Body weights of mice were determined immediately prior to saline administration, 
i.e. at the end of the fasting period of the fasted mice, and, in the case of the fasted 
mice, also immediately prior to the onset of the fasting period. The body weights of 
fed mice were similar in both strains (Table 3.1.1). After a 16 hour fasting period, all 
mice had lost a proportion of body weight, the extent of which was variable 
depending on the time of day when the animals were first deprived of food (Table 
3.1.2, Figure 3.1.1). Onset of fasting during daytime, afternoon and early evening 
(16:00 to 18:45) led to a mean loss of body weight of just below 10% to almost 12%.  
With an onset of fasting at midnight, it dropped to 8% on average, though the 
difference was not statistically significant. When the fasting period was started later 
in the night (3, 5 or 6 am), the loss of body weight was significantly lower than in 
the afternoon and early evening and at midnight, below 5% (Figure 3.1.1). The least 
extensive body weight loss was observed when the fasting period started at 3 am. 
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Table 3.1.1. Mean body weight (g) of fed male CD-1 and C57BL/6J mice at different times of 
day, immediately prior to saline dosing.  
CD-1 C57BL/6J p-value 
CD-1 vs 
C57BL/6J 
ToD  Mean  SD p-value 
ToD 
killing 
Mean  SD p-value 
16:00 28.5 2.3 
NS 
18:00 28.2 1.5 
NS 
NS 
18:15 28.0 1.7 03:00 29.4 1.0 
18:30 29.6 2.3 05:00 30.2 1.1 
18:45 29.2 1.6 06:00 31.1 1.0 
00:00 29.7 1.9 - - - - 
ToD - time of day; SD - standard deviation; NS - not significant. 
 
 
Table 3.1.2. Mean body weight loss (g), standard deviation and p-value of fasted male CD-1 
and C57BL/6J mice prior and immediately after the fasting period, at different times of day.  
 
Strains ToD fasting* ToD refeeding* n Mean SD p-value 
CD-1 
16:00 08:00 5 9.85 2.00 
vs 3:00; 0.0001 
vs 5:00 & 6:00: 
0.0005 
18:00 10:00 4 10.29 4.32 
C57BL/6J 18:00 10:00 6 11.35 1.53 
CD-1 
18:15 10:15 5 11.14 3.15 
18:30 10:30 4 11.77 1.73 
18:45 10:45 5 10.45 2.59 
00:00 16:00 5 8.08 1.50 vs 3:00; 0.0087 
C57BL/6J 
03:00 19:00 6 3.13 1.02 - 
05:00 21:00 6 4.82 0.80 vs 3:00; 0.0102 
vs 0:00; 0.0027 06:00 22:00 6 4.91 0.92 
ToD - time of day; n – number of animals used; SD - standard deviation;  
* ToD onset of fasting and refeeding, respectively. 
 
 
 
 
 
 
Figure 3.1.1. Percentage of body weight loss in male CD-1 and C57BL/6J mice after fasting, 
in relation to the time of day at the onset of the fasting period. 
The percentage of body weight loss after a 16 h fasting period that had started at different 
times of day is illustrated (as listed in Table 3.1.2). Values are expressed as mean±SD (4 to 6 
animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.1.2    Effect of fasting on hepatic glutathione (GSH) content 
3.1.2.1   Hepatic GSH levels in fed CD-1 and C57BL/6J mice  
Hepatic GSH levels were examined over a 24 hours time period at different times of 
day in male CD-1 and C57BL/6J mice that had been fed ad libitum to determine the 
circadian variation in GSH levels. When hepatic GSH levels were assessed from 
morning to afternoon (10:00 to 15:00), a steady decline was observed in both CD-1 
and C57BL/6J mice. In the evening (20:45 in CD-1 mice or 20:00 in C57BL/6J), levels 
were significantly the lowest (Figure 3.1.2A). If the stress of handling and 
intraperitoneal application of 0.9% saline did have an effect on food uptake and 
thereby GSH levels, this was not apparent from 24 hours onwards, as examination 
of C57BL/6J mice at 24, 30 and 36 hpd, at 10:00 and 14:00, did yield GSH levels 
similar to those previously obtained at the same time of day (Figure 3.1.2B).  
 
 
 
 
 
 
Figure 3.1.2. Hepatic GSH content in fed CD-1 and C57BL/6J mice at different times of day. 
The hepatic GSH content was assessed at different times of the day in male, fed CD-1 (A) 
and C57BL/6J (B) mice that had received 0.9% saline i.p. at different time points prior to 
euthanasia (not shown). Values are expressed as mean±SD (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. ToD - time of day; (+1) – time of day on the following 
day; (+2) – time of day on the next 2 days. 
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A comparison of GSH levels in both groups of mice showed that the hepatic GSH 
content was significantly higher in the C57BL/6J mice at all times including morning, 
midday and evening (Table 3.1.3). 
 
Table 3.1.3. Hepatic GSH levels (nmol/mg) in fed male CD-1 and C57BL/6J mice.  
GSH levels in the liver were determined at different times of day and compared between 
CD-1 and C57BL/6J mice. Values are expressed as mean±SD (4 to 6 animals per group).  
CD-1  C57BL/6J  p-value 
CD-1 vs C57BL/6J ToD killing Mean SD ToD killing Mean SD 
Morning: 
10:30, 
10:55 
 
40.34 
47.36 
 
4.48 
5.75 
Morning: 
10:00, 
11:00, 
10:00 (+1), 
10:00 (+2) 
 
73.57 
83.85 
82.26 
78.46 
 
2.88 
6.65 
5.48 
4.91 
0.0036 
Midday: 
13:00, 
14:00 
 
36.30 
31.11 
 
5.04 
5.00 
Midday:  
12:00, 
14:00, 
15:00 
 
57.16 
64.06 
53.21 
 
9.79 
3.03 
8.86 
 
0.0146 
Evening: 
20:45 
 
20.60 
 
5.13 
Evening: 
20:00 
 
40.12 
 
7.52 
 
0.0357 
  ToD - time of day; SD – standard deviation 
 
3.1.2.2  Hepatic GSH levels in fed and fasted CD-1 and C57BL/6J mice 
Hepatic GSH levels were also examined over a 24 hour (CD-1 mice) and 36 hour 
(C57BL/6J mice) time period and at different times of day in male CD-1 and 
C57BL/6J mice that had been fasted for 16 or 24 hours and then refed for a variable 
length of time (fasted mice). Intraperitoneal application of 0.9% saline was the 
event after which the animals were refed. In both groups of mice, upon completion 
of the fasting period (at 10:00 and 10:30, respectively), the mean hepatic GSH 
content was significantly lower than in the fed mice, though not lower than in the 
evening (20:00 and 20:45, respectively) in the fed mice (Figure 3.1.3A,B).  
 
In CD-1 mice, GSH levels returned to those of fed animals at 1 hour of refeeding. 
Interestingly, they appeared to then rise further and at 10 hours of refeeding, 
reached a peak value almost double of any level in fed mice; this was at 20:00, 
around the time when the level was at the significantly lower minimum circadian 
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level in the evening (20:45). After 24 hours of refeeding, levels had dropped to 
those of fed mice at the same time of day, i.e. in the morning (Figure 3.1.3A). 
 
In C57BL/6J mice, GSH levels were still low after 5 hours of refeeding, but increased 
dramatically thereafter. They were already higher at 10 hours, though not 
significantly, and peaked at 15 hours of refeeding, when they were significantly 
higher than in the fed animals at the same time of day (12:00). Levels subsequently 
dropped and, at 24 hours of refeeding, were significantly lower than in fed animals; 
at 36 hours, they were similar to those in fed mice (Figure 3.1.3B). 
 
 
CD-1 
 
 
 
Figure 3.1.3. Hepatic GSH content in male CD-1 and C57BL/6J mice that had been fed or 
fasted for 16 or 24 h and then refed for variable time spans.  
Both the time of day (ToD) of refeeding (and saline dosing) and of killing are provided to 
highlight any effect of fasting, the length of refeeding (0 - 24 h) and the time of day on 
hepatic GSH levels. Values are expressed as mean±SD (4 to 6 animals per group). 
**P<0.005, **P<0.01 and *P<0.05. 
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3.1.3 Effect of fasting on hepatic ATP levels 
The hepatic ATP content was determined to study the effect of fasting on the 
hepatic energy content. In fed CD-1 mice, ATP levels did not vary much over the 24 
hour time period, and there was not much variation between individual animals 
(Table 3.6). After 16 and/or 24 hours of fasting, the ATP content was reduced by 
almost 90% and increased only minimally within the first hour of refeeding. By 3 
hours, the ATP content had increased significantly and reached a peak (at 
approximately 50% of the levels in fed mice) after 5 hours of refeeding, before it 
dropped again at 10 hours and 15 hours and increased thereafter. However, by 24 
hours, the hepatic ATP content was still only at approximately 50% of the level in 
fed CD-1 mice (Table 3.1.4, Figure 3.1.4A,B).  
Table 3.1.4. Hepatic ATP levels (nmol/mg) in fed and fasted CD-1 mice at the different time 
points post saline application.  
hps – hours post saline (and onset of refeeding); SD - standard deviation; NS - not 
significant. 
 
 
Hepatic ATP levels were also assessed in C57BL/6J mice at selected time points. In 
fed C57BL/6J mice, ATP levels did not vary much either (Table 3.1.5); however, they 
were overall 16.3% lower than in the fed CD-1 mice (Figure 3.1.4E). The early time 
points after the onset of refeeding were not available for the fasted mice, however, 
over the examined time period (5-36 hours of refeeding), a steady increase in ATP 
levels was observed, with significant differences between the time points (Table 
3.1.5). Different from the CD-1 mice which did not only show a significant drop in 
Time 
(hps) 
Fed Fasted 
p-value fed 
vs fasted Mean SD 
p-value  
fed vs fed 
Mean SD 
p-value  
fasted vs fasted 
0 35.4 2.0 
NS 
4.2 2.6 
3 h: 0.0375 
5 h: 0.0405 
0.0005 
0.5 31.3 3.1 4.1 2.7 0.0011 
1 32.1 5.6 5.3 3.7 0.0003 
3 25.9 4.9 11.0 1.2 10 h: 0.0431 0.0057 
5 35.5 4.0 17.1 5.3 15 h: 0.0337 0.0082 
10 30.2 6.4 13.7 1.4 5 h: 0.012 0.0094 
15 32.7 1.8 10.3 4.1 10 h: NS 0.0060 
20 31.8 3.4 14.7 2.3 
0, 0.5, 1 h: 0.0058 
0.0091 
24 33.1 2.1 16.4 3.7 0.0059 
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the otherwise rising ATP levels at 15 hours of refeeding, the fasted C57BL/6J mice 
had reached ATP levels similar to those of fed mice by 20 hours of refeeding (Table 
3.1.5, Figure 3.1.4C,D). The difference in the ATP level was statistically significant in 
comparison to the fasted CD-1 mice at the same time point (Table 3.1.5 and Figure 
3.1.4F). 
 
 
Table 3.1.5. Hepatic ATP levels (nmol/mg) in fed and fasted C57BL/6J mice at the different 
time points post saline application and comparison to time matched CD-1 mice.  
hps – hours post saline (and onset of refeeding); SD-standard deviation, NS- not significant. 
 
  
Time 
(hps) 
Fed Fasted 
p-value fed 
vs  fasted 
C57BL/6J Mean SD 
p-value 
vs. fed 
C57BL/
6J 
p-value 
vs. fed 
CD-1 
Mean SD 
p-value vs. 
fasted 
C57BL/6J 
p-value 
vs. 
fasted 
CD-1 
5 24.6 5.2 
NS NS 
12.8 3.5 20 h: 0.0211 
36 h: 0.0358 
NS 0.0265 
10 28 4.53 13.95 2.33 NS 0.0173 
15 - - 19.55 1.63 
5 &10 h: 
0.0403 
NS - 
20 30.2 3.25 25.2 3.25 5 h: 0.0221 0.009 NS 
30 26.75 2.33 - - - - - 
36 24.48 5.26 28.15 4.6 - - - 
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Figure 3.1.4. Hepatic ATP levels in saline dosed male CD-1 and C57BL/6J mice.   
Hepatic ATP levels in fasted male CD-1 (A) and C57BL/6J (C) mice and comparison to ATP 
levels in fed mice (C, D). The hepatic ATP contents were also compared between fed (E) and 
fasted (F) CD-1 and C57BL/6J mice (as listed in Table 3.1.4 and 3.1.5). Values are expressed 
as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.1.4 Effect of fasting on hepatic GSH and ATP contents  
We found both hepatic ATP and GSH depleted after the fasting period (see Chapter 
3.1.2 and 3.1.3) and wanted to investigate whether there is evidence that the GSH 
depletion is a consequence of the ATP loss, because a previous study reported that 
glutathione depletion is inhibited by mitochondrial ATP (Lu, 1999). The values of 
fasted mice were normalised to time-matched fed mice and the fold change 
determine as a means to assess whether the GSH or ATP levels were upregulated 
(>1.0) or downregulated (<1.0) after refeeding. In fasting CD-1 mice, the ATP 
content was reduced throughout the observation period. We observed an increase 
in hepatic GSH levels at 1 and 4 hps (without significant difference) and a significant 
increase at 10 hours of refeeding compared to fed mice (Table 3.1.6, Figure 3.1.5A). 
Similarly, the hepatic ATP of fasted C57BL/6J mice was always decreased at 4, 10 
and 20 hps compared to fed mice, whereas the GSH level was still low at 4 hps but 
then increased at 10 to 36 hours of refeeding (except 24 hours), though no 
significant differences between GSH and ATP levels except at 10 hps (Table 3.1.6). 
 
Table 3.1.6. Hepatic GSH and ATP content after fasting in CD-1 and C57BL/6J mice. Fold 
changes were determined by dividing the values of fasted with time-matched fed mice.  
Time 
(hps) 
CD-1 
GSH (mean) Fold 
change 
ATP (mean) Fold 
change 
p-value 
Fed Fasted Fed Fasted 
0 31.1 20.3 0.65 35.4 4.2 0.12 NS 
1 40.3 41.3 1.02 32.1 5.3 0.17 NS 
4 36.3 47.7 1.32 35.5 17.1 0.48 NS 
10 20.6 85.4 4.14 30.2 13.7 0.45 0.007 
15 - - - 32.7 10.3 0.31 - 
20 - - - 31.8 14.7 0.46 - 
24 47.7 55.9 1.18 33.1 16.4 0.50 NS 
Time 
(hps) 
C57BL/6J 
GSH (mean) Fold 
change 
ATP (mean) Fold 
change 
p-value 
Fed Fasted Fed Fasted 
0 73.57 42.07 0.57 - - - - 
4 83.9 38.2 0.46 24.6 12.8 0.52 NS 
10 40.1 81.38 2.03 28 14.0 0.50 0.047 
15 57.2 125.29 2.19 - 19.6 - - 
20 53.2 75.3 1.42 30.2 25.2 0.83 NS 
24 82.3 38.23 0.46 - - - - 
36 78.46 87.98 1.12 24.48 28.15 1.15 NS 
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Figure 3.1.5. Hepatic GSH and ATP content (fold changes in comparison to fed mice) in male 
CD-1 and C57BL/6J mice.  
Hepatic GSH and ATP levels were compared after fasting in male CD-1 (A) and C57BL/6J (B) 
mice at different times of day (ToD) (as listed in Table 3.1.6). Values are expressed as 
mean±SD (4 to 6 animals per group). **P<0.01 and *P<0.05. Fold change= 1: levels in saline 
dosed fed mice. 
 
 
3.1.5 Effect of fasting on serum alanine-aminotransferase (ALT) levels  
Serum alanine-aminotransaminase (ALT) levels were determined in fed and fasted 
CD-1 and C57BL/6J mice over a 24 hour (CD-1 mice) and 36 hour (C57BL/6J mice) 
time period and at different times of day to observe if fasting promotes serum ALT 
release from the liver. 
In fed CD-1 mice, ALT levels varied markedly between individuals at most time 
points, with a maximum standard deviation of more than 60 U/L (Table 3.1.7 and 
individual data in Table 6.6), ranging from a minimum of 13 U/L to a maximum of 
198 U/L. Despite the high variance also between average ALT levels at different 
times of day (and post saline application), these differences were never significant. 
Also in fasted animals, from which samples were taken at the end of the fasting 
period and after 5 hours and 24 hours of refeeding, marked interindividual variation 
was observed (Table 3.1.7) and there was no significant difference between ALT 
levels at the different time points post fasting. Interestingly, however, ALT levels 
were significantly lower immediately after fasting than with feeding at libitum, and 
after 24 hours of refeeding they were significantly higher (Figure 3.1.6A). 
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Table 3.1.7. Serum ALT levels (U/L) in fed and fasted male CD-1 mice. 
Serum ALT enzyme activities are shown together with the number of animals examined at 
the different time points post saline application (and refeeding of the fasted animals).  
Time 
(hps) 
ToD 
dosing 
ToD 
killing 
n 
Fed Fasted p-value fed 
vs fasted Range Mean (SD) Range Mean (SD) 
0 10:00 10:00 6 45-98 68.33 (20.12) 12-58 41.5 (16.1) 0.042 
1 09:30 10:30 4 22-70 51.63 (21.83) - - - 
2 09:30 11:30 4 13-90 40.98 (34.69) - - - 
4 10:00 13:00 4 20-50 31.17 (13.64) - - - 
5 10:00 15:00 6 35-198 78.0 (60.84) 14-85 49.8 (27.5) NS 
8 10:00 18:00 4 14-39 22.55 (10.97) - - - 
24 10:00 
10:00 
(+1) 
6 22-37 27.5 (5.39) 36-109 63.2 (22.5) 0.033 
hps - hours post saline (and onset of refeeding); ToD - time of day; n - number of mice per 
group; SD - standard deviation; NS – not significant. 
 
Both in fed and fasted C57BL/6J mice, ALT values were less variable (Table 3.1.8) 
and significantly lower than in the CD-1 mice (Figure 3.1.6B) throughout the 
experiments. Fasting was not associated with significant changes in ALT levels in the 
C57BL/6J mice at any time point (Table 3.1.8). 
 
Table 3.1.8. Serum ALT levels (U/L) in fed and fasted C57BL/6J mice. 
Serum ALT enzyme activities are shown together with the number of animals examined at 
the different time points post saline application (and refeeding of the fasted animals).  
Time 
(hps) 
ToD 
dosing 
ToD 
killing 
n 
Fed Fasted 
p-
value 
fed vs 
fasted 
Range 
Mean 
(SD) 
p-
value 
vs 
CD1 
Range 
Mean 
(SD) 
p-
value 
vs 
CD1 
5 10:00 15:00 5 10-35 
14.92 
(10.41) 
NS 10-22 
11.67 
(7.16) 
NS 
NS 
10 10:00 20:00 5 20-36 
29.75 
(8.66) 
- 20-38 
36.03 
(8.66) 
- 
15 17:00 
8:00 
(+1) 
5 19-29 
22.88 
(6.70) 
- 18-33 
29.85 
(7.6) 
- 
20 11:00 
7:00 
(+1) 
5 20-35 
28.00 
(7.24) 
- 19-26 
24.59 
(2.90) 
- 
24 10:00 
10:00 
(+1) 
5 7-20 
8.49 
(7.28) 
NS 12-25 
12.39 
(6.81) 
NS 
36 7:00 
19:00 
(+2) 
5 10-27 
15.78 
(7.24) 
- 19-33 
26.00 
(5.61) 
- 
hps - hours post saline; ToD - time of day; n - number of mice per group; SD - standard 
deviation; NS - not significant. 
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A comparison of ALT enzyme activities between CD-1 and C57BL/6J mice did not 
reveal any significant differences in either fed or fasted animals at the examined 
time points (data not shown). Overall, the serum ALT levels of all time points were 
not significantly different between CD-1 and C57BL/6J mice, both fed and fasted 
mice (Table 3.1.9, Figure 3.1.6C).   
 
 
 
 
 
                    
 
Figure 3.1.6. Serum ALT levels in fed and fasted CD-1 and C57BL/6J mice.   
Serum ALT levels in male CD-1 (A) and C57BL/6J (B) mice at different times of day as listed 
respectively in Tables 3.1.7 and 3.1.8. (C) Pooled serum ALT levels were used for the 
comparison of ALT levels in fed and fasted CD-1 and C57BL/6J mice (as listed in Table 3.1.9). 
Animals had received 0.9% saline i.p., after which time point the fasted animals were fed ad 
libitum again. Values are expressed as mean±SD (4 to 6 animals per group). *P<0.05. hps- 
hour post saline dosing; ToD – Time of day. 
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Table 3.1.9. Pooled serum ALT levels (U/L) at all time points in saline dosed CD-1 and 
C57BL/6J mice. 
 
Condition of 
mice 
Strains p-value  
CD-1 vs 
C57BL/6J 
CD-1 C57BL/6J 
Mean SD Mean SD 
Fed 45.73 23.93 19.97 7.92 NS 
Fasted 51.17 23.56 23.42 6.46 NS 
           SD - standard deviation; NS – not significant. 
 
3.1.6    Effect of fasting on histological features and hepatocellular glycogen content 
A histological examination was performed on the liver of the different groups of 
mice. This did not reveal any histological abnormalities in any of the fed or fasted 
mice at any time points. In particular, there was also no evidence of hepatocellular 
degeneration or death. In fed animals and after refeeding, hepatocytes exhibited 
the typical cloudy cytoplasmic vacuolation indicative of glycogen accumulation 
(Figure 3.1.7). Staining of the livers for the presence of glycogen, using the PAS 
reaction, confirmed these findings. In both CD-1 and C57BL/6J mice examined 
immediately after completion of the 16 or 24 hour fasting period cytoplasmic 
vacuolation of hepatocytes was not apparent; this indicated the absence of 
glycogen accumulation and corresponded to the completely negative PAS reaction, 
providing evidence of complete glycogen depletion (Figure 3.1.7). 
After only 0.5 hours of refeeding, there was morphological evidence of glycogen 
restitution. This was evident by a variable number of random individual PAS-
positive hepatocytes in CD-1 mice (Figure 3.1.8A), whereas a weak diffuse PAS 
reaction was seen in C57BL/6J mice (Figure 3.1.8B). The latter was apparent in the 
CD-1 mice after 1 hour of refeeding (Figure 3.1.8C), at which time glycogen 
accumulation appeared to be fully restored in the C57BL/6J mice (Figure 3.1.8D). At 
4 hours of refeeding, full glycogen restitution was also apparent in the CD-1 mice. 
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Figure 3.1.7. Histological features and glycogen content in fed and fasted CD-1 and 
C57BL/6J mice. HE stain and PAS reaction. 
A-D: Fed mice. Cytoplasmic vacuolation of all hepatocytes is seen in the HE-stained section 
(A, B) and the PAS reaction (C, D) confirms the presence of diffuse glycogen in both CD-1 (A, 
C) and C57BL/6J (B, D) mice. E-H: Fasted mice. Immediately after completion of the 16 hour 
fasting period, the cytoplasmic vacuolation is not apparent in the HE stained sections (E, F), 
and the PAS reaction (G, H) confirms the complete lack of glycogen in both CD-1 (E, G) and 
C57BL/6J (F, H) mice. 400x (HE) and 200x (PAS) magnification. 
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Figure 3.1.8. Hepatocellular glycogen content in CD-1 and C57BL/6J mice that have been 
refed for 30 and 60 minutes. PAS reaction. 
A, B. After 0.5 hour refeeding, random individual PAS-positive hepatocytes (black arrows) 
are seen in CD-1 mice (A), indicating some glycogen restitution. In C57BL/6J mice (B), the 
PAS reaction indicates diffuse low level glycogen accumulation. C, D. After 1 hour of 
refeeding, the PAS reaction indicates patchy glycogen restitution in CD-1 mice (C) and 
diffuse, complete glycogen restitution in C57BL/6J mice (D). 200x magnification. 
 
 
 
3.1.7 Effect of fasting on cytokine expression 
In an attempt to establish whether fasting has an effect on the hepatic and splenic 
transcription of cytokines that are responsible for the priming of hepatocytes for 
proliferation, TNF-α, IL-6, and IL-10 mRNA levels were determined in liver, the TNF-
α and IL-6 mRNA levels in the spleen of mice that have been fed or fasted prior to 
saline dosing. Serum TNF-α and IL-6 levels were also determined in order to detect 
a potential systemic inflammatory effect of fasting.  
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3.1.7.1 Hepatic transcription of TNF-α, IL-6 and IL-10 
In order to assess the (constitutive) hepatic transcription of hallmark cytokines that 
are involved in inflammatory and/or regenerative processes in the liver, TNF-α, IL-6 
and IL-10 mRNA levels were determined in the liver of both fed and fasted saline 
dosed control CD-1 (Table 6.7) and C57BL/6J (Table 6.8) mice at different times of 
day and at different time points of refeeding (0-24 hours). Relative transcription of 
the cytokines was assessed, using GAPDH as a housekeeping gene to obtain the 
delta Ct values (2-ΔCt), and assess the fold change by comparative Ct value method 
(2-ΔΔCt). The cytokine values obtained from fasted mice were normalised to those of 
time-matched fed mice to determine the fold change of mRNA levels after fasting. 
The transcription of a given cytokine was considered as upregulated when a value 
of >1.0 was obtained for the fasted mice, whereas it was considered as 
downregulated when the value was <1.0. 
All three cytokines were found to be transcribed in the liver, at very low level for IL-
10 and slightly higher levels for IL-6 for both CD-1 and C57BL/6J mice. However, 
TNF-α seem to transcribe higher than those in C57BL/6J mice (Figure 3.1.9, Tables 
6.7: CD-1 and 6.8: C57BL/6J mice).  
Showing the fold changes in transcription levels after fasting confirms that fasting 
did not result in a significant change of TNF-α, IL-6 and IL-10 transcription at any 
time point in CD-1 and C57BL/6J mice (Figure 3.1.10).  
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Figure 3.1.9. Hepatic TNF-α, IL-6 and IL-10 transcription in saline dosed CD-1 and C57BL/6J 
mice (delta Ct value). 
TNF-α, IL-6 and IL-10 mRNA levels were determined in fed and fasted male CD1 and 
C57BL/6J mice at 0, 1, 4 and 24 h post 0.9% i.p. saline administration and compared using 
delta CT values (2-ΔCt). Data is given as mean±SD (4 to 6 animals per group).  
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Table 3.1.10. Relative transcription levels of TNF-α, IL-6 and IL-10 in CD-1 and C57BL/6J 
mice using the comparative Ct value method (fold change). Statistical analysis did not 
identify any significant differences between or within the groups for all examined cytokines.   
hps – hours post saline (and refeeding); NS – not significant. 
 
 
 
 
Figure 3.1.10. Hepatic TNF-α, IL-6 and IL-10 transcription in fasted saline dosed CD-1 and 
C57BL/6J mice (fold change method). 
Hepatic TNF-α (A), IL-6 (B) and IL-10 (C) mRNA levels were compared between male CD-1 
and C57BL/6J mice at 0, 1, 4 and 24 h post 0.9% i.p. saline administration. Hepatic mRNA 
levels are calculated using the comparative Ct values, assessing the fold change of fasted 
mice relative to time-matched fed saline dosed animals (2-ΔCt fasted/2-ΔCt fed). Data is given 
as mean±SD (4 to 6 animals per group). Fold change 1 = levels in fed dosed control mice 
indicated by dashed lines. There is no statistically significant difference in the cytokine 
levels between CD-1 and C57BL/6J mice at any time points.    
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0 1.65 1.92 
NS 
0.39 0.44 
NS 
0.35 0.67 
NS 
1 2.13 1.39 1.34 0.85 1.93 0.86 
4/5 1.78 0.51 0.95 1.34 1.75 1.24 
10 0.91 1.95 0.83 0.80 1.28 0.69 
24 0.49 0.76 0.69 1.71 0.44 1.33 
 Chapter 3.1 
86 
 
3.1.7.2  Splenic transcription of TNF-α and IL-6  
In order to gather data on the constitutive transcription of the inflammatory 
cytokines TNF-α and IL-6 as indicators of a systemic inflammatory response, the real 
time qPCR for both cytokines was also applied to the spleen. Both cytokines were 
found to be transcribed at a higher level in the spleen than in the liver, but without 
significant quantitative differences between fed and fasted CD-1 (Table 3.1.11) and 
C57BL/6J (Table 3.1.12) mice.   
 
 
Table 3.1.11. Comparison of mRNA transcription levels (2-ΔCt) and fold change (2-ΔCt fasted/2-
ΔCt fed) of TNF-α and IL-6 in the spleen of fed and fasted male CD-1 mice over a 24 h time 
period after i.p. application of 0.9% saline (and refeeding).  
hps – hours post saline (and refeeding); ToD – time of day; SD – standard deviation; NS – 
not significant. 
 
 
 
Table 3.1.12. Comparison of relative transcription levels (2-ΔCt) and fold change (2-ΔCt 
fasted/2-ΔCt fed) of TNF-α and IL-6 in the spleen of fed and fasted male C57BL/6J mice over a 
24 h time period after i.p. application of 0.9% saline (and refeeding). 
Time of day of dosing was at 10:00 and of killing at 15:00 (5 h) and 10:00 (+1) (24 h) for 
both fed and fasted mice. hps – hours post saline (and refeeding); NS – not significant. 
 
 
  
Time 
(hps) 
ToD 
dosing 
ToD 
killing 
TNF-α IL-6 
Fed Fasted 
Fold 
change 
p-value Fed Fasted 
Fold 
change 
p-value 
0 14:00 14:00 0.115 0.101 0.878 NS 0.054 0.01 0.185 NS 
1 09:30 10:30 - 0.071 - - - 0.038 - - 
10 10:45 20:45 0.031 0.050 1.61 NS 0.024 0.033 - - 
24 10:55 
10:55 
(+1) 
0.024 0.017 0.708 NS 0.024 0.028 1.17 NS 
Time 
(hps) 
TNF-α IL-6 
Fed Fasted 
Fold 
change 
p-value 5 
vs 24 h 
p-value 
to CD-1 
Fed Fasted 
Fold 
change 
p-value 5 
vs 24 h 
p-value 
to CD-1 
5 0.0081 0.0037 0.46 
NS 
- 0.0083 0. 0034 0.42 
NS 
- 
24 0.0012 0.0016 1.13 0.032 0.0064 0.0059 0.92 NS 
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3.1.7.3  Serum TNF-α and IL-6 levels  
TNF-α and IL-6 levels were determined in the serum using mouse ELISA 
immunoassay kits at different time points up to 36 hours post saline application 
(and refeeding) in C57BL/6J mice, and at 5 and 24 hours in CD-1 mice. Fasted mice 
had been deprived of food for 16 and/or 24 hours prior to refeeding. In all mice, 
both cytokines were detected in the blood at very low levels. These did not differ 
significantly between fed and fasted mice at any time point (CD-1 mice: Table 
3.1.13, Figure 3.1.11A,C; C57BL/6J mice: Table 3.1.14; Figure 3.1.11B,D). 
 
 
Table 3.1.13. Serum TNF-α and IL-6 levels (pg/mL) in fed and fasted CD-1 mice. 
Comparison of serum TNF-α (A) and IL-6 (B) levels in fed and fasted mice at 5 and 24 h post 
i.p. application of 0.9% saline (and refeeding).  
hps – hours post saline; ToD – time of day; SD – standard deviation; NS – not significant. 
 
 
 
Table 3.1.14. Serum TNF-α and IL-6 levels (pg/mL) in saline dosed C57BL/6J mice. 
Comparison of serum TNF-α and IL-6 levels in fed and fasted control mice at 5 h and 24 h 
post i.p. application of 0.9% saline (and refeeding).  
hps – hours post saline; ToD – time of day; SD – standard deviation; NS – not significant. 
  
Time  
(hps) 
ToD 
dosing 
ToD  
killing 
TNF-α IL-6 
Mean (SD) p-value 
fed vs 
fasted 
Mean (SD) 
p-value fed 
vs fasted Fed Fasted Fed Fasted 
5 10:00 15:00 51.4 (12.4) 57.1 (13.3) NS  25.4 (6.7) 23.1 (4.1) NS  
24 10:00 10:00 (+1) 45.8 (6.4) 63.1 (19.7) NS  30.1 (2.1) 27.49 (12.6) NS  
p-value  
5 vs 24 h 
  NS NS  NS NS  
Time 
(hps) 
ToD   
dosing 
ToD  
killing 
TNF-α IL-6 
Mean (SD) p-value fed 
vs fasted 
Mean (SD) p-value fed 
vs fasted Fed Fasted Fed Fasted 
5 10:00 15:00 3.3 (2.1) 11.3 (6.3) NS 28.5 (1.9) 19.86 (2.7) NS 
10 10:00 20:00 11.8 (2.8) 26.3 (5.9) NS 23.2 (5.2) 15.6 (4.6) NS 
15 17:00 08:00 14.6 (3.2) 21.3 (8.1) NS 25.6 (4.6) 21.5 (3.2) NS 
20 11:00 07:00 15.5 (2.0) 13.8 (2.0) NS 27.5 (3.2) 19.5 (5.9) NS 
24 10:00 
10:00 
(+1) 
3.6 (4.3) 20.3 (5.1) NS 14.2 (3.8) 24.5 (8.1) NS 
30 9:00 
15:00 
(+1) 
7.3 (1.2) - - 17.1 (1.0) - - 
36 7:00 
19:00 
(+2) 
10.0 (0.3) 25.4 (5.7) NS 20.3 (0.6) 16.9 (2.9) NS 
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A. TNF-α CD-1                     B.  TNF-α C57BL/6J 
      
 
   
 
Figure 3.1.11. Serum TNF-α and IL-6 levels in fed and fasted CD-1 and C57BL/6J mice. 
Cytokine levels were determined in fed and fasted male CD-1 (A, C) and C57BL/6J (B, D) 
mice at 5 and 24 h (CD-1 mice) and 5 to 36 h (C57BL/6J mice) post 0.9% i.p. saline 
administration. Data is given as mean±SD (4 to 6 animals per group). There is no statistically 
significant difference in the cytokine levels of both groups at each time point.   
 
 
However, a comparison of serum TNF-α and IL-6 levels between CD-1 and C57BL/6J 
mice showed that the TNF-α levels of the fed and fasted CD-1 mice were 
significantly higher than those of C57BL/6J mice at both tested time points (5 and 
24 hours) but the IL-6 levels were similar in both strains (Table 3.1.15). 
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Table 3.1.15. Comparison of serum TNF-α and IL-6 levels (pg/mL) in fed and fasted CD-1 
and C57BL/6J mice. The levels were determined in fed and fasted mice at 5 and 24 h post 
i.p. application of 0.9% saline (and refeeding).  
 
     hps – hours post saline; ToD – time of day; NS – not significant. 
 
3.1.8 Effect of fasting on hepatocellular proliferation  
3.1.8.1 Assessment of NF-kB and cyclin-D1 transcription levels as markers of 
hepatocellular proliferation 
The constitutive transcription of NF-kB, a transcription factor that is strongly linked 
with hepatic regenerative processes, and cyclin-D1 as a marker of proliferating 
hepatocytes in the G phase (Bhushan et al., 2014; Fausto, 2000), were determined 
in the liver of both fed and fasted saline dosed control CD-1 and C57BL/6J mice at 
different times of day and at different time points of refeeding (0-24 hours). The 
relative transcription of both markers was assessed using GAPDH as a housekeeping 
gene, by the delta Ct value, 2-ΔCt. Overall, CD-1 mice showed higher NF-kB and lower 
cyclin-D1 transcription levels than C57BL/6J mice. Also, fasting seemed to have no 
change on the expression of both markers at any time points, as transcription levels 
were generally similar (Figure 3.1.12A-D).  
To compare the effects of fasting on the transcription of NF-kB and cyclin-D1 in CD-
1 (Table 6.10) and C57BL/6J mice (Table 6.11), the comparative Ct value (fold 
change) method was used. No significant difference was seen for any time points 
for both NF-kB and cyclin-D1 (Figure 3.1.12E,F). 
Time (hps) 
TNF-α 
Fed Fasted 
CD-1  C57BL/6J p-value  CD-1  C57BL/6J p-value 
5 51.4 3.3 0.0021 57.1 11.3 0.020 
24 45.8 3.6 0.0056 63.1 20.3 0.012 
p-value 5 vs 24 h NS NS  NS NS  
Time (hps) 
IL-6 
Fed Fasted 
CD-1  C57BL/6J p-value  CD-1  C57BL/6J p-value 
5 25.4 28.5 NS 23.1 19.86 NS 
24 30.1 14.2 NS 27.49 24.5 NS 
p-value 5 vs 24 h NS NS  NS NS  
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Figure 3.1.12. Changes in hepatic transcription of NF-kB and cyclin-D1 in fasted compared 
to fed male CD-1 and C57BL/6J mice. 
Relative NF-kB and cyclin-D1 mRNA levels were determined in relation to GAPDH mRNA, 
using the delta Ct, 2-ΔCt values.  The levels of NF-kB and cyclin-D1 using comparative Ct 
values by fold change (2-ΔCtfasted/2-ΔCtfed) method were also determined. Fold change = 1 : 
levels in fed dosed control mice as indicated by dashed line. No statistical significant 
differences were observed at any time point for CD-1 and C57BL/6J mice.    
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3.1.8.2  In situ identification of proliferating hepatocytes 
For the evaluation of the degree of cellular turnover in the unaltered liver of control 
mice and the potential effect of fasting on this, immunohistology for the expression 
of proliferating cell nuclear antigen (PCNA) was applied to the liver of fed and fasted 
control CD-1 mice over a 24 hours period after the onset of refeeding the fasted 
mice. PCNA is a nuclear protein that is involved in DNA synthesis which is expressed 
in the nucleus in the early phase of the cell cycle, i.e. the G1 and S phases. 
Immediately prior to and during mitosis, it is (also) expressed in the cytoplasm 
(Figure 3.1.13; (Kubben et al., 1994; Kurki et al., 1986)). 
 
 
Figure 3.1.13. PCNA expression pattern in hepatocytes. 
Liver, fed male CD-1 mouse. PCNA expression in nuclei (red arrow; cells in G1 or S phase) 
and in the cytoplasm (black arrow; cell at G2 phase immediately prior to mitosis). PAP 
method, Papanicolaou’s haematoxylin counterstain; 400x magnification. 
 
 
 
In CD-1 mice, PCNA expression was seen in a relatively variable proportion of cells 
(average 0.59 - 21% PCNA-positive hepatocytes) with very few cells immediately 
prior to or in the process of mitosis, as indicated by the cytoplasmic expression of 
PCNA (0 - 1.19%; Table 6.12). This indicates a various degree of hepatocyte 
proliferation in the normal liver. Fasting did not result in a significant change in the 
number of PCNA-positive cells regardless of the length of fasting (16 or 24 hours) 
and the time span of refeeding (0, 0.5, 1, 5, 10, 15, 20, 24 h), although the 
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proportion of positive cells was lower in the fasted animals upon completion of the 
fasting phase (Table 6.12). However, the proportion of cells in the cell cycle (as 
reflected by their nuclear PCNA expression) sometimes varied significantly over the 
course of the day, but without any obvious pattern. 
Evaluation of proliferating hepatocytes in control C57BL/6J mice was only 
undertaken in fed and fasted animals immediately after saline administration, as 
this was the only time point at which some differences were seen in the CD-1 mice. 
While the proportion of PCNA-positive cells was also lower in the fasted C57BL/6J 
mice, the difference was again not significant (Table 6.13).   
A comparison of the figures for CD-1 and C57BL/6J mice showed that the overall 
amount of proliferating hepatocytes (cells showing nuclear and/or cytoplasmic 
PCNA expression) was significantly higher in fed CD-1 than in fed C57BL/6J mice; in 
fasted mice, the difference was still obvious, but it was not significant (Table 
3.1.16). There was also no significant difference in the amount of hepatocytes 
showing cytoplasmic PCNA expression, i.e. hepatocyte immediately prior to or 
undergoing mitosis, in fed or fasted CD1 and C57BL/6J mice.    
 
 
Table 3.1.16. Comparison of the amount of proliferating hepatocytes (% nuclear and 
cytoplasmic PCNA expression; “PCNA+”) and hepatocytes that were prior to/in mitosis (% 
cytoplasmic PCNA expression; “Cyto+”) in CD-1 and C57BL/6J mice that had been fed ad 
libitum or fasted, immediately after saline dosing (0 hour of refeeding). 
 
Strains 
Fed Fasted 
ToD  
killing 
% PCNA+ 
Mean [SD] 
% Cyto+  
Mean [SD] 
ToD 
killing 
% PCNA+  
Mean [SD] 
% Cyto+  
Mean [SD] 
CD-1 10:00  21.0 [8.1] 0.66 [0.6] 10:00 6.27 [3.64] 0.16 [0.14] 
C57BL/6J 10:00 2.21 [1.41] 0.31[0.52] 10:00 1.18 [0.47] 0.15 [0.09] 
p-value  0.0113 NS  NS NS 
 ToD – time of day; NS – not significant, Cyto – cytoplasmic. 
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3.2  Effect of fasting on the response of the liver and/or spleen in CD-1 mice to 
APAP treatment 
In an attempt to evaluate the effect of fasting on the response of the liver to acute 
toxic injury, male CD-1 mice that had been fed ad libitum (fed mice) and mice that 
had been fasted for 16 hours or 24 hours received a sublethal dose of APAP 
intraperitoneally. Saline (0.9%) was applied to control mice. Immediately after 
dosing, the fasted mice were allowed access to food ad libitum.  
None of the dosed animals exhibited clinical signs and resumed and maintained 
feeding. They were killed at different time points (0-24 hours) after dosing and 
several serum and liver parameters were assessed in order to monitor the hepatic 
and systemic effect of APAP overdosing, including serum ALT activity levels, hepatic 
glutathione levels, hepatic ATP levels and hepatocellular glycogen content as well as 
histopathological changes in the liver. The inflammatory and regenerative response 
of hepatocytes was also investigated by relative quantification of cytokine 
transcription (TNF-α, IL-6, IL-10) and hepatocyte proliferation, assessing NF-kB, 
cyclin-D1 transcription and the amount of PCNA expressing hepatocytes. A potential 
systemic inflammatory response was assessed based on the splenic transcription 
and serum levels of the pro-inflammatory cytokines TNF-α and IL-6. 
 
3.2.1  Hepatic GSH content  
GSH is an antioxidant important for the detoxification of free radicals and oxygen 
species (Pompella et al., 2003). GSH depletion is long known to be a prerequisite for 
the onset of APAP hepatotoxicity (Mitchell et al., 1973).  
In the present study, the consumption of GSH after acetaminophen administration 
was assessed by comparing untreated and treated fed mice (Table 3.2.1, Figure 
3.2.1A). After APAP treatment, the hepatic GSH levels dropped significantly within 1 
hour (5.30±3.65 nmol/mg) and had dropped further by 4 hours (4.95±0.56 
nmol/mg). However, at 10 hpd, the hepatic GSH content was significantly higher 
(40.28±0.74 nmol/mg) and almost twice as high as in the control animals (20.6±5.13 
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nmol/mg) at the same time of day, at 20:45, when these exhibited the lowest 
circadian value (see Chapter 3.1.2). Also, the amount of GSH was significantly higher 
at 15 hpd (44.32±12.6 nmol/mg), 20 hpd (35.05±18.49 nmol/mg) and 24 hpd 
(45.47±10.05 nmol/mg) than at 1 hpd and 4 hpd (Table 3.2.1, Figure 3.2.1B).  By 24 
hpd, GSH levels were similar to those of the control animals, as those of the latter 
had doubled from evening to morning. The comparison of hepatic GSH levels at 
different time points post APAP administration is demonstrated in Table 3.2.1 and 
Figure 3.2.1B.  
Table 3.2.1. Hepatic GSH levels (nmol/mg) in fed control and APAP dosed mice.  
 
Time 
(hpd) 
ToD 
dosing 
ToD killing 
Control APAP  p-value 
control vs 
APAP 
p-value APAP 
vs APAP Mean SD Mean SD 
0 14:00 14:00 28.81 5.00 - - - 1 h: 0.0159 
1 9:30 10:30 40.34 4.48 5.30 3.65 0.0286  
20 h: 0.0257 
24 h: 0.0289 
4 9:00 13:00 36.30 5.04 4.95 0.56 0.0286  
0 h: 0.0159, 
10 h: 0.0001 
10 10:45 20:45 20.60 5.13 40.28 0.74 0.0357  
1 h: 0.0002 
0 h: 0.0357 
15 18:00 9:00(+1) - - 44.32 12.64 - 4 h: 0.0471 
20 12:20 8:20(+1) - - 35.05 18.49 - 4 h: 0.0286 
24 10:55 10:55(+1) 47.36 5.75 45.47 10.05 NS 4 h: 0.0356 
hpd – hours post dosing; ToD - time of day; SD - standard deviation.  
 
        A. Control vs APAP                                 B. APAP 
 
 
Figure 3.2.1. Hepatic GSH levels in fed male CD-1 mice after APAP treatment. 
Hepatic GSH levels were measured in fed mice at different time points (0-24 h) after APAP 
treatment (530 mg/kg) or 0.9% saline application (control). (A) Comparison of GSH levels in 
APAP treated and control mice. (B) Comparison of GSH levels in treated animals at different 
time points post dosing. Values are expressed as mean±SD (4 to 6 animals per group). 
***P<0.001, **P<0.01 and *P<0.05. 
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In fasted APAP treated mice, GSH levels had significantly dropped within 1 hpd to 
levels lower than in control animals upon completion of the fasting period (0 hpd). 
They were significantly lower at 1, 4 and 10 hpd compared to those of control 
animals after the same time spans of refeeding, where the hepatic GSH levels 
increased gradually and reached a peak after 10 hours of refeeding before both 
APAP treated and control mice reached similar levels at 24 hpd (Table 3.2.2, Figure 
3.2.2A).  The GSH levels of APAP dosed animals were significantly higher at 15 to 24 
hpd than earlier time points (Figure 3.2.2B).  
Table 3.2.2. Hepatic GSH levels (nmol/mg) in mice that had been fasted and then dosed 
with APAP or 0.9% saline (control mice) and fed ad libitum again, over a 24 hour period.  
 
Time 
(hpd) 
ToD 
refed 
ToD killing 
Control APAP  p-value 
control vs 
APAP 
p-value APAP 
vs APAP Mean SD Mean SD 
0 10:00 10:00 20.34 3.23 - -  
20 h: 0.0008  
5 h: 0.0011 
1 10:00 11:00 41.25 10.98 13.67 8.25 0.0286  20 h: 0.0005 
4 8:00 12:00 47.70 4.67 4.47 3.57 0.0001  
24 h: 0.0142  
20 h: 0.0001 
10* 10:00 20:00 86.36 22.10 5.28 1.24 0.0001  
24 h: 0.0158  
0 h: 0.0001 
15 16:00 7:00(+1) - - 33.98 16.15 - 4 h: 0.0491 
20 10:45 6:45(+1) - - 49.26 7.82 - 10 h: 0.0002 
24 10:15 10:15(+1) 55.85 7.46 50.57 25.22 NS  1 h: 0.0276 
10*: The fasted APAP dosed animals that had been killed 10 h after dosing and refeeding 
had been fasted for 24 h prior to refeeding, whereas all other fasted animals had been 
fasted for 16 h. Tod - time of day.  
A. Control vs APAP                    B. APAP 
 
 
Figure 3.2.2. Hepatic GSH levels in fasted male APAP dosed CD-1 mice. 
Hepatic GSH levels were measured in fasted mice at different time points (0-24 h) after 
APAP treatment (530 mg/kg) or 0.9% saline application (control). (A) Comparison of GSH 
levels in APAP treated and control mice. (B) Comparison of GSH levels in treated animals at 
different time points post dosing. Values are expressed as mean±SD (4 to 6 animals per 
group). ***P<0.005, **P<0.01 and *P<0.05.  
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Table 3.2.3 illustrates the differences in GSH levels between animals that had been 
fed or fasted prior to APAP treatment. The time course was similar in both groups, 
though there were significant differences at 0 and 10 hpd, when levels were 
significantly lower in the fasted animals. In the latter, the GSH levels had increased 
to those of fed treated animals from 15 hpd onwards (Table 3.2.3, Figure 3.2.3).  
 
Table 3.2.3. Comparison of mean GSH levels (nmol/mg) in mice that had been fed or fasted 
prior to APAP dosing, over a 24 hours period. 
 
Time 
(hpd) 
Fed Fasted p-value fed 
vs fasted 
APAP 
ToD 
dosing 
ToD 
killing 
Mean SD 
ToD 
dosing 
ToD 
killing 
Mean SD 
1 9:30 10:30 5.30 3.65 10:00 11:00 13.67 8.25 NS  
4 9:00 13:00 4.95 0.56 8:00 12:00 4.47 3.57 NS 
10 10:45 20:45 40.28 0.74 10:00 20:00 5.28 1.24 0.0001  
15 18:00 
9:00 
(+1) 
44.32 12.64 16:00 
7:00 
(+1) 
33.98 16.15 NS  
20 12:20 
8:20 
(+1) 
35.05 18.49 10:45 
6:45 
(+1) 
49.26 7.82 NS  
24 10:55 
10:55 
(+1) 
45.47 10.05 10:15 
10:15 
(+1) 
50.57 25.22 NS  
hpd - hours post dosing; ToD -  time of day; SD - standard deviation; NS - not significant.   
 
 
 
Figure 3.2.3. Comparison of hepatic GSH levels in fed and fasted APAP dosed male CD-1 
mice.  
Hepatic GSH levels were determined in fed and fasted mice at different time points post 
APAP treatment. Values are expressed as mean±SD (4 to 6 animals per group). ***P<0.005. 
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3.2.2 Hepatic ATP content  
The hepatic ATP content was assessed in fed mice after APAP dosing in comparison 
to saline dosed control animals. APAP dosed mice showed a significantly lower 
hepatic ATP content at 5 hpd (10.5±2.3 nmol/mg) and 10 hpd (18.3±5.7 nmol/mg) 
compared to control animals at the same time points (Table 3.2.4, Figure 3.2.4A).  
 
Table 3.2.4. Hepatic ATP levels (nmol/mg) in fed CD-1 mice with p-value at the different 
time points post saline application (control) and APAP dosing.  
hpd - hours post dosing; ToD - time of day; SD - standard deviation; NS - not significant. 
 
In the fasted APAP dosed mice, the hepatic ATP content was significantly lower 
than in the fasted control mice, from 3 hpd onwards until the end of the experiment 
at 24 hpd (Table 3.2.5, Figure 3.2.4B). A comparison of the ATP content in the 
fasted, APAP treated mice over the time course showed that levels were 
significantly lower at 1 and 10 hpd than at 24 hpd (Table 3.2.5). 
The comparison of ATP values in fed and fasted, APAP treated mice showed 
significantly lower levels in fasted mice compared to time-matched fed mice at all 
time points throughout the experiments (Table 3.2.5, Figure 3.2.4C).   
 
  
Time 
(hpd) 
ToD 
dosing 
ToD 
killing 
Control APAP  p-value 
control 
vs APAP 
Mean SD Mean SD 
p-value APAP  
vs APAP 
0 10:00 10:00 35.4 2.0 35.9 1.7 
5 h: 0.0069  
10 h: 0.0092 
NS 
1 10:00 11:00 32.1 5.6 31.4 5.1 5 h: 0.0167  
10 h: 0.0303 
NS 
3 10:00 13:00 25.9 4.9 29.8 5.5 NS 
5 10:00 15:00 35.5 4.0 10.5 2.3 10 h: NS 0.0056 
10 10:00 20:00 30.2 6.4 18.3 5.7 - 0.0405 
24 10:00  
10:00 
(+1) 
33.1 2.1 35.4 3.9 
5 h: 0.0060  
10 h: 0.0277 
NS 
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Table 3.2.5. Hepatic ATP levels (nmol/mg) in fasted CD-1 mice with p-value at the different 
time points post saline application (control) and APAP dosing.  
hpd - hours post dosing; ToD -  time of day; SD - standard deviation; NS - not significant. 
 
 
 
 
Figure 3.2.4. Hepatic ATP levels after APAP dosing of fed and fasted CD-1 mice. 
Hepatic ATP levels were measured at different time points (0-24 h) after APAP treatment 
(530 mg/kg) or 0.9% saline application (control) in fed (A) and fasted (B) mice. (C)  
Comparison of GSH levels in fed and fasted APAP dosed animals at different time points 
post treatment. Values are expressed as mean±SD (4 to 6 animals per group). ***P<0.005, 
**P<0.01 and *P<0.05. 
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Time 
(hpd) 
ToD 
dosing 
ToD  
killing 
Control APAP  p-value 
control vs 
APAP 
p-value 
fasted vs 
fed APAP Mean SD Mean SD p-value  
0 10:00 10:00 4.2 2.6 5.0 2.3 NS NS 0.0003 
1 10:00 11:00 5.3 3.7 4.2 0.9 
24 h: 
0.024 
NS 0.0019 
3 10:00 13:00 11.0 1.2 5.6 2.5 NS 0.0398 0.0055 
5 10:00 15:00 17.1 5.3 3.5 4.9 NS 0.0087 0.0402 
10 10:00 20:00 13.7 1.4 3.4 1.2 
24 h: 
0.045 
0.0060 0.0375 
24 10:00  10:00 (+1)  16.4 3.7 8.1 1.3 NS 0.0083 0.0005 
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3.2.3   Hepatic ATP and GSH levels  
The fold change of hepatic GSH and ATP levels was determined by normalising the 
values in dosed mice to time-matched control mice that had been fed or fasted 
prior to dosing.  
Following APAP administration in fed mice, the GSH levels were reduced 
significantly more extensively at 1 hpd, but at 10 hpd, it increased significantly 
compared to hepatic ATP levels. However, at 24 hpd hepatic ATP and GSH levels in 
fed APAP treated mice were similar to those in control fed mice (Table 3.2.6, Figure 
3.2.5A).  
In fasted mice, although the fold change differences between GSH and ATP levels 
were insignificant at any time except at 1 hpd, both remained lower in APAP dosed 
mice compared to respective saline dosed mice throughout the experiment (Table 
3.2.6, Figure 3.2.5B).  
 
 
Table 3.2.6. Comparison of fold changes in hepatic GSH and ATP levels in fed and fasted, 
APAP dosed male CD-1 mice. 
 
Time 
(hpd) 
Fed 
GSH ATP p-value GSH 
vs ATP Control APAP Fold change Control APAP Fold change 
1 40.34 5.3 0.13 32.1 31.4 0.98 0.0034 
3 - - - 25.9 29.8 1.15 - 
4 36.3 4.95 0.14 35.5 10.5 0.30 NS 
10 20.6 40.28 1.96 30.2 18.3 0.61 0.0005 
24 47.36 45.47 0.96 33.1 35.4 1.07 NS 
Time 
(hpd) 
Fasted 
GSH ATP p-value GSH 
vs ATP Control APAP Fold change Control APAP Fold change 
1 41.25 13.67 0.33 5.3 4.2 0.79 0.0335 
3 - - - 11.0 5.6 0.51 - 
4 47.7 4.47 0.09 17.1 3.5 0.20 NS 
10 86.36 5.28 0.06 13.7 3.4 0.25 NS 
24 55.85 50.57 0.33 16.4 8.1 0.49 NS 
hpd - hours post dosing; ToD - time of day; SD - standard deviation; NS - not significant. 
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Figure 3.2.5. Hepatic ATP and GSH levels in male CD-1 mice after APAP overdose.  
Fold changes in ATP and GSH levels in fed (A) and fasted (B) male CD-1 mice after APAP 
overdose. The levels in APAP dosed mice were normalised to those in time-matched control 
mice. Values are expressed as mean (4 to 6 animals per group). **P<0.01 and *P<0.05. Fold 
change = 1: levels in saline dosed control mice. 
 
3.2.4  Serum ALT levels  
The injurious effect of APAP was assessed by measuring a well-established, though 
non-specific, widely used serum marker of liver damage, the serum ALT activity. In 
fed mice, serum ALT levels were significantly increased at 5, 8 and 24 hpd in 
comparison to control animals (Table 3.2.7 and Figure 3.2.6A). ALT activities 
increased progressively and showed significant differences over the time course 
post APAP dosing: they were significantly higher at 5 hpd than at 1 and 2 hpd. 
Similarly, they were significantly higher at 24 hpd than at 1, 2 and 4 hpd (Table 3.2.7 
and Figure 3.2.6B).  
Table 3.2.7. Mean serum ALT levels (U/L) with standard deviation (SD) in fed control (0.9% 
saline) and APAP dosed mice at different times post dosing.  
 
hpd - hours post dosing; ToD - time of day; SD - standard deviation; NS - not significant. 
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B. Fasted 
GSH
ATP
 * 
Time 
(hpd) 
ToD 
dosing 
ToD 
killing 
Control APAP  p value control 
vs APAP 
p-value APAP 
vs APAP Mean SD Mean SD 
1 9:30 10:30 51.63 21.83 477.0 2 564.23 NS 5 h: 0.0011 
2 9:30 11:30 40.98 34.69 198.80 283.87 NS 24 h: 0.0001 
4 9:00 13:00 31.17 13.64 698.49 693.98 NS 24 h: 0.0081 
5 10:00 15:00 78.20 65.40 2,146.40 1012.30 0.0307 2 h: 0.0286 
8 10:00 18:00 22.55 10.97 2333.97 2910.77 0.0074 5 & 24 h: NS 
24 10:00 
10:00 
(+1) 
27.5 5.70 2,654.5 334.50 0.0091 1 h: 0.0019 
Chapter 3.2 
101 
 
A. Control vs APAP       B. APAP 
 
Figure 3.2.6. Serum ALT levels after APAP overdose in male fed CD-1 mice. 
The effect of APAP (530 mg/kg) dosing on the serum ALT activity was assessed at different 
time points up to 24 h after APAP and 0.9% saline (control) dosing (A). Comparison of ALT 
activity levels at the different time points post APAP dosing (B). Values are expressed as 
mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
 
The effect of overnight fasting on the serum ALT activity after APAP overdose was 
assessed at two relevant time points, 5 and 24 hpd. At both time points treated 
mice showed significantly higher serum ALT activities than the respective control 
animals (Table 3.2.8 and Figure 3.2.7A). Also, in the dosed animals, the activity was 
significantly higher at 24 hpd than at 5 hpd (Table 3.2.8, Figure 3.2.7B).    
 
 
Table 3.2.8. Mean serum ALT levels (U/L) with standard deviation (SD) in fasted control 
(0.9% saline) and APAP dosed mice at 5 and 24 hpd.  
 
hpd - hours post dosing; ToD - time of day; SD - standard deviation; NS - not significant. 
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Time (hpd) 
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ToD  
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Control APAP  p-value control 
vs APAP Mean SD Mean SD 
5 10:00 15:00 49.8 27.5 2,048.6 461.7 0.0086 
24 10:00 10:00 (+1) 63.2 22.5 3,603.8 508.8 0.0055 
p-value    NS 0.007  
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A. Control vs APAP                                         B. APAP  
 
 
Figure 3.2.7. Serum ALT levels after APAP-induced liver injury in fasted CD-1 mice. 
(A) Serum ALT levels were measured in fed mice at 5 and 24 h after APAP treatment (530 
mg/kg) or 0.9% saline (control) application. (B) Comparison of serum ALT levels in treated 
animals at 5 and 24 h post APAP treatment. Values are expressed as mean±SD (4 to 5 
animals per group). **P<0.01. 
 
 
Subsequently, the serum ALT activity levels at 5 and 24 hpd were compared 
between mice that been fed or fasted prior to APAP dosing. At 5 hpd, no significant 
difference was observed, but at 24 hpd, levels were significantly higher in the fasted 
animals (Table 3.2.9 and Figure 3.2.8). 
Table 3.2.9. Mean serum ALT levels (U/L) with standard deviation (SD) in fed and fasted 
APAP dosed mice at 5 and 24 hpd.  
 
 
 
 
                hpd - hours post dosing; SD - standard deviation; NS - not significant. 
 
 
 
 
Figure 3.2.8. Serum ALT levels after APAP-induced liver injury in CD-1 mice. 
Comparison of serum ALT levels at 5 and 24 hpd in APAP treated animals that had been fed 
or fasted prior to treatment. Values are expressed as mean±SD (4 to 6 animals per group). 
**P<0.01. 
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24 2,654.5 334.5 3,603.8 508.8 0.033 
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3.2.5  Histological features and glycogen content of the liver  
The effect of APAP dosing was assessed histologically, using consecutive sections 
that were stained with haematoxylin-eosin (HE) and underwent the Periodic Acid 
Schiff (PAS) reaction. The APAP-induced toxic liver changes were scored according 
to a previously applied scoring system (Antoine et al., 2009b) and the PAS reaction 
served to evaluate the hepatocellular glycogen content. For the identification of 
hepatocytes that underwent apoptosis, a further section underwent the 
immunohistological staining for the demonstration of cleaved caspase-3 (Antoine et 
al., 2010) in selected cases. All animals had been dosed in the morning (at 9:30 to 
10:00). Detailed descriptions of the histological findings and DILI scores of all 
animals were prepared by Fazila Hamid and Prof Anja Kipar independently and in a 
blinded fashion. After a consultative discussion, final descriptions and scores were 
prepared (fed mice: Tables 3.2.10 and 6.14; fasted mice: Tables 3.2.12 and 6.15). 
Briefly, in fed APAP dosed mice, the earliest histological changes were seen at 2 
hpd when a wide, well demarcated rim of hepatocellular glycogen loss was seen at 
zone 3. The innermost 1-2 centrilobular cell layers often appeared slightly swollen 
and vacuolated (early hydropic degeneration). By 3 hpd, centrilobular cell loss with 
numerous apoptotic hepatocytes, confirmed by their expression of cleaved caspase-
3 (Figure 3.2.10), was seen; the hepatocellular glycogen had been lost entirely or 
was only seen in random patchy aggregates of PAS-positive cells. Similar to animals 
at 3 hpd, mice that had been killed at 4 and 5 hpd showed centrilobular cell loss 
with minimal neutrophils infiltration, and no glycogen, with numerous cleaved 
caspase-3 positive apoptotic cells (Figure 3.2.11). At 8 and 10 hpd, mild ongoing cell 
damage was seen, it was reflected by the presence of occasional apoptotic 
hepatocytes. Hydropic degeneration was observed in hepatocytes surrounding 
affected areas, whereas patchy random aggregates of hepatocytes containing 
glycogen indicated glycogen restitution (Figure 3.2.12). No evidence of ongoing cell 
damage, but some degree of hydropic degeneration and increased numbers of 
mitotic figures were seen at 15 and 20 hpd, when almost diffuse hepatocellular 
glycogen reconstitution was apparent, with the exception of centrilobular areas 
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with PAS-negative hepatocytes at 20 hpd. By 24 hpd, the livers appeared unaltered 
with diffuse hepatocellular glycogen accumulation, although with the presence of 
numerous mitotic figures (Figure 3.2.13). 
Table 3.2.10. Histological findings in APAP dosed fed male CD-1 mice (time course). The 
histological findings are summarised for each group of animals including the number of 
animals examined at each time point and the range of DILI grading scores for each group. 
hpd - hours post dosing, n - no of animals used per group; HD - hydropic degeneration, NL - 
neutrophilic leukocytes, hpc - hepatocytes, CL – centrilobular, CN – coagulative necrosis, 
CC3 – Cleaved caspase-3, CC3: Negative (-), Positive (+mild,++moderate,+++numerous)hpc. 
 
A summary of the findings with the range of scores and average scores is recorded 
over the time course in Table 3.2.11 and Figure 3.2.9. DILI scores varied between 
animals in each group, with individual animals showing a score of 0 even at the time 
points, when the most severe damage was observed. However, a comparison of the 
Time 
(hpd) 
[n] 
Score 
range 
[mean] 
Histological findings 
0[9] 0 NHAIR; PAS: diffuse hepatocellular glycogen accumulation 
0 [5] 0 NHAIR; PAS:  diffuse hepatocellular glycogen accumulation 
1 
[9] 
0 
NHAIR; PAS: diffuse hepatocellular glycogen accumulation (in 6/9 animals 
evidence of increased glycogen content in CL hpc) 
2 
[4] 
0 
CL hpc appear slightly swollen or condensed and partly vacuolated and/or exhibit 
large nuclei (two most CL cell layers); PAS: wide and well demarcated CL rim (8-
10 cell layers) of hepatocellular glycogen loss 
3 
[5] 
0 - 2.5 
[1.25] 
CL hpc loss (mainly in zone 2), with evidence of apoptotic cells and small NL 
aggregates; PAS: No glycogen (4/6) or patchy glycogen (2/6); CC3: ++ 
disseminated in zone 3 and mainly zone 2.  
4 
[4] 
1 - 2.75 
[2.44] 
CL hpc loss and extending towards zone 2, with several NL and HD of remaining 
hpc in affected areas; PAS: no glycogen in affected CL areas; CC3: ++/+ 
5 
[13] 
0 - 3.25 
[2.2] 
No evidence of ongoing cell death (5/13), ongoing apoptotic/necrotic CL cell death 
(8/13), some degree of HD in remaining cells (4/13); PAS: extensive to complete 
CL glycogen loss; CC3: + (5/13), +++ (4/13), negative (4/13) 
8 
[4] 
0.5 - 4 
[1.25] 
No evidence of ongoing cell death with no inflammatory infiltrate or evidence of 
CL coagulative necrosis in few severely affected lobes; PAS: almost diffuse to 
variable degree of glycogen restoration 
10 
[11] 
0 - 3.25 
[1.0] 
Slight ongoing CL hpc death (5/6, via apoptosis); HD of hpc surrounding affected 
areas; PAS: patchy to randomly distributed hpc with glycogen; CC3: scattered 
individual CL positive hpc  
15 
[11] 
0 - 2.5 
[1.125] 
Increased mitotic figures, no evidence of ongoing cell death, but some degree of 
HD and disorderly arrangement of hpc in affected areas; PAS: diffuse glycogen 
except CL (affected) areas  
20 
[6] 
0-1 
[0.65] 
Numerous mitotic figures; no ongoing cell death; some HD in affected areas (2/6); 
PAS: large proportion of CL hpc devoid of glycogen 
24 
[8] 
[0] 
Numerous mitotic figures, but otherwise unaltered appearing; PAS: diffuse 
hepatocellular glycogen accumulation (variable amount); CC3: negative 
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average DILI scores seen at each time point showed the significantly highest mean 
scores at 3, 4 and 5 hpd (score 1.25-2.44) and a drop thereafter (Table 3. 2.11). 
 
Table 3.2.11. Histological scores in APAP dosed fed CD-1 mice (time course). 
 
hpd – hours post dosing; ToD – time of day, n – number of mice; SD –standard deviation. 
 
Apart from the animals that were killed at 15 hpd which had been dosed at 16:00 in 
the afternoon, all fasted animals had been dosed in the morning (between 8:00 and 
10:45). In fasted APAP dosed mice, complete glycogen loss was observed at 0 hour 
(see Chapter 3.1.6). In fasted mice, at 30 and 60 min after APAP dosing, a low 
degree of glycogen restitution was seen, represented by a few individual, PAS-
positive hepatocytes; this had a lower intensity than in time-matched control mice. 
No histological abnormality was detected, apart from evidence of early 
centrilobular hepatocellular hydropic degeneration at 1 hpd (Table 3.2.12). 
Although fasted mice showed extensive centrilobular cell loss with evidence of 
scattered necrotic cells and evidence of inflammatory cell (mainly neutrophils) 
recruitment at 3 to 5 hpd, the average DILI scores were not significantly higher than 
in fed mice (Figure 3.2.9). There was no evidence of glycogen reconstitution and 
very occasional scattered cleaved caspase-3 positive apoptotic cells were recorded 
at 3 and 5 hpd (Table 3.2.12, Figure 3.2.10). By 10 hpd, areas of centrilobular cell 
loss were surrounded by hepatocytes with mild hydropic degeneration and 
scattered necrotic cells. At that time, there was either no evidence of hepatocellular 
Time 
(hpd) 
ToD  
dosing 
ToD  
killing 
n 
Score range 
[mean] 
SD 
p-value APAP        
vs APAP 
0.5 10:00 10:30 5 [0] 0 
0.5,1,2 h: NS 1 9:30 10:30 9 [0] 0 
2 9:30 11:30 4 [0] 0 
3 10:00 13:00 5 0-2.5 [1.25] 1.04 
 0.5,1,2 h: 0.0318 
5 h: NS 
4 9:00 13:00 4 1-2.75 [2.44] 1.25 0.5,1,2 h: 0.0093 
5 10:00 15:00 13 0-3.25 [2.2] 1.28 0.5,1,2 h: 0.0197 
8 10:00 18:00 4 0.5-4 [1.25] - - 
10 10:00 20:00 11 0-3.25 [1] 0.89 5 h: NS 
15 16:00 08:00 11 0-2.5 [1.13] 1.04 10 h: NS 
20 10:00 6:00 (+1) 6 0-1 [0.65] 0.27 15 h: NS 
24 10:00 10:00 (+1) 
4 
[0] 
0 
10 h: NS 
4 - 
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glycogen reconstitution or glycogen accumulation in individual random hepatocytes 
(Figure 3.2.12). The degree of centrilobular cell loss remained the same but the 
number of glycogen-containing hepatocytes was higher outside centrilobular 
regions at 15 hpd (Table 3.2.12). At 20 and 24 hpd, there was evidence of 
coagulative necrosis of the innermost centrilobular cell layer and diffuse glycogen 
hepatocellular accumulation outside centrilobular areas with occasionally scattered 
cleaved caspase-3 positive apoptotic cells (Table 3.2.12, Figure 3.2.13).  
Table 3.2.12. Histological findings in APAP dosed fasted male CD-1 mice (time course). The 
histological findings are summarised for each group of animals including the number of 
animals examined at each time point and the range of DILI grading scores for each group. 
hpd - hours post dosing, n - number of animals used per group; HD - hydropic degeneration, 
NL – neutrophilic leukocytes, hpc - hepatocytes, CL – centrilobular, CN – coagulative 
necrosis, CC3 – Cleaved caspase-3, CC3: Negative (-), Positive (+mild,++moderate, 
+++numerous) hpc. 
Time 
(hpd) 
[n] 
Fasting 
time (h) 
Score 
range 
[mean] 
Histological findings 
16 24 
0 [4]  x 0 NHAIR; complete glycogen loss 
0.5 
[5] 
x  0 
NHAIR; PAS: no glycogen (4/5), some degree of glycogen restitution in 
individuals cells (1/5) 
1 
[5] 
x  0 
CL hpc with variably sized cytoplasmic vacuoles (4-5 layers; evidence 
of early HD), only very mild outside CL; PAS: no glycogen (2/5) or low 
degree of glycogen restitution in individuals cells (3/5) 
3 
[5] 
 x 
0.5 - 3 
[2.05] 
CL hpc loss; CL hpc in particular are vacuolated, several swollen cells 
with clumped chromatinscattered necrotic cells; PAS: no glycogen. 
CC3: very occasional scattered pos. cells 
4 [4] x  
1 - 
3[2.1] 
Marked reduction of CL hpc, HD of remaining hpc; PAS: no glycogen. 
5 
[5] 
 x 
1 - 3 
[2.5] 
CL hpc that round up and exhibit loose vacuolation and chromatin 
clumping; PAS: no glycogen. 
10 
[5] 
 x 
2 - 4 
[2.6] 
CL hpc loss surrounded by hpc with HD; occasional NL at transition to 
unaltered areas; PAS: few cells with/no glycogen. CC3: + 
15 
[7] 
x  
0 - 4 
[2.15] 
In areas without CL cell loss (and scattered necrotic/ apoptotic hpc, with 
occ. NL) CL 3 hpc layers with homogenous, slightly basophilic 
cytoplasm (degeneration/early stage of CN), surrounded by hpc with 
increasing cytoplasmic vacuolation; occasional NL between CL hpc; 
PAS: diffuse glycogen (variable amount) outside CL areas 
20 
[10] 
x  
0 -5 
[2.75] 
Disorganised CL hpc with cytoplasm like CN, with some necrotic hpc 
(5-6 cell layers); a few NL in CV and affected areas; score 5 in 
subcapsular areas; PAS: diffuse glycogen outside affected CL areas 
24 
[10] 
 
 
[5] 
x 
 
 
0 - 4 
[2.35] 
Well delineated CL area of HD with inner layer of hpc with features of 
CN (and loss of nucleus), 5-6 cell layers, a few NL in CV and affected 
areas; affected areas surrounded by 1 layer of dense, otherwise 
unaltered cells; PAS: diffuse glycogen except 2-3 layers of zone 3 
 
x 
 
1 - 4 
[2.4] 
CL cell loss, remaining cells often mildly to moderately vacuolated (HD), 
scattered necrotic cells, small no. of NL within CV, scattered mitotic 
cells; PAS: diffuse glycogen outside the affected areas; CC3: +/++ 
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Table 3.2.13. Histological scores in APAP dosed fasted CD-1 mice (time course). 
hpd – hours post dosing; ToD – time of day; n – number of animals; SD – standard 
deviation; NS – not significant; 24h (16h) – 16 hours fasted mice at 24 hpd.  
 
Since the DILI scores in the fasted animals were similar regardless of the length of 
the fasting period (16 or 24 hpd), the fasted groups were looked at together for the 
comparison between fed and fasted mice at each time point (Table 3.2.14 and 
Figure 3.2.9C). This confirmed that the APAP-induced damage was more severe in 
fasted animals, where the average scores were significantly higher at 10, 20 and 24 
hpd (Table 3.2.14, Figure 3.2.9C).  
Table 3.2.14. Comparison of histological scores in APAP dosed fed and fasted male CD-1 
mice (time course).  
Time 
(hpd) 
Fed: 
Mean score [n] 
Fasted: Mean score [n] p-value fed vs 
fasted APAP 16 h fasting 24 h fasting 
1 0 [5] 0 [5] - NS 
3 1.25 [5] - 2.05 [5] NS 
4 2.44 [4] 2.125 [4] - NS 
5 2.2 [13] - 2.5 [5] NS 
10 1 [11] - 2.6 [5] 0.0406 
15 1.125 [11] 2.15 [5] - NS 
20 0.65 [6] 2.75 [5] - 0.0043 
24 
0 [4] 2.35 [5] - 0.0160 
0 [4] - 2.4 [5] 0.0159 
- 2.35 [5] 2.4 [5] NS 
0 [4] 2.375 [10] 0.0001 
Time 
(hpd) 
Fasting 
time (h) ToD 
refed 
ToD  
killing 
n 
Score range 
[mean] 
SD 
p-value  
APAP vs APAP 
16 24 
0.5 x  9:00 9:30 5 [0] 0 - 
1 x  8:30 9:30 5 [0] 0 0.5 h: NS 
3  x 10:00 13:00 5 0.5-2.75 [2.05] 1.04 
0.5 h: 0.0115 
1 h: 0.0115 
4 x  8:00 12:00 4 1-3 [2.125] 0.48 - 
5  x 10:00 15:00 5 1-3 [2.5] 1.41 
1 h: NS  
3 h: NS 
10  x 10:00 20:00 5 2-4 [2.6] 0.42 
1 h: 0.0002 
5 h: NS 
15 x  16:00 7:00 (+1) 5 0-4 [2.15] 0.78 
1 h: 0.0036 
10 h: NS 
20 x  10:45 6:45 (+1) 5 0-5 [2.75] 0.43 
1 h: 0.0079 
15 h: NS 
24 
 x 10:00 10:00 (+1) 5 1-4 [2.4] 0.89 1 h: 0.0003 
20 h: NS 
24h (16h): NS x  10:15 10:15 (+1) 5 0-4 [2.35] 0.45 
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 A. Fed                                             B. Fasted 
 
         C. Fed vs fasted 
 
Figure 3.2.9. Histological scoring in CD-1 mice after APAP overdose. 
Histological scoring after APAP overdose (530 mg/kg) over 0-24 hpd in fed (A) and 16 or 24 
h fasted (B) mice. (C) Comparison between fed and fasted mice (combined 16 and 24 h 
fasted mice) with regards to the histological grading score. Data represent mean±SD (4 to 
13 animals per group). ***P<0.005, **P<0.01 and *P<0.05.  
 
 
The histopathological features of the liver in fed and fasted APAP dosed mice were 
compared at 3 hpd (Figure 3.2.10), 5 hpd (Figure 3.2.11), 10 hpd (Figure 3.2.12) and 
24 hpd (Figure 3.2.13). At early time points, both fed and fasted mice showed a 
similar degree of centrilobular cell loss, but with more evidence of neutrophils in 
the fasted mice. At later time points, there was no evidence of further hepatocyte 
damage in fed mice, and the liver parenchyma appeared unaltered, suggesting that 
the liver damage had subsided and almost complete regeneration and diffuse 
glycogen restoration had taken place by 24 hpd. At the same time point, in fasted 
mice, there was still evidence of ongoing cell damage, while glycogen was restored 
outside the affected centrilobular areas. The semiquantitative assessment of the 
amount of cleaved caspase-3 positive apoptotic cells showed that numerous cells in 
the affected centrilobular areas died of apoptosis in fed mice at 3 hpd (++) and even 
more at 5 hpd (++/+++) (Figure 3.2.10). In contrast, in fasted mice no or only few 
apoptotic cells (-/+) at centrilobular areas were seen at the same time points.  
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               Fed        Fasted
 
 
 
 
 
 
Figure 3.2.10. Assessment of histopathological features and glycogen content in fed and 
fasted male CD-1 mice at 3 h post APAP (530 mg/kg) treatment.  
In fed animals, there was centrilobular cell loss (score 1.25) (A) and no evidence of 
hepatocellular glycogen reconstitution apart from in a few individual PAS-positive cells 
(black arrows) (C). In fasted mice, the centrilobular damage was more intense (score 2.05) 
and there were necrotic cells (white arrows) with moderate infiltration of neutrophils (black 
arrows) (B) and no evidence of hepatocellular glycogen reconstitution (D). In fed mice, the 
presence of a large number of centrilobular apoptotic cells was confirmed by staining for 
cleaved caspase-3 (black arrows) (E); their number was much lower in fasted mice (F). A, B: 
HE stain; C, D: PAS reaction: E, F: PAP method, Papanicolaou’s haematoxylin counterstain. 
Magnification x400 (A, B, E, F) and x100 (C, D). 
 
A 
D C 
B 
E F 
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Figure 3.2.11. Assessment of histopathological features and glycogen content in fed and 
fasted male CD-1 mice at 5 h post APAP (530 mg/kg) treatment.  
In fed mice, centrilobular hepatocyte loss (score 2.2) is seen, affecting zones 3 and 2 (A). 
Patchy random aggregates of hepatocytes with glycogen accumulation are present (C), 
representing glycogen reconstitution. In fasted mice, more intense centrilobular hepatocyte 
loss (score 2.5) and necrotic cells (black arrow) are seen (B), and there is no evidence of 
hepatocellular glycogen reconstitution (D). The higher magnification shows some 
neutrophils rolling along the endothelium of a central vein (black arrows) in a fed mouse 
(E), whereas in a fasted mouse numerous neutrophils are seen infiltrating the sinuses 
adjacent to the affected centrilobular area (black arrows) (F). A, B, E, F: HE stain: C, D: PAS 
reaction. Magnification x200 (A, B, E), x100 (C, D) and x400 (F). 
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Figure 3.2.12. Assessment of histopathological features and glycogen content in fed and 
fasted male CD-1 mice at 10 h post APAP (530 mg/kg) treatment.  
In fed mice (A), there is still evidence of centrilobular cell loss (score 1), but to a lesser 
degree than at the earlier time points with evidence of hydropic degeneration of a few 
hepatocytes (black arrows) and mitotic figures (white arrows). There is evidence of 
complete hepatocellular glycogen reconstitution outside affected areas of centrilobular 
region (C). In fasted mice (B), extensive centrilobular cell loss (score 2.6) and necrosis of 
hepatocytes (black arrows) as well as moderate neutrophil infiltration is seen (B). Only 
scattered random individual hepatocytes show evidence of glycogen accumulation (D). 
Staining for cleaved caspase-3 reveals a few apoptotic hepatocytes in affected centrilobular 
areas (black arrows) in fed mice (E). Their number was substantially higher in fasted mice 
(F). A, B: HE stain; C, D: PAS reaction; E, F: PAP method, Papanicolaou’s haematoxylin 
counterstain. Magnification x100 (A, B, C, D) and x200 (E, F).   
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Figure 3.2.13. Assessment of histopathological features and glycogen content in fed and 
fasted male CD-1 mice at 24 h post APAP (530 mg/kg) treatment.  
In fed mice, there is no evidence of cell loss (score 0), suggesting complete hepatic 
regeneration; numerous mitotic figures are seen (black arrows) (A). There is diffuse 
hepatocellular glycogen accumulation (C). In fasted mice, there are well delineated 
centrilobular areas of swollen hepatocytes undergoing hydropic degeneration (score 2.4) 
(black arrows) and coagulative necrosis of cells in the innermost layer (B), with diffuse 
hepatocellular glycogen restitution outside the affected centrilobular layers (D). A, B: HE 
stain; C, D: Absent of apoptosis in fed mice (E), but presence of several centrilobular 
apoptotic cells which was confirmed by cleaved caspase-3 staining (black arrows) (F). PAS 
reaction: E, F: PAP method, Papanicolaou’s haematoxylin counterstain. Magnification x200 
(A, B), x40 (C, D) and x400 (E, F).  
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3.2.6 Overall assessment of liver damage based on all parameters  
We combined the data obtained testing the various parameters (levels of hepatic 
GSH, ATP, serum ALT and DILI score) in order to have better illustration of overall 
degree of liver damage following APAP overdosing in fed and fasted CD-1 mice over 
24 hours (Table 3.2.15, Figure 3.2.14). Data are presented as fold change relative to 
time matched control mice, except for the DILI scores (raw data). In fed mice, 
depletion of GSH and ATP at early time points coincides with histological evidence 
of acute liver injury (scores) and high serum ALT activity. The damage subsides at 
the end of the study period when GSH and ATP levels return to control animal levels 
(Figure 3.2.14A).  
In contrast, fasted mice showed prolonged depletion of hepatic GSH and ATP which 
coincides with the morphological evidence of more pronounced liver injury and 
higher serum ALT activity (Figure 3.2.14B). Briefly, over the 24 hour time course 
fasted CD-1 mice had higher DILI scores and higher serum ALT levels with more 
intense hepatic GSH and ATP depletion than fed mice (Table 3.2.15, Figure 3.2.14C).  
 
 
Table 3.2.15. Comparison of GSH, ATP, ALT fold changes and DILI scores in fed and fasted 
male CD-1 mice following APAP overdose. 
 
Time 
(hpd) 
GSH ATP ALT DILI score 
Fed Fast Fed Fast Fed Fast Fed Fast 
1 0.13 0.33 0.98 0.79 9.24 - 0 0 
3 - - 1.15 0.51 - - 1.25 2.05 
4 0.14 0.09 0.3 0.2 22.41 - 2.44 2.13 
5 - - - - 27.45 41.14** 2.2 2.5 
10 1.96*** 0.06 0.61 0.25 - - 1 2.6* 
15 - - - - - - 
1.12
5 
2.15 
20 - - - - - - 0.65 2.75*** 
24 0.96 0.33 1.07 0.49 96.53*** 57.02 0 2.4*** 
Statistical significant, *P<0.05, **P<0.01 and ***P<0.005 are seen in comparison between 
fed and fasted APAP dosed CD-1 mice.  hpd - hours post dosing.   
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Figure 3.2.14. Assessment of liver damage in fed and fasted male CD-1 mice following APAP 
overdose.  
The liver GSH and ATP and the serum ALT levels and the DILI scores were compared over 1-
24 h in animals that had been fed (A) or fasted (B) prior to APAP administration. The levels 
were also compared between fed and fasted CD-1 mice (C). The values of GSH, ATP and ALT 
are assessed by fold change that is calculated on relative to time-matched control mice, on 
exemption of DILI score (as listed in Table 3.2.15). Data represent mean (4 to 6 animals per 
group). Fold change = 1: levels in saline dosed control mice indicated by dashed lines. NE – 
not examined.  
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3.2.7 Cytokine transcription in liver and spleen and cytokine levels in the blood 
of APAP dosed CD-1 mice  
3.2.7.1  Hepatic transcription of TNF-α, IL-6 and IL-10  
The relative transcription of TNF-α, IL-6 and IL-10 in the liver and spleen of APAP 
dosed mice was assessed in relation to the constitutive transcription levels in fed 
and fasted control mice, using the values for the housekeeping gene GAPDH as 
initial reference values, using the delta Ct values, 2-ΔCt to compare the transcription 
activities of control and APAP dosed mice (Figure 3.2.15). Overall, mRNA levels of all 
cytokines are highly expressed in APAP dosed mice than those in controls.  
In both fed and fasted CD-1 mice, increased TNF-α transcription was observed at 
1, 4 and 10 hpd in comparison to time-matched control mice, at 24 hpd, it was 
lower (Figure 3.2.15). In fed mice, IL-6 and IL-10 transcription levels increased 
gradually and peaked at 15 hpd (for IL-10) and 20 hpd (for IL-6). At 24 hpd, levels 
were lower again, but still higher than in the control mice (Table 6.16, Figure 
3.2.15C,E), but the no substantial change was seen in fasted mice (Table 6.18, 
Figure 3.2.15D,F).  Details of the hepatic TNF-α, IL-6 and IL-10 mRNA levels using 
the delta Ct and comparative Ct value method are provided in the Appendix (fed 
mice: Table 6.16; fasted mice: Table 6.18). 
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Figure 3.2.15. Hepatic TNF-α, IL-6 and IL-10 transcription levels after APAP dosing of fed 
and fasted male CD-1 mice.  
The hepatic mRNA levels of cytokines TNF-α (A, B), IL-6 (C, D) and IL-10 (E, F) were 
compared between 0.9% saline (control) and 530 mg/kg APAP dosed fed and fasted mice. 
Hepatic mRNA levels are calculated using the Ct value formula, 2-ΔCt. Data represent 
mean±SD (4 to 6 animals per group).  
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Comparison of the transcription levels was carried out by comparative Ct value 
method, assessing the fold change of treatment groups after normalising to 
controls. Statistical analysis was determined by the fold change in treated vs. time 
matched control mice. Details of the cytokines transcription were prepared in 
Appendix (fed mice: Tables 6.16-17 and fasted mice: Tables 6.18-19). 
TNF-α mRNA levels showed a significant 6-fold peak increase at 4 hpd and 4.5-fold 
increase at 10 hpd and had returned to control mouse levels at 24 hpd in fed mice 
(Figure 3.2.16A, Table 6.16). In fasted mice, TNF-α mRNA levels were not 
significantly increased at 1 and 4 hpd, but were statistically higher at 10 hpd (5.3-
fold) and 24 hpd (3.9-fold) compared to those in control mice (Figure 3.2.16B). In 
APAP dosed mice, TNF-α showed a gradual increase at 4 hpd (2.3-fold) and 10 hpd 
(5.3-fold) and reached a peak at 15 hpd (14.3-fold) before it went down significantly 
and was 4.8-fold higher at 20 hpd and 3.9-fold higher at 24 hpd (Table 6.18).  
In fed animals, although quite variable, IL-6 mRNA levels were significantly 
increased in APAP dosed mice throughout the experiment, with the following fold 
changes: 1 hpd (5-fold), 4 hpd (5.7-fold), 10 hpd (9.3-fold), and 24 hpd (5.6-fold) 
(Figure 3.2.16C, Table 6.16). In fasted mice, the IL-6 mRNA expression was 
upregulated consistently over the entire study period, with a significant increase at 
4 hpd (3.6-fold), 10 hpd (2.3-fold), and 24 hpd (6-fold) (Figure 3.2.16D, Table 6.18).   
IL-10 mRNA levels showed a significant 8-fold increase in fed APAP dosed mice at 4, 
10 and 24 hpd compared to the time matched control mice. Moreover, the levels 
reached a peak at 15 hpd (12-fold) before decreasing slightly, reaching an 8.7-fold 
higher level than control mice at 24 hpd, a difference that was not statistically 
significant upon comparison with the 4 to 24 hpd fold changes (Figure 3.2.16E, 
Table 6.16). In fasting mice, IL-10 transcription levels were similar to those observed 
in control mice at the earlier time points, but were increased significantly at 20 hpd 
(10.6-fold) and 24 hpd (12-fold) (Figure 3.2.16F, Table 6.18).   
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Figure 3.2.16. Hepatic TNF-α, IL-6 and IL-10 transcription levels in fed and fasted male CD-1 
mice after APAP dosing.  
The hepatic mRNA levels of cytokines TNF-α (A, B), IL-6 (C, D) and IL-10 (E, F) are shown in 
fed and fasted CD-1 mice after 530 mg/kg APAP administration. Hepatic mRNA levels are 
calculated using the comparative Ct values, assessing the fold change relative to respective 
time matched control mice, except *15 (relative to 10 h post saline) and *20 hpd (relative 
to 24 h post saline). Data represent mean±SD (4 to 6 animals per group). ***P<0.005, 
**P<0.01 and *P<0.05.  
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In order to assess the changes in cytokine levels in APAP dosed mice over the entire 
time period, we compared those to pooled values where different time-matched of 
all control mice had been taken together because we had not identified any 
statistical significant difference in their values over the study period (see Chapter 
3.1.7.1). This approach also detected a statistically significant difference in the 
hepatic TNF-α, IL-6 and IL-10 levels at different time points. Details of mRNA levels 
of these cytokines are provided in Appendix (fed: Table 6.17 and fasted: Table 6.19). 
In fed mice, the previous results were confirmed (see also Figure 3.2.16A) and TNF-
α mRNA levels were found to be significantly increased at 4 hpd (6.3-fold) and 10 
hpd (4.5-fold) before returning to basal levels at 15 to 24 hpd (Table 6.17). In fasted 
mice, similar to the previous results, significantly higher TNF-α mRNA levels were 
only observed at 10 hpd (6.8-fold) and 15 hpd (18.3-fold) (Table 6.19). While hepatic 
TNF-α mRNA levels were increased significantly at 4 hpd in fed mice, fasted mice 
had a sharp peak at 15 hpd before returned to controls thereafter (Figure 3.2.17A).  
 IL-6 mRNA levels were found to be significantly increased in fed APAP dosed mice 
at 4 hpd (6-fold), 10 hpd (7.9-fold), 20 hpd (15.8-fold), and 24 hpd (7.6-fold) while 
the previous results showed a significant increase also at 15 hpd (Table 6.17). In 
fasted mice, the IL-6 mRNA expression was upregulated gradually over the entire 
study period, with a significant increase at 4 hpd (4.7-fold), 20 hpd (5.3-fold) and 24 
hpd (7.4-fold) (Table 6.19), but the previous results (see Figure 3.2.16D) had a 
significant increase at 10 and 15 hpd. Meanwhile, hepatic IL-6 transcription was 
significantly higher at 10 hpd and much higher at 20 hpd in fed mice compared to 
fasted mice, before both reached a similar level at 24 hpd (Figure 3.2.17B).  
In fed animals, IL-10 mRNA levels were significantly increased in APAP dosed mice 
at 4 hpd (3.9-fold), 10 hpd (9-fold) and reached a peak at 15 hpd (13.2-fold) before 
decreasing slowly at 20 hpd (10.4-fold) and 24 hpd (8.8-fold) compared to pooled 
control mice (Table 6.17), which was similar to the previous results (Figure 3.2.16E). 
In fasting mice, different from the previous results (see Figure 3.2.16F), IL-10 mRNA 
levels was increased significantly at 20 hpd (4.6-fold) and 24 hpd (5.2-fold) only 
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(Table 6.19). Following APAP treatment, transcription of IL-10 was significantly 
higher in fed mice at 10, 15 and 20 hpd compared to fasted mice (Figure 3.2.17C). 
 
 
 
Figure 3.2.17. Hepatic TNF-α, IL-6 and IL-10 transcription levels in fed and fasted male CD-1 
mice after APAP dosing.  
Hepatic TNF-α (A), IL-6 (B) and IL-10 (C) transcription levels are compared between fed and 
fasted APAP dosed male CD-1 mice. Hepatic mRNA levels are calculated using the 
comparative Ct values, assessing the fold change relative to pooled control animals. Data is 
given as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.2.7.2 Splenic transcription of TNF-α and IL-6  
 
In order to assess whether APAP overdosing leads to a systemic inflammatory 
response as a consequence of hepatic damage, the splenic TNF-α and IL-6 
transcription was assessed at 10 to 24 hpd, using the delta Ct value and fold change 
method to compare the levels in fed and fasted treated and control mice (Table 
6.20, Figure 3.2.18).  
In fed animals, splenic TNF-α transcription levels were significantly higher at 10 hpd 
(3.9-fold) in APAP dosed mice and were found to have declined after that. IL-6 
mRNA levels were significantly higher at 20 hpd (3.9-fold) and 24 hpd (3.7-fold) 
compared to control mice and APAP dosed mice at earlier time-points (Table 6.20). 
In fasted mice, TNF-α transcription levels were significantly higher at 15 hpd (4.3-
fold), 20 hpd (7.2-fold) and 24 hpd (6.3-fold). In contrast, the IL-6 mRNA levels did 
not differ significantly from those of control animals at any time point (Table 6.20).  
The comparison of fed and fasted mice did not identify a statistically significant 
difference in the transcription of both TNF-α and IL-6 at 10 and 15 hpd; after that, 
at 20 and 24 hpd, the TNF-α mRNA levels were significantly higher and the IL-6 
mRNA levels were significantly lower in fasted mice (Table 6.20, Figure 3.2.18E,F).  
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Figure 3.2.18. Splenic TNF-α and IL-6 transcription in male CD-1 mice that had been either 
fed or fasted prior to APAP dosing.  
TNF-α and IL-6 mRNA levels were determined in fed (A, C) and fasted (B, D) CD-1 mice using 
the delta Ct value, 2-ΔCt. A comparison of levels in fed and fasted mice was undertaken using 
the comparative Ct value as fold change relative to respective to time-matched control 
mice, except *15 (relative to 10 h post saline) and *20 hpd (relative to 24 h post saline) for 
TNF-α (E) and IL-6 (F). Data represent mean±SD (4 to 6 animals per group). ***P<0.005, 
**P<0.01 and *P<0.05. 
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We also assessed the mRNA cytokine levels using pooled control values for the 
compare with those of APAP dosed mice at different time points, because we had 
not identified any statistical significant difference in the values of control animals 
over the entire time course (see Chapter 3.1.7.2). In fed animals, a statistical 
significant increase of splenic TNF-α transcription than pooled control mice was only 
seen at 10 hpd (4.4-fold) (Table 6.21). However, in fasted mice, the levels were 
always significantly higher at 10 hpd (4.1-fold), more extensively at 15 hpd (6.5-fold) 
and then reduced gradually at 20 (3.6-fold) and 24 hpd (3.2-fold). The comparison 
of values in fed and fasted mice did not recognise significant differences in TNF-α 
mRNA levels at 10 and 20 hpd, but a significant increase at 15 and 24 hpd in fasted 
compared to fed mice (Table 6.21, Figure 3.2.19A), but  the levels was also 
significant at 20 hpd (see Figure 3.2.18E). 
In contrast to splenic TNF-α, the IL-6 mRNA levels in the spleen were significantly 
increased at 20 hpd (3.8-fold) and 24 hpd (3.7-fold) in APAP dosed fed mice, but not 
at any time point in fasted treated animals. The comparison of both groups showed 
that splenic IL-6 mRNA levels were significantly higher at 20 and 24 hpd (both were 
approximately 3.8-fold) in the fed APAP dosed mice (Table 6.21, Figure 3.2.19B) as 
similar results shown previously (see Figure 3.2.18F).  
 
 
 
Figure 3.2.19. Splenic TNF-α and IL-6 transcription of in APAP dosed CD-1 mice. 
Splenic TNF-α and IL-6 mRNA levels are compared between fed and fasted APAP dosed 
male CD-1 mice. Splenic mRNA levels were compared using the comparative Ct value as 
fold change relative to pooled control animals. Data is given as mean±SD (4 to 6 animals per 
group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.2.7.3  Serum TNF-α and IL-6 levels  
Serum TNF-α and IL-6 levels were measured at 5 and 24 hpd. In fed mice, TNF-α 
levels were similar to those of the control mice at 5 hpd, but were significantly 
higher at 24 hpd (95.0±14.1 pg/mL) (Figure 3.2.20A). In fasted mice, serum TNF-α 
levels were significantly higher (227.8±53.6 pg/mL) at the same time point in 
comparison to control animals (63.1±19.7 pg/mL) (Figure 3.2.20B), these levels 
were also significantly higher than those of the fed mice at 24 hpd (Table 3.2.16). 
 Serum IL-6 levels were significantly higher in both fed (203.0±39.61 pg/mL) and 
fasted (96.4±35.2 pg/mL) APAP dosed mice in comparison to control mice 
(27.5±12.6 pg/mL) at 5 and 24 hpd (Figure 3.2.20C,D). The comparison of fed and 
fasted dosed mice showed that the IL-6 levels were significantly higher in the fed 
mice (Table 3.2.17).  
 
Table 3.2.16. Comparison of serum TNF-α and IL-6 levels (pg/mL) in control and APAP 
treated fed and fasted CD1 mice. Data is given as mean SD of 4 mice per group.  
 
hpd - hours post dosing, ToD -  time of day, SD - standard deviation, NS - not significant. 
Time 
(hpd) 
ToD 
dosing 
ToD 
killing 
Fed Fasted p-value 
fed vs 
fasted 
APAP  
Control 
(SD) 
APAP 
(SD) 
p-value 
control vs 
APAP 
Control 
(SD) 
APAP 
(SD) 
p-value 
control vs 
APAP 
5 10:00 15:00 
51.4  
(12.4) 
62.1 
(13.5) 
NS 
57.1  
(13.3) 
101.2 
(40.1) 
NS NS 
24 10:00 
10:00 
(+1) 
45.8  
(6.4) 
95.0 
(14.1) 
0.010 
63.1  
(19.7) 
227.8 
(53.6) 
0.007 0.022 
p-value   NS NS  NS 0.039   
Time 
(hpd) 
ToD   
dosing 
ToD  
killing 
Fed Fasted p-value 
fed vs 
fasted 
APAP 
Control 
(SD) 
APAP 
(SD) 
p-value 
control vs 
APAP 
Control 
(SD) 
APAP 
(SD) 
p-value 
control vs 
APAP 
5 10:00 15:00 
25.4  
(6.7) 
54.3  
(10.2) 
0.045 
23.1  
(4.1) 
35.4  
(10.5) 
0.049 0.039 
24 10:00 
10:00 
(+1) 
30.1 
(2.08) 
203.0  
(39.6) 
0.007 
27.49 
(12.6) 
96.4  
(35.2) 
0.020 0.009 
p-value    NS 0.006  NS NS   
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Figure 3.2.20. Serum TNF-α and IL-6 levels in control and APAP dosed male CD-1 mice. 
Serum TNF-α levels were determined after the administration of 530 mg/kg APAP or 0.9% 
saline (controls) in fed (A) and fasted (B) mice. Levels are compared between fed and fasted 
APAP dosed mice (C). Data is given as mean±SD (4 to 6 animals per group). **P<0.01 and 
*P<0.05. 
 
 
3.2.8 Assessment of liver regeneration based on hepatocellular proliferation   
Liver regeneration after acute APAP induced injury was assessed on the basis of 
three parameters: 1) NF-kB mRNA expression, as NF-kB appears to be a 
transcription factor that is upregulated by TNF-α and able to promote liver 
regeneration (Bhushan et al., 2014), 2) the transcription of cyclin-D1, a protein 
expressed in cells that have passed the G1 restriction point and entered the G1 
phase (Fausto, 2000), and 3) the expression of PCNA, a protein expressed in cells 
that have entered the cell cycle and head towards mitosis (Kurki et al., 1986). 
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3.2.8.1  Hepatic NF-kB mRNA transcription  
 
In fed APAP dosed mice, hepatic NF-kB mRNA levels were higher than in time 
matched saline dosed mice in the delta Ct method (Figure 3.2.21A), when the fold 
changes were assessed, NF-kB mRNA levels were found to be significantly increased 
at 4 hpd (4.7-fold), 10 hpd (17.6-fold), 15 hpd (13-fold), and 20 hpd (18.6-fold). 
After that they dropped, but were still 11.7-fold higher than in control animals at 24 
hpd (Table 6.22).  
In fasted mice, NF-kB transcription levels were not as high as in fed mice, but they 
were higher than in time matched fasted control animals at all time points (Figure 
3.2.21B). Comparative assessment of fold change showed the mRNA levels were 
similar at 15, 20 and 24 hpd and significantly higher than in the control animals (up 
to 6-fold), and they were significantly higher than the levels at 1, 4 and 10 hpd 
where an up to 3-fold increase was seen (Table 6.22). A comparison between fed 
and fasted mice showed that the NF-kB mRNA levels were significantly higher in the 
fed mice from 10 hpd until the end of experiment at 24 hpd (Table 6.22, Figure 
3.2.21C).  
The NF-kB mRNA levels of APAP dosed animals were also assessed relative to 
pooled control mice values because values had been found to be similar in saline 
dosed mice over the entire time course (see Chapter 3.1.8.1). Fed animals showed a 
statistically significant rapid increase in NF-kB mRNA levels at 10 hpd (13.3-fold) 
before decreasing slightly at 15 hpd (9.9-fold), 20 hpd (9.5-fold) and 24 hpd (6.1-
fold) (Table 6.23). In fasted mice, a significant increase was only recognised at 20 
and 24 hpd (both 4.7-fold). However, NF-kB mRNA levels were significantly higher in 
the fed mice at 10, 15 and 20 hpd compared to the fasted mice following APAP 
dosing (Table 6.23, Figure 3.2.21D), similar to the previous results for all time points 
apart from 24 hpd (see Figure 3.2.21C).  
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Figure 3.2.21. Hepatic NF-kB transcription in control and APAP dosed CD-1 mice.  
Hepatic NF-kB mRNA levels in fed (A) and fasted (B) were calculated using the delta Ct 
value, 2-ΔCt. NF-kB mRNA levels in fed and fasted (C) were compared using the comparative 
Ct values, assessing the fold change relative to respective time matched control mice, 
except *15 (relative to 10 h post saline) and *20 hpd (relative to 24 h post saline). Hepatic 
mRNA levels are also calculated using the comparative Ct values, assessing the fold change 
relative to pooled control animals (D). Data is given as mean±SD (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. 
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3.2.8.2  Hepatic cyclin-D1 transcription  
Hepatic cyclin-D1 transcription was also assessed as an indirect tool to quantify the 
proliferating hepatocytes, i.e. hepatocytes that are committed to DNA replication.  
Similar to NF-kB, cyclin-D1 transcription was significantly increased at 4, 10 and 24 
hpd in fed APAP dosed mice compared to saline dosed time matched control mice 
(Table 6.24). By using the fold change method, the significant increase at 4 hpd (8.6-
fold) was confirmed; after that the fold changes were less high, at 10 hpd (4.9-fold) 
and 15 hpd (3.9-fold), though the difference was still significant. However, at 20 hpd 
it had increased again and a peak (16-fold increase) was seen which was 
maintained, though at a slightly lower level, until 24 hpd (12.4-fold).  
In fasted mice, significantly increased cyclin-D1 mRNA levels were observed at 15 
hpd (6-fold), 20 hpd (4.3-fold) and 24 hpd (7.6-fold) compared to time matched 
saline dosed mice (Table 6.24). These levels were significantly higher than the 1, 4 
and 10 hpd levels, when a less than 3.0-fold change was observed in the APAP 
dosed animals. Over the time course, a significantly higher transcription level was 
seen in fed mice at 4 hpd, with no difference to fasted mice at 10 and 15 hpd, but 
significantly higher levels again at 20 and 24 hpd (Figure 3.2.22C).  
When the cyclin-D1 mRNA levels in APAP dosed animals were compared to pooled 
control animal values, the hepatic cyclin-D1 transcription was found to be 
significantly increased in fed treated animals as early as 4 hpd (8.1-fold), but also at 
10 and 15 hpd and even more at 20 hpd before it was slightly lower, but still 
significantly than in control mice at 24 hpd (Table 6.25). In fasted mice, however, a 
significant increase was only observed at 15 hpd (9-fold) and 24 hpd (6-fold). A 
comparison between fed and fasted APAP dosed animals confirmed that the cyclin-
D1 mRNA levels in fed mice were significantly higher at 4, 20 and 24 hpd (Table 
6.25, Figure 3.2.22D; see also Figure 3.2.22C).   
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Figure 3.2.22. Hepatic transcription of cyclin-D1 in male CD-1 mice.  
Hepatic cyclin-D1 mRNA levels in fed (A) and fasted (B) were determined using the delta Ct 
value, 2-ΔCt. Cyclin-D1 mRNA levels in fed and fasted (C) were compared using the 
comparative Ct values, assessing the fold change relative to respective time matched 
control mice, except *15 (relative to 10 h post saline) and *20 hpd (relative to 24 h post 
saline). Hepatic mRNA levels are also calculated using the comparative Ct values, assessing 
the fold change relative to pooled control animals (D). Data is given as mean±SD (4 to 6 
animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.2.8.3  Quantification of PCNA-positive, proliferating hepatocytes  
PCNA is a nuclear protein that is expressed in late G1 and throughout the S phase of 
the mitotic cycle, with translocation from the nucleus to the cytoplasm during the 
G2 and M phase (Kubben et al., 1994). The quantitative analysis of hepatocytes 
showing PCNA expression in immunohistologically stained sections was used to 
compare the degree of hepatocyte regeneration in fed and fasted APAP dosed mice. 
The pooled PCNA values of the saline dosed control animals served as control 
values, since no relevant differences in the amount of PCNA positive cells were seen 
throughout the time course (see Chapter 3.1.8.2).  
In fed APAP treated mice, the amount of PCNA-positive hepatocytes (both nuclear 
and cytoplasmic staining) was increased in comparison to control animals over the 
entire time course except at 15 hpd. APAP treatment induced increased PCNA 
expression in hepatocytes as early as 1 hpd (7.92% vs 7.39% in controls), though the 
difference was not significant. Interestingly, this was followed by a significant peak 
at 3 hpd (25.96%), a time when hepatocyte death (represented by the presence of 
apoptotic cells) and loss was seen. The level was reduced when tested at 5 and 10 
hpd, before it was found to have dropped substantially by 15 hpd, when the 
amount of PCNA-positive cells was lower than in control animals, though not 
significantly. After that, a progressively higher, significant increase was seen at 20 
and 24 hpd (Tables 6.26 and 6.27, Figure 3.2.24A).  
In fasted mice, the amount of PCNA-positive, proliferating hepatocytes was already 
increased slightly, but not significantly, at 0.5 hpd (10.42%) and 1 hpd (10.25%) 
(both groups of mice had been fasted for 16 hours prior to APAP dosing) in 
comparison to the control mice (5.3%). At 3, 5 and 10 hpd, mice that had been 
fasted for 24 hours prior to dosing were examined. In these, the PCNA levels were 
all slightly, but not significantly lower (at approximately 3%) than in the control 
mice. At the later time points, when 16 hour fasted mice were examined, at 15 hpd 
(9.3 %), 20 hpd (15.7%) and 24 hpd (13.1%), the number of PCNA-positive 
proliferating cells was found to be significantly increased in comparison to the 
control mice (Figure 3.2.24B). Interestingly, when a group of mice that had fasted 
Chapter 3.2 
131 
 
for 24 hours prior to APAP dosing was examined at 24 hpd, the amount of PCNA-
positive cells was significantly lower than in the mice that had fasted for 16 hours 
(Tables 6.26 and 6.27, Figure 3.2.24B).  
A comparison between fed and fasted CD-1 mice showed that the amount of PCNA 
expressing cells was significantly higher in fed mice at 3, 5 and 10 hpd (Figures 
3.2.24C, Table 6.27). The high amount of PCNA positive cells can be seen in fed but 
none in fasted mice at 5 hpd (Figure 3.2.23A,B). However, at 24 hpd, the PCNA 
expressing cells were obvious in both groups (Figure 3.2.23C,D).   
 
 
  Fed            Fasted 
 
 
 
Figure 3.2.23. Immunohistological demonstration of PCNA expression in the liver of fed and 
fasted APAP dosed male CD-1 mice. 
In fed mice, a large number of hepatocytes exhibit nuclear (white arrows), cytoplasmic 
(black arrows) PCNA expression at 5 hpd (A) and 24 hpd (C). In contrast, fasted mice show 
no PCNA-positive hepatocytes at 5 hpd (B), but a high amount at 24 hpd (D). PAP method, 
Papanicolaou’s haematoxylin counterstain; Magnification 400x.  
A B 
C D 
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Figure 3.2.24. Assessment of proliferating hepatocytes, based on the expression of 
proliferating cell nuclear antigen (PCNA). 
Quantification (%) of PCNA-positive hepatocytes (nuclear and cytoplasmic expression) in 
fed (A) and fasted (B) control and APAP dosed male CD-1 mice. The amount was also 
compared between fed and fasted treated mice (C). *Control – pooled control animals (fed: 
0 + 10 h post saline; fasted 0 – 24 h post saline). Data represent means±SD (4 to 6 animals 
per group). ***P<0.005, **P<0.01 and *P<0.05.  
 
 
Fed mice showed a step-wise increase in the number of cells exhibiting cytoplasmic 
PCNA expression (i.e. cells immediately prior to or undergoing mitosis), which was 
significant and at a peak at 5 hpd (1.02%). The amount of positive cells had dropped 
at 10 hpd and was again significantly increased at 20 hpd (1.04%) and 24 hpd 
(0.94%) compared to control animals (Table 6.29, Figure 3.2.25A). This was 
associated with an increase in histologically evident mitotic figures. In contrast, in 
fasted APAP dosed mice, we observed a rapid and significant increase in 
hepatocytes showing cytoplasmic PCNA expression compared to control animals as 
early as 0.5 hpd and until 5 hpd. Similar to fed animals, after a drop at 10 hpd, the 
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amount of positive cells progressively increased until 24 hpd (Figure 3.2.25B, Table 
6.29).   
Over the entire time period, the difference between fed and fasted APAP treated 
mice in the number of hepatocytes with cytoplasmic PCNA expression was not 
significant, apart from at 10 hpd, when their number was significantly higher in fed 
mice (0.27%) than in fasted mice (0.06%) (Figure 3.2.25C, Table 6.29).  
 
 
 
 
 
Figure 3.2.25. Assessment of hepatocytes exhibiting cytoplasmic PCNA expression. 
Quantification (%) of hepatocytes with cytoplasmic PCNA expression in fed (A) and fasted 
(B) APAP dosed male CD-1 mice. The percentage of positive hepatocytes was also 
compared between fed and fasted mice (C). *Control – pooled control animals (fed: 0 + 10 
h post saline; fasted 0 – 24 h post saline); Cyto – cytoplasmic.Data represent means±SD (4 
to 5 animals per group). **P<0.01 and *P<0.05.  
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Assessment of PCNA expression in fed mice over the entire time course shows a 
first peak of PCNA-positive cells at 3 hpd, indicating that a substantial proportion of 
remaining cells entered the cell cycle immediately after onset of hepatocellular cell 
loss. A first peak in the number of cells with cytoplasmic PCNA, i.e. prior to or in 
mitosis, was seen a bit later, at 5 hpd, subsequently, both numbers declined steadily 
until 10 hpd, indicating that the first cell cycle, i.e. wave of cell proliferation in 
response to APAP induced damage was completed. It also indicates that new 
hepatocytes then entered the cell cycle, leading to an increase in PCNA-positive 
cells after 15 hpd and a second wave of cell division towards 24 hpd (Table 6.27, 
Figure 3.2.26).  
However, in fasted mice, the first wave of PCNA expression, i.e. cell proliferation is 
not seen and there is evidence that proliferation only sets in after 10 hpd. Instead, 
the immediate increase in cytoplasmic PCNA expression, i.e. the number of cells 
prior to or within mitosis, that is seen between 1 and 5 hpd indicates that cells that 
were in the cell cycle when injury occurred (their amount would be represented by 
the number of PCNA-positive cells in control animals) are induced to rapidly 
complete the cell cycle upon injury (Table 6.29, Figure 3.2.26A,B).  
 
 
Figure 3.2.26. Assessment of hepatocytes exhibiting PCNA expression. 
The amount (%) of PCNA-positive cells (nuclear and cytoplasmic expression) (A) and of 
hepatocytes with cytoplasmic PCNA expression (B) was compared between fed and fasted 
APAP-dosed male CD-1 mice. *Control – pooled control animals (fed: 0 + 10 h post saline; 
fasted 0 – 24 h post saline); Cyto – cytoplasmic.Data represent means±SD (4 to 6 animals 
per group). ***P<0.005, **P<0.01 and *P<0.05.  
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3.2.9   Overall assessment of liver regeneration  
In this present study, we gathered quantitative data on parameters that provide 
information on the extent and capacity of the liver to regenerate, i.e. the 
transcription of TNF-α, IL-6 and IL-10), NF-kB and cyclin-D1 and the extent of PCNA 
expression to evaluate the effect of fasting on the capacity of liver to regenerate 
following APAP injury of CD-1 mice. To allow a comparative assessment of the data, 
the fold changes of each parameter was determined over the entire time course. 
In fed mice, an initial increment of TNF-α level was followed by an almost 
progressive increase in the transcription of IL-6 and IL-10, with a peak at 20 and 15 
hpd, respectively. By 10 hpd, a peak upregulation of TNF-α was accompanied by 
increased NF-kB and subsequently cyclin-D1 transcription that reached the highest 
levels at 20 hpd before all these markers reduced slightly at 24 hpd when complete 
regeneration appeared to have taken place. However, at this stage these levels 
were still significantly higher than in control mice. Meanwhile, hepatocytes showed 
an increased overall and cytoplasmic PCNA expression at 4 hpd and at the end of 
experiment, 20 and/or 24 hpd (Table 3.2.18).  
In contrast, in fasted mice, hardly any relevant changes were observed at early time 
points except for an increase in hepatocytes showing cytoplasmic PCNA expression. 
At 10 and 15 hpd, TNF-α upregulation was seen accompanied by the production of 
other markers, including IL-6, IL-10, NF-kB and cyclin-D1 and an increase in 
hepatocytes exhibiting cytoplasmic PCNA expression prior to its subsequent 
reduction to levels that were nonetheless still significantly higher than those of 
control mice.  Briefly, although values in fed and fasted mice did not differ much at 
4 hpd, fed mice showed higher expression of regeneration markers at 10 hpd which 
goes alongside the morphological evidence of better liver regeneration in the fed 
mice (Table 3.2.18, Figure 3.2.27).     
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Table 3.2.18. Fold change in the levels of TNF-α, IL-6, IL-10, NF-kB, cyclin-D1 and PCNA 
expression in fed and fasted male CD-1 mice following APAP dosing. 
Statistical significant, ***P<0.005, **P<0.01 and *P<0.05 are seen in the comparison to the 
pooled control mice; whereas ⱡP<0.05, ⱡⱡP<0.01, and ⱡⱡⱡP<0.005 are observed in comparison 
to fed and fasted APAP dosed CD-1 mice. hpd – hours post dosing; Cyto – cytoplasmic.  
 
 
 
Figure 3.2.27.  Assessment of liver regeneration in fed and fasted male CD-1 mice. 
The levels of hepatic TNF-α, IL-6, IL-10, NF-kB and cyclin-D1 mRNA and PCNA expression  
were evaluated over 1-24 h in animals that had been fed (A) or fasted (B) prior to APAP 
administration. A comparison of fed and fasted mice following APAP dosing is shown for 
each marker (as listed in Table 3.2.18). Fold changes are calculated relative to pooled 
control mice. Cyto – cytoplasmic. Data represent mean (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. 
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Fed 
Time 
(hpd) 
TNF-α IL-6 IL-10 NF-kB Cyclin-D1 
PCNA 
Nuclear + 
Cyto 
Cyto 
1 2.76 2.6 3.0 1.2 0.7 1.07 0.64 
4 4.4*ⱡ 6.0** 3.9* 2.1 8.1**ⱡ 2.11**ⱡⱡⱡ 3.64** 
10 7.9** 7.9**ⱡⱡ 9.0**ⱡⱡⱡ 13.3*** 8.7** 1.04ⱡ 0.96ⱡ 
15 2.0 4.5 13.2***ⱡⱡⱡ 9.85***ⱡⱡ 7.0* 0.52 1.25 
20 2.1 15.8***ⱡⱡⱡ 10.4***ⱡ 9.5***ⱡⱡ 12.8***ⱡⱡⱡ 1.33 3.71* 
24 1.77 7.6* 8.8** 6.1** 9.6**ⱡⱡ 2.03* 3.36* 
Fasted 
 Time 
(hpd) 
TNF-α IL-6 IL-10 NF-kB Cyclin-D1 
PCNA 
Nuclear + 
Cyto 
Cyto 
1 1.0 1.7 2.6 1.7 0.8 1.94 5.38*** 
4 2.3 4.7* 1.5 2.1 4.0 0.61 5.62*** 
10 6.8* 2.2 1.8 1.5 4.2 0.56 0.23 
15 18.3***ⱡⱡⱡ 4.5 3.9 3.2 9.0*** 2.20** 14.92** 
20 1.9 5.3* 4.6* 4.7* 3.2 2.97*** 4.77** 
24 1.5 7.4** 5.2* 4.7* 6.0* 1.58* 3.54*** 
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3.3  The response of fed and fasted C57BL/6J mice to APAP overdose and 
comparison to the response of CD-1 mice 
 
To test the response of C57BL/6J mice to APAP, in a similar fashion to the CD-1 
mice, male C57BL/6J mice that had been fed ad libitum throughout (fed mice) or 
had been fasted for 16 hours (fasted mice) received a sublethal dose of APAP or 
0.9% saline (control mice) intraperitoneally. The fasted mice were allowed access to 
food ad libitum immediately after dosing. This approach was taken for two reasons: 
a) to assess the potential differences in the response of the two groups of mice to 
APAP overdose with regards to the type and degree of acute liver injury and 
regeneration, and b) to assess the effect of fasting on the response in the C57BL/6J 
mice.  
None of the animals exhibited clinical signs, all resumed feeding after fasting and/or 
treatment. Groups of mice were euthanised at different time points between 0 and 
36 hpd, and, like in the CD-1 mice, several serum and liver parameters were 
assessed in order to monitor the hepatic and systemic effect of APAP dosing 
including serum ALT activity levels, hepatic GSH and ATP levels and the 
hepatocellular glycogen content as well as histopathological changes of the liver. 
The inflammatory and proliferative response of hepatocytes was also assessed by 
measuring the transcription levels of cytokines TNF-α, IL-6 and IL-10, and of the 
transcription factors NF-kB and cyclin-D1. The amount of PCNA-positive, 
proliferating hepatocytes was also assessed.   
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3.3.1    Hepatic GSH content  
In fed APAP dosed C57BL/6J mice, GSH levels had significantly dropped as early as 
30 minutes after APAP dosing, then showed a slight, but not significant further 
decrease at 1 hpd and reached the lowest value by 3 hpd. After that, the GSH 
content increased gradually from 5 to 30 hpd. At 24 hpd, it was still significantly 
lower than in control animals at the same time of day, while it was significantly 
higher at 30 hpd, a time of day, when levels were comparatively low in control 
mice. At 36 hpd, levels were similar to those of control mice (Table 3.3.1, Figure 
3.3.1A; see also Chapter 3.1.2 for the circadian control mouse values). 
 
Table 3.3.1. Mean GSH content (nmol/mg) with standard deviation (SD) in fed control 
(saline dosed) and APAP dosed male C57BL/6J mice at different times post dosing, with a 
comparison to the values obtained in CD-1 mice.  
Time 
(hpd) 
C57BL/6J CD-1 
ToD 
dosing 
ToD 
killing 
Mean (SD) p-value 
control vs 
APAP 
p-value APAP 
vs APAP 
Mean 
(SD) 
APAP 
p-value vs 
APAP 
C57BL/6J 
Control APAP 
0 10:00 10:00 - 
73.57 
(2.88) 
- 
0.5 h: 0.0004 
1 h: 0.0001  
5 h: 0.0002 
10,15 h: 0.0035 
28.81 
(5.0) 
NS 
0.5 10:00 10:30 - 
31.94 
(3.76) 
- 
5 h: 0.0004 
3 h: 0.0006 
- - 
1 10:00 11:00 - 
25.42 
(7.28) 
- 3 h: 0.0047 
5.30 
(3.65) 
0.0286 ↓ 
3 9:00 12:00 - 
1.68 
(0.85) 
- 
5 h: 0.003  
10 h: 0.0025 
- - 
*5 10:00 15:00 
83.85 
(6.65) 
17.78 
(8.77) 
0.006 20 h: 0.0021 
4.95 
(0.56) 
NS 
10 10:00 20:00 
40.12 
(7.52) 
31.28 
(6.45) 
NS 
3 h: 0.0027  
5 h: 0.0013 
40.28 
(0.74) 
NS 
15 17:00 8:00 
46.66 
(8.19) 
38.00 
(2.80) 
NS 
5 h: 0.0016  
20 h: 0.0199 
44.32 
(12.64) 
NS 
20 11:00 7:00 
53.21 
(8.86) 
61.30 
(11.0) 
NS 
30 h: 0.0072  
10 h: 0.019 
35.05 
(18.49) 
0.0294 ↓ 
24 10:00 
10:00 
(+1) 
82.26 
(5.48) 
69.75 
(7.86) 
0.034 
36 h: 0.0457  
15 h: 0.0283  
5 h: 0.0193 
45.47 
(10.05) 
0.0002 ↓ 
30 9:00 
15:00 
(+1) 
64.06 
(3.03) 
99.13 
(14.61) 
0.014 5 h: 0.0009 - 
24 h: 
0.0014 ↓ 
36 7:00 
19:00 
(+2) 
60.46 
(4.91) 
75.45 
(13.25) 
NS 15 h: 0.0088 - 
24 h: 
0.0128  ↓ 
hpd - hours post dosing;  ToD - time of day; SD - standard deviation; NS – not significant; *5 
– values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
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In comparison to time-matched APAP dosed CD-1 mice, the GSH levels were 
significantly higher at 1, 20 and 24 hpd in the C57BL/6J mice which were examined 
at the same time of day (Figure 3.3.1C).  
 
 
 
 
Figure 3.3.1. Hepatic GSH levels in fed male C57BL/6J mice after APAP treatment and 
comparison to fed CD-1 mice.  
Hepatic GSH levels were measured in fed mice at different time points (0-36 hpd) after 
APAP treatment (530 mg/kg) or 0.9% saline application (controls). (A) Comparison of GSH 
levels in APAP treated and control mice. (B) Comparison of GSH levels in treated C57BL/6J 
animals at different time points post treatment. (C) Comparison of GSH levels in fed APAP 
dosed C57BL/6J and CD-1 mice (as listed in Table 3.3.1). Values were expressed as mean±SD 
(4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
 
 
APAP treatment of fasted mice also led to an immediate drop in GSH levels as early 
as 30 minutes (Table 3.3.2, Figure 3.3.2A) compared to mice at 0 hpd which 
exhibited low GSH value due to the preceding fasting (see Chapter 3.1.2). The 
lowest level was again reached at 3 hpd, after which a gradual increase with until 20 
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hpd, followed by a slight, possibly time of day-related drop at 24 hpd but still 
significantly lower than basal levels. After that,  it reach a peak at 36 hpd and only 
had a same levels to controls(Table 3.3.2, Figure 3.3.2A); at both latter time points 
values did not differ significantly from those of the control animals at the same time 
of day. Over the time course post dosing, the values in treated animals varied 
significantly between time points (Table 3.3.2, Figure 3.3.2B).  
 
Table 3.3.2. Mean hepatic GSH content (nmol/mg) with standard deviation (SD) in control 
and APAP treated fasted C57BL/6J at different times post dosing, with p-value to CD-1 
APAP dosed mice. 
hpd - hours post dosing;  ToD - time of day; SD - standard deviation; NS – not significant; [1 
h] – values of CD-1 mice were obtained at 1 hpd; [4 h] – values of CD-1 mice were obtained 
at 4 hpd; [24 h] - values of CD-1 mice were obtained at 24 hpd.  
 
  
Time 
(hpd) 
C57BL/6J CD-1 
ToD 
dosing 
ToD 
killing 
Mean (SD) p value 
control vs 
APAP 
p-value 
APAP 
vs APAP 
p-value 
fasted vs 
fed 
Mean (SD) 
APAP 
p-value vs 
APAP 
C57BL/6J Control APAP 
0 10:00 10:00 - 41.52 
(6.85) 
- 
0.5 h: 0.0002 
3 h: 0.0001 
36 h: 0.0005 
0.034 
20.34 
(3.23) 
NS 
0.5 10:00 10:30 - 15.30 
(4.83) 
- 
3 h: 0.0054 
24 h: 0.0116 
36 h: 0.0001 
0.042 
[1 h]  
13.67 
(8.25) 
0.5 h: NS 
3 h:  
0.0134 ↑ 
3 9:00 12:00 - 2.02 
(0.14) 
- 
15 h: 0.0087 
20 h: 0.0256 
36 h: 0.0001 
NS - - 
5 10:00 15:00 
38.20 
(3.09) 
4.18 
(0.7) 
0.036 
15 h: 0.0122 
36 h: 0.0001 
0.034 
[4 h] 
4.47 
(3.57) 
5 h: NS 
10 10:00 20:00 
81.38 
(31.63) 
13.65 
(6.91) 
0.0001 36 h: 0.0002 0.017 
5.28 
(1.24) 
NS 
15 17:00 8:00 
125.29 
(5.45) 
22.04 
(6.47) 
0.0008 36 h: 0.0003 0.010 
33.98 
(16.15) 
NS 
20 11:00 7:00 
75.30 
(3.82) 
36.49 
(16.47) 
0.014 
0 h: 0.0028  
5 h: 0.029 
0.049 
49.26 
(7.82) 
NS 
24 10:00 
10:00 
(+1) 
38.23 
(4.6) 
29.94 
(3.77) 
0.045 
0 h: 0.0397  
5 h: 0.0044 
0.006 [24 h] 
50.57 
(25.22) 
 
NS 
36 7:00 
19:00 
(+2) 
87.98 
(2.12) 
72.43 
(1.38) 
NS 20 h: 0.0227 NS 36 h: NS 
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The comparison of GSH levels in fed and fasted APAP dosed mice which were 
always dosed and killed at the same time of day showed significantly lower GSH 
levels in the fasted mice at the early time points (0 and 5 hpd). However, at 10, 15 
and 20 hpd, the GSH content was significantly higher in the fasted mice (Table 3.3.2, 
Figure 3.3.2C). The comparison of GSH levels in fasted, APAP dosed C57BL/6J and 
CD-1 mice did not show any significant differences (Figure 3.3.2D).  
 
 
 
 
 
Figure 3.3.2. Hepatic GSH levels in fasted male C57BL/6J after APAP treatment and 
comparison to fasted CD-1 mice.  
Hepatic GSH levels were measured in fasted mice at different time points (0-36 h) after 
APAP treatment (530 mg/kg) or 0.9% saline application (controls). (A) Comparison of APAP 
treated and control C57BL/6J mice. (B)  Comparison of GSH levels in treated C57BL/6J mice 
at different time points. (C) Comparison of hepatic GSH content to that of fed APAP treated 
C57BL/6J mice), and also to fasted APAP treated CD-1 mice (D) (as listed in Table 3.3.2. 
Values were expressed as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and 
*P<0.05. 
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3.3.2  Hepatic ATP content 
In APAP treated fed C57BL/6J mice, hepatic ATP levels were determined between 5 
and 36 hpd compared to pooled control mice as no statistical significant was 
observed in control mice at any time points (see Chapter 3.1.3). At 5, 10 and 15 hpd, 
they were significantly lower than those in the control mice (Figure 3.3.3A), 
reaching levels similar to those of control animals at the same time of day by 20 hpd 
(Table 3.3.3). Looking at the time course, a significant increase in the ATP levels was 
seen from 5 to 20 hpd, after which the levels remained stable (Figure 3.3.3B). There 
was no difference in ATP levels between C57BL/6J and CD-1 mice except at 5 hpd 
when they were significantly higher in CD-1 mice (Table 3.3.3, Figure 3.3.3C).   
 
Table 3.3.3. Hepatic ATP content (nmol/mg) with standard deviation (SD) in fed control 
(saline) and APAP dosed mice at different time points post dosing. 
 
Time 
(hpd) 
C57BL/6J CD-1 
ToD 
dosing 
ToD 
killing 
Mean (SD) p-value 
control vs 
APAP 
p-value 
APAP vs 
APAP  
Mean 
(SD) 
APAP 
p-value vs 
APAP 
C57BL/6J 
Control APAP 
5 10:00 15:00 - 
4.95 
(2.47) 
- 
10 h: 0.0487 
15 h: 0.0032 
10.5 
(2.3) 
0.0057 ↑ 
10 10:00 20:00 
28.0 
(4.53) 
14.03 
(3.26) 
0.034 15 h: 0.025 
18.3 
(5.7) 
NS 
15 17:00 8:00 - 
21.10 
(3.47) 
- 
20 h: 0.0151 
36 h: 0.0094 
- - 
20 11:00 7:00 
30.2 
(3.25) 
29.38 
(4.82) 
NS 
5 h: 0.0015 
10 h: 0.0053 
15 h: 0.026 
 
- - 
24 10:00 
10:00 
(+1) 
- 
26.70 
(5.37) 
- 
35.4 
(3.9) 
NS 
30 9:00 
15:00 
(+1) 
26.75 
(2.33) 
24.98 
(5.25) 
NS - - 
36 7:00 
19:00 
(+2) 
24.48 
(5.26) 
29.50 
(1.97) 
NS - - 
Pooled 
control 
- - 
25.36 
(3.84) 
- 
5 h: 0.0001 
10 h: 0.0051 
15 h: 0.0253 
20, 24, 30, 
36 h: NS 
- - - 
hpd - hours post dosing;  ToD - time of day; SD - standard deviation; NS – not significant. 
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Figure 3.3.3. Hepatic ATP levels in fed male C57BL/6J mice after APAP treatment and 
comparison to fed CD-1 mice.  
Hepatic ATP levels were measured in fed C57BL/6J mice at different time points (5-36 h) 
after APAP treatment (530 mg/kg) or 0.9% saline application (controls). (A) Comparison of 
APAP treated and control C57BL/6J mice. (B) Comparison of ATP levels in treated C57BL/6J 
animals at different time points post treatment. (C) Comparison of hepatic ATP levels in 
APAP dosed C57BL/6J and CD-1 mice at 5, 10 and 24 hpd (as listed in Table 3.3.3). *Control - 
pooled control values. Values were expressed as mean±SD (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. 
 
In fasted C57BL/6J mice, hepatic ATP levels were measured between 5 and 36 hpd, 
the latter being the time point when the values returned to those of control mice in 
the fed APAP dosed group. After APAP dosing, ATP levels in fasted mice remained 
very low over the entirely time period and were significantly lower than in the 
respective time-matched control mice (Table 3.3.4, Figure 3.3.4A), remaining at the 
same very low level throughout (Figure 3.3.4B). There was a significant difference 
between ATP levels in fed and fasted C57BL/6J mice, as the ATP levels in the fed 
mice had rapidly recovered post APAP insult (Figure 3 3.4C). For a comparison to 
CD-1 mice, only a few values were available. These indicate that the liver of fasted 
CD-1 mice regains ATP faster than the liver of C57BL/6J mice (Figure 3.3.4D).  
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Table 3.3.4. Hepatic ATP content (nmol/mg) with standard deviation (SD) in fasted control 
(saline) and APAP dosed C57BL/6J mice at different times post dosing (10-36 hpd).  
 
Time 
(hpd) 
C57BL/6J CD-1 
ToD 
dosing 
ToD 
killing 
Mean (SD) p-value 
control vs 
APAP 
p-value 
vs APAP 
fasted 
p-value 
fasted 
vs fed  
Mean 
(SD) 
APAP 
p-value 
vs APAP 
C57BL/6J  
Control  APAP  
5 10:00 15:00 
12.8 
(3.5) 
3.27 
(2.03) 
0.0389 
NS at 
any time 
point 
NS 
3.5 
(4.9) 
NS 
10 10:00 20:00 
13.95 
(2.33) 
3.48 
(2.23) 
0.0405 0.0067 
3.4 
(1.2) 
NS 
15 17:00 8:00 
19.55 
(1.63) 
3.18 
(1.60) 
0.0079 0.0042 - - 
20 11:00 7:00 
25.2 
(3.25) 
2.48 
(1.59) 
0.0023 0.0038 
[24 h]  
8.1 
(1.3) 
20 h: 
0.010 ↑ 
36 7:00 
19:00 
(+2) 
28.15 
(4.60) 
4.48 
(2.31) 
0.0056 0.0025 36 h: NS 
hpd - hours post dosing;  ToD - time of day; SD - standard deviation; NS – not significant; [24 
h] – values of CD-1 mice were obtained at 24 hpd. 
 
 
 
 
 
Figure 3.3.4. Hepatic ATP levels in fasted male C57BL/6J mice after APAP treatment and 
comparison to CD-1 mice.  
Hepatic ATP levels were measured in fasted C57BL/6Jmice at different time points (10-36 h) 
after APAP treatment (530 mg/kg) or 0.9% saline application (controls). (A) Comparison of 
APAP dosed and control mice. (B) Comparison of ATP levels in APAP treated C57BL/6J mice 
at different time points. (C) Hepatic ATP levels in fed and fasted APAP dosed C57BL/6J mice. 
(D) Comparison of ATP levels in fasted APAP dosed C57BL/6J and CD-1 mice. Values were 
expressed as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.3.3  Hepatic GSH and ATP levels  
Similar to CD-1 mice (see Chapter 3.2.3), the fold changes in hepatic GSH and ATP 
levels were assessed in APAP dosed C57BL/6J mice and subsequently compared to 
those in APAP dosed CD-1 mice. APAP treatment of fed C57BL/6J mice resulted in a 
drop in hepatic GSH and ATP levels, with a similar fold change between 5 and 15 
hpd. At 20 and 24 hpd, levels had returned to levels close to those of control mice. 
At 30 hpd, while ATP levels were still low, the GSH levels were significantly higher 
than in controls (see also Figure 3.3.1A); by 36 hpd, both ATP and GSH levels were 
higher than in control animals (Table 3.3.5, Figure 3.3.5A). A comparison with fed 
CD-1 mice showed that at 10 hpd the GSH fold change was significantly higher in 
the CD-1 than in the C57BL/6J mice, while the ATP content was at a similar level in 
both strains (Figure 3.3.5B). However, at 24 hpd, ATP and GSH levels in both strains 
were similar to each other and to the time matched saline control mice (Table 3.3.5, 
Figure 3.3.5B).  
In fasted APAP dosed C57BL/6J mice, both GSH and ATP levels did not recover 
within 30 hours post dosing, though the GSH levels increased but ATP level was still 
significantly depleted (Figure 3.3.5C). The tendency was similar in fasted CD-1 mice, 
when the values at 10 hpd and the GSH values at 24 hpd were compared. 
Interestingly, at the end of the experiment, i.e. at 24 hpd in CD-1 mice and at 36 
hpd in C57BL/6J mice, the value was still lower in the C57BL/6J mice, though 
without statistical significance (Table 3.3.5, Figure 3.3.5D).    
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Table 3.3.5. Comparison of GSH and ATP levels in fed and fasted male C57BL/6J mice after 
APAP overdose and comparison to CD-1 mice.  
 
Time 
(hpd) 
Fed 
GSH ATP 
p-value 
GSH vs 
ATP 
C57BL/6J 
Control APAP 
Fold 
change 
p-
value 
vs 
CD-1 
Control APAP 
Fold 
change 
p-
value 
vs 
CD-1 
5 83.85 17.78 0.21 - - 4.95 (0.18) - NS 
10 40.12 31.28 0.78 0.01 28.00 14.03 0.50 NS NS 
15 46.66 38.00 0.81 - 29.00 21.10 0.75 - NS 
20 53.21 61.30 1.15 - 30.20 29.38 0.97 - NS 
24 82.26 69.75 0.85 NS 28.00 26.70 1.00 NS NS 
30 64.06 99.13 1.55 - 26.75 24.98 0.93 - NS 
36 60.46 75.45 1.25 - 24.48 29.50 1.21 - NS 
Time 
(hpd) 
Fasted 
GSH ATP 
p-value 
GSH vs 
ATP 
C57BL/6J 
Control APAP 
Fold 
change 
p-
value 
vs 
CD-1 
Control APAP 
Fold 
change 
p-value 
vs  
CD-1 
10 81.38 13.65 0.17 NS 13.95 3.48 0.25 NS NS 
15 125.3 22.04 0.18 - 19.55 3.18 0.16 - NS 
20 75.30 36.49 0.48 - 25.20 2.48 0.10 - NS 
24 38.23 29.94 0.78 NS - - - - - 
36 87.98 72.43 0.82 - 28.15 4.48 0.16 
(24h) 
NS 
0.027 
(24 h) - 24 hpd values of CD-1 mice were compared with the 36 hpd values of fasted 
C57BL/6J mice; (0.18) - fold change ATP obtained at 5 h post APAP was normalised to 10 h 
post saline.  
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Figure 3.3.5. Hepatic ATP and GSH levels in male C57BL/6J mice after APAP overdose and 
comparison to CD-1 mice.  
The fold change in hepatic ATP and GSH levels was determined in male C57BL/6J mice after 
APAP treatment of fed (A) and fasted (C) mice. The fold changes were also compared 
between C57BL/6J and CD-1 mice at 10 and 24 hpd in animals that had been fed (B) or 
fasted (D) prior to dosing (as listed in Table 3.3.5). The fold changes in APAP dosed mice 
were normalised to control mice. *ATP – ATP values obtained at 36 hpd in C57BL/6J mice 
and at 24 hpd in CD-1 mice. Values were expressed as mean (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. Fold change = 1 : Levels in saline dosed control mice. 
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3.3.4   Serum ALT levels    
Following APAP dosing, fed C57BL/6J mice exhibited significantly elevated ALT 
throughout the entire examination period, between 3 and 36 hpd (Table 3.3.6 and 
Figure 3.3.6A). Looking at the time course it becomes obvious that after the initial 
raise in serum ALT towards 3 hpd, the increase towards 5 hpd was again significant. 
Between 5 and 15 hpd, values remained at a similar level, after which they 
increased further and reached a peak at 24 hpd, followed by a significant drop 
towards 36 hpd (Figure 3.3.6B). ALT values were available from CD-1 mice at 5 and 
24 hpd, these were very similar to those of the C57BL/6J mice (Figure 3.3.6C). 
 
Table 3.3.6. Mean serum ALT levels (U/L) with standard deviation (SD) in fed control 
(saline) and APAP dosed male C57BL/6J mice at different times post dosing, including 
comparison to values in CD-1 mice.  
 
hpd - hours post dosing; ToD - time of day; SD - standard deviation; NS – not significant; 
Pooled control – average of all values from control animals at all different time points. 
  
Time 
(hpd) 
ToD 
dosing 
ToD 
killing 
Control APAP p-value 
control vs 
APAP 
p-value APAP 
vs APAP 
p-value 
vs 
APAP 
CD-1 
Mean SD Mean SD 
3 9:00 12:00 - - 1004.74 252.56 - 5 h: 0.0286 - 
5 10:00 15:00 14.92 10.41 2056.82 214.47 0.012 
20 h: 0.0233  
24 h: 0.0024 
NS 
10 10:00 20:00 29.75 8.66 2066.58 79.56 0.016 - - 
15 17:00 8:00 22.88 6.7 1964.11 246.04 0.022 24 h: 0.0024 - 
20 11:00 7:00 28.00 7.24 2598.31 217.24 0.008 - - 
24 10:00 10:00 (+1) 8.49 7.28 2709.49 231.65 0.004 36 h: 0.0491 NS 
36 7:00 19:00 (+2) 15.78 7.24 1763.94 539.04 0.042 - - 
Pooled 
control 
- - 18.86 7.54 - - 
3 h: 0.0059  
5 h: 0.0033 
10 h: 0.0002 
15 h: 0.0031  
20 h: 0.0006 
24 h: 0.0001 
36 h: 0.0078 
- - 
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Figure 3.3.6. Serum ALT levels in male fed C57BL/6J mice after APAP overdose and 
comparison to fed CD-1 mice. 
The serum ALT levels in fed C57BL/6J mice were assessed over 3-36 h in 0.9% saline 
(control) and APAP (530 mg/kg) dosed mice. (A) Comparison of APAP dosed and control 
mice. (B)  Comparison of ALT levels in treated C57BL/6J animals over time and (C) 
comparison to fed APAP treated CD-1 mice (as listed in Table 3.3.6). *Control – pooled 
control values. Values were expressed as mean±SD (4 to 6 animals per group). ***P<0.005, 
**P<0.01 and *P<0.05.  
 
In fasted C57BL/6J mice, a similar increase in ALT activity was observed after APAP 
dosing, with significantly elevated levels throughout the entire examination period, 
i.e. between 3 and 36 hpd (Figure 3.3.7A). Early after APAP dosing, at 3, 5 and 10 
hpd, levels in fasted mice were similar to those in fed mice; however, at the later 
time points, they were significantly higher than in the fed mice and had only 
dropped minimally towards 36 hpd (Table 3.3.7 and Figure 3.3.7B,C). Again, ALT 
values in fasted CD-1 mice which were available at 5 and 24 hpd, were very similar 
to those of the C57BL/6J mice (Figure 3.3.7D).  
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Table 3.3.7. Mean serum ALT levels (U/L) with standard deviation (SD) in fasted control 
(saline) and APAP dosed C57BL/6J mice and comparison to CD-1 mice.  
 
 
Figure 3.3.7. Serum ALT levels in fasted C57BL/6J mice after APAP overdose and 
comparison to fasted CD-1 mice. 
The serum ALT levels in fasted C57BL/6J mice were assessed over 3-36 h in 0.9% saline 
(control) and APAP (530 mg/kg) dosed mice. (A) Comparison of APAP treated and control 
mice. (B) Comparison of ALT levels in treated C57BL/6J mice over time and (C) comparison 
to fed mice. (D) Comparison of serum ALT levels to fasted APAP dosed CD-1 mice (as listed 
in Table 3.3.7). *Control – pooled control values. Values were expressed as mean±SD (4 to 6 
animals per group). ***P<0.005, **P<0.01 and *P<0.05.  
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3 - - 1470.74 345.02 - 5 h: NS NS - 
5 11.67 7.16 2240.83 425.04 0.0057 24 h: 0.0133 NS NS 
10 36.03 8.66 1972.96 836.01 0.0238 
15 h: 0.0087  
36 h: 0.0288 
NS - 
15 29.85 7.6 3064.23 91.18 0.0018 24 h: NS NS - 
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3.3.5 Histopathological features and glycogen content of the liver 
Similar to CD-1 mice (see Chapter 3.2.5), the effect of APAP dosing in C57BL/6J mice 
was also assessed histologically, using HE-stained liver sections and those stained 
with the PAS reaction. All of animals had been dosed in the morning (10:00), except 
15 hpd (17:00). Detailed descriptions of the histological findings and DILI scores of 
all animals were prepared by Fazila Hamid and Prof Anja Kipar independently and in 
a blinded fashion. After a consultative discussion, final descriptions and scores were 
prepared (fed mice: Tables 3.3.8 and 6.31; fasted mice: Tables 3.3.10 and 6.32).  
In fed C57BL/6J mice, at 0, 0.5 and 1 hpd, no histopathological changes and diffuse 
hepatocellular glycogen accumulation were observed. At 3 hpd, centrilobular cell 
loss with no or very few apoptotic hepatocytes was seen (Figure 3.3.10A). The 
presence of apoptotic cells was confrmed by their cleaved caspase-3 expression. 
Alongside this, the presence of several neutrophils in centrilobular areas suggested 
recruitment of inflammatory cells. In these areas, some hepatocytes appeared 
slightly swollen and vacuolated (early hydropic degeneration) and the 
hepatocellular glycogen had been lost.  
Mice that had been killed at 5 hpd showed more extensive centrilobular cell loss 
than those at 3 hpd while there were no or only very occasional cleaved caspase-3 
positive apoptotic cells, and marked neutrophil infiltration with erythrocytes filling 
up the areas of hepatocytes loss; no hepatocellular glycogen was seen in the 
affected zone 3. At 10 hpd, ongoing cell damage with morphological features of 
apoptosis was still present, but to a lesser extent, and few mitotic figures were seen 
in hepatocytes. Mice that had been killed at 15 hpd showed more centrilobular cell 
loss and PAS-negative centrilobular hepatocytes than at 10 hpd; however, these 
mice had been dosed in the late afternoon (17:00) whereas all other mice had been 
dosed between 7:00 to 11:00 in the morning. At 20 hpd, ongoing centrilobular cell 
death was seen, as reflected by the presence of occasional apoptotic hepatocytes 
similarly as morphological observed at 24 hpd (Figure 3.3.11A). At this stage, diffuse 
hepatocellular glycogen accumulation was seen, sparing the innermost centrilobular 
cell layers. Hydropic degeneration was seen in hepatocytes surrounding the 
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affected area. At 30 and 36 hpd, the innermost centrilobular cell layer exhibited 
coagulative necrosis and a few apoptotic cells as well as a few infiltrating 
neutrophils, but almost complete glycogen deposition (Table 3.3.8, Figure 3.3.14).  
Table 3.3.8. Histological findings in APAP dosed fed C57BL/6J mice (time course). The 
histological findings are summarised for each group of animals examined at each time point 
and the range of DILI grading scores of each group (4 to 6 animals per group). CL – 
centrilobular; HD - hydropic degeneration, hpc - hepatocytes, CN - coagulative necrosis, NL 
– neutrophilic leukocytes; CC3 – Cleaved caspase-3; haemorrhage – erythrocytes filling up 
the space in areas of hepatocyte loss. 
 
A summary of the findings with the range of scores and average scores is recorded 
over the time course in Table 3.3.9 and Figure 3.3.8. The earliest histological 
damage was seen at 3 hpd. At 5 hpd, the most severe changes were observed, with 
a drop thereafter (Figure 3.3.8A), except at 15 hpd, which was the group of animals 
that had been dosed at 17:00.  
Although DILI scores in C57BL/6J mice were always higher than in CD-1 mice, 
statistically significant differences were only identified at 24 hpd; the differences 
were also significant at 30 and 36 hpd, in which liver damage was still present in fed 
C57BL/6J mice compared to CD-1 mice at 24 hpd (0 score) where complete 
Time 
(hpd) 
Score range 
[mean] 
Histological findings 
0 0 NHAIR; PAS:  Diffuse glycogen 
0.5 0 NHAIR; PAS: Diffuse glycogen 
1 0 NHAIR; PAS: Diffuse glycogen 
3 0.5-2 [1.25] 
CL hpc loss and haemorrhage with several infiltrating NL;  no or very 
occasional apoptotic hpc and HD of remaining cells in affected CL areas; 
PAS: loss of glycogen in hpc surrounding affected areas; CC3: + 
5 1-4 [2.75] 
More extensive CL hpc loss with haemorrhage and marked NL infiltration; 
PAS:  loss of glycogen in hpc surrounding affected areas; CC3: + 
10 1-2.5 [1.5] 
CL hpc loss with moderate NL infiltration; scattered mitotic figures; PAS: no 
glycogen in 3-4 layers of hpc in affected CL areas 
15 1-2.5 [2.17] 
CL hpc loss with haemorrhage and moderate NL infiltration at zone 3 and 2; 
PAS: no glycogen in affected CL areas. 
20 0-2.5 [1.3] 
CN and HD of remaining CL hpc with evidence of apoptotic cells and NL 
infiltration; PAS: no glycogen in hpc in affected CL areas. 
24 1-1.5 [1.15] 
CN and HD of remaining CL hpc with mild NL infiltration; PAS: no glycogen in 
2-3 CL hpc layers; CC3: +/++ 
30 0-1.5 [0.75] 
2-3 innermost CL hpc layers with CN and few infiltrating NL; PAS: no 
glycogen in CL hpc layers; CC3: + 
36 0-1.5 [0.8] 
CN of 1-2 innermost CL hpc layers with some apoptotic cells; PAS: diffuse 
glycogen in hpc surrounding the CN layers; CC3: + 
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regeneration was observed (Figure 3.3.8B). In the C57BL/6J mice, ongoing cell 
damage was represented by the presence of cleaved caspase-3 positive apoptotic 
cells and cells with morphological features of coagulative necrosis in the innermost 
centrilobular hepatocyte layers, surrounded by a layer of cells with hydropic 
degeneration; this was accompanied by a lack of hepatocellular glycogen 
accumulation in affected areas (Figure 3.3.12A,C,E). In the fed CD-1 mice, the 
histological features suggested complete regeneration and complete glycogen 
restitution at 24 hpd (Figure 3.3.12B,D,F), whereas the pictures in the fed C57BL/6J 
mice was similar to that seen in the fasted CD-1 at this time point (see also Figure 
3.2.13). 
 
Table 3.3.9. Histological DILI scores in APAP dosed fed C57BL/6J mice (time course) and 
comparison to CD-1 mice.  
Time 
(hpd) 
C57BL/6J CD-1  
ToD 
dosing 
ToD 
killing 
n 
Score 
range 
[mean]  
SD 
p-value 
APAP fed 
Mean 
score 
p-value to 
fed APAP  to 
C57BL/6J 
0 10:00 10:00 4 0 0 
Score 0 vs: 
3 h: 0.0286  
5 h: 0.0206 
20 h: 0.0028 
24 h: 0.023 
36 h: 0.0286 
0 NS 
0.5 10:00 10:30 4 0 0 0 NS 
1 10:00 11:00 4 0 0 0 NS 
3 9:00 12:00 4 0.5-2 [1.25] 0.58 - 1.25 NS 
5 10:00 15:00 6 1-4 [2.75] 1.22 24 h: 0.0405 2.2 NS 
10 10:00 20:00 9 1-2.5 [1.5] 0.5 - 1 NS 
15 17:00 8:00 8 1-2.5 [2.17] 0.58 20 h: 0.0273 1.125 NS 
20 11:00 7:00 9 0-2.5 [1.3] 0.61 24 h: 0.0357 0.65 NS 
24 10:00 
10:00 
(+1) 
5 1-1.5 [1.15] 0.47 15 h: 0.0263 0 0.0231 
30 9:00 
15:00 
(+1) 
4 0-1.5 [0.75] 0.61 5 h: 0.0383 - ~ 0.0447 
36 7:00 
19:00 
(+2) 
4 0-1.5 [0.8] 0.13 
15 h: 0.0471 
5 h: 0.0435 
- ~ 0.0095 
hpd – hours post dosing; ToD – time of days; n - number of animals used per group; SD – 
standard deviation; NS – not significant; ~ - p-value of histological score at 30 or 36 hpd in 
C57BL/6J mice compared to 24 hpd scores in CD-1 mice.  
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A. Fed C57BL/6J                                              B. Fed C57BL/6J and CD-1 
 
 
Figure 3.3.8. Histological scoring in fed C57BL/6J mice after APAP overdose and comparison 
to the scores in CD-1 mice. 
(A) Average histological grading scores in fed C57BL/6J mice over 0-36 hpd. (B) Comparison 
of scores in fed C57BL/6J and CD-1 mice (as listed in Table 3.3.9). Data represent mean±SD 
(4 to 9 animals per group). *P<0.05, and histological score at 30 or 36 hpd in C57BL/6J mice 
compared to 24 hpd scores in CD-1 mice (B). 
 
In fasted C57BL/6J mice, no histological abnormalities were detected up to 3 hpd 
(Figures 3.3.8 and 3.3.10B). While complete glycogen cell loss was seen immediately 
after fasting (at 0 hpd; see Chapter 3.1.6), a low degree of glycogen restitution was 
seen at 30 minutes up to 3 hpd (Figure 3.3.10D). However, by 5 hpd, fasted mice 
showed the highest DILI scores (score 3.25) with extensive centrilobular cell loss and 
bridging necrosis. Meanwhile, PAS-positive cells were hardly seen except in some 
periportal regions. Centrilobular cell loss associated with scattered apoptotic cells 
and no or few hepatocytes that contained glycogen were seen at 10 and 15 hpd, 
with similar DILI scores to fed mice. At 20 and 24 hpd, there was evidence of 
coagulative necrosis of the innermost centrilobular cell layers and hydropic 
degeneration surrounding the areas of cell loss, whereas glycogen was accumulated 
in hepatocytes outside the affected areas (Figure 3.3.13C). At 36 hpd, the degree of 
centrilobular cell loss was slightly less intense and diffuse hepatocellular glycogen 
accumulation was seen outside the centrilobular areas with still some evidence of 
apoptotic cells centrilobularly (Figure 3.3.14).    
  
0
1
2
3
4
0 0.5 1 3 5 10 15 20 24 36
H
is
to
lo
gi
ca
l s
co
re
 
Time (hpd) 
Fed
  * 
  * 
 * 
  * 
  * 
 * 
   * 
0
1
2
3
4
0 0.5 1 3 5 10 15 20 24 30 36
H
is
to
lo
gi
ca
l s
co
re
 
Time (hpd) 
C57BL/6J
CD-1
* 
* * 
Chapter 3.3 
155 
 
Table 3.3.10. Histological findings in APAP dosed fasted C57BL/6J mice (time course).  
The histological findings are summarised for each group of animals examined at each time 
point and the range of grading scores of each group (4-6 animals per group). hpd – hours 
post dosing; NHAIR – no histological abnormality is recognised; CL - centrilobular; hpc – 
hepatocytes; NL – neutrophilic leukocytes; HD - hydrophic degeneration; CN – coagulative 
necrosis; CC3 – Cleaved caspase-3.  
 
 
The comparison between fed and fasted C57BL/6J mice showed that fed C57BL/6J 
mice started to show cell loss and a score at 3 hpd, whereas the fasted mice showed 
still no morphological abnormality (Figure 3.3.10A-D); but the first evidence of 
APAP-induced damage only at 5 hpd, however, at this time point, the most severe 
damage was observed (highest scores), before the scores dropped again. Fasted 
mice showed more severe liver injury than fed mice, with significantly higher 
average scores at 24 hpd (Figure 3.3.11). By 36 hpd, centrilobular cell loss with 
morphological features of coagulative necrosis, and glycogen loss was more 
extensive in fasted mice with evidence of cleaved caspase-3 positive cells 
centrilobularly (Figure 3.3.14A-F).     
Time 
(hpd) 
Score 
range 
[mean] 
Histological findings 
0 0 NHAIR; PAS: No glycogen 
0.5 0 NHAIR; PAS: Diffuse glycogen (relatively low amount) 
1 0 NHAIR; PAS: Diffuse glycogen 
3 0 NHAIR; PAS: Diffuse glycogen with variable intensity 
5 
2-4  
[3.25] 
CL cell loss with bridging necrosis of innermost CL hpc layers and numerous NL; 
PAS: diffuse glycogen loss, except in some periportal hpc with variable amount 
10 
1-3  
[2.13] 
CL cell loss with NL infiltration, few apoptotic cells; PAS: scattered random hpc 
containing glycogen 
15 
1-2  
[1.75] 
CL cell loss with a few scattered apoptotic cells and substantial NL infiltration;  
PAS: no glycogen 
20 
1-3  
[2] 
CN of innermost 2-3 CL hpc layers with HD of few remaining hpc at zone 2 
(between affected and unaffected areas); few apoptotic cells; PAS: no glycogen 
except in a few scattered random individual hpc 
24 
2-2.5 
[2.1] 
Similar to 20 hpd; CN, HD and occasional apoptosis of remaining hpc in affected CL 
areas; PAS: no glycogen in affected CL areas of zone 3. CC3: ++ 
36 
1-2 
[1.5] 
CN of innermost 2-3 CL hpc layers with moderate NL infiltration and some apoptotic 
hpc; PAS: diffuse glycogen outside affected areas. CC3: +  
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Table 3.3.11. Histological scores in APAP dosed fasted C57BL/6J mice (time course) and 
comparison to CD-1 mice. 
hpd – hours post dosing; n - number of animals in group; SD – standard deviation; NS – not 
significant. 
 
 
 
 
Figure 3.3.9. Histological scoring in fasted C57BL/6J and CD-1 mice after APAP overdose. 
(A) Histological grading score in fasted C57BL/6J mice over 0-36 hpd. (B) Comparison of 
APAP scores in fed and fasted APAP treated C57BL/6J mice. (C) Scores in fasted APAP 
treated C57BL/6J mice were compared to those in CD-1 mice (as listed in Table 3.3.11). 
Data represent mean±SD (4 to 9 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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Fed                                                         Fasted 
 
   
 
 
 
Figure 3.3.10. Assessment of histopathological features and glycogen content in fed and 
fasted C57BL/6J mice with comparison to CD-1 mice at 3 hours post APAP (530 mg/kg) 
treatment.  
There is centrilobular hepatocyte loss (score 1.25) with haemorrhage (black arrows) in fed 
C57BL/6J mice (A), together with a loss of hepatocellular glycogen at affected areas (C). In 
fasted C57BL/6J mice, no histological abnormality is identified (score 0) (B), and the almost 
diffuse glycogen accumulation (D) indicates glycogen restitution after the fasting period. At 
the same time point, CD-1 mice showed similar degree of hepatocytes loss (score 1.25) in 
fed (E) and more intense centrilobular cell loss (score 2.05) in fasted (F) animals (see also 
Figure 3.2.10). A, B, E, F: HE stain; C, D: PAS reaction. Magnification 100x. 
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Figure 3.3.11. Assessment of histopathological features and glycogen content in fed and 
fasted C57BL/6J mice at 24 h post APAP (530 mg/kg) treatment.  
Fed mice (A) showed centrilobular hepatocyte loss and coagulative necrosis (score 1.15), 
surrounded by a layer of hepatocytes with hydropic degeneration (black arrows). In fasted 
mice (B), changes were similar but generally more extensive (score 2.1) with marked 
neutrophil infiltration (black arrows) was seen. HE stain. Magnification x200 (A, B). 
 
Comparison of average scores in fasted animals of both strains showed higher DILI 
scores in CD-1 mice from 10 to 24 hpd, but without statistically significant 
difference. The latter was only found at 3 hpd, as fasted CD-1 mice exhibited liver 
damage earlier than fasted C57BL/6J mice. In fasting animals, hepatocellular 
damage that reflected by coagulative necrosis was similar in C57BL/6J mice and CD-
1 mice with no glycogen at affected region, but more neutrophils infiltration was 
seen in C57BL/6J mice (Figure 3.3.13A-D; see also Figure 3.3.11B). Meanwhile, 
evidence of ongoing cell death by expression of positive cleaved caspase-3 was also 
not differ in both CD-1 and C57BL/6J mice (Figure 3.3.13E,F).  
A 
B 
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Figure 3.3.12. Assessment of histopathological features and glycogen content in fed 
C57BL/6J and CD-1 mice at 24 h post APAP (530 mg/kg) treatment.  
In C57BL/6J mice, there is evidence of ongoing centrilobular cell death (score 1.15) (via 
coagulative necrosis and apoptosis (A, E) and degeneration (A; see also Figure 3.3.11A) and 
a lack of hepatocellular glycogen in affected areas (C). In contrast, livers of CD-1 mice 
appeared unaltered and showed evidence of complete regeneration with evidence of 
numerous mitotic figures (score 0) (B) and diffuse glycogen restitution (D) and without 
evidence of apoptosis (F). A, B: HE stain: C, D: PAS reaction. E, F: Staining for cleaved 
caspase-3, PAP method, Papanicolaou’s haematoxylin counterstain. Magnification x200 (A, 
B), x40 (C, D) and x400 (E, F).   
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     C57BL/6J                          CD-1 
 
 
  
 
 
 
Figure 3.3.13. Assessment of histopathological features and glycogen content in fasted 
C57BL/6J and CD-1 mice at 24 h post APAP (530 mg/kg) treatment.  
In C57BL/6J mice, there is centrilobular hepatocyte loss (score 2.1), surrounded by layers of 
coagulative necrosis (A) and apoptotic cells death (E). Affected centrilobular areas lack 
glycogen and the amount of glycogen outside these areas is low and variable (C). In CD-1 
mice, coagulative necrosis of the innermost centrilobular hepatocyte layer is seen (score 
2.38), surrounded by hepatocytes undergoing hydropic degeneration (black arrows) (B), 
intermingled with a few apoptotic cells (F). There is diffuse glycogen restitution outside the 
affected centrilobular areas (D). A, B: HE stain; C, D: PAS reaction; E, F: Staining for cleaved 
caspase-3, PAP method, Papanicolaou’s haematoxylin counterstain. Magnification x200 (A, 
B, E, F) and x100 (C, D).  
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Figure 3.3.14. Assessment of histopathological features and glycogen content in fed and 
fasted C57BL/6J at 36 h post APAP (530 mg/kg) treatment.  
In fed mice, mild centrolobular coagulative necrosis (score 0.8) (A; black arrow) and 
occasional hepatocyte apoptosis (E; black arrows) is seen. There is diffuse glycogen 
accumulation outside a centrilobular, approximately 2-3 cell layer wide area (C) In fasted 
mice, ongoing centrilobular cell death was more extensive (score 1.5), with innermost 
layers of coagulative necrosis (B; black arrows) and apoptosis (F; black arrows). There is 
diffuse hepatocellular glycogen accumulation outside the affected centrilobular areas (D). 
A, B: HE stain; C, D: PAS reaction; E, F: Staining for cleaved caspase-3, PAP method, 
Papanicolaou’s haematoxylin counterstain (E). Magnification x200 (A, B, E, F) and x100 (C, 
D).   
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3.3.6 Overall assessment and comparison of liver damage in C57BL/6J and CD-1 
mice  
The degree of liver damage following APAP overdose was assessed in male C57BL/6J 
and CD-1 mice based on the levels of hepatic GSH and ATP and serum ALT, together 
with the DILI scores at 5, 10 and 24 hpd (Table 3.3.12). Data are presented as fold 
change relative to time-matched control animals, except for the DILI scores (use of 
raw data).  
In control animals, serum ALT levels in C57BL/6J mice were generally lower than in 
CD-1 mice, although the difference was not significant (see Chapter 1, Figure 3.1.6). 
Following APAP treatment of fed mice, however, significant differences were found 
between both strains. The fold change of the increase was significantly higher in the 
C57BL/6J mice at both examined time points (5 and 24 hpd). A comparison between 
hepatic GSH levels was possible at 10 and 24 hpd, and the fold change of increase 
was significantly higher in the CD-1 mice at 10 hpd (Figure 3.3.15A).  
In fasted mice, the difference was restricted to serum ALT, where the fold changes 
were significantly higher in the C57BL/6J mice at both available time points, 5 and 
24 hpd (Figure 3.3.15B).   
 
Table 3.3.12. Comparison of GSH, ATP, ALT and DILI score in male C57BL/6J and CD-1 mice 
in animals that had been fed or fasted prior to APAP dosing using comparative value, 
assessing fold change relative to control animals.  
 
Time 
(hpd) 
Mice 
GSH ATP ALT DILI score 
C57BL/ 
6J 
CD-1 
C57BL/ 
6J 
CD-1 
C57BL/ 
6J 
CD-1 
C57BL/ 
6J 
CD-
1 
5 
Fed 0.21 - 0.18 - 137.9*** 27.45 2.75 2.2 
Fasted - - - - 192.0*** 41.14 3.25 2.5 
10 
Fed 0.78 1.96* 0.50 0.61 69.5 - 1.5 1.0 
Fasted 0.17 0.06 0.25 0.25 54.8 - 2.13 2.6 
24 
Fed 0.85 0.96 1.00 1.07 319.1*** 96.53 1.15* 0 
Fasted 0.78 0.33 - 0.49 290.3*** 57.02 2.1 2.4 
Statistical significant, *P<0.05 and ***P<0.005 are seen in the comparison between 
C57BL/6J and CD-1 mice that had been either fed or fasted prior to APAP dosing; hpd – 
hours post dosing. 
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Figure 3.3.15. Assessment of liver damage in fed and fasted male C57BL/6J and CD-1 mice 
after APAP dosing. 
The hepatic GSH and ATP levels, serum ALT levels and DILI scores were compared between 
C57BL/6J and CD-1 at 5, 10 and 24 hpd in animals that had been fed (A) or fasted (B) prior 
to 530 mg/kg APAP dosing (as listed in Table 3.3.12). The GSH, ATP and ALT values are 
assessed as fold change relative to the levels in time-matched control mice, the DILI scores 
as raw data. Data represents mean (4 to 6 animals per group). ***P<0.005 and *P<0.05. 
Fold change = 1 : levels in saline dosed control mice indicated by dashed lines. 
 
3.3.7 Quantification of cytokine expression in liver, spleen and sera levels in 
C57BL/6J mice and comparison to CD-1 mice  
3.3.7.1  Hepatic transcription of TNF-α, IL-6 and IL-10  
An evidence of upregulation of TNF-α, IL-6 and IL-10 cytokines at several time points 
of post APAP dosing showed that the transcription was obviously seen in fed rather 
than fasted mice, like it was also observed in the CD-1 mice (see Chapter 3.2.7), by 
using delta Ct values normalised to the housekeeping gene GAPDH (fed mice: Table 
6.33; fasted mice: Table 6.35; Figure 3.3.16).  
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Figure 3.3.16. Hepatic TNF-α, IL-6 and IL-10 mRNA levels in control and APAP dosed fed and 
fasted male C57BL/6J mice over 1-36 hpd.  
The hepatic mRNA levels of cytokines TNF-α (A, B), IL-6 (C, D) and IL-10 (E, F) were 
compared between 0.9% saline (control mice) and 530 mg/kg APAP dosed fed and fasted 
C57BL/6J mice. Hepatic mRNA levels were calculated using the delta Ct value formula, 2-ΔCt. 
Data represent mean±SD (4 to 6 animals per group). 
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Thus, similar to CD-1 mice (see Chapter 3.2.7), the cytokine transcription levels 
were assessed by the comparative Ct value as fold change relative to time-matched 
control C57BL/6J mice. In fed C57BL/6J mice, a significant, 6-fold increase in hepatic 
TNF-α transcription in comparison to time-matched control animals was seen at 5 
hpd (Figure 3.3.17A). In fasted mice, significant fold changes in TNF-α mRNA levels 
were observed at later time points, i.e. at 20 hpd (4.2-fold), 24 hpd (9.6-fold) and 36 
hpd (7.9-fold). Comparing fed and fasted C57BL/6J mice, we observed that the TNF-
α transcription was significantly higher in the fed mice at 5 hpd (6-fold increase) and 
then dropped again (Table 6.33), whereas fasted C57BL/6J mice showed 
upregulation of TNF-α transcription from 20 hpd onwards, with the highest fold 
change at 24 hpd before a slight drop was seen at 36 hpd, over this time period, 
fold changes were significantly higher than in fed mice at the same time points 
(Table 6.35, Figure 3.3.17A). 
The comparison of fed APAP dosed mice over the time course showed a significantly 
higher increase in CD-1 than in C57BL/6J mice at 10 hpd (4.5-fold), but at other time 
points a similar pattern and comparable fold change was seen in both groups of 
mice (Table 6.33, Figure 3.3.17B). In fasting mice, at 10 and 15 hpd, the TNF-α 
upregulation was significantly more intense in CD-1 mice (10 hpd: 1.6-fold vs 5.3-
fold increase in C57BL/6J and CD-1 mice, respectively). In the CD-1 mice, a further 
increase was seen from 10 to 15 hpd, when the peak was seen (14.3-fold 
upregulation). Transcription levels then dropped in the CD-1 mice, whereas another 
increase was seen in the C57BL/6J mice, with a peak at 24 hpd, when the fold 
changes were significantly higher in the C57BL/6J mice (9.6-fold in C57BL/6J vs. 3.9-
fold in CD-1 mice) (Table 6.35, Figure 3.3.17C). 
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Figure 3.3.17. Fold changes in hepatic TNF-α transcription levels in fed and fasted APAP 
dosed C57BL/6J mice and comparison to CD-1 mice. 
Hepatic TNF-α transcription levels were determined after APAP (530 mg/kg; 1-36 hpd) 
dosing of fed and fasted male C57BL/6J mice (A). The levels were also compared between 
C57BL/6J and CD-1 mice in either fed (B) or fasted (C) mice prior to APAP dosing. Hepatic 
TNF-α mRNA levels are calculated using the comparative Ct values, assessing the fold 
change relative time-matched control animals. Data is given as mean±SD (4 to 6 animals per 
group). ***P<0.005, **P<0.01 and *P<0.05. 
 
 
Hepatic mRNA transcription levels were also assessed by the comparative Ct value 
as fold change relative to the pooled control levels as no significant differences 
were seen in the control animal levels at any time point (fed mice: Table 6.34; 
fasted mice: Table 6.36). This confirmed the significant fold change in hepatic TNF-α 
mRNA level in fed APAP dosed mice at 5 hpd (11.7-fold) and a significant 
upregulation in fasted mice at 20 hpd (2.3-fold), 24 hpd (4.2-fold) and 36 hpd (3.8-
fold) (Table 6.36, Figure 3.3.18A) as similar result obtained in Figure 3.3.17A. 
Comparing these results with those from CD-1 mice (APAP overdose at each time 
point vs pooled control values) significant differences were seen in the fed mice. In 
C57BL/6J, the fold change was significantly higher at 5 hpd (11.7-fold vs 4.4-fold), 
but significantly lower at 10 hpd (7.9-fold vs 2.2-fold) (Table 6.34, Figure 3.3.18B). In 
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fasted mice, the results were the same as those obtained with the time matched 
controls (Table 6.36, Figure 3.3.18C; for comparison, see Figure 3.3.17C). 
  
 
Figure 3.3.18. Fold changes in hepatic TNF-α transcription levels in fed and fasted APAP 
dosed C57BL/6J mice and comparison to CD-1 mice. 
Hepatic TNF-α transcription levels were determined after APAP (530 mg/kg; 1-36 hpd) 
dosing of fed and fasted male C57BL/6J mice (A). Comparison of fold changes in fed (B) and 
fasted (C) APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA levels are calculated using 
the comparative Ct values, assessing the fold change relative pooled control animals. *5 - 
values of 5 h C57BL/6J was compared to 4 h CD-1 mice. Data is given as mean±SD (4 to 6 
animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
 
In fed APAP dosed C57BL/6J mice, the IL-6 level was found to have increased by 4.6-
fold in comparison to time-matched control mice at 15 and 20 hpd. At 24 hpd (8.5-
fold), it reached a peak, and then dropped slightly towards 36 hpd (7.3-fold); the 
difference was significant from 15 to 36 hpd (Table 6.33). In fasted C57BL/6J mice, 
IL-6 mRNA levels rose steadily, and the upregulation was significant at 24 hpd (3.5-
fold) and 36 hpd (4.8-fold) (Figure 3.3.20B). However, the fold changes were 
consistently lower in the fasted mice, and the difference was significant at 15 and 
24 hpd. While at the latter time point the peak value was seen in the fed mice, it 
was not yet the case in the fasted mice (Table 6.35, Figure 3.3.19A).  
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In comparison to fed CD-1 mice, the hepatic IL-6 upregulation was almost 
consistently significantly less intense in fed C57BL/6 mice and appeared to be 
delayed, still rising at 24 hpd, while the CD-1 mice exhibited a significant increase as 
early as 1 hpd, with increasing fold changes over 5 hpd (5-fold), 10 hpd (9.3-fold) 
and 20 hpd (11.5-fold), with a peak at the latter time point (Table 6.33, Figure 
3.3.19B) when histological evidence of ongoing liver damage had subsided in CD-1 
mice whereas in C57BL/6J mice, ongoing cell death was observed (see Chapter 
3.2.6). In fasted mice, a similar pattern, with a steady increase was observed, but 
the fold changes were consistently higher in the CD-1 mice. This difference was 
significant at 4/5 hpd (CD-1 mice: 4 hpd (3.6-fold); C57BL/6J mice: 5 hpd (0.7-fold)) 
and 15 hpd (5.3-fold in C57BL/6J) (Table 6.35, Figure 3.3.19C).   
 
 
 
Figure 3.3.19. Fold changes in hepatic IL-6 transcription levels in fed and fasted APAP dosed 
C57BL/6J mice and comparison to CD-1 mice. 
Hepatic IL-6 transcription levels were determined after APAP (530 mg/kg; 1-36 hpd) dosing 
of fed and fasted male C57BL/6J mice (A). Comparison of fold changes in fed (B) and fasted 
(C) APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA levels are calculated using the 
comparative Ct values, assessing the fold change relative time-matched control animals. 
Data is given as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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Looking at the fold changes relative to pooled control mouse values,  the 
significantly higher increase in IL-6 transcription level in the fed C57BL/6J mice at 15 
and 24 hpd was confirmed, and a significantly higher fold change was additionally 
detected at 36 hpd (7.2-fold) in comparison to the fasted mice (Table 6.36, Figure 
3.3.20A). The comparison of fed mice of both groups did not confirm the 
significantly higher increase in the CD-1 at 1 hpd which was detected before (Table 
6.34, Figure 3.3.20B; for comparison, see Figure 3.3.19B). In the fasted mice, the 
previous results were confirmed (Table 6.36, Figure 3.3.20C; for comparison, see 
Figure 3.3.19C).   
 
 
 
Figure 3.3.20. Fold changes in hepatic IL-6 transcription levels in fed and fasted APAP dosed 
C57BL/6J mice and comparison to CD-1 mice. 
Hepatic IL-6 transcription levels were determined after APAP (530 mg/kg; 1-36 hpd) dosing 
of fed and fasted male C57BL/6J mice (A). Comparison of fold changes in fed (B) and fasted 
(C) APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA levels are calculated using the 
comparative Ct values, assessing the fold change relative pooled control animals.*5- values 
of 5 h C57BL/6J was compared to 4 h CD-1 mice. Data is given as mean±SD (4 to 6 animals 
per group). ***P<0.005, **P<0.01 and *P<0.05. 
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In fed animals, the hepatic IL-10 transcription increased steadily and was 
significantly upregulated in APAP dosed C57BL/6J mice in comparison to time-
matched control mice at 15 hpd (7.5-fold), 20 hpd (8.4-fold), 24 hpd (10.6-fold) and 
36 hpd (6.6-fold) (Table 6.33). In fasted C57BL/6J mice, the fold changes in IL-10 
transcriptions levels were much lower, with a significant difference to saline-dosed 
mice at 24 hpd (3.5-fold) and 36 hpd (6.1-fold) only (Table 6.35). By 36 hpd, the fold 
change was similar to that one seen in fed APAP dosed mice, while the fold changes 
were significantly higher at the earlier time points (15, 20 and 24 hpd) in the fed 
mice (Table 6.36, Figure 3.3.21A).  
 
The comparison to CD-1 mice showed that the upregulation in these mice occurred 
earlier and at a higher level (significant difference at at 4/5 hpd (8.9-fold vs. 1.3-
fold) and 10 hpd (8.2-fold vs. 3.2-fold). In CD-1 mice, the peak fold change in IL-10 
transcription was at 15 hpd after which time point a mild decline was seen, whereas 
in the C57BL/6J a later and steady increase was observed, with the peak at 24 hpd 
(Table 6.33, Figure 3.3.21B; see also Figure 3.3.20B). In fasted CD-1 mice, IL-10 
mRNA fold changes were equally low during the early phase post APAP dosing. 
However, at 20 hpd (10.6-fold vs. 2.2-fold) and 24 hpd (12.1-fold vs. 3.5-fold) a 
marked upregulation was seen and the difference to the IL-10 transcription level in 
C57BL/6J mice was significant (Table 6.35, Figure 3.3.21C). 
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Figure 3.3.21. Fold changes in hepatic IL-10 transcription levels in fed and fasted APAP 
dosed C57BL/6J mice and comparison to CD-1 mice. 
Hepatic IL-10 transcription levels were determined after APAP (530 mg/kg; 1-36 hpd) 
dosing of fed and fasted male C57BL/6J mice (A). Comparison of fold changes in fed (B) and 
fasted (C) APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA levels are calculated using 
the comparative Ct values, assessing the fold change relative time-matched control 
animals. Data is given as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and 
*P<0.05. 
 
However, when the fold change relative to the pooled control values was assessed, 
the significant increase in hepatic IL-10 mRNA levels in fed C57BL/6J mice at 15 and 
20 hpd was confirmed, without a difference to fasted mice at 24 hpd (Tables 6.34 
and 6.36, Figure 3.3.22A). The comparison of fed animals of both groups confirmed 
the previous findings (Table 6.34, Figure 3.3.22B; for comparison see Figure 
3.3.21B). However, in the fasted groups, a significant upregulation of IL-10 was 
detected in CD-1 mice at 20 hpd (4.6-fold vs. 3.0-fold), whereas the significantly 
higher increase at 24 hpd in the CD-1 mice was not confirmed (Table 6.36, Figure 
3.3.22C; for comparison see Figure 3.3.21C). 
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Figure 3.3.22. Fold changes in hepatic IL-10 transcription levels in fed and fasted APAP 
dosed C57BL/6J mice and comparison to CD-1 mice. 
Hepatic IL-10 transcription levels were determined after APAP (530 mg/kg; 1-36 hpd) 
dosing of fed and fasted male C57BL/6J mice (A). Comparison of fold changes in fed (B) and 
fasted (C) APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA levels are calculated using 
the comparative Ct values, assessing the fold change relative pooled control animals. *5- 
values of 5 h C57BL/6J was compared to 4 h CD-1 mice. Data is given as mean±SD (4 to 6 
animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
 
3.3.7.2  Splenic transcription of TNF-α and IL-6  
For the quantitative assessment of splenic TNF-α and IL-6 transcription levels at 5 
and 24 hpd in C57BL/6J mice the fold change method was applied. At 5 hpd, no 
treatment induced fold changes were observed in either fed or fasted mice; this 
was also the case in fed mice at 24 hpd (Table 6.37). In contrast, a significant, up to 
10-fold increase in splenic TNF-α transcription was observed in fasted mice at 24 
hpd compared to fed control and APAP dosed mice (Table 6.37, Figure 3.3.23A). At 
24 hpd, splenic TNF-α mRNA level was significantly higher in fasted than in fed mice 
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in both strains (Table 6.37), however, there was no difference between C57BL/6J 
mice and CD-1 in either the fed or fasted group (Figure 3.3.23B).  
In contrast, IL-6 transcription was significantly upregulated in fed C57BL/6J mice at 
5 hpd in comparison to control and fasted APAP dosed mice (Table 6.37). In fasted 
C57BL/6J mice, the IL-6 transcription was instead significantly upregulated at 24 hpd 
(8.6-fold), however, this upregulation was far less pronounced than that observed 
in fed C57BL/6J mice at 5 hpd (7.9-fold) (Figure 3.3.23C). Interestingly, by 24 hpd, it 
was also significantly (i.e. almost 4-fold) higher in the fed CD-1 mice, whereas in the 
fasted mice at this time point, IL-6 transcription was a significant 8.6-fold change 
higher than in the fed C57BL/6J mice and fasted CD-1 mice (Figure 3.3.23D).  
 
 
 
Figure 3.3.23. Fold change in splenic TNF-α and IL-6 transcription levels after APAP dosing 
in C57BL/6J mice and comparison to CD-1 mice. 
Splenic TNF-α and IL-6 transcription levels were assessed after  APAP (530 mg/kg) dosing of 
fed and fasted male C57BL/6J mice (A, C) at 5 and 24 hpd. Comparison of splenic TNF-α (B) 
and IL-6 (D) at 24 hpd in APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA levels are 
calculated using comparative Ct values, assessing fold change relative to time-matched 
control animals. Values were expressed as mean±SD (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. 
0
2
4
6
8
10
12
14
5 24
Fo
ld
 c
h
an
ge
  
Time (hpd) 
A. C57BL/6J TNF-α 
Fed
Fasted
 ** 
0
2
4
6
8
10
12
14
Fed Fasted
Fo
ld
 c
h
an
ge
 
24 hpd 
B. TNF-α 
C57BL/6J
CD-1
0
2
4
6
8
10
12
14
5 24
Fo
ld
 c
h
an
ge
 
Time (hpd) 
C. C57BL/6J IL-6 
Fed
Fasted
   ** 
   * 
0
2
4
6
8
10
12
14
Fed Fasted
Fo
ld
 c
h
an
ge
 
D. IL-6 
C57BL/6J
CD-1
  * 
*** 
  24 hpd 
Chapter 3.3 
174 
 
3.3.7.3  Serum TNF-α and IL-6 levels  
Serum TNF-α and IL-6 levels were measured over a 0-36 hpd time course in both fed 
and fasted APAP dosed and time-matched (for 5-36 hpd) and pooled saline control 
C57BL/6J mice. In fed APAP dosed mice, TNF-α level increased steadily up to 10 hpd 
and then declined until the end of the experiment at 36 hpd; however, they were 
always significantly higher than in the time matched as well as in the pooled 
controls (Table 3.3.13, Figure 3.3.24A,B).  
Table 3.3.13. TNF-α serum levels (pg/mL) in control and APAP treated fed C57BL/6J mice 
with p-value and comparison to levels in fed CD-1 mice.  
hpd – hours post dosing; SD – standard deviation; NS – not significant. 
 
Time 
(hpd) 
Control APAP p-value control 
vs APAP 
p-value 
APAP vs APAP 
p-value vs 
fed APAP CD-1 Mean SD Mean SD 
0 - - 22.86 6.95 - 
1 h: 0.0095  
3 h: 0.0001  
5 h: 0.0004 
10 h: 0.0001 
15 h: 0.0037 
20h: 0.0009 
24h: 0.0005 
30h: 0.0026  
36h: 0.0069  
- 
0.5 - - 20.14 3.65 - - 
1 - - 39.01 2.69 - 
3 h: 0.0008 
10 h: 0.0009 
- 
3 - - 67.52 9.07 - 10 h: 0.0057 - 
5 3.3 2.09 74.37 7.13 0.0066 
10 h: 0.004  
30 h: 0.0418 
NS 
10 11.83 2.83 104.36 17.37 0.0094 
20 h: 0.0234 
36 h: 0.0069  
- 
15 14.58 3.25 94.75 31.70 0.0407 
30 h: 0.042 
36 h: 0.0228 
- 
20 15.50 2.01 72.13 10.31 0.0323 36 h: 0.0225 - 
24 3.60 4.33 75.86 7.94 0.0250 
30 h: 0.023 
36 h: 0.006 
NS 
30 7.33 1.2 62.75 5.30 0.0171 36 h: 0.046 - 
36 10.04 0.29 56.29 0.88 0.0078 0 h: 0.0005 - 
Pooled 
control 
11.09 3.12 - - 
1 h: 0.0480 
3 h: 0.0125 
5 h: 0.0109 
10 h: 0.0012 
15 h: 0.0073 
20 h: 0.0052 
24 h: 0.0066 
30 h: 0.0207  
36 h: 0.0195 
- - 
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Figure 3.3.24. Serum TNF-α level in fed male C57BL/6J mice.  
(A) Serum TNF-α levels at different time points after 0.9% saline (control) and 530mg/kg 
APAP administration to fed C57BL/6J mice. (B)  Serum TNF-α level over 36 h post APAP 
dosing in fed C57BL/6J mice (as listed in Table 3.3.12). *Control – pooled control. Values 
were expressed as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and 
*P<0.05. 
 
In fasted APAP dosed mice, serum TNF-α level was also significantly higher than the 
time-matched and pooled control mouse values throughout the experiment (Table 
3.3.14, Figure 3.3.25A). However, the time course differed from the one found in 
the fed APAP treated mice, as the serum TNF-α levels were increased, but remained 
similar between 3 and 15 hpd, afterwards showing a further, significant increase (up 
to 250 pg/mL) from 20 to 36 hpd (Figure 3.3.25B). At the latter time points, the 
serum TNF-α level of the fasted mice were significantly higher than those of the fed 
mice post APAP dosing (Figure 3.3.25C).  
A comparison of the serum TNF-α level in fed and fasted, APAP dosed C57BL/6J and 
CD-1 mice at 5 and 24 hpd showed similar levels in both groups of mice (Figure 
3.3.25D).  
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Table 3.3.14. TNF-α serum levels (pg/mL) in control and APAP treated fasted C57BL/6J mice 
with p-value and comparison to levels in fasted CD-1 mice. 
hpd – hours post dosing; SD – standard deviation; NS – not significant. 
  
Time 
(hpd) 
Control APAP p-value 
control vs 
APAP 
p-value APAP 
vs APAP 
p-value 
fasted vs 
fed APAP 
p-value 
vs fasted 
APAP CD-1 
Mean SD Mean SD 
0 - - 18.2 7.21 - 1 h: 0.0004 
36 h: 0.0002 
NS - 
0.5 - - 20.31 6.41 - NS - 
1 - - 62.34 8.52 - 3 h: 0.0001 NS - 
3 - - 145.32 17.84 - 
3,5,10,15 h:  
NS (a) 
NS - 
5 11.25 6.31 123.94 23.73 0.0001 
0,0.5 h vs (a): 
0.0053 
NS NS 
10 26.29 5.89 122.17 18.85 0.0018 24 h: 0.0043 NS - 
15 21.25 8.13 144.04 26.93 0.0014 
20 h: 0.0134  
36 h: 0.0048 
NS - 
20 13.83 2.01 212.00 5.30 0.0028 
20,24,30,36 
h: NS (b) 
0.0093 - 
24 20.33 5.1 249.81 39.55 0.0023 
(a) vs (b): 
0.034 
0.0108 NS 
36 25.36 5.65 226.86 22.12 0.0045 10 h: 0.0007 0.0024 - 
Pooled 
control 
19.37 5.80 - - 
1 h: 0.034 
3 h: 0.0003 
5 h: 0.0018 
10 h: 0.0059 
15 h: 0.0005 
20 h: 0.0001 
24 h: 0.0001 
36 h: 0.0001 
- - - 
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Figure 3.3.25. Serum TNF-α level in C57BL/6J mice, and comparison to CD-1 mice.  
(A) Serum TNF-α level at different time points after 0.9% saline (control) and 530 mg/kg 
APAP administration in fasted male C57BL/6J mice. (B) Serum TNF-α level over 36 h post 
APAP dosing in fasted C57BL/6J mice. (C) Comparison to fed APAP dosed C57BL/6J mice. 
Comparison of serum TNF-α level in fed and fasted APAP dosed C57BL/6J and CD-1 mice (D) 
(as listed in Table 3.3.13). *Control – pooled control. Values were expressed as mean±SD (4 
to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
 
Similar to serum TNF-α levels, serum IL-6 levels were also significantly increased in 
comparison to time matched and pooled control mice over the entire time couse 
(Table 3.3.15, Figure 3.3.26A). They reached a peak at 20 and 24 hpd, being twice as 
high as at 10 and 15 hpd before a slight drop was seen at 30 and 36 hpd (Figure 
3.3.26B). Fed treated C57BL/6J mice showed a similar serum IL-6 profile to CD-1 
mice at 5 and 24 hpd (Table 3.3.15, Figure 3.3.27D). 
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Table 3.3.15. IL-6 serum levels (pg/mL) in control and APAP treated fed C57BL/6J mice with 
p-value and comparison to levels in fed CD-1 mice. 
hpd - hours post dosing;  SD - standard deviation; NS – not significant. 
 
 
 
 
Figure 3.3.26. Serum IL-6 levels in fed male C57BL/6J mice.  
(A) Serum IL-6 levels at different time points after 0.9% saline (control) and 530 mg/kg 
APAP administration to fed C57BL/6J mice. (B)  Serum IL-6 levels over 36 h post APAP 
dosing in fed C57BL/6J mice (as listed in Table 3.3.15). *Control – pooled control. Values 
were expressed as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and 
*P<0.05. 
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Time 
(hpd) 
C57BL/6J CD-1 
Control APAP p-value 
control vs 
APAP 
p-value APAP 
vs APAP 
APAP 
Mean 
(SD) 
p-value 
vs APAP 
C57BL/6J Mean SD Mean SD 
0 - - 4.15 1.02 - 1 h: 0.031 
3, 5 h: 0.0019 
- - 
0.5 - - 5.32 2.1 - - - 
1 - - 40.49 14.21 - 3 h: 0.0405 - - 
3 - - 64.02 10.63 - 
10,15 h: 0.0010 
20,24 h: 0.0003 
- - 
5 - - 61.69 5.75 - 
54.3 
(10.2) 
NS 
10 23.24 5.24 111.9 25.19 0.0314 20,24 h: 0.0046 
30,36 h: 0.0232 
- - 
15 25.62 4.58 104.53 19.07 0.0164 - - 
20 27.52 3.2 240.02 17.92 0.0001 
0,0.5 h: 0.0001 
30,36 h: 0.0457 
- - 
24 14.2 3.8 228.83 38.25 0.0004 
203 
(39.6) 
NS 
30 17.05 0.95 171.71 42.96 0.0026 3,5 h: 0.0002 
10,15 h: 0.0051 
- - 
36 20.3 0.6 180.14 23.72 0.0009 - - 
Pool
ed 
contr
ol  
20.03 3.16 - - 
10 h: 0.0069 
15 h: 0.0092 
20 h: 0.0001 
24 h: 0.0007 
30 h: 0.0012 
36 h: 0.0001 
- - - 
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In fasted C57BL/6J mice, serum IL-6 levels were significantly increased in 
comparison to levels in time matched control animals from 15 hpd onwards, in 
comparison to pooled control animal levels from 20 hpd (Table 3.3.16, Figure 
3.3.27A), showing similar levels between 1 and 15 hpd, and another, but 
significantly higher level plateau between 20 and 36 hpd (Figure 3.3.27B).  
Overall, serum IL-6 levels were lower in fasted than in fed APAP dosed mice, with a 
significant difference at 15, 20 and 24 hpd (Figure 3.3.27C). Also, fasted mice did 
not show an obvious peak level throughout the experiment. Similarly, fasted 
treated C57BL/6J and CD-1 mice also showed a similar serum IL-6 profile at 5 and 24 
hpd (Figure 3.3.27D).  
 
Table 3.3.16. IL-6 serum levels (pg/mL) in control and APAP treated fasted C57BL/6J mice 
with p-value and comparison to levels in fasted CD-1 mice. 
 
Time 
(hpd) 
C57BL/6J CD-1 
Control Fasted APAP 
p-value 
control vs 
APAP 
p-value 
APAP vs 
APAP 
p-
value 
fasted 
vs fed 
Mean 
(SD) 
APAP 
p-value 
vs fasted 
APAP 
C57BL/6J 
Mean SD Mean SD 
0 - - 17.25 5.62 - 1,3 h: 
0.026 
NS - - 
0.5 - - 19.21 6.51 - NS - - 
1 - - 43.75 8.63 - 5,10, 
15 h: NS 
20,24 h: 
0.0035 
36 h: 
0.0055 
NS - - 
3 - - 41.28 10.65 - NS - - 
5 - - 56.29 12.34 - 
0,0.5 h: 
0.0031 
NS 
35.4 
(10.5) 
NS 
10 15.63 4.59 40.25 34.94 NS - NS - - 
15 21.45 3.15 52.08 15.35 0.0057 
20,24,36 
h: 0.0177 
0.027 - - 
20 19.46 5.92 103.15 23.24 0.0003 
0,0.5 h: 
0.0002 
1,3 h: 
0.0009 
0.002 - - 
24 24.51 8.1 94.31 35.72 0.0019 
5 h: 
0.0016 
0.001 
96.4 
(35.2) 
NS 
36 16.95 2.88 130.88 51.2 0.0045 
20,24 h: 
NS 1,3 h: 
0.0007 
NS - - 
Pooled 
control  
19.29 5.14 - - 
20 h:0.0029  
24 h:0.0044  
36 h:0.0007 
- - - - 
hpd - hours post dosing;  SD - standard deviation; NS – not significant. 
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Figure 3.3.27. Serum IL-6 levels in C57BL/6J mice, and comparison to CD-1 mice.  
(A) Serum IL-6 levels at different time points after 0.9% saline (control) and 530 mg/kg 
APAP administration in fasted male C57BL/6J mice. (B) Serum TNF-α level over 36 h post 
APAP dosing in fasted C57BL/6J mice. (C) Comparison to fed APAP dosed C57BL/6J mice. 
Comparison of serum TNF-α level in fed and fasted APAP dosed C57BL/6J and CD-1 mice (D) 
(as listed in Table 3.3.16). *Control – pooled control. Values were expressed as mean±SD (4 
to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
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3.3.8 Assessment of liver regeneration based on hepatocellular proliferation  
3.3.8.1  Hepatic NF-kB mRNA transcription  
There was an upregulation of hepatic NF-kB at later time points both in fed and 
fasted mice when assessing transcription levels of NF-kB by delta Ct method (Figure 
3.3.31A,B).  
When the fold change was used as a basis for the statistical evaluation, a significant 
increase in NF-kB transcription was observed in fed APAP dosed C57BL/6J mice 
compared to time-matched control animals; this was, for example, 2.7-fold at 5 
hpd, 5.7-fold at 10 hpd, 6.9-fold at 15 hpd and still 4.7-fold at 36 hpd (Table 6.38, 
Figure 3.3.31C). In fasted APAP dosed mice, significant upregulation of the NF-kB 
transcription in comparison to control animals was seen from 15 until 36 hpd 
(Figure 3.3.31D). However, transcription levels were significantly higher in the fed 
animals when levels peaked at 10 and 15 hpd (Table 6.38, Figure 3.3.31E).  
 
The comparison of NF-kB transcription levels in fed APAP dosed C57BL/6J and CD-1 
mice showed a significantly more intense upregulation in CD-1 mice at 10, 15, 20 
and 24 hpd (Figure 3.3.32A). In the fasted APAP dosed mice, however, transcription 
levels were slightly higher in the CD-1 mice, though never with a significant 
difference (Table 6.38, Figure 3.3.32B). 
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Figure 3.3.28. Hepatic NF-kB transcription in fed and fasted C57BL/6J mice and comparison 
to CD-1 mice.  
Hepatic NF-kB transcription levels in (A) fed and (B) fasted control and APAP dosed 
C57BL/6J mice were determined using the delta Ct value, 2-ΔCt. The hepatic NF-kB mRNA 
levels were also calculated in fed and fasted C57BL/6J mice (C), using the comparative Ct 
value method, assessing the fold change relative to time-matched control animals. The 
levels were also compared in fed (D) and fasted (E) APAP dosed C57BL/6J and CD-1 mice. 
Values were expressed as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and 
*P<0.05. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
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The values in APAP dosed mice were also compared to pooled control animal values 
as we did not recognise any differences in controls over the time course (see 
Chapter 3.1.8.1). In fed mice, similar to Figure 3.3.28D, the upregulation of hepatic 
NF-kB mRNA transcription was significant from 10 hpd onwards, in fasted mice the 
upregulation was significant from at 20 hpd onwards (Table 6.39). The comparison 
of fed and fasted animals showed similliar results as seen with the time matched 
controls (Table 6.39, Figure 3.3.29A; see also Figure 3.3.28C). The findings were also 
compared to CD-1 mice. The latter had higher levels throughout, and the difference 
was significant in fed mice at 10 (2.8-fold in C57BL/6J vs 13.3-fold in CD-1 mice) and 
20 hpd (5.3-fold in C57BL/6J vs 9.5-fold in CD-1 mice) (Table 6.39, Figure 3.3.29A), 
whereas no significant differences were seen in fasted mice at any time post APAP 
dosing (Figure 3.3.29B).  
 
  
 
Figure 3.3.29. Hepatic NF-kB transcription in APAP dosed male C57BL/6J mice.  
Hepatic NF-kB transcription levels were determined after 530 mg/kg APAP administration in 
fed and fasted C57BL/6J mice (A). Comparison of fed (B) and fasted (C) APAP dosed 
C57BL/6J and CD-1 mice. Hepatic mRNA levels are calculated using the comparative Ct 
values, assessing the fold change relative to pooled control animals. Data is given as 
mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. *5- values of 5 h 
C57BL/6J was compared to 4 h CD-1 mice. 
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3.3.8.2  Hepatic cyclin-D1 transcription 
By delta Ct method, fed APAP dosed mice generally showed higher cyclin-D1 mRNA 
levels than time-matched control mice from 15 hpd onwards (Figure 3.3.30A). In 
fasted mice, a peak was seen at 36 hpd (Table 6.40, Figure 3.3.30B).  
Using comparison of the delta Ct method, in fed APAP dosed C57BL/6J mice, 
upregulation of cyclin-D1 transcription was seen from 5 hpd onwards, with a 
significant difference to control mice at the later time points, i.e. 15 hpd (9-fold), 20 
hpd (6-fold), 24 hpd (6.6-fold) and 36 hpd (5.4-fold) (Table 6.40).  
In fasted mice, the difference to control mice was significant at 24 hpd (3.2-fold) 
and 36 hpd (4.6-fold) (Figure 3.35D). In general, however, mRNA levels were lower 
in the fasted mice, and the difference was significant at 10 to 24 hpd (Table 6.40). 
A comparison of the cyclin-D1 transcription in fed and fasted APAP dosed C57BL/6J 
and CD-1 mice showed an overall higher fold change in CD-1 mice (Figure 3.3.30C). 
In the fed animals, the difference was significant at 4/5 hpd (8.6-fold), at 20 hpd 
(16-fold), when a peak was seen in the CD-1 mice, and at 24 hpd (12.4-fold) (Table 
6.40, Figure 3.3.30D). In the fasted mice, it was significant between 15 hpd (6-fold) 
and 24 hpd (7.6-fold) (Figure 3.3.30E). 
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Figure 3.3.30. Hepatic cyclin-D1 transcription in fed and fasted C57BL/6J mice and 
comparison to CD-1 mice.  
Hepatic cyclin-D1 transcription levels in (A) fed and (B) fasted control and APAP dosed 
C57BL/6J mice were determined using the delta Ct value, 2-ΔCt. The hepatic cyclin-D1 mRNA 
levels were also calculated in fed and fasted C57BL/6J mice (C), using the comparative Ct 
value method, assessing the fold change relative to time-matched control animals. The 
levels were also compared in fed (D) and fasted (E) APAP dosed C57BL/6J and CD-1 mice. 
Values were expressed as mean±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and 
*P<0.05. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
 
0.0E+00
5.0E-07
1.0E-06
1.5E-06
2.0E-06
1 3 5 10 15 20 24 36
2
^(
-Δ
C
t)
 
Time (hpd) 
A. Fed control vs APAP 
Control
APAP
0.0E+00
5.0E-07
1.0E-06
1.5E-06
2.0E-06
1 3 5 10 15 20 24 36
2
^(
-Δ
C
t)
 
Time (hpd) 
B. Fasted control vs APAP 
Control
APAP
0
5
10
15
20
1 3 5 10 15 20 24 36
Fo
ld
 c
h
an
ge
 
Time (hpd) 
C. Fed vs fasted C57BL/6J 
Fed
Fasted
 *** 
     * 
 * 
 * 
0
5
10
15
20
1 *5 10 15 20 24
Fo
ld
 c
h
an
ge
 
Time (hpd) 
D. Fed C57BL/6J vs CD-1 
C57BL/6J
CD-1
 ** 
  *** 
** 
0
5
10
15
20
1 *5 10 15 20 24
Fo
ld
 c
h
an
ge
 
Time (hpd) 
E. Fasted C57BL/6J vs CD-1 
C57BL/6J
CD-1
 ** ** 
* 
Chapter 3.3 
186 
 
As no differences in cyclin-D1 mRNA levels were observed in control animals over 
the entire time course (see Chapter 3.1.8.1), all saline dosed animal values were 
gathered as pooled control values. This approach confirmed the previous results, 
whereas in fasted mice, only the 36 hpd level was found to be significantly higher 
with this approach (Table 6.41). The comparison of fed and fasted APAP dosed mice 
recognised statistical difference at 15, 20 and 24 hpd only (Table 6.41, Figure 
3.3.31A). The hepatic cyclin-D1 mRNA levels in APAP dosed CD-1 mice were 
significantly higher at 4/5 hpd (8.1-fold), 10 and 20 hpd in fed animals (Table 6.41, 
Figure 3.3.31B) and at 15 (9-fold) to 24 hpd in fasted animals than those in C57BL/6J 
mice (Figure 3.3.31C).  
 
 
 
 
 
Figure 3.3.31. Hepatic cyclin-D1 transcription in APAP dosed C57BL/6J mice and comparison 
to CD-1 mice.  
Hepatic cyclin-D1 transcription levels were determined after 530 mg/kg APAP 
administration between fed and fasted APAP dosed male CD-1 mice (A). The levels were 
compared in fed (B) and fasted (C) APAP dosed C57BL/6J and CD-1 mice. Hepatic mRNA 
levels are calculated using the comparative Ct values, assessing the fold change relative to 
pooled control animals. Data is given as mean±SD (4 to 6 animals per group). ***P<0.005, 
**P<0.01 and *P<0.05. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
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3.3.8.3 Assessment of hepatocyte proliferation based on the immunohistological 
expression of PCNA 
 
In C57BL/6J mice, the potential changes in the number of proliferating PCNA-
positive hepatocytes were assessed in APAP dosed mice at 5 to 36 hpd. In fed APAP 
dosed C57BL/6J mice, the number of PCNA-positive proliferating hepatocytes was 
found to rise steadily after 5 hpd, at 10 to 36 hpd, when it reached a peak with 
around 25% positive cells (Table 3.3.17). In fasted APAP dosed mice, an increase 
was only seen from 20 hpd onwards, and it was significant compared to controls 
from then until 36 hpd (Table 3.3.17). However, the extent of the increase was less 
intense in fasted mice, with a significant difference in the number of PCNA-positive 
cells from 15 to 36 hpd (Table 3.3.17, Figure 3.3.33A).  
 
 
Table 3.3.17. Range and average amount (%) of PCNA-positive, proliferating cells in fed 
control mice at 0 h and in APAP dosed C57BL/6J mice at different time points post dosing. 
The values were also compared to those obtained in CD-1 mice. 
 
Time 
(hpd) 
Fed  Fasted  
p-value fed 
vs fasted 
C57BL/6J 
Mean 
(SD) 
p-value 
APAP 
C57BL/6J 
p-value 
C57BL/6J 
vs CD-1 
Mean 
(SD) 
p-value 
APAP 
C57BL/6J 
p-value 
C57BL/6J 
vs CD-1 
Control 
0 
2.21 
(1.41) 
- (NS) 
1.18 
(0.47) 
- (NS) NS 
5 
2.11 
(1.79) 
15 h: 
0.016 
0.0008 ↑ 
1.20 
(0.3) 
20 h: 0.027 NS NS 
10 
5.53 
(1.22) 
 NS 
2.84 
(2.26) 
24 h: 0.013 NS NS 
15 
8.04 
(1.67) 
20 h: 
0.018 
NS 
1.02 
(0.13) 
20 h: 0.025 0.014 ↑ 0.0159 
20 
19.53 
(0.76) 
5 h: 0.029 0.0009 ↓ 
5.98 
(2.4) 
24 h: NS NS 0.0007 
24 
23.15 
(1.95) 
15 h: 
0.025 
NS 
13.02 
(6.55) 
5 h: 0.0092 
15 h: 0.0098 
NS 0.0493 
36 
24.97 
(7.49) 
15 h: 
0.014 
24 h: NS 
12.7 
(2.68) 
5 h: 0.034  
10 h: 0.029 
15 h: 0.034 
24h (24):  
0.0411 ↓ 
24h (16):  
0.0472 ↓ 
0.0419 
(NS) - p-value of 0 h C57BL/6J vs pooled control values of all time points in CD-1; hpd – 
hours post dosing; SD – standard deviation; 24h (24) – 24 h fasting period at 24 hours post 
dosing; 24h (16) – 16-h fasting period at 24 hours post dosing.  
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The results were then compared to CD-1 mice (see Chapter 3.2.8.3). By 24 hpd, 
amount of PCNA expressing hepatocytes were higher in fed in both strains (Figure 
3.3.32). Fed and fasted mice of both strains showed significantly higher amounts of 
PCNA-positive hepatocytes in the fed CD-1 mice at 5 hpd. However, it needs to be 
noted that the number of PCNA-positive hepatocytes was also higher in the controls 
(see Chapter 3.1.8.2, Table 3.1.16). At 10 and 15 hpd, the amounts were similar to 
those in the fed C57BL/6J mice in which no substantial increase had so far been 
seen. At the later time points (20 and 24 hpd), the amount of proliferating cells was 
higher in the C57BL/6J mice, although a significant difference was only seen at 20 
hpd (Figure 3.3.33B). In fasted mice, the amount was similarly low in both groups of 
mice up to 10 hpd. At 15 and 20 hpd, it was higher in the CD-1 mice, with a 
significant difference at 15 hpd. At 24 hpd, the amount was higher in the C57BL/6J 
mice, though without a significant difference (Table 3.3.17, Figure 3.3.33C). 
 
C57BL/6J     CD-1 
 
 
 
Figure 3.3.32. Immunohistological demonstration of PCNA expression in the liver of fed and 
fasted male C57BL/6J and CD-1 mice at 24 hpd. 
In fed mice, a large number of hepatocytes exhibit nuclear (white arrows) and cytoplasmic 
(black arrows) PCNA expression in both C57BL/6J (A) and CD-1 (B) mice. In fasted mice the 
amounts of PCNA-positive hepatocytes were much lower in both strains (C, D). PAP 
method, Papanicolaou’s haematoxylin counterstain. Magnification 400x.   
B A 
C D 
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           A. Fed vs fasted C57BL/6J 
 
  
Figure 3.3.33. Assessment of proliferating hepatocytes, based on the expression of 
proliferating cell nuclear antigen (PCNA) and comparison to CD-1 mice. 
Quantification (percentage) of PCNA-positive hepatocytes (nuclear and cytoplasmic 
expression) in fed and fasted APAP dosed C57BL/6J mice (A). Percentages of PCNA-positive 
hepatocytes in fed (A) and fasted (B) C57BL/6J and CD-1 mice (as listed in Table 3.3.17). 
Data represent means±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05. 
 
 
Over the entire time course, the amount of hepatocytes with cytoplasmic PCNA 
expression (i.e. cells in the G2 or M phase)  did not vary significantly in fed APAP 
dosed C57BL/6J mice in comparison to saline dosed mice (0 hour) (Table 3.3.18, 
Figure 3.3.34A). In fasted C57BL/6J mice, however, a significant increase (up to 2% 
positive cells) was seen at 20 hpd, but the numbers dropped thereafter (Figure 
3.3.34B).  In comparison, the fed mice exhibited a significantly higher number of 
hepatocytes with cytoplasmic PCNA expression at 10 hpd, whereas the number was 
significantly higher in the fasted C57BL/6J mice at 20 hpd (Figure 3.3.34C). There 
was no statistical significant difference in the amount of hepatocytes with 
cytoplasmic PCNA expression between fed and fasted APAP dosed C57BL/6J and 
CD-1 mice with the exception of the 5 hpd time point in the fed mice, where the 
number was significantly higher in the CD-1 mice, and at 10 hpd, when it was 
significantly lower (Table 3.3.18). 
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Table 3.3.18. Average amount (%) of hepatocytes with cytoplasmic PCNA expression in fed 
and fasted APAP dosed male C57BL/6J mice and comparison to the amount in CD-1 mice.  
 
Time 
(hpd) 
Fed  Fasted  p-value 
fed vs 
fasted 
C57BL/6J 
Mean  
(SD) 
p-value 
APAP 
C57BL/6J 
p-value 
C57BL/6J 
vs CD-1 
Mean  
(SD) 
p-value 
APAP 
C57BL/6J 
p-value 
C57BL/6J 
vs CD-1 
Control 
0 
0.31 
(0.52) 
All NS at 
any time 
points 
NS 
0.15 
(0.09) 
- NS NS 
5 
0.16 
(0.09) 
0.0008 ↑ 
0.12 
(0.04) 
20 h: 0.0063 NS NS 
10 
1.43 
(0.38) 
0.0021 ↓ 
0.18 
(0.2) 
20 h: 0.0088 NS 0.013 
15 
0.52 
(0.09) 
NS 
0.26 
(0.1) 
20 h: 0.0069 NS NS 
20 
0.83 
(0.27) 
NS 
1.74 
(0.48) 
36 h: 0.0061 NS 0.0222 
24 
1.06 
(0.19) 
NS 
0.93 
(0.91) 
- NS NS 
36 
0.51 
(0.30) 
- 
0.14 
(0.08) 
- - NS 
hpd – hours post dosing; SD – standard deviation; NS – not significant. 
 
               A. Fed vs fasted C57BL/6J 
 
  
Figure 3.3.34. Assessment of hepatocytes exhibiting cytoplasmic PCNA expression and 
comparison to CD-1 mice.  
Quantification % of cytosolic PCNA expressing hepatocytes in fed and fasted APAP dosed 
male C57BL/6J mice (A) (as listed in Table 3.3.18). Percentages of cytoplasmic PCNA-
positive hepatocytes in fed (A) and fasted (B) C57BL/6J and CD-1 mice following APAP 
dosing. *Control – C57BL/6J at 0 hpd, CD-1 is pooled control (0+10 h post saline). Data 
represent means±SD (4 to 6 animals per group). ***P<0.005, **P<0.01 and *P<0.05.  
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The time course of PCNA expression in C57BL/6J and CD-1 mice was compared to 
identify any differences in the length of the cell cycle and the onset of proliferation 
after APAP dosing. In fed APAP dosed CD-1 mice, a first peak of PCNA expression 
was seen at 5 hpd, with a second peak at 24 hpd, suggesting a cell cycle of 
approximately 19 hours (Figure 3.3.35A). As C57BL/6J mice showed a progressive 
increase of overall PCNA expression, it is difficult to define the onset of proliferation 
(Figure 3.3.35C). Only at 10 hpd, cytoplasmic PCNA expression was significantly 
higher in the C57BL/6J mice, whereas it was significantly higher in the CD-1 mice at 
5 hpd, before both were similar again at 15 hpd and thereafter (Figure 3.3.35B). 
However, PCNA-positive hepatocytes increased later in fasted than in fed mice, with 
a first peak at 20 hpd. Although PCNA expressions follow each other in both strains, 
the percentages of PCNA-positive cells in C57BL/6J mice seem to increase later and 
were significantly lower than in the CD-1 mice at 15 hpd (Figure 3.3.35C). Moreover, 
we observed that the cytoplasmic PCNA expression in fasting mice started to rise at 
later time points, with same levels in both strains (Figure 3.3.35D).  
  
 
 
Figure 3.3.35. Assessment of hepatocytes exhibiting PCNA and cytoplasmic PCNA 
expression in C57BL/6J and CD-1 mice after APAP dosing.  
Quantification % of overall and cytoplasmic PCNA-positive hepatocytes in fed (A, C) and 
fasted (B, D) C57BL/6J and CD-1 mice after APAP dosing. *Control – C57BL/6J at 0 hpd, CD-1 
is pooled control (0+10 h post saline). Data represent means±SD (4 to 6 animals per group). 
***P<0.005, **P<0.01 and *P<0.05. Cyto – cytoplasmic.  
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3.3.9  Overall assessment of liver regeneration in C57BL/6J and CD-1 mice 
The extent of liver regeneration following APAP overdose in C57BL/6J and CD-1 
mice was comparatively assessed by several parameters at 4/5, 10 and 24 hpd 
including TNF-α, IL-6, IL-10, NF-kB, cyclin-D1 and PCNA expression (Table 3.3.19, 
Figure 3.3.36). Fed CD-1 showed significantly higher hepatic IL-6, IL-10, NF-kB and 
cyclin-D1 mRNA upregulation at 4/5 hpd, and higher levels at 10 hpd, before both 
strains showed a similar level at 24 hpd. However, while the amount of PCNA-
positive hepatocytes was signifantly higher at 4/5 hpd in CD-1 mice, this was 
reversed at 10 and 24 hpd (Figure 3.3.36A). However, at 24 hpd, while IL-6 and 
cyclin-D1 were highly transcribed in the liver, the amount of PCNA-positive 
hepatocytes was significantly lower in CD-1 mice (Table 3.3.19, Figure 3.3.36B).   
Table 3.3.19. Assesment of liver regeneration of the levels of TNF-α, IL-6, IL-10, NF-kB, 
cyclin-D1 and PCNA expression in the liver by comparative value, assessing the fold change 
relative to pooled control animals. 
 
Fed 
Time (hpd) *5 10 24 
Liver 
parameters 
C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J CD-1 
TNF-α 11.7 4.4* 2.18 7.9* 0.59 1.77 
IL-6 2.33 6.0* 3.71 7.9* 7.02 7.6 
IL-10 0.81 3.9* 3.14 9.0* 7.17 8.8 
NF-kB 0.67 2.1 2.83 13.3*** 4.70 6.1 
Cyclin-D1 2.48 8.1*** 2.12 8.7** 7.04 9.6 
PCNA 0.95 2.11* 2.5 1.04 10.5 2.03** 
PCNA Cyto 0.65 3.64* 4.5 0.96* 3.5 3.36 
 
Fasted 
Time (hpd) *5 10 24 
Liver 
parameters 
C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J CD-1 
TNF-α 1.49 2.3 3.14 6.8* 4.19 1.5* 
IL-6 1.11 4.7* 1.36 2.2 3.01 7.4* 
IL-10 1.81 1.5 1.69 1.8 3.71 5.2 
NF-kB 0.33 2.1 0.66 1.5 6.33 4.7 
Cyclin-D1 3.17 4.0 1.01 4.2 1.80 6.0** 
PCNA 1.0 0.61 2.4 0.56 11.0 1.58*** 
PCNA Cyto 0.67 5.62** 1.3 0.23 6.0 3.54 
Statistical significant differences (***P<0.005, **P<0.01 and *P<0.05) are seen in CD-1 mice 
in comparison to C57BL/6J mice after APAP dosing. hpd – hours post dosing; Cyto – 
cytoplasmic; *5 - values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
Chapter 3.3 
193 
 
 
 
 
 
 
 
 
Figure 3.3.36. Assessment of liver regeneration in male fed and fasted C57BL/6J and CD-1 
mice after APAP dosing. 
The levels of hepatic TNF-α, IL-6, IL-10, NF-kB, cyclin-D1 and PCNA expression  were 
evaluated at 5, 10 and 24 hpd in animals that had been fed (A) or fasted (B) prior to APAP 
administration (as listed in Table 3.3.19). Fold changes are calculated relative to pooled 
control mice. Data represent mean (4 to 6 animals per group). *5- values of 5 h C57BL/6J 
was compared to 4 h CD-1 mice. Cyto-cytoplasmic. 
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4    DISCUSSION 
Despite the extensive use of laboratory mice in DILI research, data on baseline 
values in commonly used out-bred and in-bred strains with regards to their 
response to fasting is still lacking. This is particularly inconvenient, since variable 
approaches are used by researchers, often accompanied by only limited information 
on the feeding and fasting protocols that were applied, thus reducing the 
reproducibility and applicability of the results and ultimately counteracting the 3R 
concepts.      
The aims of this thesis were to gather relevant basic information on the 
inflammatory and regenerative response in commonly used in vivo models of DILI, 
assessing and characterising them by a chosen set of quantifiable liver parameters 
on two strains of mice, the out-bred CD-1 and the more commonly used in-bred 
C57BL/6J mice. A recent study reported an impaired regenerative capacity after high 
dose (600 mg/kg) APAP treatment, however, this experiment was carried out in 
male C57BL/6J mice that had been fasted for 12 hours only (Bhushan et al., 2014). 
Taking this into consideration, we wanted to establish whether fasting or strain 
differences profoundly change the potential of the liver to regenerate. Hence, the 
studies in this thesis have been undertaken to investigate the effects of fasting on 
acute hepatotoxicity and regeneration in mice of these two strains.  
To characterise the APAP models of hepatotoxicity, markers of toxicity and necrosis 
(serum ALT and histopathology), apoptosis (cleaved caspase-3), relevant metabolic 
processes (hepatic GSH content) and energy levels (hepatic ATP content) were 
evaluated in both fed and fasted CD-1 and C57BL/6J control and APAP dosed mice. 
As hypothesis had fully fulfilled, that The degree of hepatic regenerative capacity 
was assessed by the immunohistological demonstration of PCNA-positive, 
proliferating hepatocytes and the transcription levels of relevant cytokines (TNF-α, 
IL-6, IL-10) and relevant transcription factor (NF-kB) and cell-cycle protein (cyclin-
D1); the inflammatory cytokines TNF-α and IL-6 also provided information on the 
(systemic) inflammatory response after APAP induced liver injury.  
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In untreated control mice, the hypothesis was partly proven correct although some 
differences in basal levels were identified between both fed and fasted CD-1 and 
C57BL/6J mice. As expected, the response to APAP differed between fed and fasted 
mice; in both strains fasting prior to APAP overdose resulted in more extensive liver 
damage, thereby leading to lesser hepatic regeneration. Surprisingly, the 
assessment of APAP dosed fed animals of both strains indicates that CD-1 mice have 
a higher regenerative capacity than C57BL/6J mice. 
 
4.1 Effects of fasting in saline dosed control male CD-1 and C57BL/6J mice 
Before the impact of fasting on APAP induced liver injury was investigated, CD-1 and 
C57BL/6J mice that had been fed and fasted prior to 0.9% saline dosing were 
assessed for the effect of fasting on relevant liver parameters. Fasting is defined as 
the withdrawal of food from animals which still have free access to water (Jensen et 
al., 2013). After fasting periods, mice generally show a substantial reduction of their 
body weight since the drinking activity corresponds to the food intake and is 
therefore reduced alongside (Kurokawa et al., 2000). It is known that mice consume 
about two thirds of their daily food and water ratio during the scotophase, with a 5-
fold increase of the eating rate in the evening (Petersen, 1978).  
Our data also showed that the body weights were basically equal in CD-1 and 
C57BL/6J mice fed ad libitum at any time of study although it has been reported 
that body weight and food intake can vary between mouse strains (Bachmanov et 
al., 2002). While this may be the case, it appears not to affect the average body 
weight loss that is seen after fasting: both the CD-1 and C57BL/6J mice showed a 
similar range of weight loss after 16 hours fasting, when the onset of fasting was at 
the same time of day. The lowest degree of body weight loss was seen when the 
fasting period had started at 3 am, indicating that the highest food intake took place 
in the first half of the night. The circadian rhythm of food consumption is well 
known in mice (Petersen, 1978), but it has also previously been shown that the 
body weight of mice undergoes a circadian rhythm (Eckel-Mahan and Sassone-Corsi, 
2013; Schnell et al., 1984), a finding that the results of our study support. 
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Interestingly, the body weight loss after fasting did not result in changes in body 
mass and liver weight (Jensen et al., 2013). It is therefore important to consider this 
variance when starting an experiment with fasted mice, in particular since mice that 
have already lost more than 10% of their body weight will reach the endpoint of a 
permitted experiment after a moderate additional weight loss due to treatment.  
The hepatic GSH level peaks at the end of the scotophase (night cycle) when mice 
have taken up the bulk of their daily food ration, and are lowest when mice sleep, at 
the end of the prolonged light period (Schnell et al., 1984); they show a diurnal 
variation (Jaeschke and Wendel, 1985). Our results confirm that the hepatic GSH 
content follows the circadian rhythm of the mice as levels were significantly higher 
in the morning than in the afternoon and at night time (20:45) in both CD-1 and 
C57BL/6J mice. It has previously been shown that fasting of mice results in reduced 
hepatic glutathione levels (Brooks and Pong, 1981; Strubelt et al., 1981b). As 
predicted, in the present study the GSH level was significantly reduced after fasting, 
but returned to levels similar to those of fed mice within 24 hours refeeding in CD-1 
mice. However, after the first 10 hours of refeeding, at a time of day when the GSH 
level in fed mice had decreased due to the circadian rhythm (20:00), the GSH level 
in the fasted mice was significantly higher and seemed to overshoot far above the 
normal maximum level, apparently overriding also the circadian rhythm. It was 
similar in C57BL/6J mice at the same time of day and length of refeeding and 
progressed to an even higher value after 15 hours of refeeding. Overshooting of 
GSH level was likely due to overeating when feeding was resumed (Bare and Cicala, 
1960). While GSH levels of CD-1 mice return to basal levels after 24 hours of re-
feeding, C57BL/6J mice took much longer and reached the levels observed in fed 
mice at 36 hours of feeding. The rate of GSH synthesis depends on the availability of 
cysteine provided with the diet (Lu, 1999). A study suggested that the enzymes 
involved in GSH synthesis are unaffected by fasting, which confirms that it strongly 
depends on the food intake (Tateishi et al., 1974). Due to rapid GSH turnover in this 
study, the mice might have changed their diurnal rhythm in order to restore the 
hepatic GSH level, but why it then overshoots remains to be clarified. It can also not 
be explained, why there is a strain differences in the speed of GSH replenishing 
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after starvation. It was also interesting to note that GSH levels were always 
significantly higher in the fed C57BL/6J mice than in the fed CD-1 mice. This appears 
not to indicate that C57BL/6J mice have a higher detoxification potential than CD-1 
mice, as a previous study has shown that the antioxidant capability depends on the 
threshold of GSH to detoxify free radicals (Casini et al., 1984). For example, 
although both CD-1 and C57BL/6J mice were induced with the same dose of APAP, 
fed CD-1 had higher caspase activation which initiate apoptosis than fed C57BL/6J 
mice (Acton, 2013).   
The amount of hepatic ATP is critical in particular during toxic insults, as it is 
essential for cells to die via apoptosis instead of necrosis, thereby protecting the 
liver from the pathological consequences of necrosis following APAP administration 
(James et al., 2003b). Furthermore, GSH synthesis also requires ATP (Lu, 1999), ATP 
thereby being a prerequisite to ensure optimal detoxification capacity. Interestingly, 
despite the circadian fluctuation of food intake and hepatic GSH, similar fluctuations 
in the hepatic ATP content were not observed. In our study, hepatic ATP levels were 
always lower in C57BL/6J than CD-1 in fed mice, though did not differ significantly. 
A previous study has showed that lower sensitivity to tissue injury in in-bred A/J 
mice than C57BL/6J mice is due to downregulation of ATP-gated P2X receptor as a 
pain sensor when ATP leaked from damaged tissue (Tsuda et al., 2002). It indicated 
the difference of ATP levels could be strain-specific. As expected, however, fasting 
of mice resulted in substantial depletion of overall hepatic ATP in CD-1 (64%) and 
C57BL/6J (38%) mice. Surprisingly, the ATP content did not return to the level in fed 
animals even after 24 hours of refeeding in the CD-1 mice, whereas in C57BL/6J 
mice, a gradual increase in the ATP content was observed after refeeding until it 
reached a level similar to fed mice after 20 hours. Starvation is believed to inhibit 
ATP production and further depletes the substrates used to synthesise ATP (Berg 
JM, 2002; Fry, 2010).  
Since hepatic GSH synthesis and ATP content can be expected to be associated, we 
investigated their fold changes alongside each other. Theoretically, GSH synthesis is 
depending on the availability of cysteine and the activity of the enzyme y-
glutamylcysteine synthetase (GCS). It includes two ATP-requiring steps; [1] L-
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glutamate + L-cysteine + ATP → γ-glutamyl-L-cysteine + ADP + Pi (inorganic 
phosphate) and [2] γ-glutamyl-L-cysteine + L-glycine + ATP → GSH + ADP + Pi (Lu, 
1999). In our study, while ATP levels remained low after the onset of refeeding 
throughout the experiment, we observed a significant increase of hepatic GSH after 
10 hours of refeeding, which indicates that the level of hepatic GSH may not 
correlate with the level of hepatic ATP, suggesting that the synthesis of GSH still 
occurs when a basic, though overall insufficient amount of ATP is present. Also, 
glycogen is synthesised when sufficient glucose and ATP are available, with one ATP 
molecule being required per glucose molecule that is incorporated into the 
polymeric branched structure of glycogen (Berg et al., 2002). The rapid refilling of 
glycogen stores that was observed in the present study makes it likely that the ATP 
is used up in this manner. Consequently, after fasting, ATP cannot be stored and is 
utilised as soon as it has been synthesised; this would explain the low ATP levels 
over such a long period of refeeding in the fasted mice. 
Serum ALT activities were measured as a means to detect potential liver damage as 
a consequence of fasting. ALT is widely used as a clinically proven, though not 
sensitive indicator of liver damage (Kim et al., 2008a). Intriguingly, our data 
revealed average ALT activities in C57BL/6J mice to always be significantly lower 
than those of CD-1 mice and to show less variance. The wide interindividual 
variation among the out-bred CD-1 mice, however, makes it difficult to formulate 
reference values and impossible to interpret subtle changes. Such variation in CD-1 
is likely due to their relatively high degree of genetic dissimilarity. In any case, the 
lack of a distinctive increase of ALT activities after fasting in either strain of mice 
confirms that fasting does not induce substantial damage to the liver.  
As expected, the histological assessment did not identify any abnormal 
morphological changes or any significant inflammatory cell recruitment as a 
consequence of fasting in CD-1 and C57BL/6J mice except the apparent lack of 
cytoplasmic vacuolation of hepatocytes that can be visualised histologically at 
higher magnification immediately after fasting. This confirms the results of a 
previous study that reported the liver structure and zonation, including periportal 
and pericentral areas, was still preserved after 72 hours of fasting (Sokolovic et al., 
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2008). Together, glycogen stores within hepatocytes appear completely lost after 
the fasting period in both strains. In agreement with this, a previous study reported 
a 90% reduction in hepatic glycogen was in C57BL/6J mice after 18 hours compared 
to 5 hours of fasting which only resulted in a 10% loss, but does not compromise 
the glycogen content in muscles (Ayala et al., 2006). It is important to note that liver 
glycogen stores is important to maintain glucose homeostasis (Klover and Mooney, 
2004), and recent studies have shown that the expression of a number of genes 
involved in the hepatic glucose metabolism is under circadian regulation (Panda et 
al.; Storch et al., 2002; Ueda et al., 2002). During fasting, glycogen stored in the liver 
are mobilised in order to replenish blood glucose and conserve energy (ATP) via 
glycogenolysis (Fry, 2010),  which explains the apparent complete hepatocellular 
glycogen depletion immediately after the fasting period. However, when feeding is 
resumed, the excess of insulin promotes the glucose conversion into glycogen for 
storage in the liver to quickly maintain its homeostatic functions. After 
reintroduction of food at a similar time of day, we found evidence of rapid glycogen 
restitution in both groups of mice. However, while it seemed to be completely 
restored after only 30 minutes in C57BL/6J mice, glycogen restitution seemed to 
take 4 hours in the CD-1 mice. This suggests that C57BL/6J mice either consumed 
food more rapidly or in larger amounts once it was reintroduced or that they have a 
more rapid glycogen reserve capacity once blood glucose levels are maintained. 
Although some studies have quantified the transcription of TNF-α, IL-6 and IL-10 in 
the liver as potential indicators of inflammatory or regenerative responses following 
chemical intoxication (i.e. APAP, CCl4 or GaIN) (Masubuchi et al., 2003a; Mehendale, 
2005; Peschon et al., 1998), study on the potential effects of starvation alone on 
their hepatic transcription and thereby the induction or reduction of a (pro-) 
inflammatory state still needs to be studied. Thus, we were interested in gathering 
baseline information on such a potential effect of fasting. However, no evidence 
was found of changes in the transcription of TNF-α, IL-6 and IL-10 in the liver or 
spleen due to fasting in CD-1 and/or C57BL/6J mice, although these cytokines were 
found to be constitutively transcribed in the spleen and, at a lower level, the liver. 
Overall, the TNF-α transcription was higher than that of IL-6 and IL-10, and it was 
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found to be transcribed at a higher level in the C57BL/6J mice. These finding provide 
baseline information to suggest that different mouse strains with their own genetic 
backgrounds can develop a different degree of immune cell activation during toxic 
insults and inflammatory responses. It should be noted that the serum TNF-α levels 
were always higher in the CD-1 mice, a feature that has so far not been reported. 
However, serum IL-6 did not differ in either strain (C57BL/6J or CD-1) in response to 
fasting, which indicates that fasting does not influence the release of this cytokine. 
Similarly, fasting appeared not to have an effect on hepatocyte turnover, since 
hepatic NF-kB and cyclin-D1 transcription levels were not altered after fasting. 
Furthermore, there was no evidence of circadian changes in their transcription. The 
results of the quantitative assessment of proliferating, PCNA-expressing 
hepatocytes confirm these findings at the in situ level. PCNA is a well-accepted 
indicator of liver regeneration and hepatocyte proliferation (Bravo et al., 1987). The 
liver mass is maintained by self-replicating hepatocytes during normal liver turnover 
(Malato et al., 2011). In both fed and fasted CD-1 and C57BL/6J mice a relatively 
low, but varying (in CD-1 mice) amount of PCNA-positive hepatocytes was seen. The 
observed overall higher number in fed CD-1 mice than in fed C57BL/6J mice at the 
time of saline application (0 h) suggests that the liver of CD-1 mice has a higher 
basal cellular turnover than that of C57BL/6J mice (Table 3.1.16). 
In summary, the present study shows that fasting alone has substantial effects on 
some liver parameters that might be of relevance for (and monitored in) any study 
in which fasted mice are used. In particular also the circadian effects that influence 
the parameters not only in fed, but also in fasted mice need to be considered as 
well. Also, while they were apparently not influenced directly by a circadian rhythm 
or fasting, other parameters including liver morphology, ALT activity, PCNA 
expression and cytokine transcription, might be of relevance. Therefore, the 
present study provides insight into differences in baseline levels in different mouse 
strains and in their response to fasting, which need to be considered before 
conducting a mouse study.   
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4.2  Effect of fasting in the response of male CD-1 and C57BL/6J mice to APAP 
overdose 
4.2.1 Drug-induced liver injury after APAP overdose 
The literature provides evidence that diet restriction prior to APAP dosing can 
increase the degree of hepatic injury (Strubelt et al., 1981a). The purpose of the 
present study was to systematically assess the influence of fasting on the extent and 
degree of APAP-induced liver damage and subsequent liver regeneration in out-
bred (CD-1) and in-bred (C57BL/6J) mice and assess whether the presence and 
extent of inflammation differs in fed and fasted animals. Accordingly, a range of 
parameters (hepatic GSH, ATP, serum ALT and histology, i.e. DILI score) were 
examined in male CD-1 and C57BL/6J mice that had been fed ad libitum or fasted 
for 16 hours (or 24 hours) prior to receiving a sublethal APAP dose.  
In both CD-1 and C57BL/6J mice fed ad libitum, hepatic GSH levels dropped 
significantly after APAP dosing, confirming the results of previous studies (Antoine 
et al., 2010; Williams et al., 2011). The drop occurred as early as 1 hpd in CD-1 mice 
and at 3 hpd in C57BL/6J mice. This might be due to the generally higher basal GSH 
content in C57BL/6J mice, which was seen when control animals of both strains 
were compared; this could allow the liver of C57BL/6J mice to initially detoxify a 
higher amount of APAP prior to succumbing to the toxic injury (Strubelt et al., 
1981a). Interestingly, GSH levels were subsequently increased significantly (at 10 
hpd) in treated CD-1 mice compared to control mice at the same time of killing, 
20:45. This suggests that the physiological circadian hepatic GSH rhythm can be 
interrupted as a consequence of GSH depletion, like in APAP overdose, due to 
excessive glutathione production in the liver in response to the loss of GSH. In CD-1 
mice, GSH returned to basal levels at the end of the study (at 24 hpd), similar to 
what was seen in Swiss Webster (SW) mice (Williams et al., 2011). In contrast, the 
GSH levels in C57BL/6J mice were similar in control and APAP dosed mice at 10 hpd 
(time of killing, 20:00). Although the levels in APAP dosed mice were increasing, 
they still did not reach control animal levels, where GSH was increased at 24 h 
saline dosed mice but not statistically higher than the 0 hpd values, with time of 
killing was at 10:00 in both. Meanwhile, over-production of GSH was also seen in 
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C57BL/6J mice at 30 hpd, with levels were higher than in CD-1 mice at 20 and 24 
hpd, at the same time points, and exceeding control animal levels at 30 hpd before 
returning to control animal levels at 36 hpd. Such fluctuating GSH levels might be 
the result of over production in order to compensate for the GSH consumption after 
APAP dosing. The difference to control animal levels cannot readily be explained but 
could theoretically also indicate further utilise of GSH due to the presence of APAP 
insult. However, this is unlikely as the half-life of metabolised APAP in the blood is 
about 4-6 hours in hepatototoxic doses (Pyrsopoulos, 2014). 
As mentioned earlier, overnight fasting of the mice resulted in significantly 
decreased basal hepatic GSH levels, indicating that the animals had a decreased 
antioxidant defence and detoxification capacity at the time of APAP dosing. 
Therefore, higher amounts of the reactive metabolite NAPQI can be expected to be 
generated, enhancing the hepatotoxic effect of an APAP dose (Brooks and Pong, 
1981; Strubelt et al., 1981b). As overnight fasting of mice does not only reduce 
hepatic glutathione levels, but also alter the diurnal GSH variation, it has been 
commonly used in studies of APAP-induced hepatotoxicity, allowing the induction 
of hepatotoxic injury at more moderate doses (Jaeschke and Wendel, 1985). The 
results of our study not only show that hepatic GSH levels are significantly lower in 
fasted than in fed mice of both strains at the same time of day, they also show that 
levels do not differ much between both strains despite the differences in the fed 
counterparts, confirming the results of previous studies (Hinson et al., 2010). 
Consequently, fasted animals developed a distinctly more intense early degree of 
liver injury following APAP administration. In line with this, the restoration of 
hepatic glutathione levels after APAP administration of C57BL/6J mice occurred 
more rapidly in fed mice (at 10 hpd) than in fasted mice where it was first seen at 
36 hpd. Interestingly, fasted, APAP treated CD-1 mice reached hepatic GSH levels 
similar to those in saline treated control mice by 24 hpd, whereas C57BL/6J had not 
fully recovered at 24 hpd, a feature also reported previously (Williams et al., 2011). 
They were only returned to basal levels at 36 hpd. At these end time points, fasted 
mice of both strains showed ongoing centrilobular damage which reduces the 
capability of hepatocytes to produce GSH (Hinson et al., 2010). These results 
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confirm that in the mouse, GSH depletion is a prerequisite for the onset of toxicity 
following APAP overdose (Davis et al., 1974). At toxic APAP doses, the reactive 
metabolite has been shown to deplete the glutathione content by up to 80-90%. 
Increased formation of reactive oxygen and nitrogen species, i.e. NAPQI in 
hepatocytes induced by APAP, can reduce the GSH content. It has been shown that 
the degree of covalent binding of the reactive metabolite to proteins determines 
the outcome of hepatocyte damage until glutathione is almost completely depleted 
(Mitchell et al., 1973; Nelson, 1990). The capability of an individual mouse to 
detoxify NAPQI determines the severity of the APAP hepatotoxicity (Hinson et al., 
2010). Furthermore, the fact that the hepatic GSH content had reached control 
levels in both strains at the end of the study period suggests that either 
physiological adaptation or regeneration had taken place within the liver, enabling 
hepatocytes to synthesise glutathione (Lu, 1999).  
Following APAP treatment, ATP levels were also severely depleted in fed CD-1 and 
C57BL/6J mice (at 5 and 10 hpd). By 24 hpd, ATP levels had returned to basal 
control animal levels in both strains. However, fed C57BL/6J mice appear to 
generate ATP earlier than CD-1 mice following APAP toxicity, and the ATP loss is 
greater in fed CD-1 mice than in fed C57BL/6J mice at 5 hpd.  While in our study ATP 
levels in fed C57BL/6J mice returned to control animal levels after 20 hpd, a 
previous study reported that in fed C57BL/6J mice ATP levels returned to basal 
levels (0 hpd) at 3 hpd. In SW mice, however, they remained low (Williams et al., 
2011). Although the APAP dose applied intraperitoneally was identical in both 
studies (530 mg/kg), the basal control mouse levels in our study based on the 
pooled values of more than 20 control mice and not on only 4-6 animals at 0 hpd in 
the previous study (Williams et al., 2011) which could have hampered the statistical 
analysis. APAP dosed fasted mice showed a significant ATP reduction compared to 
both saline dosed fasted and APAP dosed fed mice for both strains from 5 hpd 
onwards, a finding that is in agreement with the results of other studies (Antoine et 
al., 2010; Lee et al., 1988). Moreover, another study also reported hepatic ATP 
reduction by 50% in mice after overnight fasting, APAP dosing of the fasted mice 
resulted in an additional decline to around 70% in both C57BL/6J and SW mice 
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(Williams et al., 2011), however the study claimed that the amount of ATP was still 
sufficient to promote caspase activation and apoptosis, though this appeared not to 
be the case in the study by  Antoine et. al. (2010). Unfortunately, the study did not 
mention specifically the time of day and length of fasting, as fasting alone influences 
the ATP levels and could therefore have influenced the results. Loss of 
mitochondrial membrane potential due to mitochondrial permeability transition as 
a consequence of increased oxidative stress due to NAPQI would reduce the ability 
of mitochondria to synthesise ATP (Hinson et al., 2010). Usually, ATP is produced by 
glycolysis, where glycogen is degraded to produce glucose which is then used to 
generate pyruvate, ATP, NADH and H+ (Berg JM, 2002). In addition, pyruvate and 
NADH derived from glycolysis also provide substrates to further synthesise ATP 
during the mitochondrial citric acid cycle (Berg JM, 2002; Fry, 2010). Furthermore, 
an in vitro study has demonstrated that APAP-induced apoptosis of hepatocytes 
does also rely on ATP produced by glycolysis (Kon et al., 2007). 
Although it is known that both hepatic GSH and ATP contents are depleted after 
APAP overdose (Antoine et al., 2010; Saito et al., 2010), very little is known about 
the potential association between GSH and ATP in the liver. In CD-1 mice, the 
hepatic GSH reduction was remarkably more intense than the ATP level reduction at 
1 hpd, however by 10 hpd, the GSH content had significantly increased whereas the 
ATP level was still low. In C57BL/6J mice, as expected, the hepatic ATP level was 
proportional to the GSH level, without significant differences in the fold change at 
all times in fed or fasted mice. In fed C57BL/6J mice, GSH and ATP levels became 
similar to those of control animals by 24 hpd, like in fed CD-1 mice, but then a slight 
increase was observed at 36 hpd. However, both GSH and ATP levels were lower in 
fasted mice of both strains at all time points, although at 36 hpd in C57BL/6J mice. 
Because the toxic effect of APAP was still more apparent in fasted compared to fed 
mice at 24 hpd, both GSH and ATP levels were still lower than in control mice at this 
point. Reduced hepatic ATP production could also result from reduced hepatic GSH 
levels, as GSH depletion results in an increased production of a reactive APAP 
metabolite, NAPQI that increases the oxidative stress and can induce mitochondrial 
permeability transition (Hinson et al., 2010).  
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Although ALT activity levels are more liver specific than  aspartate aminotransferase 
(AST) levels (Giannini et al., 2005), AST is not a specific marker for APAP-induced 
liver damage because it is also highly present in skeletal, cardiac muscle and kidneys 
(Lindblom et al., 2007). Nevertheless, both are not sensitive marker for 
hepatotoxicity as also been released in other non-toxic liver diseases, such as viral 
infections, alcoholic and steatohepatitis (Jadhao et al., 2004). Furthermore, the 
serum half-life of ALT is long, ranging from 37 to 60 hours, leading to consistently 
elevated levels after peak liver damage (Hawker, 1991; Seneviratne et al., 2006). 
This explains why the serum ALT level was still significantly elevated in fed CD-1 mice 
at 24 hpd, when the histological examination of the liver suggested complete 
recovery. Nonetheless, the serum ALT activity is a well-established indicator of 
APAP-induced acute liver damage (Giannini et al., 2005; Jaeschke et al., 2014); in 
the present studies, while a time dependent increase in APAP hepatotoxic changes 
was seen in the early phase in both fed and fasted CD-1 and C57BL/6J mice, the ALT 
activity was higher at later phases in fasted than fed for both strains (CD-1 mice: 24 
hpd; C57BL/6J mice: 20, 24 and 36 hpd), in the latter reflecting the ongoing damage 
that was seen in the histological specimens. Serum ALT levels were compared at 5 
and 24 hpd and were similar in fed and fasted APAP dosed mice of both strains, at 
these time points, suggesting that the extent of liver injury after APAP was the 
same; this was, but, not confirmed by the histological examination.  
The type of liver change induced by APAP in mice, i.e. centrilobular cell 
loss/necrosis, is well known (Gujral et al., 2002; Jaeschke et al., 2003); however, 
information on the mode of cell death is still partly controversial, and both 
apoptosis and necrosis are being mentioned (Guicciardi et al., 2013; Gujral et al., 
2002). The literature has demonstrated that fasting of mice prior to dosing can 
elevate the level of hepatic necrosis, thereby increasing the severity of liver damage 
in animal models (Strubelt et al., 1981a); already in an older study it was stated that 
in fasted mice, apoptotic cell death is less likely to be found because it is an energy 
dependent process (Kerr et al., 1972). Other literature considered apoptosis as less 
likely to be a key feature of APAP induced liver injury because of the rapid drop in 
ATP and the oxidative stress that do not facilitate caspase activation (Cover et al., 
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2005; Gujral et al., 2002; Gunawan et al., 2006; Lawson et al., 2000). However, 
these studies were all done in animals that had been fasted prior to dosing. In a 
study in fed CD-1 mice it was clearly shown that apoptosis is a relevant form of cell 
death in the early stage, i.e. as early as 3 hours after APAP overdose. The 
histological and immunohistological findings were supported by biochemical 
markers of apoptosis, i.e. cytokeratin 18 cleavage, DNA laddering and procaspase-3 
processing (Antoine et al., 2010). In contrast, a subsequent study demonstrated 
that hepatic ATP contents did not correlate with APAP-induced caspase activation in 
SW and C57BL/6J mice and concluded that its activation to promote apoptosis is 
strain specific (Williams et al., 2011). 
The present study shows that there are again differences between the two mouse 
strains. In CD-1 mice, relatively numerous apoptotic cells were seen in fed animals 
at 3 and 5 hpd, these were not observed in the fasted animals. As discussed above, 
in fed mice, we identified a significant drop in hepatic ATP content only at 5 hpd, 
which suggests that apoptotic cell death at the early time points is possible due to 
sufficient ATP amounts. A previous study reports contradicting results, i.e. the 
absence of apoptotic cells at 3 and 5 hours post APAP dosing, but early evidence of 
oncotic, i.e. swelling necrosis with features of karyolysis and loss of membrane 
integrity using TUNEL staining in both fed and fasted out-bred SW mice, with no 
difference in the type and extent of injury in both groups (Williams et al., 2011). 
Although apoptosis was not observed histologically, Williams et. al. showed an 
increase in caspase-3 activity at 3 hpd, but not at 5 hpd in fed SW mice, a feature 
not seen in the fasted mice which corresponds to earlier findings in the study by 
Antoine et. al. (Antoine et al., 2010). However, at 24 hpd, the authors reported 
morphological features of oncotic necrosis  but no evidence of apoptosis in both fed 
and fasted SW and C57BL/6J mice (Williams et al., 2011). These results could be due 
to the mouse strain used, though this needs to be investigated further. At 10 hpd, 
we still observed centrilobular hepatocyte necrosis, although the DILI score 
decreased after 5 hpd (apart from at 15 hpd, which was a group of mice dosed 
accidentally at 17:00) and intriguingly, at 24 hpd, the histological features of the 
liver in CD-1 mice suggested complete regeneration, with presence of numerous 
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mitotic figures as also been reported previously, where normal liver architecture 
was restored after 24 hours of 500 mg/kg APAP dosed CD-1 mice (Apte et al., 
2009b). Also, in the fed mice there was no histological evidence of substantial 
inflammatory cell influx at any time point. These results are in accordance with a 
previous study on APAP induced hepatotoxicity in fed CD-1 mice (Antoine et al., 
2010). They provide further evidence that regeneration is the final outcome of drug-
induced liver toxicity including APAP toxicity, as has been claimed previously based 
on rodent models (Apte et al., 2009b; Mehendale, 2005). It was hypothesised that 
with the metabolism of APAP unaffected by fasting in these systems, the decrease 
in basal GSH would not play a major role in the inhibition of later events during 
APAP hepatotoxicity, such as apoptosis. Low ATP content that we observed 
previously in fasted mice could explain the dominance of necrosis that we observed 
histologically. Rather, depletion of ATP due to fasting to below a threshold level can 
lead to reduction of apoptotic cell death and switch to necrosis (Antoine et al., 
2010). Moreover, it also has been claimed that genes which facilitate apoptosis 
were down-regulated in mice after restricted feeding (Matthias et al., 2004).  
In contrast to CD-1 mice, fed C57BL/6J mice still showed centrilobular cell loss, 
neutrophil infiltration and ongoing cell degeneration and death via apoptosis and 
coagulative necrosis at later time points. The extent of the ongoing damage was 
apparently slowly decreasing, indicated by the drop in the average DILI score from 
1.15 at 24 hpd to 0.75 at 30 hpd and 0.8 at 36 hpd, whereas the fed CD-1 did not 
show any evidence of centrilobular damage at 24 hpd. This indicates that the 
primary mode of cell death at these later time points is apoptosis followed or 
accompanied by necrosis; however, the cause for this ongoing centrilobular injury is 
still unclear and needs to be investigated. However, it cannot be excluded that low 
energy levels due to mitochondrial damage could be a reason that contributes to 
prolonged cell death following APAP dosing. A comparative study of resistant and 
susceptible strains (i.e. SJL and C57BL/6J mice) by genomic and proteomic 
approaches revealed that C57BL/6J mice had a lesser cytoprotective gene like HSP 
(heat shock protein) 70, and more protoxicant gene (i.e. osteopontin), thereby 
contributing to intense hepatotoxicity following APAP overdose (Welch et al., 2006). 
Chapter 4 
210 
 
Interestingly, morphological evidence of liver damage was seen later in fasted (at 5 
hpd) than in fed (at 3 hpd) C57BL/6J mice, which was also later than in fed and 
fasted CD-1 mice, where liver damage was obvious at 3 hpd. It is possible that the 
delay in the fasted C57BL/6J mice to respond to the toxic insult might be due to very 
high ATP levels in association with refeeding at a time point before 5 hpd (these 
were not examined in this study), because we could see in saline dosed fasted 
C57BL/6J mice that their hepatic ATP levels recovered earlier than that of CD-1 mice. 
Over time, marked centrilobular cell loss and evidence of coagulative necrosis of the 
innermost remaining hepatocyte layer and hydropic degeneration of hepatocytes 
surrounding the latter was present in both fasted CD-1 and C57BL/6J mice; a 
feature also seen at the later time points in fed C57BL/6J mice and in a previous 
study (Williams et al., 2011). The extent of liver damage was significantly higher in 
fasted CD-1 mice at 10, 20 and 24 hpd. In C57BL/6J mice, the damage also persisted 
in the fasted mice and was found to be more extensive even at 30 hpd (score 2.1) 
and 36 hpd (score 1.5), when it was found to decrease as well. It has previously 
been suggested that the hepatic ATP reduction in fasted mice promotes necrotic 
cell death in response to APAP overdose, leading to the release of reduced HMGB-1 
which triggers the recruitment of inflammatory cells and the formation of pro-
inflammatory cytokines (Antoine et al., 2010; Robertson et al., 2000). Release of 
these proteins from the cells during necrosis into the extracellular space attracts 
leukocytes to damaged areas (Robertson et al., 2000). Accordingly, neutrophils 
were found in the affected areas in fasted APAP dosed mice until the end of the 
study period, which was more pronounced in the C57BL/6J mice. A similar study 
also reported more neutrophils in the liver of C57BL/6J than in SW mice (Williams et 
al., 2011). While the authors observed a comparable degree of injury and neutrophil 
infiltration at 3 and 5 hpd in both fed and fasted C57BL/6J mice, they observed less 
extensive necrosis in the fed mice at 24 hpd, similar to our study. However, there 
was no evidence of decreasing neutrophil infiltration, as high amounts of 
neutrophils were located between the necrotic cells (Williams et al., 2011). In 
conjunction with the finding, Williams et al. also observed no upregulation of 
caspase-3 activity at 3, 5 and 24 hpd. Alongside the morphological evidence of 
centrilobular hepatocyte necrosis, we used staining for cleaved caspase-3 to 
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confirm the presence of a few apoptotic cells alongside these until 36 hpd in our 
study. As mentioned previously, this indicates that both necrosis and apoptosis 
occur simultaneously; also, the amount of apoptotic cells might even be 
underestimated, because it is likely that cells undergoing coagulative necrosis 
remain visible longer than apoptotic cells/bodies which are rapidly phagocytosed 
(Corcoran et al., 1994; Sahota et al., 2013). 
The extent of hepatic carbohydrate or glycogen content within hepatocytes was 
assessed by staining with the PAS reaction. This is a crude method, since it does not 
allow precise quantification, but has the advantage of allowing comments on the 
distribution of glycogen-containing hepatocytes. In the present study, we used the 
PAS reaction to examine the liver of fed CD-1 mice over the entire time course, but 
in particular also in the early phase after APAP overdose (0, 0.5, 1, 2 and 3 hpd). The 
glycogen content was reduced already at 1 hpd and was completely lost apart from 
a few scattered individual PAS-positive cells at 3 and 5 hpd. This suggests that the 
animals had not resumed food consumption immediately after APAP treatment, 
when food was reintroduced. Thereafter, glycogen started to accumulate again 
throughout the parenchyma, except for the innermost centrilobular areas where it 
was still generally absent at 10 to 20 hpd. In fed mice, complete glycogen restitution 
was indicated at 24 hpd in CD-1 mice, where morphological evidence of complete 
liver regeneration, whereas C57BL/6J mice revealed consistently PAS-negative in 
cell damage of centrilobular hepatocytes until 36 hpd. In fasted mice, we observed 
a different scenario: At the time of dosing, i.e. immediately after completion of the 
16 or 24 hour fasting period, there was no evidence of hepatocellular glycogen 
content. This is in accordance with a previous publication that suggested near 
complete depletion of hepatic glycogen stores and thereby reduced generation of 
cellular ATP through glycolysis and the citric acid cycle as a prominent biochemical 
feature of fasting (Strubelt et al., 1981a). The hepatocellular glycogen was gradually 
restored outside the affected centrilobular areas in APAP treated animals, sparing 
the centrilobular areas with ongoing hepatocellular damage in both strains.  
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4.2.2 Inflammatory response and regeneration of the liver after APAP induced 
liver injury in male CD-1 mice and C57BL/6J mice 
Many DILI studies have demonstrated compensatory liver regeneration as its final 
outcome (Anand et al., 2003; Apte et al., 2009a; Hu and Colletti, 2008). 
Nevertheless, knowledge about the mechanism of liver regeneration following 
APAP toxicity is limited, and still needs to be further elucidated. The present study 
did not only undertake a quantitative assessment of liver regeneration after APAP-
induced DILI, but also continued to define the role played by inflammatory 
cytokines that are believed to be produced (Bhushan et al., 2014). To determine the 
time frame of the onset of inflammation and/or regeneration in our model, the 
degree of TNF-α, IL-6 and IL-10 transcription in the liver was assessed alongside the 
histological changes of liver toxicity and any other pathological response. To assess 
the associated systemic response, the TNF-α and IL-6 transcription levels in the 
spleen and their serum protein levels were also measured, as these would indicate 
cytokine production in tissues/cells outside the liver known to potentially 
contribute to systemic changes. After liver injury, many other cells are also 
responsible for serum protein levels including circulating monocytes, splenic or 
enteric macrophages (Abbas et al., 2015), whereby the levels have been shown to 
correspond to mRNA expression levels (Okubo et al., 2013).   
All examined cytokines were expressed at mRNA level in the examined tissues of 
fed and fasted control mice of both strains, albeit at very low relative levels, and 
without significant differences at any time point (after refeeding). In contrast, 
changes were observed following APAP overdose. The comparative Ct value, 2-ΔΔCt 
was employed to assess the relative gene transcription. Previous studies have 
assessed the hepatic mRNA transcription levels of a range of cytokines after APAP 
overdose relative to 0 h or pooled control livers (Apte et al., 2009b; Bhushan et al., 
2014; Fisher et al., 2013). In the present study, the mRNA transcription after APAP 
overdose was assessed in comparison to both time-matched and pooled controls. 
The results of these two approaches were not same, which might be due to the 
variability between individual and total number of animals used. However, the 
expression pattern did not vary much, ensuring that the evaluations are valid. 
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After APAP overdose, hepatic TNF-α mRNA levels were upregulated and peaked 
early (5 hpd) in fed animals of both strains, before the levels in fasted mice 
increased more pronounced and reached a peak at 15 hpd in CD-1 mice and 24 hpd 
in C57BL/6J mice (Figure 3.3.18), which confirmed the results of a previous study 
(Bhushan et al., 2014). Similarly, splenic mRNA and serum protein TNF-α levels were 
significantly higher in fasted mice of both strains (and at similar levels) at the end of 
the study period. TNF-α upregulation would activate leukocytes and vascular 
endothelial cell activation, increasing the adhesion of leucocytes to endothelial cells 
via increased adhesion molecule expression, which would lead to the recruitment of 
leukocytes into the liver and, potentially, a systemic inflammatory response. 
Therefore, leucocytes infiltration contributed to more tissue necrosis (Blazka et al., 
1996b; Blazka et al., 1995). The nucleic acids of necrotic cells is believed to leak into 
the circulation (Fournie et al., 1995; Jahr et al., 2001; Melkonyan et al., 2008), and 
HMGB-1 released by necrotic cells can generate an inflammatory response, in the 
liver by activating Kupffer cells through binding of TLR-4 receptors on the cell 
surface, leading to the release of cytokines (i.e. TNF-α) (Scaffidi et al., 2002; Tsung 
et al., 2005), and in other tissues, like the spleen (Yin et al., 2011), leading to a 
systemic inflammatory response. This study also showed that both hepatic and 
splenic cytokine transcription is a consistent feature after partial hepatectomy. 
Previous studies have suggested that the up-regulation of TNF-α in the liver is a 
result of the cumulative activation of neutrophils and Kupffer cells following APAP 
treatment (Jaeschke, 2006b; Su et al., 2005). However, we saw TNF-α upregulation 
also in the liver of fed mice, and early after APAP injury, without any remarkable 
influx of neutrophils. This strongly indicates that TNF-α is expressed by liver cells, 
i.e. likely also hepatocytes which have anyway previously been shown to produce 
cytokines, i.e. after endotoxin stimulation (Panesar et al., 1999). In fasted mice the 
hepatic TNF-α expression increased further at later time points, when the observed, 
though still low level, neutrophil influx and delayed regeneration was observed. 
While the expression of TNF-α in the liver was then decreasing, further upregulation 
was seen in the spleen at 24 hpd (6.5-fold; CD-1 mice and 9.4-fold; C57BL/6J mice) 
of fasted mice. A previous study has reported that in C57BL/6J mice at 24 hpd, liver 
injury and TNF-α expression in the liver is also higher than in Balb/c mice 
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(Masubuchi et al., 2009), confirming that C57BL/6J mice are apparently more prone 
to APAP induced DILI than other strains. Splenic TNF-α release could account for or 
at least contribute substantially to the observed elevation of the serum TNF-α level, 
confirming the systemic release of TNF-α following APAP induced liver injury also 
reported previously (Antoine et al., 2010; Walker et al., 1982).  
The role of IL-6 in liver injury and regeneration is complex, as it has been claimed to 
have both pro- and anti-inflammatory properties (Heinrich et al., 2003; Hirano, 
1998). In the present study, in fed mice, IL-6 mRNA levels peaked substantially later 
than TNF-α mRNA levels in both strains (CD-1: 20 hpd, C57BL/6J: 36 hpd), 
accompanied by a significant increase in splenic IL-6 transcription (CD-1 mice: 20 
and 24 hpd (splenic IL-6 levels before 10 hpd were not examined); C57BL/6J: 5 hpd) 
compared to fasted mice. However, splenic IL-6 upregulation was not seen in fasted 
CD-1 mice until the end of the study period at 24 hpd, whereas it was increased 
(8.6-fold) in fasted C57BL/6J mice at 24 hpd. A previous study has shown that the 
increase in hepatic IL-6 mRNA levels after APAP administration is induced by TNF-α 
(Masubuchi et al., 2003c). Both, IL-6 and TNF-α, have been shown to be important 
for priming hepatocytes to enter the cell cycle (Chiu et al., 2003; Fausto, 2000). A 
previous study in APAP dosed (600 mg/kg) fasted C57BL/6J mice revealed an 
upregulation of hepatic IL-6 from 3 hpd onwards and a peak at 12 hpd, followed by 
a drop at 24 hpd (Bhushan et al., 2014). In the present study, hepatic IL-6 
transcription was upregulated at much lower levels after APAP overdose in fasted 
mice of both strains (and levels were similar in both) than in fed mice. However, this 
confirm that IL-6 signalling was not interrupted and liver regeneration possible, 
though consistent with the apparent lower regeneration activity in the fasted mice, 
as indicated by the significantly lower number of PCNA-positive, proliferating 
hepatocytes at most time points. Interestingly, the IL-6 expression patterns were 
similar in spleen and serum in both groups of mice, showing IL-6 production at later 
time points and a significant upregulation only in the fed mice, correlating with the 
transcription levels in the liver. The serum IL-6 does likely results from the release 
by both liver and spleen (Khalil et al., 1996; Kitamura et al., 1997). IL-6 binds to its 
receptor, gp130 at the cell membrane, which results in the phosphorylation and 
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nuclear translocation of STAT-3, inducing the transcription of many target genes 
(Cressman et al., 1995). IL-6 is considered to play a major role in the initiation of 
repair processes and to promote regeneration of the liver after APAP overdose 
(Fausto, 2000). The results of a previous study provide evidence that after the peak 
of injury, i.e. within 12-24 hours of APAP overdose, infiltrating macrophages and 
Kupffer cells generate IL-6 to downregulate inflammation and promote tissue 
recovery and have a high chance of phagocytosis (Laskin and Laskin, 2009).  
While the role of TNF-α and IL-6 in the progression or regression of APAP induced 
hepatotoxicity has been widely studied, little is known about the role of IL-10, an 
anti-inflammatory cytokine that has also been shown to play a role in liver 
regeneration in the partial hepatectomy (PHx) model (Yin et al., 2011). In the 
present study, significant upregulation of hepatic IL-10 mRNA was observed in fed 
APAP dosed mice (CD-1 mice: from 10 hpd onwards; C57BL/6J mice: from 15 hpd 
onwards) and continued to increase until the end of study. In fasted CD-1 mice, a 
similar tendency was observed, but the upregulation started later and was apparent 
only at 20 and 24 hpd. In fasted C57BL/6J mice, it was only apparent at 24 hpd and 
increased towards 36 hpd. The earlier upregulation of IL-10 transcription in the fed 
mice corresponds to the observed earlier evidence of liver regeneration in these 
animals (for example, in CD-1 mice, regeneration appeared to be almost complete 
by 24 hpd, after upregulation of IL-10 transcription from 10 hpd onwards) and 
suggests a role of IL-10 in liver regeneration also after toxic insults. A previous study 
reported increased susceptibility to APAP hepatotoxicity in IL-10 KO mice (Bourdi et 
al., 2002), and another study confirmed the role of IL-10 in promoting liver 
regeneration (Huang et al., 2006). However, IL-10 deficient mice can still show 
enhanced liver regeneration via STAT-3 activation after partial hepatectomy (Yin et 
al., 2011). However, the depletion of these cells reduced the IL-10 expression in 
regenerating liver after PHx (Yin et al., 2011), but in our study IL-10 was upregulated 
at later time points after APAP hepatotoxicity.  
In the present study, we assessed the expression of NF-kB in the APAP DILI model, 
as it is believed to be activated by TNF-α (Schutze et al., 1995). Following APAP 
dosing, we observed an increase in NF-kB transcription (13-fold at 10 hpd) in fed 
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CD-1 mice which remained elevated until the end of the experiment; this was 
associated with histological evidence of better liver regeneration than in the time-
matched fasted mice. In the latter, a significant rise in NF-kB transcription in 
comparison to controls was seen at the end of the study, but no difference between 
both strains. It shows that increased NF-kB transcription correlates with the 
stimulation of liver recovery in fed APAP dosed mice and is in line with another 
study which indicated that NF-kB is able to generate a pro-regenerative response by 
inducing the expression of survival genes like BCLXL and AP1, thereby improving liver 
regeneration after injury (Fausto, 2000; Malhi et al., 2006).  
We further studied the transcription and expression of proteins that are expressed 
during the cell cycle, cyclin-D1 and proliferating cell nuclear antigen (PCNA). Cyclin-
D1 is responsible for the regulation of cell cycle entry and is widely used as a marker 
of proliferating hepatocytes that passed the G1 restriction point and are committed 
to DNA replication (Fausto, 2000). In our study, cyclin-D1 transcription was first 
seen to be upregulated in fed CD-1 mice as early as 4 hpd, and it was even higher at 
20 hpd, when hepatocellular damage had subsided, confirming the increase in the 
amount of hepatocytes that had started DNA proliferation. However, in fed 
C57BL/6J mice, a similar upregulation was only seen from 15 hpd onwards, which 
coincided with the lower degree of proliferation (8% overall and 0.5% cytoplasmic 
PCNA-expressing cells vs. 3.9% and 0.35% in CD-1 mice) and the comparatively 
delayed IL-6 and IL-10 mRNA upregulation in this group of mice. In fasted mice of 
both strains, where ongoing hepatocellular damage was still observed after 24 
hours, cyclin-D1 upregulation was seen from 15 hpd (CD-1 mice) and 24 hpd 
(C57BL/6J mice) onwards, and at lower levels than in fed mice of both strains. 
Therefore, this data also confirms that cyclin-D1 transcription is a good marker for 
liver regeneration (Yang et al., 2009a; Yang et al., 2012c). A study on mice also 
reported that DNA synthesis starts within 12-16 hours after PHx (Michalopoulos, 
1990), but the peak of DNA synthesis is seen later, at 36-40 hours, depending on the 
strains (Taub, 2004). The increase in DNA synthesis appeared well synchronised and 
started in periportal hepatocytes, then moving towards centrilobular areas (Taub, 
2004). However, toxic agents can have different effects. For example, after massive 
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liver necrosis or apoptosis induced by CCl4, DNA synthesis was observed, but the 
cell-cycle response was not synchronised, different from the response to PHx 
(Fausto, 1999; Koniaris et al., 2003). Hepatocytes seem to have a variable 
regenerative capability, only few hepatocytes are needed to regenerate the liver 
and restore its function after pronounced liver injury (Satyanarayana et al., 2004).  
Some authors believed that the necrosis of hepatocytes results in a growth factor 
and cytokine response similar to that seen in the PHx model (Dabeva and Shafritz, 
1993). The results of the present study suggest a peak in DNA synthesis in fed APAP 
dosed CD-1 mice at 3 hpd, followed by a gradual decrease towards 5 and 10 hpd, 
followed by a further increase between 15 and 24 hpd. In fed C57BL/6J mice, a 
gradual increase was seen until 36 hpd. This suggests strain-specific differences. The 
cyclin-D1 results are complemented by the results of the PCNA staining. These 
indicate that fed CD-1 mice react to hepatocyte loss with a brief priming phase in 
which a significant proportion of hepatocytes (approximately 25%) enter the cell 
cycle. The latter appears to be completed at around 10 hpd, the time when 
hepatocytes most likely completed the S phase which has been shown to occur 
after about 8 hours in mice (Alberts et. al., 2002). A second replication cycle occurs 
after this, with a peak at or after 24 hpd. In comparison, fasting prior to the toxic 
insult does not allow the first peak to occur and it appears that entry of cells from 
the G0 phase into the cell cycle is delayed. This might be, because the more 
pronounced liver injury and marked cell death inhibits the entry of hepatocytes into 
the cell cycle at an early stage. A study has reported inhibition of liver regeneration 
following APAP overdose in fasted C57BL/6J mice as a result of p21 protein 
induction, an active inhibitor of the cell cycle, due to increased cellular stress 
(Bhushan et al., 2014). The results of the present study indicate that at this early 
stage (up to 5 hpd), regeneration in fasted APAP dosed mice does entirely rely on 
cells that were in the cell cycle at the time of injury, as cytoplasmic PCNA expression 
was significantly increased. At the later stage, the extent of hepatic regeneration, as 
represented by both nuclear and cytoplasmic hepatocellular PCNA expression, 
appear to be similar in fed and fasted mice. The lack of the initial proliferation peak 
after fasting would then explain the still apparent hepatocyte loss at 24 hpd.  
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The amount of cytoplasmic PCNA expression was also assessed to identify 
hepatocytes that had entered the M and/or G2 phase of the cell cycle. In 
regenerating hepatocytes, the exact mechanism that could restrict hepatocytes to 
enter the M phase still needs to be further studied (Miyaoka and Miyajima, 2013). 
The amount of cells in the M phase (mitosis) was always lower than that of the cells 
in the early, i.e. G1/S phase of the cell cycle. Upon completion of DNA synthesis, 
hepatocytes need to pass the G2 checkpoints, ensuring that genome stability is 
maintained before they undergo mitosis (Stark and Taylor, 2004). In the present 
study, cytoplasmic PCNA expression was seen earlier in fed CD-1 mice than in fed 
C57BL/6J mice. Intriguingly, we also observed a rapid (as early as 0.5 hpd until 5 
hpd) and significant increase in hepatocytes showing cytoplasmic PCNA expression 
in fasted CD-1 mice compared to control animals, which likely represents cells that 
were in the G1 phase at the time of injury and were activated rapidly to undergo 
mitosis. However, in fasted C57BL/6J mice, the increase in overall PCNA-positive 
hepatocytes started later, suggesting a further delay in DNA synthesis (from 15 hpd 
onwards) in comparison to fasted CD-1 mice (at 10 hpd onwards). The findings in 
fasted mice are in line with another study in rats where hepatocyte proliferation 
was reduced after a fasting period but increased after food was resumed (Kouda et 
al., 2004). A previous study on C57BL/6J mice exposed to different APAP doses 
showed delayed onset of liver proliferation with more intense liver damage after 
fasting, which was believed to be due to the suppression of many proteins involved 
in the regulation of the cell cycle, including cyclins and cyclin-dependent kinases, or 
the inhibition of cell cycle progression, such as p21 or p38 (Bhushan et al., 2014).  
The following sequence of actions of liver regeneration is likely: TNFα-TNFR1-NFkB-
IL6-IL10. Animals deficient in TNF receptor 1 (TNFR1) that received TNF-α 
neutralising antibodies show a reduction in hepatic DNA synthesis and STAT3 
activation after APAP overdose (Diehl, 1995; Gardner et al., 2003; Yamada et al., 
1997). Despite the fact that TNF-α has a pro-inflammatory role, studies in TNFR1-
deficient mice have shown that TNFR1 is important for liver regeneration following 
APAP injury in the mouse (Chiu et al., 2003). A modest elevation of hepatic TNF-α 
would increase the binding of TNF-α to TNFR1 which would result in nuclear 
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translocation of NF-kB and its activation, which could in turn prevent further cell 
death and promote a proliferative response by increasing cell progression in the G1 
and S phase (Yamada and Fausto, 1998; Yamada et al., 1997). This mechanism could 
be responsible for the high cyclin-D1 and PCNA expression and thereby the 
regeneration seen in fed animals in our study. Our data showed TNF-α/NF-kB 
transcription was upregulated earlier in fed than in fasted mice; this would suggest 
that TNF-α indeed has a role in liver regeneration following APAP overdose, as 
indicated in previous studies (Bhushan et al., 2014; Hinson et al., 2010). At the same 
time, NF-kB activation can enhance the hepatic IL-6 transcription, which will 
stimulate the JAK/STAT pathway to initiate and trigger STAT-3 activation (Cressman 
et al., 1996; Wuestefeld et al., 2003). STAT-3 is a signal transduction factor that 
activates a large number of genes, i.e. cfos, IRF-1 or AP1 for hepatocyte 
regeneration (Li et al., 2002). IL-6/STAT-3 signalling has promitotic effects on 
various cells for hepatic regeneration and improves cell survival (Kovalovich et al., 
2001; Michalopoulos and DeFrances, 1997). Accordingly, the upregulation of IL-6 
transcription that we observed after the upregulation of TNF-α and NF-kB in the fed 
APAP dosed mice suggests that this pathway is also active in the regenerative 
processes after APAP induced liver injury.  
Cyclin-D1 is an important transcriptional target of NF-kB, activating its expression 
(Guttridge et al., 1999). Furthermore, IL-6 also increases the expression of IL-10 as 
IL-6 alone is unable to stimulate the proliferation of hepatocytes in vivo (Bourdi et 
al., 2002). Without a potent stimulation towards liver recovery, IL-10 does regulate 
regeneration and inhibit inflammation by attenuating ROS and peroxynitrite 
production (Krenkel et al., 2014). Our data suggest that the less extensive 
transcription of NF-kB in the liver may be one of the reasons for the observed less 
intense cyclin-D1 transcription and delayed/less intense hepatic regeneration in 
fasted APAP dosed mice as seen in our study. Thus, our results indicate that 
depending on the conditions, a given APAP dose can be toxic, inducing only brief 
damage to the liver, as regeneration rapidly restores the integrity, or leading to a 
more prolonged damage, with delayed regeneration and a systemic inflammatory 
response, providing a scenario in which further (functional) challenges to the liver 
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would likely be more harmful (Prescott, 2000). In any case, our data clearly indicate 
that fasted mice have a reduced regenerative capacity of the liver, likely due to 
delayed and less intense activation of the TNF-α/NF-kB, IL-6/STAT3 and IL-10 
pathways and a subsequent delayed and reduced induction of cyclin-D1 and PCNA 
expression, leading to reduced cell proliferation. Multiple mechanisms are likely 
involved in the facilitation of liver regeneration following toxic injury, in which the 
above mentioned appear to play significant roles (Figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic diagramme of mechanisms involved in APAP induced toxic liver injury 
and subsequent regeneration.  
APAP is metabolised by cytochrome P450 (CYP450) to NAPQI which binds to and thereby 
depletes glutathione (GSH) and covalently binds to proteins. Loss of GSH leads to oxidative 
stress by increasing the formation of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) that alter the calcium metabolism of mitochondria. This initiates 
mitochondrial permeability transition (MPT) that inhibits the mitochondrial membrane 
potential and thereby the synthesis of ATP. Consequently, hepatocytes die either via 
apoptosis or necrosis, depending on the availability of ATP. Cytokines like TNF-α is released 
after inflammatory cells are sensitised as a consequence of, among others (i.e. HMGB-1), 
ROS and RNS. The TNF-α/NF-kB pathway is activated, followed by IL-6/STAT-3, cyclin-D1 
and IL-10 expression which promote hepatocyte proliferation and thereby liver 
regeneration. 
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4.2.3 Differences in the response to APAP injury and the subsequent regenerative 
process in fed and fasted CD-1 and C57BL/6J mice 
The present study represents a thorough comparative investigation into the time 
course and events following APAP overdose in fed and fasted male CD-1 and 
C57BL/6J mice, covering the period from immediately after dosing to a time point 
when in fed CD-1 mice there was evidence of full regeneration at 24 hpd, these 
were considered as the “standard” for the study which is believed to correlate with 
the levels of GSH, ATP, ALT and DILI score. A comparison of fed and fasted mice of 
each strain and an overall comparison between both strains is provided in the 
Appendix (Table 6.30: CD-1; Table 6.42: C57BL/6J; Table 6.43: both strains). 
In summary, in fed CD-1 mice, first evidence of centrilobular cell loss due to cell 
death via apoptosis and necrosis and minimal neutrophil infiltration, accompanied 
by loss of glycogen stores, is seen at 3 hpd and intensified at 5 hpd; this coincides 
with GSH and ATP depletion. In conjunction with these findings, PCNA expressing 
hepatocytes were increased in number at the same time points, indicating that a 
proportion of remaining intact cells entered the cell cycle immediately after the 
onset of cell loss, which was also supported by the observed upregulation of cyclin-
D1 and TNF-α transcription. At the same time, IL-6, IL-10 and NF-kB transcription 
also showed onset of a progressive increase. While GSH and ATP depletion was still 
evident at 10 hpd, centrilobular damage and inflammatory response had declined 
and the number of PCNA-positive proliferating cells was very low, indicating that 
the first cell cycle after injury was already completed by then. From 15 hpd 
onwards, the PCNA expression increased again and was correlated with an 
elevation in hepatic cyclin-D1 transcription. DILI scores decreased further and 
complete regeneration with numerous mitotic figures and diffuse hepatocellular 
glycogen restitution by 24 hpd, the time when GSH and ATP levels had returned to 
control mice, and only ALT activities remaining high. At this time, the transcription 
of all examined cytokines and transcription factors had started to decline. Briefly, 
fed C57BL/6J mice differed from CD-1 mice in the response to APAP overdose in so 
far, that the extent of injury and inflammatory cell recruitment was more 
pronounced and prolonged. Even at 36 hpd, the liver had not completely recovered 
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and showed ongoing centrilobular hepatocyte degeneration and death, even 
though GSH and ATP levels had returned to those of control animals. Moreover, the 
expression of markers of regeneration (NF-kB, cyclin-D1 and PCNA) was lower at the 
early time points, then increased over time and finally reached levels similar to CD-1 
mice. These findings are consistent with strain specific differences in the response 
to APAP overdose that could lead to very different results and interpretations 
depending on the type of study and parameters tested.  
In fasted animals of both strains, higher DILI scores and more pronounced 
neutrophil infiltration was seen, with impaired glycogen restitution was seen as 
early as 3 to 5 hpd. This was associated with higher serum ALT levels than in fed 
mice. This correlated with marked depletion of the levels of GSH, ATP and glycogen 
stores that had already been diminished significantly due to the prior fasting alone. 
This confirms that fasting compromises the hepatic detoxification capacity due to 
GSH depletion, leading to increased susceptibility to APAP hepatotoxicity (Larson, 
2007). Coupled with the prolonged reduction of hepatic ATP, this contributes to the 
increased ALT activities and exacerbates hepatocellular damage (Antoine et al., 
2010; Walker et al., 1982). Thereafter, DILI scores declined in both strains over time 
until the end of the experiment. The observed TNF-α upregulation at later time 
points correlates with the neutrophil influx and the larger extent of hepatocyte 
necrosis. Both strains also showed an increase of IL-6, IL-10, NF-kB and cyclin-D1 
transcription, again more pronounced at the later time points. Accordingly, the 
increase in hepatocyte proliferation was also delayed, with a first peak in overall 
PCNA-positive hepatocytes only at 20 hpd; there was only minimal histological 
evidence of liver regeneration until the end of the study period at 24 and 36 hpd, 
respectively. These differences can explain the delay of liver recovery in the fasted 
groups, where very similar results were obtained for both strains. They are of 
quantitative or time-related nature, without evidence of major mechanistic 
differences. To date, the cause for the difference in susceptibility to APAP overdose 
in various mouse strains is not fully understood. However, it was believed that the 
differences of basal gene expression including drug metabolism, innate immune and 
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stress response could influence the response (Jaeschke et al., 2012) Jaeschke et al., 
2012). 
 
4.3 CONCLUSIONS 
Fasting prior to dosing is a routine procedure in scientific experimentation. 
However, thorough investigations to address the potential implications of fasting in 
each animal model and whether these might compromise animal welfare or 
generate an unintended variability in some parameters that would interfere with 
the study outcome have so far not reported. The present study has addressed this 
knowledge gap and provides insight into differences in baseline levels between an 
example out-bred (CD-1) and an in-bred (C57BL/6J) mouse strain and in their 
response to fasting, which need to be considered before conducting a mouse study. 
Our study revealed that fed C57BL/6J mice had higher GSH levels but lower ATP 
content than CD-1 mice. While fed mice of both strains showed GSH-oriented 
circadian rhythm, fasting mice had produced GSH excessively after 10 hours of 
refeeding. Meanwhile, refeeding C57BL/6J mice exhibited better ATP recovery and 
glycogen restititution than those in CD-1 mice. The response exhibited by different 
mouse strain could not be ignored. The background information of different mouse 
model could provide better understanding on choice of mouse model for DILI 
studies.  
The present study also provides further insight into the processes and mechanisms 
leading to toxic liver changes after APAP overdose, covering the period of acute 
liver injury to full regeneration. Our findings confirm that fasting prior to APAP 
overdose has a substantial effect on the GSH and ATP content, the extent of liver 
damage and serum ALT activities and the presence and extent of a systemic 
inflammatory response. Fasting also delays the onset and extent of liver 
regeneration.  In fed animals, a less intense and short-lived upregulation of TNF-α 
transcription in combination with IL-6 and IL-10, NF-kB and cyclin-D1 mRNA 
upregulation as well as a more pronounced hepatocellular PCNA expression reflects 
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the better hepatic regenerative capacity as it was indicated by the histological 
examination. The quantitative differences in the transcription of the listed markers 
appear informative to evaluate the degree of liver damage and regeneration in the 
murine model of APAP hepatotoxicity. Therefore, further studies using respective 
knock-out mice would be beneficial to clarify the role played by these cytokines in 
particular in the regeneration of the liver after toxic injury.  
The present study also confirms that different mouse strains respond differently to 
the same APAP dose. However, the differences were almost exclusively restricted to 
the time-related and quantitative aspects of the response to APAP overdose. Fed 
C57BL/6J mice showed evidence of a higher susceptibility to APAP toxicity than fed 
CD-1 mice, and accordingly delays in the subsequent regenerative processes; this 
does, however, not suggest differences in the principle toxic and regenerative 
mechanisms. It would be interesting to extend the study to assess the time required 
for complete liver regeneration in fasted CD-1 as well as fed and fasted C57BL/6J 
mice. Additionally, further investigations would be required to fully illustrate the 
mechanisms involved in the delay of the hepatic recovery and also to explain the 
differences between mouse strains. Documentation of the latter would allow 
researchers to optimise their experimental approach by choosing the most suitable 
mouse model. Hence, this could minimise the risk of highly variable and/or 
controversial results and further enhance the validity of the studies. Since the liver 
has a major regenerative capacity that is triggered by several cytokines and growth 
factors, future investigations are needed to provide more insight into signalling 
pathways that are important for liver regeneration, as a tool to identify novel 
targets for the treatment of acetaminophen intoxication.  
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Table 6.1. List of experiments from which samples for the current study were recruited. 
 
Time 
(hpd) 
CD-1 C57BL/6J 
Fed Fasted Fed 16 h fasting 
Control APAP 
16 h fasting 24 h fasting 
Control APAP Control APAP 
Control APAP Control APAP 
0 1, 5 1, 5 5 5 1 1 2 2 2 2 
0.5 1 1 - - 1 1 2 2 2 2 
1 1, 3 1, 3 5 4 1 1 2 2 2 2 
2 3 3 - - - - - - - - 
3 1 1 - - 1 1 2 2 2 2 
4 3, 5  3, 5 5 5 - - - - - - 
5 1 1 - - 1 1 2 2 2 2 
8 3 3 - - - - - - - - 
10 1, 5 1, 5 - - 2 2 5 2, 5 5 5 
15 1, 5 1, 5 5 5 1 1 5 2, 5 5 5 
20 1, 5 1, 5 5 5 1 1 5 2, 5 5 5 
24 1, 5 1, 5 5 5 1 1 2 2 2 2 
30 - - - - - - 5 5 - - 
36 - - - - - - 5 5 5 5 
 
Legend: Experiments performed by 1 - Daniel Antoine (2009/2010), 2 - Craig Benson (2011), 3 - Phil Starkey Lewis (2011), 4 - Harley Webb 
(2013) and 5 - Fazila Hamid (2013/2014). hpd – hours post dosing; h – hours.  
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Table 6.2. List of tests performed on samples from CD-1 mice according to the respective studies.  
 
Time 
(hpd) 
Liver 
GSH 
Liver 
ATP 
 Histopathological examination 
Serum 
protein levels 
Relative quantification of cytokine transcription 
Serum 
ALT 
Histology Immunohistology Liver Spleen 
 
HE PAS 
Caspase-
3 
PCNA TNF-α IL-6 TNF-𝛼 IL-6 IL-10 NF-kB 
Cyclin-
D1 
TNF-α IL-6 
0 1, 5 1, 5 1, 5 1, 5 1, 5 - 1, 5 - - 5 5 5 5 5 - - 
0.5 - - - 1, 4 1, 4 - 1 - - - - - - - - - 
1 1, 3 1 1, 3 1,3,4 1,3,4 - 1 - - 3 3 3 3 3 - - 
2 - - 3 3 3 - - - - - - - - - - - 
3 - 1 - 1 1 1 1 - - - - - - - - - 
4 3, 5 - 3, 5 3, 5 3, 5 - - - - 3, 5 3, 5 3, 5 3, 5 3, 5 - - 
5 - 1 1 1 1 1 1 1 1 - - - - - - - 
8 - - 3 3 3 - - - - - - - - - - - 
10 2, 5 1 2, 5 1, 2, 5 1, 2, 5 1, 2, 5 1 5 5 2, 5 2, 5 2, 5 2, 5 2, 5 5 5 
15 5 - 5 1, 4, 5 1, 4, 5 - 5 5 5 5 5 5 5 5 5 5 
20 5 - 5 1, 4, 5 1, 4, 5 - 5 5 5 5 5 5 5 5 5 5 
24 1, 5 1 1, 5 1, 4, 5 1, 4, 5 1, 5 1, 5 1, 5 1, 5 5 5 5 5 5 5 5 
 
Legend: Experiments performed by 1 - Daniel Antoine (2009/2010), 2 - Craig Benson [fasted only] (2011), 3 - Phil Starkey Lewis [fed only] (2011), 4 - 
Harley Webb [fasted only] (2013), and 5 - Fazila Hamid (2013/2014).  
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Table 6.3. List of tests performed on samples from C57BL/6J mice according to the respective studies.  
 
Time 
(hpd) 
Liver 
GSH 
Liver 
ATP 
Serum 
ALT 
Histopathological examination Serum 
protein levels 
Relative quantification of cytokine transcription 
Histology Immunostaining Liver Spleen 
HE PAS 
Caspase-
3 
PCNA TNF-α IL-6 TNF-𝛼 IL-6 IL-10 NF-kB 
Cyclin
-D1 
TNF-α IL-6 
0 2 - 2 2 2 - - 2 2 2 2 2 2 2 - - 
0.5 2 - 2 2, 4 2, 4 - - 2 2 2 2 2 2 2 - - 
1 2 - 2 2 2 - - 2 2 2 2 2 2 2 - - 
3 2 - 2 2 2 2 - 2 2 2 2 2 2 2 - - 
5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 - - 
10 5 5 5 4, 5 4, 5 5 5 5 5 5 5 5 5 5 5 5 
15 5 5 5 4, 5 4, 5 5 5 5 5 5 5 5 5 5 5 5 
20 5 5 5 4, 5 4, 5 5 5 5 5 5 5 5 5 5 5 5 
24 2 - 2 2 2 2 5 2 2 2 2 2 2 2 - - 
30 5 5 5 5 5 5 - 5 5 5 5 5 5 5 5 5 
36 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
 
Legend: Experiments performed by 2 - Craig Benson (2011), 4 - Harley Webb [fed only] (2013), and 5 - Fazila Hamid (2013/2014).   
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Table 6.4. List of experiments performed in CD-1 mice, with time of day of dosing (controls: 0.9 % saline; treated: or 530 mg/kg APAP) and endpoint, that had 
been fed ad libitum or fasted for 16 or 24 h prior to dosing.   
 
Time 
(hpd) 
Exp 
Fed 16 h Fasting 24 h Fasting 
ToD dosing ToD killing ToD fasting ToD dosing ToD killing ToD fasting ToD dosing ToD killing 
0 
1 10:00 10:00 - - - 10:00 10:00 (+1) 10:00 
5 14:00 14:00 18:00 10:30 (+1) 10:30 - - - 
0.5 
1 10:00 10:30 - - - 10:00 10:00(+1) 10:30 
4 - - 17:00 09:00 (+1) 09:30 - - - 
1 
1 10:00 11:00 18:00 10:00 11:00 10:00 10:00 (+1) 11:00 
4 - - 16:30 08:30 (+1) 09:30 - - - 
3 09:30 10:30 - - - - - - 
2 3 09:30 11:30 - - - - - - 
3 1 10:00 13:00 - - - 10:00 10:00 (+1) 13:00 
4 
3 09:00 13:00 - - - - - - 
5 - - 16:00 08:00 (+1) 12:00 - - - 
5 1 10:00 15:00 - - - 10:00 10:00 (+1) 15:00 
8 3 10:00 18:00 - - - - - - 
10 
1 10:00 20:00 - - - 10:00 10:00 (+1) 20:00 
2 - - - - - 10:00 10:00 (+1) 20:00 
5 10:45 20:45 - - - - - - 
15 
1 10:00 01:00 - - - 10:00 10:00 (+1) 01:00 (+1) 
4 - - 16:08 08:08 (+1) 23:08 - - - 
5 18:00 09:00 (+1) 00:00 16:00 07:00 (+1) - - - 
20 
1 10:00 06:00 (+1) - - - 10:00 10:00 (+1) 06:00 (+1) 
4 - - 17:07 09:07 (+1) 05:07 (+1) - - - 
5 12:20 08:20 (+1) 18:45 10:45 (+1) 06:45 (+1) - - - 
24 
1 10:00 10:00 (+1) - - - 10:00 10:00 (+1) 10:00 (+1) 
4 - - 16:23 08:23 (+1) 08:23 (+1) - - - 
5 10:55 10:55 (+1) 18:15 10:15 (+1) 10:15 (+1) - - - 
Exp – Experiments performed by 1 - Daniel Antoine (2009/2010), 2 - Craig Benson (2011), 3 - Phil Starkey Lewis (2011), 4 - Harley Webb (2013), and  5 - 
Fazila Hamid (2013/2014).  hpd - hours post dosing; ToD – time of day; (+1) - time of day on the following day. 
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Table 6.5. List of experiments performed in C57BL/6J mice, with time of day of dosing (controls: 0.9 % saline; treated: or 530 mg/kg 
APAP) and endpoint, that had been fed ad libitum or fasted for 16 h prior to dosing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp – Experiments carried out by 2 - Craig Benson (2011), 4 - Harley Webb (2013), and 5 - Fazila Hamid (2013/2014). 
hpd – hours post dosing; ToD – time of day; (+1) - time of day on the following day. 
Time (hpd) Exp 
Fed 16 h Fasting 
ToD dosing ToD killing ToD fasting ToD dosing ToD killing 
0 2 10:00 10:00 18:00 10:00 (+1) 10:00 
0.5 
4 09:00 09:30 - - - 
2 10:00 10:30 18:00 10:00 (+1) 10:30 
1 2 10:00 11:00 18:00 10:00 (+1) 11:00 
3 2 09:00 12:00 17:00 09:00 (+1) 12:00 
5 2 10:00 15:00 18:00 10:00 (+1) 15:00 
10 
4 08:00 18:00 - - - 
5 10:00 20:00 18:00 10:00 (+1) 20:00 
15 
4 08:00 23:00 - - - 
5 17:00 08:00 (+1) 01:00 17:00 08:00 (+1) 
20 
4 09:00 05:00 (+1) - - - 
5 11:00 07:00 (+1) 19:00 11:00 (+1) 07:00 (+1) 
24 2 10:00 10:00 (+1) 18:00 10:00 (+1) 10:00 (+1) 
30 5 09:00 15:00 (+1) - - - 
36 5 07:00 19:00 (+1) 15:00 07:00 (+1) 19:00 (+1) 
Appendix 
253 
 
A. 0.9% saline dosed (control) CD-1 and C57BL/6J mice 
Table 6.6. Individual serum ALT values of fed CD-1 mice at different time points post saline application (control animals). 
 
 
 
 
 
 
 
 
 
 
 
Table 6.7. Relative transcription levels (illustrated as 2
-ΔCt
 relative to GAPDH) of TNF-α, IL-6 and IL-10 in fed and fasted male CD-1 mice over a 24 h time 
period after i.p. application of 0.9% saline. The fold change was assessed to explore changes in the transcription levels due to fasting by dividing the 2
-ΔCt
 
value of fasted by the 2
-ΔCt
 values of time-matched fed animals. 
  
Animal 
ID 
Time (hpd) 
0 1 2 4 5 8 24 
1 71 22 22 50 198 20 25 
2 45 49 39 20 80 18 22 
3 80 70 13 32 41 14 37 
4 47 66 90 23 58 39 27 
5 69 - - - 35 - 24 
6 98 - - - 56 - 30 
Mean 68.33 51.63 40.98 31.17 78.0 22.55 27.5 
(SD) 20.12 21.83 34.69 13.64 60.84 10.97 5.39 
Time 
(hps) 
ToD 
dosing 
ToD 
killing 
TNF-α IL-6 IL-10 
Fed Fasted Fold change Fed Fasted 
Fold 
change 
Fed Fasted Fold change 
0 14:00 14:00 1.59E-03 2.64E-03 1.65 3.65E-04 1.43E-04 0.39 3.66E-06 1.27E-06 0.35 
1 09:30 10:30 1.92E-03 4.09E-03 2.13 1.55E-04 2.07E-04 1.34 2.7E-06 5.2E-06 1.93 
4 09:00 13:00 1.60E-03 2.85E-03 1.78 3.12E-04 2.96E-04 0.95 1.15E-06 2.01E-06 1.75 
10 10:45 20:45 4.04E-03 3.68E-03 0.91 2.53E-04 2.09E-04 0.83 2.87E-06 3.67E-06 1.28 
24 10:55 10:55 (+1) 2.32E-03 1.14E-03 0.49 4.08E-04 2.81E-04 0.69 2.62E-06 1.14E-06 0.44 
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Table 6.8. Relative transcription levels (illustrated as 2
-ΔCt
 relative to GAPDH) of TNF-α, IL-6 and IL-10 in fed and fasted male C57BL/6J mice over a 24 h 
time period after i.p. application of 0.9% saline. The fold change was assessed to explore changes in the transcription levels due to fasting by dividing the 2
-ΔCt
 
value of fasted by the 2
-ΔCt
 values of time-matched fed animals. 
 
 
Table 6.9. Relative transcription levels (2
-ΔCt
) of TNF-α, IL-6 and IL-10 in comparison of CD-1 and C57BL/6J mice that had either been fed or fasted prior to 
saline dosing. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
  
Time 
(hps) 
ToD 
dosing 
ToD 
killing 
TNF-α IL-6 IL-10 
Fed Fasted Fold change Fed Fasted Fold change Fed Fasted Fold change 
0 10:00 10:00 3.20E-04 6.14E-04 1.92 2.50E-04 1.10E-04 0.44 4.9E-06 3.3E-06 0.67 
1 10:00 11:00 3.90E-04 5.41E-04 1.39 2.70E-04 2.30E-04 0.85 2.8E-06 2.4E-06 0.86 
5 10:00 15:00 7.30E-04 3.73E-04 0.51 3.80E-04 5.10E-04 1.34 2.5E-06 3.1E-06 1.24 
10 10:00 20:00 3.70E-04 7.21E-04 1.95 5.50E-04 4.40E-04 0.8 3.9E-06 2.7E-06 0.69 
24 10:00 10:00 (+1) 2.10E-04 1.59E-04 0.76 1.70E-04 2.90E-04 1.71 2.7E-06 3.6E-06 1.33 
Time 
(hps) 
TNF-α IL-6 IL-10 
Fed Fasted Fed Fasted Fed Fasted 
CD-1 C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J 
0 1.59E-03 3.20E-04 2.64E-03 6.14E-04 3.65E-04 2.50E-04 1.43E-04 1.10E-04 3.66E-06 4.9E-06 1.27E-06 3.3E-06 
1 1.92E-03 3.90E-04 4.09E-03 5.41E-04 1.55E-04 2.70E-04 2.07E-04 2.30E-04 2.7E-06 2.8E-06 5.2E-06 2.4E-06 
*5 1.60E-03 7.30E-04 2.85E-03 3.73E-04 3.12E-04 3.80E-04 2.96E-04 5.10E-04 1.15E-06 2.5E-06 2.01E-06 3.1E-06 
10 4.04E-03 3.70E-04 3.68E-03 7.21E-04 2.53E-04 5.50E-04 2.09E-04 4.40E-04 2.87E-06 3.9E-06 3.67E-06 2.7E-06 
24 2.32E-03 2.10E-04 1.14E-03 1.59E-04 4.08E-04 1.70E-04 2.81E-04 2.90E-04 2.62E-06 2.7E-06 1.14E-06 3.6E-06 
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Table 6.10. Relative transcription levels (illustrated as 2
-ΔCt
 relative to GAPDH) and fold change (2
-ΔΔCt
) of NF-kB and cyclin-D1 in fed and fasted CD-1 mice 
over a 24 h time period after i.p. application of 0.9% saline and refeeding of the fasted animals. The fold change was assessed to explore changes in the 
transcription levels due to fasting by dividing the 2
-ΔCt
 value of fasted by the 2
-ΔCt
 values of time-matched fed animals. 
 
 
Table 6.11. Relative transcription levels (illustrated as 2
-ΔCt
 relative to GAPDH) and fold change (2
-ΔΔCt
) of NF-kB and cyclin-D1 in fed and fasted C57BL/6J 
mice over a 24 h time period after i.p. application of 0.9% saline and refeeding of the fasted animals. The fold change was assessed to explore changes in the 
transcription levels due to fasting by dividing the 2
-ΔCt
 value of fasted by the 2
-ΔCt
 values of time-matched fed animals. 
 
Time 
(hps) 
ToD 
dosing 
ToD 
killing 
NF-kB Cyclin-D1 
Fed Fasted Fold 
change 
SD 
Fed Fasted Fold 
change 
SD 
Mean SD Mean SD Mean SD Mean SD 
0 10:00 10:00 4.0E-04 8.4E-05 8.0E-05 6.4E-05 0.21 0.11 3E-07 4.5E-08 2.8E-07 1.1E-07 0.93 0.35 
1 10:00 11:00 3.0E-04 7.0E-05 2.2E-04 1.4E-04 0.67 0.43 1.6E-07 7.2E-08 5.7E-08 1.5E-08 0.36 0.11 
5 10:00 15:00 1.0E-04 2.8E-05 1.0E-04 8.7E-05 1.00 0.50 2.5E-07 4.5E-08 3.4E-07 8.9E-08 1.36 0.68 
10 10:00 20:00 2.0E-04 8.2E-05 9.0E-05 5.0E-05 0.45 0.22 1.3E-07 5.4E-08 2.4E-07 8.9E-08 1.85 0.66 
24 10:00 
10:00 
(+1) 
5.0E-04 1.2E-04 6.7E-04 2.3E-04 1.34 0.23 1.7E-07 3.3E-08 1.1E-07 9.5E-08 0.65 0.22 
 
  
Time 
(hps) 
  NF-kB Cyclin-D1 
ToD 
dosing 
ToD 
killing 
Fed Fasted Fold 
change 
SD 
Fed Fasted Fold 
change 
SD 
Mean SD Mean SD Mean SD Mean SD 
0 14:00 14:00 7.1E-05 3.0E-05 4.3E-05 3.2E-05 0.61 0.41 4.6E-06 2E-06 1.1E-06 2E-06 0.24 0.13 
1 09:30 10:30 7.2E-05 9.3E-06 6.3E-05 2.9E-05 0.88 0.36 2.3E-06 3E-06 3.7E-06 1E-06 1.61 0.78 
4 09:00 13:00 5.4E-05 3.2E-05 9.0E-05 1.8E-05 1.67 0.55 3.9E-06 1E-06 6.2E-06 4E-06 1.59 0.47 
10 10:45 20:45 4.0E-05 2.1E-05 7.0E-05 3.0E-05 1.75 0.67 8.0E-06 3E-06 6.0E-06 2E-06 0.75 0.55 
24 10:55 
10:55 
(+1) 
2.7E-05 1.1E-05 5.1E-05 2.8E-05 1.89 0.23 3.5E-06 2E-06 3.1E-06 5E-06 0.89 0.53 
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Table 6.12. Comparison of the amount (%) of proliferating hepatocytes (nuclear and cytoplasmic PCNA expression; “PCNA+”) and hepatocytes that exhibited 
cytoplasmic PCNA expression (“Cyto+”) in fed and fasted CD-1 mice over a course of 24 h post 0.9% saline dosing and refeeding of the fasted animals. n – 
number of animals used per group; NS - not significant; Cyto – cytoplasmic.  
 
Time 
(hps) 
Fed Fasted 
p-value  fed 
vs fasted 
%PCNA+ 
p-value fed 
vs fasted 
%Cyto+ 
n 
ToD 
killing 
%PCNA+ 
Range 
[mean] 
% Cyto+ 
Range 
[mean] 
Fasting time (h) 
n 
ToD  
killing 
% PCNA+ Range 
[mean] 
% Cyto+ 
Range [mean] 16 24 
0 4 10:00 
15.3 - 26.7 
[21.0] 
0.27-1.05 
[0.66] 
 x 4 10:00 
2.27 - 9.4 
[6.27] 
0 - 0.27 
[0.16] 
NS NS 
0.5 - - - - x  5 09:30 
2.58 - 19.05 
[6.75] 
0.08 - 2.42 
[1.19] 
- - 
1 - - - - x  5 09:30 
0.8 - 5.6 
[2.89] 
0 - 0.46 
[0.18] 
- - 
5 - - - -  x 5 15:00 
0.77 - 1.12 
[1.89] 
0.14 - 0.3 
[0.22] 
- - 
10 5 20:00 
0.31 - 0.73 
[0.59] 
0 - 0.16 
[0.1] 
 x 5 20:00 
0.08 - 2.7 
[1.26] 
0 NS NS 
15 - - - - x  5 23:08 2.79 - 22.4 [7.9] 0 - - 
20 - - - - x  5 05:07 2.69 - 21.0 [10.34] 0 - 0.19 [0.05] - - 
24 - - - - x  5 08:23 1.54 - 16.4 [6.34] 0.06 - 0.21 [0.11] - - 
p-value 
(time 
points) 
 10:00 vs 20:00: NS 
10:00 vs 
20:00: NS 
    
10 vs 15h: 0.0075** 
 
Others: NS 
0.5 vs 1 h: 0.0125 
10 vs 24 h: 0.0073 
15 vs 24 h: 0.0079 
Others: NS 
- - 
 
Table 6.13. Comparison of the amount (%) of proliferating hepatocytes (nuclear and cytoplasmic PCNA expression; “PCNA+”) and hepatocytes that exhibited 
cytoplasmic PCNA expression (“Cyto+”) in fed and fasted C57BL/6J mice over a course of 24 h post 0.9% saline dosing and refeeding of the fasted animals. 
n – number of animals used per group; NS - not significant; Cyto – cytoplasmic. 
 
Time 
(hps) 
Fed mice Fasted mice 
p-value  
fed vs fasted n 
% PCNA+ 
(average [SD]) 
% Cyto+ 
(average [SD]) 
Length of 
fasting 
n 
% PCNA+ 
(average [SD]) 
% Cyto+ 
(average [SD]) 
0 4 2.21 [1.41] 
0.31  
[0.52] 
16 h 4 1.18 [0.47] 0.15 [0.09] 
% PCNA: NS 
% Cyto: NS 
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B. APAP dosed CD-1 mice  
Table 6.14. Histological findings in APAP dosed fed CD-1 mice (time course). The histological findings and average grading scores for individual animals at 
each time point were recorded over a 24 h time course. hpd - hours post dosing; NHAIR - no histological abnormality is recognised; CL – centrilobular; HD - 
hydropic degeneration; NL - neutrophilic leukocytes; hpc – hepatocytes; pos. – positive; neg. – negative; occ. - occasional; ind. - individual; CC3 – cleaved 
caspase-3; mod. – moderate; CV – central vein; apop. – apoptosis; nec. – necrosis. 
 
Time 
(hpd) 
Case 
no. 
Score 
range 
[mean] 
Histological descriptions Exp  
1 
11L-4456 0 NHAIR; PAS: Diffuse glycogen 
4 
11L-4457 0 NHAIR; PAS: Diffuse glycogen 
11L-4458 0 NHAIR; PAS: Diffuse glycogen 
11L-4459 0 NHAIR; PAS: Diffuse glycogen 
11L-4460 0 NHAIR; PAS: Diffuse glycogen 
Summary [0] NHAIR; PAS: Diffuse glycogen 
11L-4571 0 NHAIR; PAS: Diffuse glycogen 
3 
11L-4572 0 NHAIR; PAS: Diffuse glycogen 
11L-4573 0 NHAIR; PAS: Diffuse glycogen 
11L-4574 0 NHAIR; PAS: Diffuse glycogen 
Summary [0] 
NHAIR; PAS: Diffuse hepatocellular glycogen accumulation (in 6/9 animals evidence of increased glycogen content in CL of 
hpc) 
3 
 
09L-993 0-1 
CL cell loss mainly in zone 2/3, very numerous apop. cells (all zones especially zone 2); several mitotic figures and also NL 
aggregates. CC3: ++ (disseminated; no obvious necrotic cells; also pos. cells with normal appearing nuclei); PAS: No glycogen except 
very few ind. hpc 
1 
09L-994 1-2 Similar to 09L-993, but more apparent of cell loss. CC3: ++; PAS: Patchy aggregates of pos. hpc 
09L-995 2 
Similar to 09L-993 and 994, with distinct cell loss mainly in zone 2; obvious loss of cells, but no necrotic cells seen. CC3: ++ (more 
intense staining than 993 and 994). PAS: No glycogen 
09L-996 0-1 
Increased CL cell loss; lesser apop. cells. CC3: Scattered pos. cells. PAS: Vacuolated cells (CL) neg., other cells patchy pos. with 
variable intensity distributed randomly 
09L-997 0-1 
Mild CL cell loss and increased NL between hepatic cords; occ. degenerate/ cell death in zone 2; some degree of vacuolation at 
remaining hpc. CC3: Small no. of disseminated pos. hpc. PAS: No glycogen 
Summary [1.25] 
CL cell loss mainly at zone 2 with evidence of apoptotic cells with small NL aggregates; CC3: ++ disseminated at zone 3 and 
mainly zone 2; PAS: No glycogen (4/6) or patchy glycogen (2/6).  
4 
11L-4587 2-3 
CL cell loss, with hydropic swelling of remaining hpc. Some NL infiltration and transit to unaffected area. CC3: +; PAS: No glycogen at 
affected area of zone 3 3 
11L-4588 2-3 Similar to 11L-4587 
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11L-4589 1-3 CL cell loss with few NL at CL; CC3:+; PAS: Variable amount of glycogen outside zone 3  
11L-4590 2-3 Increased CL cell loss and extend to zone 2, HD of remaining hpc; CC3:++; PAS: No glycogen at zone 3 
Summary [2.44] 
Cell loss centrilobularly and several NL extending towards zone 2, with HD of remaining hpc in affected areas; CC3: ++/+; 
PAS: No glycogen in affected CL areas 
5 
07L-3572 2-3 
Focal subcapsular haemorrhage; vacuolated cells adjacent to cell loss; mild increase in NL between hepatic cords and at border to 
cell loss; occ. necrotic/apoptotic cells; increased mitotic figures. CC3: + (scattered pos. cells); PAS: No glycogen 
1 
07L-3573 0-2 CL loss; numerous mitotic figures; small NL aggregates; occ. necrotic cells. CC3: +; PAS: Few pos. hpc. 
07L-3576 2-3 
Hepatocellular vacuolation at border to cell loss; very mild NL increase; some mitotic cells (border); no nec./apop. cells. CC3: + (Very 
occ. pos. hpc). PAS: No glycogen 
07L-3577 2-3 Few vacuolation of hpc at border; scattered dying hpc; some mitotic figures. CC3: + (Occ. pos. hpc).  
07L-4218 0-1 Vacuolated cells in zones 1 and 2; increased mitotic figures (mainly zone 3). CC3: Neg. 
07L-4219 0-1 Same to 4218, but more mitotic figures; CL have no vacuolation and very dense cytoplasm. CC3: Neg. 
07L-4220 1-2 
Cell loss CL, but not apop. or nec. cells seen; mitotic figures in particular at border. CC3: Neg. PAS: Patchy glycogen outside affected 
areas of zone 3 
07L-4221 1 
Almost random numerous apoptotic/necrotic hpc; some small NL aggregates; increased mitotic figures. CC3: ++/+++ PAS: Occ. pos. 
hpc outside affected areas of zone 3 
07L-4222 2-3 
Numerous apoptotic/necrotic cells, like wide band in zone 2; increased mitotic figures. CC3:++/+++. PAS: Occ. pos. hpc outside 
affected areas of zone 3 
07L-4223 2-3 Similar to 07L-4222 
07L-4224 1-2 
Similar, but slightly less severe than 07L-4222 and 4223; occ. hpc that have phagocytosed apoptotic cells; small NL aggregates. CC3: 
+/++ PAS: Scattered glycogen to ind. hpc randomly 
08L-619 2 No dying cells, just cell loss with hyperaemia/haemorrhage CL, scattered pos. NL. CC3: ++ PAS: Occ. scattered pos. hpc   
08L-620 2-3 No dying cells, just cell loss with hyperaemia/haemorrhage CL. CC3: Neg. PAS: diffuse patchy glycogen 
Summary [1.46] 
No evidence of ongoing cell death (4/13), ongoing apoptotic/necrotic cell death (9/13), some degree of HD in remaining cells 
(4/13); CC3: + (4/13), +++ (5/13), negative (4/13). PAS: extensive to complete glycogen loss centrilobularly 
10 
09L-892 1 
CL cell loss; in zone 3: hpc with dense, rounded nuclei, hpc with vacuoles, appear irregularly arranged; often a few NL in zone 2 or at 
transition to unaltered parenchyma; occ. scattered or small groups of apoptotic and necrotic hpc. CC3: + (Occ. 1-3 pos. hpc). PAS: 
Patchy pos. cells mainly in zone 1; cells with vacuoles in zone 3 neg. 
1 
09L-893 2 
CL cell loss, no obvious dying cells; hpc adjacent to loss with vacuoles; some NL in CV with some rolling; CC3: + (Very occ. ind. pos. 
hpc); PAS: patchy glycogen at hpc randomly 
09L-894 1 
CL cell loss with vacuolated hpc and occ. dense nuclei (see 09L-892); scattered apop. cells and nec. cells (some small degree of CN); 
increased NL in CV, rolling between adjacent hpc.; mild portal infiltration; increased mitosis. CC3: +(Scattered ind. pos. hpc); PAS: 
Mod. pos. hpc. distributed randomly  
09L-895 1 
CL cell loss and hpc. vacuolation; some small NL aggregates and NL rolling in CV; very occ. dying (apoptotic/necrotic) cells. CC3: + 
(Scattered ind. pos. hpc). PAS: Ind. pos. hpc 
09L-896 1-2 CL cell loss; hpc vacuolation adjacent to cell loss, occ. dying (necrotic) hpc. CC3: Negative 
09L-897 0-1 
CL slight cell loss apparent, with vacuolated hpc; some hpc with dark condensed nuclei (see 892) at CL; scattered apoptotic and 
necrotic hpc. CC3: + (Scattered ind. pos. hpc). PAS: Ind. pos. hpc 
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13L-1443 1 CL cell loss with vacuolated hpc, scattered apop./nec. Cells; few NL at CL; CC3: +; PAS: Ind. pos. hpc. 
5 
13L-1444 2 Similar to 13L-1443 but the cell loss is more intense.  
13L-1445 1 CL cell loss with some hpc with HD and PAS: Diffuse glycogen except 4-5 layers of zone 3 
13L-1446 1 CL loss (4-6 cell layers); some NL rolling in CV and affected areas. PAS: Patchy to diffuse glycogen except 2-3 layer of zone 3  
13L-1447 0-4 CL cell loss with scattered apop./nec. cells; CC3: +; PAS: Patchy to diffuse glycogen except zone 3 
Summary  [1.0] 
Slight ongoing hpc death (5/6, via apoptosis); HD of hpc surrounding affected areas; CC3: scattered individual CL positive 
hpc. PAS: patchy to randomly distributed hpc with glycogen. 
15 
09L-898 1-2 
Some CL cell loss, with several vacuolated hpc in that area; numerous mitotic figures, also with bizarre large nuclei (in periphery of 
previously affected zone); no dying cells; a few NL (and small aggregates) between hepatic cords. PAS: Diffuse glycogen with variable 
intensity except 2-3 layers of CL 
1 
09L-899 0-1 
Irregular arrangement at CL; some NL aggregates between cords and some NL rolling in CV; numerous mitotic figures; PAS: Patchy 
to diffuse glycogen except affected area of zone 3 
09L-900 1-2 
CL cell loss, but evidence of "filling up" with swollen hpc that often exhibit vacuoles; no dying cells; only mild increase in NL and NL 
rolling in CV. PAS: Low density of glycogen outside affected areas  
09L-901 1-2 
CL cell loss with only low amount of "filling up", but by vacuolated hpc; increased mitotic figures, also immediately adjacent to cell loss. 
PAS: No glycogen at affected areas with variable amount  
09L-902 1 Very similar to 899, but mitotic figures not too numerous; scattered multinucleated cells  
09L-903 0-1 
CL cell loss but evidence of "filling up" with swollen hpc that often exhibit vacuoles; no dying cells; some NL aggregates and NL rolling 
in CV; numerous mitotic figures, also along necrotic area 
13L-1993 0-2 
CL cell loss with blood with vacuolated hpc surrounded the affected areas; No ongoing cell death is seen. Few evidence of mitotic 
figures. PAS: No glycogen at affected areas of zone 3. 
5 
13L-1994 1-3 
CL cell loss few evidence of CN, with HD of remaining hpc and rim around affected area; PAS: No glycogen outside affected areas of 
zone 3  
13L-1995 0-2 Similar to 13L-1993 
13L-1996 2-3 CL cell loss with blood; vacuoles in cells outside affected areas; PAS: No glycogen at affected areas.  
13L-1997 1-2 Some areas with central 1 layer of early CN of hpc; some evidence of mitotic figures. PAS: Diffuse glycogen except 4-6 layers of CL 
Summary  [1.125] 
CL cell loss with some degree of HD and disorderly arrangement of hpc in affected areas; increased mitotic figures, no 
evidence of ongoing cell death; PAS: Diffuse glycogen except CL (affected) areas 
20 
09L-904 0 
No apparent reduced cell nos., but possibly CL swollen hpc and some irregular arrangement; numerous mitotic figures. PAS: Large 
proportion of CL hpc devoid of glycogen 
1 
09L-905 0-1 
Reduced cell no. CL and irregularly arranged hpc; hpc in general relatively vacuolated; numerous mitotic figures. PAS: Most hpc 
positive (in vacuoles) 
09L-906 0-1 
Some degree of CL irregular arrangement; numerous mitotic figures. PAS: diffuse glycogen with variable amount except affected 
areas 
09L-907 0-1 
Some degree of CL irregular arrangement; numerous mitotic figures and occ. giant nuclei; PAS: almost diffuse glycogen at low 
amount 
09L-908 0 Some degree of CL irregular arrangement; numerous mitotic figures; PAS: Large proportion of CL hpc devoid of glycogen 
09L-909 0 Similar to 09L-908 
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Summary [0.65] 
Numerous mitotic figures; no ongoing cell death; some HD in affected areas (2/6); PAS: large proportion of CL hpc devoid of 
glycogen  
24 
09L-910 0 
Numerous mitotic figures, but otherwise unaltered appearing. PAS: Most hpc. pos. with variable amount (in vacuoles); cells in mitosis 
partly neg. 
1 09L-911 0 Numerous mitotic figures (or these large dense ovoid nuclei), otherwise unaltered appearing; CC3: Neg.PAS: Diffuse glycogen  
09L-912 0 Numerous mitotic figures, otherwise unaltered appearing. PAS: Diffuse glycogen  
09L-913 0 Numerous mitotic figures, otherwise unaltered appearing. PAS: Diffuse glycogen  
13L-1453 0 Reduced cellularity of 1-2 cell layers CL, CC3: Neg. PAS: Diffuse glycogen except 1-2 layer of zone 3 
5 
13L-1454 0 Similar to 13L-1453 but diffuse glycogen is seen 
13L-1455 0 
Some area is intact but some still evidence of small rim (1 cell layer) of hpc necrosis CL and NL along CV and between cords; PAS: 
Diffuse glycogen except 3-4 cell layers of CL 
13L-1456 0 Similar to 13L-1455 but less intense and all CL are almost intact. PAS: Diffuse except 1-2 layer of zone 3 
Summary  [0] 
Numerous mitotic figures, but otherwise unaltered appearing and almost similar to controls; CC3: Negative; PAS: Diffuse 
hepatocellular glycogen accumulation 
Exp – Experiments performed by 1 - Daniel Antoine (2009/2010), 2 - Craig Benson (2011), 3 - Phil Starkey Lewis (2011), 4 - Harley Webb (2013), and  5 - 
Fazila Hamid (2013/2014).   
 
Table 6.15. Histological findings in APAP dosed fasted CD-1 mice (time course). The histological findings and average grading scores for individual animals 
at each time point were recorded over a 24 h time course. hpd - hours post dosing; NHAIR - no histological abnormality is recognised; CL – centrilobular; HD - 
hydropic degeneration; NL - neutrophilic leukocytes; hpc – hepatocytes; pos. – positive; neg. – negative; occ. - occasional; ind. - individual; CC3 – cleaved 
caspase-3; mod. – moderate; CV – central vein; apop. – apoptosis; nec. – necrosis. 
 
Time 
(hpd) 
Case 
no. 
Score 
range 
[mean] 
Histological descriptions Exp 
0.5 
11L-4431 0 Hpc with slight and distinct small cyto vacuoles. PAS: Disseminated small no. of hpc with glycogen 
4 
11L-4432 0 Hpc with variable sized cyto vacuoles and few distinct small vacuoles (>intense CL). PAS: No glycogen 
11L-4433 0 Hpc with variable sized cyto vacuoles CL (4-5 cell layers), very mild outside this. PAS: No glycogen 
11L-4434 0 Hpc with variable sized cyto vacuoles CL (4-5 cell layers), very mild outside this. PAS: No glycogen 
11L-4435 0 Hpc with variable sized cyto vacuoles CL (4-5 cell layers), outside this less intense. PAS: No glycogen 
Summary [0] 
NHAIR, except slight evidence of variable sized cyto vacuoles suggestive of early CL HD. PAS: No evidence (4/5) or some 
degree of glycogen restitution (1/5; not diffuse, but in individual cells).  
1 
11L-4436 0 
Hpc with variable sized cyto vacuoles CL (4-5 cell layers), outside this less intense; scattered small aggregates of NL with ind. 
apoptotic/necrotic hpc. PAS: No glycogen 
4 
11L-4437 0 
Hpc with variable sized cyto vacuoles CL (4-5 cell layers; early HD), only very mild outside this (obvious transition). PAS: 
Disseminated small number of hpc with glycogen (outside CL areas) 
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11L-4438 0 
Hpc with variable sized cyto vacuoles CL (up to 50% of lobe; early HD), only very mild outside this (obvious transition). PAS: Outside 
CL areas disseminated mod. no. of hpc with glycogen 
11L-4439 0 Hpc  with variable sized cyto CL (4-5 cell layers), outside this less intense. PAS: No glycogen 
11L-4440 0 
Hpc with variable sized cyto vacuoles CL (4-5 cell layers), outside this less intense (slight transition). PAS: Outside CL areas 
disseminated scattered hpc with glycogen 
Summary [0] 
NHAIR, except evidence of hpc with variable sized cytoplasmic vacuoles CL (4-5 layers; evidence of early HD), only very 
mild outside CL; PAS: no glycogen (2/5) or low degree of glycogen restitution in individuals cells (3/5) 
3 
09L-988 1-2 
Cell loss in zone 2; no dying cells; occ. small NL aggregates. CC3: Very occ. pos. cell; few pos. cells also in zone 2. PAS: No 
glycogen 
1 
09L-989 2-3 
Cell loss mainly in zone 2; extending to zone 3 (CL); occ. dying cells; some swollen/vacuolated cells immediately adjacent to area of 
cell loss. CC3: Scattered pos. cells in zones of cell loss. PAS: Neg. 
09L-990 0-1 
Mild CL cell loss; CL cells in particular are vacuolated, several swollen cells with clumped chromatin; few scattered necrotic cells. 
CC3: Scattered pos. cells, swollen cells are neg. PAS: Neg. 
09L-991 2-3 
Some swollen cells (see 09L-990) still present, CL cell loss; cells with swollen vacuoles close to necrosis; some necrotic cells; some 
small NL aggregates. CC3: Scattered pos. cells. PAS: Neg. 
09L-992 2-3 Cell loss CL at zone 2; vacuolated and swollen cells CL (see 990). CC3: Very occ. pos. cell. PAS: Neg. 
Summary [2.05] 
CL cell loss; CL cells in particular are vacuolated, several swollen cells with clumped chromatin; scattered necrotic cells; 
PAS: no glycogen. CC3: Very occasional scattered pos. cells 
4 
13L-1729 1-3 CL cell loss and filled with blood, with HD of remaining hpc and occ. ind. nec. cell. PAS: No glycogen 
5 
13L-1730 0-3 CL cell loss and filled with blood, with hydropic swelling of remaining hpc. PAS: No glycogen 
13L-1731 1-3 Same as above 
13L-1732 1-3 Same as above 
Summary [2.125] Marked reduction of hpc and blood at CL, hydrophic swelling of remaining hpc; PAS: Neg. 
5 
08L-611 3 CL cell loss; no dying cells; vacuole cell close to area of cell loss; CC3: Few pos CL hpc. PAS: Neg. 
1 
08L-612 1-3 Cells with vacuole close to area of cell loss. CC3: Negative. PAS: No glycogen 
08L-613 2 CL hpc that round up and exhibit loose vacuolation and chromatin clumping; CC3: Neg.; PAS: Neg. 
08L-614 2 Similar to 08L-613, occ. necrotic hpc, CC3: Neg. PAS: Neg. 
08L-615 1-3 Scattered necrotic cells; occ. cells as in 08L-613; increased no. of NL. CC3: Neg. PAS: Neg. 
Summary [2.5] CL hpc round up and loose vacuolation and chromatin clumping; some vacuoles; PAS: Neg. 
10 
10L-722 3-4 More extensive CL cell loss; HD surrounding affected areas; occ. NL at transition to unaltered areas. PAS: Pos. at ind. hpc 
2 
10L-723 3-4 Similar to 10L-722. PAS: no glycogen except some scattered ind. hpc 
10L-724 3-4 Similar to 10L-723; some NL in affected areas (transition to unaltered ones). PAS: No glycogen  
10L-725 2-4 Mod. no. of NL and occ. necrotic cells in affected areas (transition). PAS: No glycogen except few hpc 
10L-726 2-3 Occ. NL at transition to normal areas. PAS: No glycogen in affected areas 
Summary [2.6] 
CL cell loss surrounded by hpc with HD; occasional NL at transition to unaltered areas; CC3: +; PAS: No glycogen except 
few scattered ind. hpc 
15 11L-4441 0-2 
In areas without CL cell loss (and scattered necrotic/apoptotic hpc, with occ. NL. CL zone (3 cell layers) of hpc with homogenous, 
slightly basophilic cyto (degeneration/early stage of CN), surrounded by hpc with cyto vacuolation; occ. NL. PAS: Diffuse glycogen 
4 
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outside affected CL areas 
11L-4442 1-4 
Surrounding areas with almost complete cell loss is rim with changes described in 11L-4441 (among those scattered necrotic and 
apoptotic cells) and then normal appearing hpc with some vacuoles; a few NL in affected areas. PAS: Hpc outside affected areas with 
variable amount of glycogen 
11L-4443 0-4 
Surrounding areas with almost complete cell loss is rim with changes described in 11L-4441 (among those scattered nec. and apop. 
cells) and then normal appearing hpc with some vacuoles; some NL in affected areas, occ. as small aggregates.  PAS: Diffuse 
glycogen outside affected CL areas 
11L-4444 2-4 
Surrounding areas with almost complete cell loss is rim with changes described in 11L-4441 (among those scattered necrotic and 
apoptotic cells) and then normal appearing hpc with some vacuoles; some NL in affected areas, occ. as small aggregates, some NL 
in CV. PAS: No glycogen 
11L-4445 1 
CL disorganised hpc with cyto like CN, with scattered necrotic hpc (3-5 cell layers); a few NL in CV and in affected areas. PAS: 
Diffuse glycogen (variable amount) outside affected CL areas. 
13L-1733 3-4 CL cell loss and CN with variable degree of HD in remaining hpc. PAS: No glycogen at affected areas.  
5 
13L-1734 0-2 CL CN with HD between and surrounding necrotic cells, PAS: 3-4 inner layers with glycogen loss. 
13L-1735 1-2 CL swelling and CN with most hpc still in place; PAS: No glycogen at affected areas of zone 3 
13L-1736 3-4 CL cell loss with blood and HD of remaining hpc; otherwise DG. PAS: No glycogen at affected areas  
Summary [2.15] 
In areas without CL cell loss (and scattered necrotic/ apoptotic hpc, with occ. NL) CL zone (3 cell layers) of hpc with 
homogenous, slightly basophilic cytoplasm (degeneration/ early stage of CN), surrounded by hpc with increasing 
cytoplasmic vacuolation; occasional NL between CL hpc; PAS: Diffuse glycogen (variable amount) outside CL areas   
20 
11L-4446 1-5 
CL disorganised hpc with cyto like CN, with some nec. hpc (5-6 cell layers); a few NL in CV and some in affected areas; large random 
blood pools; score 5 in subcapsular areas. PAS: No glycogen 
4 
11L-4447 1-2 
CL disorganised hpc with cyto like CN, with several necrotic hpc (5-6 cell layers; inner 1-2 cell layers apparent complete CN). PAS: 
Mod. no. of hpc in unaltered areas with glycogen 
11L-4448 1-2 
CL disorganised hpc with cyto like CN, with few necrotic hpc (5-6 cell layers; inner 1(-2) cell layers apparent complete CN); scattered 
NL in CV & affected areas. PAS: Diffuse glycogen outside zone 3 
11L-4449 1-2 Similar as in 11L-4448. PAS: Numerous hpc with glycogen in unaltered areas 
11L-4450 1-5 
CL disorganised hpc with cytoplasm like CN, with some necrotic hpc (5-6 cell layers); a few NL in CV and some to several in affected 
areas; score 5 in subcapsular areas. PAS: Pos. at unaffected areas 
13L-1738 0-1 
CL swelling and CN and/or apoptosis, with most hpc still in place; outside DG; some CV with a few NL; PAS: 1-2 layers affected area 
with glycogen loss 
5 
13L-1739 1-2 
CL swelling and CN and/or apoptosis with most hpc still in place; often with several NL between cords, at border to intact hpc; 
surrounded by 1-2 layers with HD; PAS: No glycogen at affected areas 
13L-1740 0-1 CL swelling and CN and/or apoptosis, PAS: 1-2 layers affected area with glycogen loss 
13L-1741 0-4 
Some intense areas of CL cell loss with blood with innermost layer of CN; still ongoing cell death and NL infiltration; PAS: No 
glycogen at affected areas 
13L-1742 0-4 Similar to 13L-1742. PAS: Diffuse glycogen except 2-3 layer of zone 3 
Summary  [2.75] 
CL disorganised hpc with cytoplasm like CN, with few necrotic hpc (5-6 cell layers); few NL in CV & affected areas; score 5 
in subcapsular areas; PAS: diffuse glycogen outside affected CL areas 
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24 
11L-4451 1 
Well delineated CL area of HD with inner layer of hpc with features of CN (and loss of nucleus), 5-6 cell layers. PAS: Diffuse glycogen 
in unaltered areas, but 1 layer without glycogen around affected areas 
4 
11L-4452 1-2 
CL cell loss, then layer of cells with HD, scattered nec. and apop. cells; some blood pools;  5-6 cell loss layers surrounded by 1 layer 
of dense, otherwise unaltered cells. PAS: No glycogen at affected areas 
11L-4453 1-4 
Well delineated CL area of HD with inner layer of hpc with features of CN (and loss of nucleus), 5-6 cell layers; score 5 is patchy 
(random); a few NL in CV and affected areas; affected areas surrounded by 1 layer of dense, otherwise unaltered cells. PAS: Diffuse 
glycogen outside the layer of dense cells 
11L-4454 2-3 Few remaining intact cells in affected areas otherwise with HD (or vacuoles). PAS: Neg. at zone 3 
11L-4455 1-2 
CL areas (4-6 cell layers) with HD and scattered nec. cells; NL in affected areas (some aggregates); one layer rim of dense, 
otherwise unaltered hpc. PAS: Diffuse glycogen outside the layer of dense cells 
Summary [2.4] 
Well delineated CL area of HD with inner layer of hpc with features of CN (and loss of nucleus), 5-6 cell layers, a few NL in 
CV and affected areas; affected areas surrounded by 1 layer of dense, otherwise unaltered cells; PAS: Diffuse glycogen 
except 2-3 layers of zone 3, (1 no glycogen) 
13L-1743 1-3 
CL swelling and CN and/or apoptosis, with most hpc still in place; surrounded by 1-2 layers with glycogen loss; some affected areas 
with NL; CC3: +; PAS: Diffuse glycogen except 1-2 layer of zone 3 
5 
13L-1744 1-3 
CL CN with frequent apop. cells, with most hpc. still in place; surrounded by 1-2 layers with glycogen loss; some affected areas with 
NL; CC3: +; PAS: Diffuse glycogen except 2-3 layers of zone 3 
13L-1745 0-3 
CL CN and/or apoptosis, with most hpc still in place; surrounded by 1-2 layers with glycogen loss; some affected areas with a few NL 
between cords; CC3: +; PAS: Diffuse glycogen except 2-3 layer of zone 3 
13L-1746 0-4 
CL CN with apoptotic cells, surrounded by a layer with HD; outside DG; sometimes several NL aligned between cords. CC3: ++; PAS: 
Diffuse glycogen except 2-3 layers of zone 3 
13L-1747 1-3 
CL CN and present of apoptotic/necrotic cells; most hpc. still in place; surrounded by a layer with HD; CC3: +; PAS: No glycogen at 
zone 3 
Summary 
(Mean 
2.375) 
[2.35] 
CL cell loss, remaining cells are mild to moderately vacuolated (HD), scattered nec./apop. cells, few NL in CV, few mitotic 
cells; CC3: +/++; PAS: Diffuse glycogen outside the affected areas 
 
Exp – Experiments performed by 1 - Daniel Antoine (2009/2010), 2 - Craig Benson (2011), 3 - Phil Starkey Lewis (2011), 4 - Harley Webb (2013), and  5 - 
Fazila Hamid (2013/2014).   
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Table 6.16. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in time-matched control and APAP treated fed CD-1 mice, using the delta Ct method,  
2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. *15- relative to 10 h post saline; *20- relative to 24 h post saline. Statistical 
significant (p-value control vs APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
TNF-α 
Time 
(hpd) 
Control APAP 
p-value control vs 
APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fed  
APAP vs APAP 
1 1.92E-03 6.45E-04 6.34E-03 9.44E-04 3.31 0.31 4 h: 0.0065 NS 
4 1.60E-03 9.74E-04 1.01E-02 1.54E-03 6.32 0.75 
10 h: 0.0407, 15 h: 0.0023,  
20 h: 0.0305, 24 h: 0.0419 
0.0077 
10 4.04E-03 8.64E-04 1.82E-02 2.55E-03 4.50 1.36 15 h: 0.0152 0.0098 
*15 - - 4.63E-03 1.97E-03 1.14 0.85 
15, 20 & 24 h : NS 
NS 
*20 - - 4.73E-03 1.67E-03 2.04 1.22 NS 
24 2.32E-03 6.45E-04 4.07E-03 1.14E-03 1.75 0.63 NS 
IL-6 
Time 
(hpd) 
Control APAP 
p-value control vs 
APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fed  
APAP vs APAP 
1 1.55E-04 6.90E-05 7.85E-04 2.51E-04 5.06 0.96 
4, 15 or 24 h: NS, 
10 h: 0.016,20 h: 0.0002 
0.0030 
4 3.12E-04 9.30E-05 1.78E-03 4.91E-04 5.71 1.25 10 h: 0.0073, 20 h: 0.0019 0.0006 
10 2.53E-04 8.30E-05 2.35E-03 3.12E-04 9.29 0.95 15 h: 0.0069, 20 h: 0.0009  24 h: 0.0077 0.0001 
*15 - - 1.34E-03 9.34E-04 5.31 1.97 20 h: 0.0089 0.0097 
*20 - - 4.71E-03 9.70E-04 11.53 2.13 24 h: 0.0065 0.0001 
24 4.08E-04 4.90E-05 2.28E-03 7.76E-04 5.59 1.5 15 h: NS 0.0056 
IL-10 
Time 
(hpd) 
Control APAP 
p-value control vs 
APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fed  
APAP vs APAP 
1 2.70E-06 3.14E-06 7.85E-06 9.66E-07 2.91 0.76 
4 h: 0.0011, 10 h: 0.0026, 15 h: 0.0006, 20 h: 
0.0009, 24 h: 0.0046 
NS 
4 1.15E-06 1.03E-06 1.02E-05 1.99E-06 8.87 1.84 15 h: 0.0433 0.0041 
10 2.87E-06 5.43E-07 2.35E-05 4.12E-06 8.19 2.37 
10, 15, 20 & 24h: NS 
0.0008 
*15 - - 3.43E-05 5.37E-06 11.95 2.47 0.0022 
*20 - - 2.71E-05 7.26E-06 10.34 3.13 0.0010 
24 2.62E-06 2.97E-06 2.28E-05 1.62E-06 8.70 1.28 0.0006 
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Table 6.17. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in pooled liver samples of fed control CD-1 mice and in APAP treated fed CD-1 mice, 
using the delta Ct method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. Statistical significant (p-value control vs APAP) is 
seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
TNF-α 
Time (hpd) 
Control APAP 
p-value control 
vs APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fed  
APAP vs APAP 
1 
2.30E-03 7.8E-04 
6.34E-03 9.44E-04 2.76 0.27 
10 h: 0.0015, 
15,20,24 h: NS 
 NS 
4 1.01E-02 1.54E-03 4.40 0.7 1 h: 0.0316 0.0315 
10 1.82E-02 2.55E-03 7.93 2.68 15,20,24 h: 0.0017 0.0055 
15 4.63E-03 1.97E-03 2.02 1.25 
4 h: 0.0397 
15,20,24 h: NS 
NS 
20 4.73E-03 1.67E-03 2.06 1.4 NS 
24 4.07E-03 1.14E-03 1.77 0.79 NS 
IL-6 
Time (hpd) 
Control APAP 
p-value control 
vs APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fed  
APAP vs APAP 
1 
2.99E-04 7.4E-05 
7.85E-04 2.51E-04 2.63 0.77 
4 h: 0.0288,10 h: 0.0076, 
20 h: 0.0002 
NS 
4 1.78E-03 4.91E-04 5.96 1.89 10 h: 0.0051, 20 h: 0.0012 0.0087 
10 2.35E-03 3.12E-04 7.87 0.8 15 h: 0.0069, 20 h: 0.0058  24 h: NS 0.0056 
15 1.34E-03 9.34E-04 4.49 1.95 20 h: 0.0001 1 h: NS NS 
20 4.71E-03 9.70E-04 15.77 4.06 24 h: 0.0070 0.0001 
24 2.28E-03 7.76E-04 7.64 2.65 15 h: 0.0233 0.0102 
IL-10 
Time (hpd) 
Control APAP 
p-value control 
vs APAP Mean SD Mean SD 
Fold 
change 
SD p-value fed APAP vs APAP 
1 
2.6E-06 1.9E-06 
7.85E-06 9.66E-07 3.02 0.78 10, 20 h: 0.0076   
15 h: 0.0020, 24 h: 0.0093 
NS 
4 1.02E-05 1.99E-06 3.92 1.52 0.0411 
10 2.35E-05 4.12E-06 9.04 2.88 15 h: 0.0491 0.0083 
15 3.43E-05 5.37E-06 13.19 3.73 24 h: 0.0088 0.0003 
20 2.71E-05 7.26E-06 10.42 3.14 10 h: NS, 15 h: 0.0289, 24 h: 0.0406 0.0018 
24 2.28E-05 1.62E-06 8.77 1.28 10,20 h: NS 0.0010 
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Table 6.18. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in time-matched control and APAP treated male CD-1 mice had been fasted for 16/24 h prior to dosing 
using delta Ct method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. *15- relative to 10 h post saline; *20- relative to 24 h post saline. 
Statistical significant (p-value control vs APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
TNF-α 
Time 
(hpd) 
Control APAP p-value 
control vs 
APAP 
p-value fasted vs fed 
APAP Mean SD Mean SD 
Fold 
change 
SD p-value fasted APAP vs APAP 
1 4.09E-03 1.25E-03 2.99E-03 1.64E-03 0.73 0.32 
4 h: 0.0094, 10 h: 0.0330, 
15 h: 0.0001, 20 h: 0.0059,  
NS 0.0134 
4 2.85E-03 8.74E-04 6.65E-03 1.85E-03 2.33 0.65 10 h: NS, 15 h: 0.0047, 20/24 h: NS NS 0.0093 
10 3.68E-03 2.38E-03 1.95E-02 6.87E-03 5.3 1.95 15 h: 0.0025, 20 or 24 h: NS 0.0033 NS 
*15 - - 5.26E-02 6.44E-03 14.27 2.02 20 h: 0.0013, 24 h: 0.0009 0.0003 0.0005 
*20 - - 5.47E-03 2.89E-03 4.81 0.98 24 h: NS 0.0404 0.0373 
24 1.14E-03 6.74E-04 4.46E-03 2.32E-03 3.92 0.60 1 h: 0.0055 0.0087 0.0477 
IL-6 
Time 
(hpd) 
Control APAP p-value 
control vs 
APAP 
p-value fasted vs fed 
APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fasted  
APAP vs APAP 
1 2.07E-04 2.05E-04 3.87E-04 1.43E-04 1.87 0.81 
4 h: 0.0453, 15 h: 0.0105,  
20 h: 0.0266, 24 h: 0.0089 
NS 0.0110 
4 2.96E-04 1.77E-04 1.06E-03 2.07E-04 3.59 1.35 24 h: 0.0255 0.0286 NS 
10 2.09E-04 1.07E-04 4.89E-04 2.96E-04 2.34 1.09 24 h: 0.0109 0.0487 0.0057 
*15 - - 1.03E-03 2.09E-04 4.91 0.95 
15, 20 or 24 h: NS 
0.0074 NS 
*20 - - 1.21E-03 1.16E-04 4.32 0.82 0.0090 0.0079 
24 2.81E-04 1.87E-04 1.68E-03 2.81E-04 5.99 1.6 0.0049 NS 
IL-10 
Time 
(hpd) 
Control APAP p-value 
control 
vsAPAP 
p-value fasted vs fed 
APAP Mean SD Mean SD 
Fold 
change 
SD 
p-value fasted  
APAP vs APAP 
1 5.20E-06 4.40E-06 6.87E-06 3.41E-06 1.3 0.97 
1,4,10 & 15 h: NS 
NS NS 
4 2.01E-06 2.40E-06 4.06E-06 2.92E-06 2.0 1.54 NS 0.0090 
10 3.67E-06 2.00E-06 4.89E-06 6.99E-07 1.3 0.54 NS 0.0068 
*15 - - 1.03E-05 1.56E-06 2.8 0.94 NS 0.0047 
*20 - - 1.21E-05 9.96E-07 10.6 2.37 
1,4,10,15 h: 0.0018, 24 h:NS 
0.0032 NS 
24 1.14E-06 3.50E-06 1.38E-05 4.01E-06 12.1 4.05 0.0001 NS 
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Table 6.19. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in pooled liver samples of fasted control CD-1 mice and in APAP treated fasted CD-1 
mice, using the delta Ct method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. Statistical significant (p-value control vs 
APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
TNF-α 
Time 
(hpd) 
Control APAP 
p-value control 
vs APAP  
p-value fasted 
vs fed APAP 
Mean SD Mean SD 
Fold 
change 
SD 
p-value fasted  
APAP vs APAP  
1 
2.88E-03 1.19E-04 
2.99E-03 1.64E-03 1.04 0.59 
10 h: 0.0340, 15 h: 0.0001   
NS NS 
4 6.65E-03 1.85E-03 2.31 0.62 NS 0.0193 
10 1.95E-02 6.87E-03 6.78 2.43 20,24 h: 0.0278 0.0292 NS 
15 5.26E-02 6.44E-03 18.28 4.79 10 h: 0.0085 0.0001 0.0015 
20 5.47E-03 2.89E-03 1.90 0.7 
1,4 h: NS, 15 h: 0.0001 
NS NS 
24 4.46E-03 2.32E-03 1.55 0.52 NS NS 
IL-6 
Time 
(hpd) 
Control APAP 
p-value control 
vs APAP 
p-value fasted 
vs fed APAP 
Mean SD Mean SD 
Fold 
change 
SD 
p-value fasted 
APAP vs APAP 
1 
2.27E-04 1.52E-04 
3.87E-04 1.43E-04 1.70 0.76 
10 h: NS, 4 h: 0.0221 
24 h: 0.0098 
NS NS 
4 1.06E-03 2.07E-04 4.67 1.65 15,20 h: NS   0.0130 NS 
10 4.89E-04 2.96E-04 2.15 0.98 15 h: 0.0411 NS 0.0060 
15 1.03E-03 2.09E-04 4.53 0.9 24 h: 0.0209 NS NS 
20 1.21E-03 1.16E-04 5.33 1.59 24 h: NS 0.0183 0.0007 
24 1.68E-03 2.81E-04 7.39 3.1 10 h: 0.0194 0.0069 NS 
IL-10 
Time 
(hpd) 
Control APAP p-value 
Control vs 
APAP  
p-value fasted 
vs fed APAP 
Mean SD Mean SD 
Fold 
change 
SD 
p-value fasted 
APAP vs APAP 
1 
2.66E-06 2.01E-06 
6.87E-06 3.41E-06 2.58 1.45 4,10 h: NS NS NS 
4 4.06E-06 2.92E-06 1.53 1.24 10 h: NS NS NS 
10 4.89E-06 6.99E-07 1.84 0.89 15 h: 0.0408 NS 0.0011 
15 1.03E-05 1.56E-06 3.88 1.35 20 h: NS NS 0.0046 
20 1.21E-05 9.96E-07 4.55 2.12 10 h: 0.0272 0.0445 0.0347 
24 1.38E-05 4.01E-06 5.19 3.87 10 h: 0.0485 0.0302 NS 
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Table 6.20. Comparison of splenic TNF-α and IL-6 cytokine transcription in fed and fasted control and APAP treated CD-1 mice in a 24 h period using delta Ct 
value, 2
-ΔCt
 and the comparative Ct value, i.e. fold change as compared to time-matched control mice. *15- relative to 10 h post saline; *20- relative to 24 h 
post saline. Statistical significant (p-value control vs APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt 
mean
). 
Time 
(hpd) 
TNF-α 
Fed Fasted p-value 
APAP 
fed vs 
fasted 
Control APAP 
Fold 
change 
SD 
p-value 
fed APAP 
Control APAP 
Fold 
change 
SD 
p-value 
fasted 
APAP  Mean SD Mean SD Mean SD Mean SD 
10 0.031 0.016 0.121 0.046 3.86 1.63 
24 h: 
0.028  
0.0496 0.0192 0.1360 0.063 2.74 1.73 
24 h: 
0.0117 
NS 
*15 - - 0.060 0.027 1.92 0.98 NS - - 0.2148 0.0293 4.33 1.47 
20 h: 
0.0296 
NS 
*20 - - 0.067 0.015 2.79 0.56 NS - - 0.1210 0.063 7.17 2.37 
10 h: 
0.0103 
0.0152 
24 0.024 0.0077 0.032 0.0086 1.35 0.65 NS 0.0169 0.009 0.1060 0.0187 6.28 0.93 20 h: NS 0.0075 
Time 
(hpd) 
IL-6 
Fed Fasted p-value 
APAP 
fed vs 
fasted 
Control APAP Fold 
change 
SD 
p-value fed 
APAP 
Control APAP Fold 
change 
SD 
p-value 
fasted 
APAP  Mean SD Mean SD Mean SD Mean SD 
10 0.0242 0.0056 0.0452 0.01 1.87 0.31 
20 h: 0.023  
24 h: 0.041  
0.033 0.007 0.0308 0.0085 0.93 0.42 NS NS 
*15 - - 0.0202 0.011 0.84 0.26 
20 h: 0.013 
24 h: 0.022 
- - 0.0628 0.0127 1.90 0.84 NS NS 
*20 - - 0.0915 0.024 3.79 0.85 24 h: NS - -  0.0416 0.0083 1.47 0.57 NS 0.034  
24 0.0241 0.0120 0.0887 0.033 3.68 1.16 - 0.0284 0.01 0.0341 0.0044 1.20 0.45 NS 0.029 
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Table 6.21. Comparison of splenic TNF-α and IL-6 cytokine transcription in fed and fasted control and APAP treated mice in a 24 h period using delta Ct 
value, 2
-ΔCt
 and the comparative Ct value, i.e. fold change as compared to pooled liver samples of the control mice. Statistical significant (p-value control vs 
APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
Time 
(hpd) 
TNF-α 
Fed Fasted p-value 
APAP 
fed vs 
fasted 
Control APAP Fold 
change 
SD 
p-value 
control vs 
APAP 
Control APAP Fold 
change 
SD 
p-value 
control vs 
APAP Mean SD Mean SD Mean SD Mean SD 
10 
0.0275 0.0119 
0.121 0.046 4.40 1.77 0.0232 
0.0333 0.0141 
0.1360 0.063 4.09 2.83 0.0456 NS 
15 0.060 0.027 2.18 1.10 NS 0.2148 0.0293 6.46 2.96 0.0067 0.0308 
20 0.067 0.015 2.44 0.53 NS 0.1210 0.0630 3.64 1.89 0.0152 NS 
24 0.032 0.0086 1.16 0.60 NS 0.1060 0.0187 3.19 0.78 0.0434 0.0255 
Time 
(hpd) 
IL-6 
Fed Fasted p-value 
APAP 
fed vs 
fasted 
Control APAP Fold 
change 
SD 
p-value fed 
control vs 
APAP 
Control APAP Fold 
change 
SD 
p-value 
control vs 
APAP Mean SD Mean SD Mean SD Mean SD 
10 
0.0242 0.0088 
0.0452 0.010 1.87 0.32 NS 
0.0307 0.0085 
0.0308 0.0085 1.00 0.55 NS NS 
15 0.0202 0.011 0.84 0.26 NS 0.0628 0.0127 2.05 0.98 NS NS 
20 0.0915 0.024 3.79 0.85 0.0130 0.0416 0.0083 1.36 0.52 NS 0.0449 
24 0.0887 0.033 3.67 1.15 0.0319 0.0341 0.0044 1.11 0.41 NS 0.0370 
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Table 6.22. Comparison of hepatic NF-kB transcription in fed and fasted control and APAP treated CD-1 mice in a 24 h period using delta Ct value, 2
-ΔCt
 and 
the comparative Ct value, i.e. fold change as compared to time-matched control mice. *15- relative to 10 h post saline; *20- relative to 24 h post saline. 
Statistical significant (p-value control vs APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
Fed 
Time 
(hpd) 
Control APAP 
p-value control vs APAP 
Mean SD Mean SD Fold change SD 
p-value fed  
APAP vs APAP 
1 7.2E-05 7.3E-06 6.3E-05 6.3E-06 0.88 0.58 
4 h: 0.032, 10 h: 0.0013, 15 h: 0.0059,  
20 h: 0.0003, 24 h: 0.0008 
NS 
4 2.4E-05 8.2E-06 1.1E-04 2.1E-05 4.74 0.49 
10 h: 0.0015, 15 h: 0.0027,  
20 h: 0.0005, 24 h: 0.0016 
NS 
10 4.0E-05 7.1E-06 7.0E-04 1.5E-04 17.60 3.56 15 h: 0.0441, 24 h: 0.0285 0.0001 
*15 - - 5.2E-04 1.4E-04 12.93 1.68 20 h: 0.0388 0.0019 
*20 - - 5.0E-04 7.5E-05 18.57 0.73 24 h: 0.0102 0.0001 
24 2.7E-05 7.3E-06 3.2E-04 9.9E-05 11.73 1.23 15 h : NS 0.0003 
Fasted 
Time 
(hpd) 
Control APAP 
p-value control  
vs APAP 
p-value APAP 
fed vs fasted Mean SD Mean SD Fold change SD 
p-value fasted  
APAP vs APAP 
1 6.3E-05 2.9E-05 1.1E-04 3.4E-05 1.67 0.90 
1, 4 or 10 h: NS,  
15, 20 and 24 h: 0.0047 
NS NS 
4 4.0E-05 3.2E-05 1.3E-04 4.3E-05 3.29 1.46 NS NS 
10 3.0E-05 1.1E-05 9.8E-05 3.1E-05 3.26 1.82 NS 0.0008 
*15 - - 2.0E-04 8.2E-05 6.67 2.25 
15, 20 or 24 h: NS 
0.0059 0.0058 
*20 - - 3.0E-04 2.2E-05 5.80 0.58 0.0020 0.0013 
24 5.1E-05 2.2E-05 3.0E-04 4.1E-05 5.85 1.50 0.0173 0.0089 
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Table 6.23. Comparison of hepatic NF-kB transcription in fed and fasted control and APAP treated mice in a 24 h period using delta Ct value, 2
-ΔCt
 and the 
comparative Ct value, i.e. fold change as compared to pooled liver samples of the control mice. Statistical significant (p-value control vs APAP) is seen in 
comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
Fed 
Time 
(hpd) 
Control APAP 
p-value control vs 
APAP Mean SD Mean SD Fold change SD 
p-value fed  
APAP vs APAP 
1 
5.28E-05 2.07E-05 
6.3E-05 6.3E-06 1.19 0.96 10 h: 0.0001, 15 h: 0.0012,  
20 h: 0.0045, 24 h: 0.0075 
NS 
4 1.1E-04 2.1E-05 2.08 0.37 NS 
10 7.0E-04 1.5E-04 13.26 3.12 15 h: 0.030 0.0001 
15 5.2E-04 1.4E-04 9.85 1.42 20 h: NS 0.0001 
20 5.0E-04 7.5E-05 9.47 0.69 10 h: 0.0129 0.0034 
24 3.2E-04 9.9E-05 6.06 1.08 20 h: 0.0061 0.0063 
Fasted 
Time (hpd) 
Control APAP 
p-value control vs 
APAP 
p-value APAP fed 
vs fasted Mean SD Mean SD 
Fold 
change 
SD 
p-value fasted  
APAP vs APAP 
1 
6.34E-05 2.74E-05 
1.1E-04 3.4E-05 1.74 0.88 
15h: NS, 20 h: 0.0317 
NS NS 
4 1.3E-04 4.3E-05 2.05 1.25 NS NS 
10 9.8E-05 3.1E-05 1.55 1.57 NS 0.0012 
15 2.0E-04 8.2E-05 3.15 2.13 20 h: NS NS 0.0072 
20 3.0E-04 2.2E-05 4.73 0.55 15 h: NS,  
10 h: 0.0445 
0.0199 0.0055 
24 3.0E-04 4.1E-05 4.73 1.32 0.0308 NS 
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Table 6.24. Comparison of hepatic cyclin-D1 transcription in fed and fasted control and APAP treated CD-1 mice in a 24 h period using delta Ct value, 2
-ΔCt
 and the 
comparative Ct value, i.e. fold change as compared to time-matched control mice. *15- relative to 10 h post saline; *20- relative to 24 h post saline. Statistical 
significant (p-value control vs APAP) is seen in comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
 
Fed 
Time 
(hpd) 
Control APAP p-value control vs APAP 
Mean SD Mean SD 
Fold 
change 
SD p-value fed APAP vs APAP  
1 2.3E-06 3.00E-06 2.9E-06 6.4E-07 1.28 0.52 
4 h: 0.0018, 10 h: 0.0402, 
20 h: 0.0003, 24 h: 0.0005 
NS 
4 3.9E-06 1.00E-06 3.6E-05 7.1E-06 8.59 1.44 15 h: 0.0156, 20 h: 0.0105, 24 h: 0.032 0.0025 
10 8.0E-06 3.00E-06 3.9E-05 9.2E-06 4.90 2.05 20 h: 0.0034, 
24 h: 0.0075 
0.0097 
*15 - - 3.1E-05 1.1E-05 3.92 1.92 0.0060 
*20 - - 5.7E-05 5.3E-06 16.14 1.57 24 h: 0.0493 0.0001 
24 3.5E-06 2.00E-06 4.3E-05 1.8E-06 12.35 1.15 - 0.0001 
Fasted 
Time 
(hpd) 
Control APAP 
p-value control vs 
APAP 
p-value 
APAP fed 
vs fasted Control SD APAP SD Fold change SD p-value fasted APAP vs APAP 
1 3.7E-06 1.00E-06 3.1E-06 1.9E-06 0.84 0.86 1,4 or 10 h: NS,  
15 h: 0.0105,  
20 h: 0.0480,  
24 h: 0.00634 
NS NS 
4 6.2E-06 4.00E-06 1.6E-05 4.3E-06 2.53 1.20 NS 0.0086 
10 6.0E-06 2.00E-06 1.7E-05 7.3E-06 2.87 1.43 NS NS 
*15 - - 3.6E-05 1.8E-06 6.02 0.83 
15, 20 & 24 h: NS 
0.0077 NS 
*20 - - 1.3E-05 6.2E-06 4.26 1.86 0.0094 0.0010 
24 3.1E-06 5.00E-06 2.4E-05 4.1E-06 7.57 1.40 0.0055 0.0077 
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Table 6.25. Comparison of hepatic NF-kB transcription in fed and fasted control and APAP treated mice in a 24 h period using delta Ct value, 2
-ΔΔCt
 and the 
comparative Ct value, i.e. fold change as compared to pooled liver samples of the control mice.Statistical significant (p-value control vs APAP) is seen in 
comparison between fold change APAP and fold change control (2
-ΔCt individual value
/2
-ΔCt mean
). 
Fed 
Time 
(hpd) 
Control APAP 
p-value control 
vs APAP Mean SD Mean SD Fold change SD 
p-value fed  
APAP vs APAP 
1 
4.46E-06 2.2E-06 
2.9E-06 6.4E-07 0.65 0.43 4,10,24 h: 0.0010, 20 h: 0.0001 NS 
4 3.6E-05 7.1E-06 8.07 1.26 10,24 h: NS, 20 h: 0.0056 0.0074 
10 3.9E-05 9.2E-06 8.74 2.48 20 h: 0.011, 24 h: NS 0.0052 
15 3.1E-05 1.1E-05 6.95 2.30 24 h: NS 0.0209 
20 5.7E-05 5.3E-06 12.78 1.33 24 h: 0.0122 0.0003 
24 4.3E-05 1.8E-06 9.64 1.05 1 h: 0.0015 0.0066 
Fasted 
Time 
(hpd) 
Control APAP 
p-value control 
vs APAP 
p-value fed vs 
fasted APAP Mean SD Mean SD Fold change SD 
p-value fasted  
APAP vs APAP 
1 
4.02E-06 2.8E-06 
3.1E-06 1.9E-06 0.77 0.72 15 h: 0.0001, 24 h: 0.0055 NS NS 
4 1.6E-05 4.3E-06 3.98 1.79 
1 h: 0.0029, 20 h: NS 
NS 0.0391 
10 1.7E-05 7.3E-06 4.23 2.03 NS NS 
15 3.6E-05 1.8E-06 8.96 1.30 4,10 h: 0.0018, 20 h: 0.0004 0.0011 NS 
20 1.3E-05 6.2E-06 3.23 1.06 24 h: 0.0330 NS 0.0009 
24 2.4E-05 4.1E-06 5.97 1.21 15 h: 0.0021 0.0273 0.0089 
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Table 6.26. Range and average amount (%) of PCNA-positive, proliferating cells in fed and16 or 24 h fasted control (saline) and APAP dosed mice at different 
time points post dosing.  
 
 
Table 6.27. Range and average amount (%) of PCNA-positive, proliferating cells in fed and16/24 h fasted pooled control (saline) and APAP dosed CD-1 
mice at different time points post dosing.  
Time 
(hpd) 
Fed  Fasted  
n 
% PCNA+ (range; [mean]) p-value 
control vs APAP 
Fasting time (h) 
n 
% PCNA+ (range; [mean]) p-value 
control vs APAP Control APAP 16 24 Control APAP 
0 4 15.3-26.7 [21.0] - -  x 4 2.27-9.4 [6.27] - - 
0.5 - - - - x  5 2.58-19.05 [6.75] 3.31-22.5 [10.42] 0.0095 
1 5 - 3.55-14.4 [7.92] 0 h: NS, 10 h: 0.0158 x  5 0.8 - 5.6 [2.89] 3.45-20.9 [10.25] NS 
3 5 - 11.95-34.9 [25.96] 0 h: NS, 10 h: 0.0036   x 5 - 1.08-7.79 [3.82] - 
5 6 - 7.35-26.9 [15.62] 0 h: NS, 10 h: 0.0007   x 5 0.77 - 1.12 [1.89] 0.4-6.98 [3.23] NS 
10 6 0.31-0.73 [0.59] 5.7-13.4 [7.71] 0 h: NS, 10 h: 0.0095   x 5 0.08 - 2.7 [1.26] 0.29-6.87 [2.98] NS 
15 6 - 1.54-24.3 [3.86] 0 h: NS, 10 h: 0.0095  x  5 2.79 - 22.4 [7.9] 6.76-21.2 [11.65] 0.0404 
20 6 - 2.96-13.48 [9.84] 0 h: NS, 10 h: NS  x  5 2.69 - 21.0 [10.34] 8.1-28.3 [15.73] 0.0297 
24 4 - 4-24.2 [15.02] 0 h: NS, 10 h: NS  
x  5 1.54 - 16.4 [6.34] 2.04-19.9 [13.09] 0.0188 
 x 5 - 1.67-4.86 [3.62] NS 
x x 10 1.54 - 16.4 [6.34] 1.67-19.9 [8.36] NS 
Time 
(hpd) 
Fed Fasted p-value 
fed vs fasted 
APAP 
n 
Control 
Mean (SD) 
APAP 
Range [mean] 
p-value 
control vs APAP 
Fasting time (h) 
n 
Control 
Mean (SD) 
APAP 
Range [mean] 
p-value 
control vs APAP 16 24 
1 5 
7.39 
(11.14) 
3.55-14.4 [7.92] 
All NS 
at any time 
points 
x  5 
5.29  
(5.63) 
3.45-20.9 [10.25] NS NS 
3 5 11.95-34.9 [25.96]  x 5 1.08-7.79 [3.82] NS 0.0044 
5 6 7.35-26.9 [15.62]  x 5 0.4-6.98 [3.23] NS 0.0011 
10 6 5.7-13.4 [7.71]  x 5 0.29-6.87 [2.98] NS 0.0303 
15 6 1.54-24.3 [3.86] x  5 6.76-21.2 [11.65] 0.0090 NS 
20 6 2.96-13.48 [9.84] x  5 8.1-28.3 [15.73] 0.0019 NS 
24 4 4-24.2 [15.02] 
x  5 2.04-19.9 [13.09] 0.0405 NS 
 x 5 1.67-4.86 [3.62] NS NS 
x x 10 1.67-19.9 [8.36] NS NS 
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Table 6.28. Range and average amount (%) of cytoplasmic PCNA-positive, proliferating mitotic cells in fed and fasted time-matched control (saline) and APAP 
dosed CD-1 mice at different time points post dosing. hpd – hours post dosing; n – no of animal per group; NS not significant; Cyto – cytoplasmic. 
Time 
(hpd) 
Fed Fasted 
n 
% Cyto+ (range; [mean]) p-value control vs 
APAP 
Fasting time (h) 
n 
% Cyto+ (range; [mean]) p-value control 
vs APAP Control APAP 16 24 Control APAP 
0 4 0.27-1.05 [0.66] -   x 4 0-0.27 [0.16] - - 
0.5 - - - - x  5 0.08 – 2.42 [1.19] 0.15-1.16 [0.67] NS 
1 5 - 0-0.39 [0.18] 0 h: NS,10 h: NS x  5 0 – 0.46 [0.18] 0.38-3.02 [1.40] NS 
3 5 - 0-1.18 [0.62] 0 h: NS,10 h: NS  x 5 - 0.16-1.62 [0.94] - 
5 6 - 0.7-2.07 [1.02] 0 h: NS, 10 h: 0.0006  x 5 0.14 – 0.3 [0.22] 0.17-3.9 [1.46] NS 
10 6 0-0.16 [0.1] 0.05-0.56 [0.27] 0 h: NS,10 h: 0.0472  x 5 0 0-0.19 [0.056] NS 
15 6 - 0.14-0.91 [0.35] 0 h: NS,10 h: 0.0275 x  5 0 0.12-13.5 [3.88] 0.0079 
20 6 - 0.24-2.12 [1.04] 0 h: NS,10 h: 0.0433 x  5 0 – 0.19[0.05] 0-2.54 [1.24] NS 
24 4 - 0.37-2.07 [0.94] 0 h: NS, 10 h: NS, 
x  5 0.06 – 0.21 [0.11] 0-1.97 [0.78] NS 
 x 5 - 0.17-1.87 [1.08] 0.0159 
x x 10 0.06 – 0.21 [0.11] 0-1.97 [0.92] 0.0360 
 
Table 6.29. Range and average amount (%) of cytoplasmic PCNA-positive, proliferating mitotic cells in fed and fasted pooled control (saline) and APAP 
dosed CD-1 mice at different time points post dosing. hpd – hours post dosing; n - no of animal per group; NS not significant; Cyto – cytoplasmic. 
Time 
(hpd) 
Fed Fasted 
p-value fed vs 
fasted APAP n 
Control 
Mean (SD) 
APAP 
Range [mean] 
p-value control 
vs APAP 
Fasting time (h) 
n 
Control 
Mean (SD) 
APAP 
Range [mean] 
p-value  
control vs APAP 16 24 
1 5 
0.28  
(0.39) 
0-0.39 [0.18] NS x  5 
0.095  
(0.121) 
0.38-3.02 [1.40] 0.0001 NS 
3 5 0-1.18 [0.62] NS  x 5 0.16-1.62 [0.94] 0.0004 NS 
5 6 0.7-2.07 [1.02] 0.0082  x 5 0.17-3.9 [1.46] 0.0003 NS 
10 6 0.05-0.56 [0.27] NS  x 5 0-0.19 [0.056] NS 0.0216 
15 6 0.14-0.91 [0.35] NS x  5 0.12-13.5 [3.88] 0.0057 NS 
20 6 0.24-2.12 [1.04] 0.0411 x  5 0-2.54 [1.24] 0.0092 NS 
24 4 0.37-2.07 [0.94] 0.0446 
x  5 0-1.97 [0.78] 0.0438 NS 
 x 5 0.17-1.87 [1.08] 0.0005 NS 
x x 10 0-1.97 [0.92] 0.0011 NS 
Appendix 
276 
 
Table 6.30. A summary comparison of the examined parameters for the assessment of APAP hepatotoxicity in fed and fasted CD-1 mice (1-24 hpd). 
Statistically significant differences were observed between the fasted and fed mice that had received APAP intraperitoneally. Hepatic or splenic mRNA levels 
were summarised based on fold change relative to pooled control animals. 4/5- Studies done at 5 hpd are serum ALT and PCNA, others are at 4 hpd. 
*P<0.005, <0.01 or <0.05. 
 
 Time (hours post APAP dosing) 
1 4/5 10 15 20 24 
Fed Fast Fed Fast Fed Fast Fed Fast Fed Fast Fed Fast 
Hepatic GSH 5.3 (3.65) 13.7(8.3) 4.95(0. 6) 4.47(3.6) 40.3(0.7) 5.3(1.2)* 44.3(12.6) 33.98(16.2) 35.1(18.5) 49.3(7.8) 45.5 (10) 50.6(25.2) 
Hepatic ATP 31.4 (5.1) 4.2 (0.9)* 10.5 (2.3) 3.5 (4.9)* 18.3 (5.7) 3.4 (1.2)* - - - - 35.4(3.9) 8.1 (1.3)* 
Fold change  
1- GSH  
2- ATP 
 
0.13 
0.98* 
 
0.33 
0.79* 
 
0.14 
0.30 
 
0.09 
0.20 
 
1.96 
0.61* 
 
0.06 
0.25 
 
- 
 
- 
 
- 
 
- 
 
0.96 
1.07 
 
0.33 
0.49 
Serum ALT 
- - 
2146.4 
(1012.3) 
2048.6 
(461.7) 
- - - - - - 
2654.5 
(334.5) 
3603.8 
(508.8)* 
HE score 0 (0) 0 (0) 2.4(0.25) 2.5 (1.41) 1 (1.31) 2.6(0.42) 1.13(1.24) 2.15 (0.78) 0.65(0.67) 2.75 (0.4)* 0 (0) 2.38(0.7)* 
TNF-α 
1- Liver 
2- Spleen 
3- Serum 
 
2.76(0.3) 
- 
- 
 
1.0(0.6) 
- 
- 
 
4.4(0.7) 
- 
62 (13.5) 
 
2.3 (0.6)* 
- 
101.2(40) 
 
7.9 (2.7) 
4.4 (1.8) 
- 
 
6.8 (2.4) 
4.9 (2.0) 
- 
 
2.0 (1.3) 
2.2 (1.1) 
- 
 
18.3 (4.8)* 
7.8 (1.6)* 
- 
 
2.1 (1.4) 
2.4 (0.5) 
- 
 
1.9 (0.7) 
4.4 (1.9) 
- 
 
1.77(0.8)
1.2(0.6) 
95 (14) 
 
1.5 (0.5) 
3.9 (0.8)* 
228 (54)* 
IL-6 
1- Liver 
2- Spleen 
3- Serum 
 
2.6 (0.8) 
- 
- 
 
1.7 (0.8) 
- 
- 
 
6.0 (1.9) 
- 
54.3(10) 
 
4.7 (1.7) 
- 
35.4(11)* 
 
7.9 (0.8) 
1.9 (0.3) 
- 
 
2.2 (1.0)* 
1.0 (0.6) 
- 
 
4.5 (2.0) 
0.8 (0.3) 
- 
 
4.5 (0.9) 
2.0 (1.0) 
- 
 
15.8 (4.0) 
3.8 (0.9) 
- 
 
5.3 (1.6)* 
1.4 (0.5)* 
- 
 
7.6 (2.7) 
3.7 (1.2) 
203(40) 
 
7.4 (3.1) 
1.1 (0.4)* 
96(35.2)* 
Hepatic IL-10 3.0 (0.8) 2.6 (1.5) 3.9 (1.5) 1.5 (1.2) 9.0 (2.9) 1.8 (0.9)* 13.2(3.7) 3.9 (1.4)* 10.4(3.1) 4.6(2.1)* 8.8 (1.3) 5.2 (3.9) 
Hepatic NF-kB 1.19 (0.96) 1.74 (0.9) 2.1 (0.4) 2.1 (1.3) 13.3(3.1) 1.5 (1.6)* 9.85(1.4) 3.2 (2.1)* 9.5(0.7) 4.7 (0.6)* 6.1 (1.1) 4.7 (1.3) 
Liver cyclin-D1 0.7 (0.4) 0.8 (0.7) 8.1 (1.3) 4.0 (1.8)* 8.7 (2.5) 4.2 (2.0) 7.0 (2.3) 9.0 (1.3) 12.8 (1.3) 3.2 (1.1)* 9.6 (1.1) 6.0 (1.2)* 
IH PCNA (%) 
1- Overall 
2- Cyto+ 
 
7.92 
0.18 
 
10.25 
1.40 
 
15.62 
1.02 
 
3.23* 
1.46 
 
7.71 
0.27 
 
2.98* 
0.06* 
 
3.86 
0.35 
 
11.65 
3.88 
 
9.84 
1.04 
 
15.73 
1.24 
 
15.02 
0.94 
 
8.36 
0.92 
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C. APAP dosed C57BL/6J mice 
 
Table 6.31. Histological findings in APAP dosed fed C57BL/6J mice (time course). The histological findings and average grading scores for individual 
animals at each time point were recorded over a 36 h time course. hpd - hours post dosing; NHAIR - no histological abnormality is recognised; CL – 
centrilobular; HD - hydropic degeneration; NL - neutrophilic leukocytes; hpc – hepatocytes; pos. – positive; neg. – negative; occ. - occasional; ind. - individual; 
CC3 – cleaved caspase-3; mod. – moderate; CV – central vein; apop. – apoptosis; nec. – necrosis.  
Time 
(hpd) 
Case  
no. 
Score 
range 
[mean] 
Histological descriptions Exp 
0 
09L-3233 0 Hepatocellular vacuolation; NHAIR; PAS: Diffuse glycogen 
2 
09L-3234 0 NHAIR; PAS: diffuse glycogen 
09L-3235 0 NHAIR; PAS: diffuse glycogen 
09L-3236 0 NHAIR; PAS: diffuse glycogen 
Summary [0] NHAIR; PAS: Diffuse glycogen in hpc 
1 
09L-3249 0 NHAIR; PAS: diffuse glycogen 
09L-3250 0 NHAIR; PAS: diffuse glycogen 
09L-3251 0 NHAIR; PAS: diffuse glycogen 
09L-3252 0 NHAIR; PAS: diffuse glycogen 
Summary [0] NHAIR; PAS: Diffuse glycogen in hpc 
3 
09L-3257 0.5-1 Mild CL cell loss; very few apoptotic hpc and increase amount of NL at CL, HD of some hpc at CL. PAS: Glycogen only at zone 1 
09L-3258 0.5-1 
Mild CL cell loss; intense cytoplasm of hpc at CL and increase NL infiltration centrilobularly, some aggregate to cell death. Very few 
apoptotic hpc. PAS: Loss of glycogen at zone 3 
09L-3259 1.5-2 CL cell loss and haemorrhage with NL infiltration. No evidence of cell death. PAS: Pos. outside zone 3 
09L-3260 1.5-2 Similar to 09L-3259 
Summary [1.25] 
CL cell loss and haemorrhage with several NL infiltration; no or very occ. apop. hpc and HD of remaining cells in affected CL 
areas; PAS: Loss of glycogen in hpc surrounding affected areas  
5 
09L-3265 1-1.5 HD at inner CL surrounded by intense cytoplasm, moderate NL at zone 3. PAS: only glycogen at zone 1 
09L-3266 2-2.5 
Extensive CL cell loss with high NL at affected area of zone 3, some evidence of NL at affected areas and CV. PAS: Glycogen at 
unaffected area of zone 1 only 
09L-3267 3.5-4 More extensive CL cell loss with haemorrhage, marked NL infiltration. PAS: No glycogen at affected areas CL 
09L-3268 3.5-4 Similar to 09L-3267 
13L-5205 1-3 CL cell loss with some NL infiltration with few aggregate to ind cell death, PAS: Glycogen at outside zone 3  
13L-5206 2-3 More extensive cell loss with some NL infiltration. PAS: No glycogen at affected areas 
Summary [2.75] 
More extensive centrilobular cell loss with haemorrhage and marked NL infiltration; PAS:  Loss of glycogen in hpc 
surrounding affected areas 
10 11L-4466 1 
Mild cell loss; scattered hpc death with aggregation of NL. Increase no of NL between hepatic cord, few hpc at CL underwent 
degeneration. PAS: Glycogen at area of unaffected area of zone 2 and 1 
4 
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11L-4467 0-1 
Very mild CL cell loss; hpc with fine vacuoles at 3-4 layers of CL; slight to mild LC infiltrates at CL; PAS: hpc with variable amount of 
glycogen at zone 2 and 1 only. (no glycogen at 4-5 layers of CL) 
11L-4468 1.5 
Some CL cell loss with increased no of NL, some NL aggregate to ind. cell death hpc. PAS: hpc with variable amount of glycogen 
except zone 3 and zone 2   
11L-4469 0-2 
CL cell loss; mild infiltration of NL at CL; hpc with no vacuolation at CL region (a few cell loss). PAS: hpc with glycogen with variable 
amount except zone 3 
11L-4470 1.5 
CL cell loss with evidence of scattered apoptotic/necrotic cell and mitotic figures of hpc (moderate); mild NL infiltration between zone 3 
& 2. PAS: Disseminated hpc with variable amount of glycogen at zone 2 
14L-0689 1-1.5 
CL cell loss with few scattered mitotic figures; mild NL with haemorrhage at zone 3; NL aggregate to cell death. CC3: +; PAS: Very 
mild scattered ind. hpc. with glycogen 
5 
14L-0690 1-1.5 Similar to 14L-0689 
14L-0691 2-2.5 
Extensive CL cell loss and moderate NL at zone 3 & 2, mitotic figure; evidence of moderate NL. CC3: very few pos. hpc. PAS: 
Moderate hpc with glycogen (almost diffuse) 
14L-0692 1-1.5 
CL cell loss; aggregation of NL to ind. cell death; high haemorrhage at zone 3 with still present of hpc nucleus. CC3: ++; PAS: Diffuse 
glycogen except 3-4 layers of zone 3 
Summary  [1.5] 
CL cell loss with moderate NL infiltration and scattered evidence of mitotic figures; CC3: +/++; PAS: No glycogen in 3-4 
layers of hpc in affected zones areas with variable densitY 
15 
11L-4471 1 
Rounded hpc with very few aggregation of NL to ind. cell death. PAS: Disseminated hpc with glycogen with variable density except 
some few layers of zone 3 and 1 
4 
11L-4472 1-2 
Reduced cellularity of CL with some NL aggregate to individual cell death; mild CL cell loss; PAS: Disseminated hpc wth variable 
density of glycogen except affected region of zone 3 
11L-4473 1 
One evidence of mitotic figures; a few scatereed aggregation of NL to individual hpc cell death; reduced cellularity of some CL; 
minimal NL infiltrate between hepatic cord; PAS: Scattered ind. glycogen with variable density distribute randomly in all zones 
11L-4474 1 
Very few scattered ind. cell death with NL aggregation, mild NL infiltrate between hepatic cord; PAS: Scattered individual glycogen hpc 
distribute randomly at all zones especially zone  
11L-4475 1-2 
Mild mitotic figures and aggregation of NL to hpc cell death, mild CL cell loss, infiltration of NL at zone 3 and 2. Hpc with variable sized 
cyto. vacuoles CL (4-5 cell layers), outside this less intense. PAS: Diffuse glycogen with variable density except 3-5 layers of zone 3  
14L-0693 2-3 
CL cell loss (almost all lobe) with high haemorrhage and moderate NL at zone 3 and 2; CC3: +; Neg.; PAS: No glycogen at affected 
areas of zone 3 
5 
14L-0695 4-5 Dead- exclude from study 
14L-0696 1-2 
CL cell loss and few scattered cell death; some NL infiltration at affected areas; no mitotic figures.CC3: +; PAS: No glycogen at 
affected areas of zone 3 
14L-0697 2-3 Similar to 14L-0693 
Summary [2.17] 
CL cell loss with haemorrhage and moderate NL infiltration at zone 3 & 2; CC3: +; PAS: No glycogen in affected zones with 
some disseminated hpc with glycogen with variable amount 
20 11L-4476 0-2 
Mild to moderate CL cell loss and some variable sized cyto vacuoles at CL; Infiltration of NL at CL and zone 2 (some aggregate to ind. 
cell death); some evidence of mitotic figures at CL and zone 2. PAS: few scattered ind. variable intensity of  glycogen randomly at all 
zones except CL 
4 
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Exp – Experiments performed by 2 - Craig Benson (2011), 4 - Harley Webb (2013), and 5 - Fazila Hamid (2013-14).   
11L-4477 1 
Mild CL cell loss and cell death; NL infiltration at CL and zone 2 (some aggregate to nec./ apop hpc). PAS: few scattered ind. variable 
intensity of  glycogen randomly at all zones except CL 
11L-4478 1-2 
Swollen and vacuolated cytoplasmic (HD) Mild CL cell loss with few necrotic hpc in some CL accompanied with NL aggregation; some 
NL circulated at zone 2 and 3. PAS: Diffuse glycogen except 3-5 layers of zone 3 
11L-4479 1-2 
Mild to moderate CL cell loss and scattered NL aggregation to necrotic cell death; NL recruit out of CV to CL; some vacuolated hpc at 
CL; PAS: No glycogen 
11L-4480 0-1 
Reduced & disorganised CL cellularity; some mild CL cell loss; some aggregation of NL to ind. apop./nec. cell. CC3: ++; PAS: Few 
scattered hpc with glycogen randomly distributed except zone 3 
14L-0701 1-1.5 
Ongoing cell damage, evidence of apoptosis with low amount of NL at zone 3. CC3: +; PAS: Diffuse glycogen except 5-6 layers of 
zone 3 
5 
14L-0702 1-1.5 
CL cell loss; with evidence of apoptosis/necrotic cells; some aggregation of NL to ind cell death. CC3: ++; PAS: Diffuse glycogen 
except 3-4 layers of zone   
14L-0703 0-1 Mild CL cell loss; CC3: +; PAS: Diffuse glycogen except 1-2 layer of zone 3 (almost intact). 
14L-0704 2-2.5 
Moderate no of scattered apoptotic cell at zone 3 with some NL aggregate to death cell. CC3: +/++; PAS: Diffuse glycogen except 
affected 2-3 layers of zone 3 
Summary [1.3] 
CN and HD of remaining CL hpc with and evidence of apoptotic cell with NL infiltration; CC3; +/++; PAS: No glycogen in hpc 
in affected zones; few scattered ind. hpc, (1/5) no glycogen 
24 
09L-3273 1-1.5 
CN of some hpc, few scattered apop. at zone 3, HD of hpc at affected and unaffected areas, few NL with aggregate to cell death. 
CC3: ++; PAS: Diffuse glycogen except 5-6 layers of affected areas 
2 
09L-3274 1 Some CL with HD on remaining hpc and aggregation of NL to cell death. CC3: +; PAS: No glycogen at affected areas of zone 3 
09L-3275 1 Numerous apoptosis to some CL with moderate no of NL to cell death, few CL are intact; CC3: +; PAS: Neg. at affected areas of CL 
13L-5207 0.5-1.5 Some CL with 1-2layer of cell loss and few NL infiltration centrilobularly, CC3: Neg.; PAS: diffuse glycogen except 2-3 layer of zone 3 
13L-5208 0.5-1 CL 1-2 layer of cell loss with mild NL infiltration. PAS: Scattered ind hpc with low glycogen amount 
Summary [1.15] CN and HD of remaining CL hpc with mild NL infiltration; CC3: +/++; PAS: Neg. in 2-3 CL layers 
30 
13L-5211 0-1 Some CL with 1-2 layer of cell loss and few NL infiltration. CC3: very few pos. hpc; PAS: Neg. at CL 
5 
13L-5212 1-1.5 
2-3 layers of CN with some NL (few aggregate to cell death between affected & unaffected areas) CC3: +; PAS: No glycogen at 
affected areas 
13L-5213 1-1.5 2-3 layers of CL with CN and moderate NL infiltration; CC3: +; PAS: No glycogen at affected areas 
13L-5214 0 NHAIR. CC3: Neg. PAS: no glycogen at 2-3 layer of zone 3  
Summary [0.75] 2-3 innermost CL hpc layers with CN and few infiltrating NL; CC3: +; PAS: Neg. in CL hpc layers 
36 
14L-0709 1 Inner zone 3 with CN surrounded by swollen cell (HD); CC3: + (Occ. pos. hpc) PAS: Diffuse glycogen except 1-2 layer of zone 3  
14L-0710 1 CN with 1-2 layer of zone 1 surrounded by intense cyto of hpc. CC3: +; PAS: Diffuse glycogen except affected area of zone 3 
14L-0711 0-1.5 Similar to 14L-0710 but CN is slightly more intense. PAS: Glycogen only on unaffected area 
14L-0712 1 
CN with 1-2 layer of zone 1; few apop. hpc, some NL infiltration with its aggregation to cell death. CC3: + (scattered ind. pos. at CL); 
PAS: Diffuse glycogen except affected areas of zone 3 
Summary [0.8] 
CN at 1-2 innermost CL hpc layers with some apoptotic cells; CC3: +; PAS: Diffuse glycogen surrounding the CN layers (3-4 
layer of zone 3) 
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Table 6.32. Histological findings in APAP dosed fasted C57BL/6J mice (time course). The histological findings and average grading scores for individual 
animals at each time point were recorded over a 36 h time course. hpd - hours post dosing; NHAIR - no histological abnormality is recognised; CL – 
centrilobular; HD - hydropic degeneration; NL - neutrophilic leukocytes; hpc – hepatocytes; pos. – positive; neg. – negative; occ. - occasional; ind. - individual; 
CC3 – cleaved caspase-3; mod. – moderate; CV – central vein; apop. – apoptosis; nec. – necrosis. 
 
Time 
(hpd) 
Case  
no. 
Score 
range 
[mean] 
Histological descriptions Exp 
0 
10L-2368 0 NHAIR; PAS: No glycogen 
2 
10L-2369 0 NHAIR; PAS: No glycogen 
10L-2370 0 NHAIR; PAS: No glycogen 
10L-2371 0 NHAIR; PAS: No glycogen 
Summary [0] NHAIR; PAS: No glycogen 
0.5 
10L-2376 0 NHAIR; PAS: Diffuse glycogen with low amount 
10L-2377 0 NHAIR; PAS: Diffuse glycogen with low amount 
10L-2378 0 NHAIR; PAS: Glycogen loss at CL 
10L-2379 0 NHAIR; PAS: Diffuse glycogen with low amount 
Summary [0] NHAIR: PAS: Diffuse glycogen (relatively low amount; one animal with CL loss of glycogen) 
1 
10L-2384 0 NHAIR; PAS: Diffuse glycogen but relatively low amount 
10L-2385 0 NHAIR; PAS: Diffuse glycogen but relatively low amount 
10L-2386 0 NHAIR; PAS: Diffuse glycogen but relatively very low amount 
10L-2387 0 NHAIR; PAS: No glycogen 
Summary [0] NHAIR; No glycogen, one animal with centrilobular HD 
3 
10L-2392 0 NHAIR; few NL at zone 3 and few HD of CL hpc. PAS: Extensive CL glycogen loss except few area with low amount 
10L-2393 0 NHAIR; PAS: Glycogen at variable amount 
10L-2394 0 NHAIR; PAS: PAS: Glycogen at variable amount, less intense at CL 
10L-2395 0 NHAIR; PAS: Glycogen at variable amount, less intense at CL 
Summary [0] NHAIR; PAS: Diffuse glycogen with variable intensity 
5 
10L-2400 2-3 
Coagulative bridging necrosis between CL with numerous NL between affected area with some evidence of apoptotic hpc. PAS: 
Glycogen at some area of zone 1 with variable amount 
10L-2401 3-4 
More extensive CL cell loss with bridging necrosis. Numerous NL infiltration mainly zone 3. PAS; No glycogen except scattered ind hpc 
at variable intensity 
10L-2402 3-4 Same as in 10L-2401, PAS; glycogen with variable amount only at zone 1 
10L-2403 3-4 CN of innermost zone 3, and bridging necrosis, high NL at affected area. PAS: Pos. with variable amount at zone 1 
Summary [3.25] 
CL cell loss with bridging necrosis of innermost CL layers with numerous NL; PAS: Diffuse glycogen loss, except in some 
periportal hpc with variable amount 
10 14L-0937 1-2 CL loss with high no of NL (some aggregate to ind. cell death), few apoptotic cell and inflammatory cells. CC3: +/++; PAS: No glycogen 5 
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except scattered ind. hpc 
14L-0938 1-2 Same as in 14L-0937 
14L-0939 2-3 More intense CL loss with high NL and few evidence of apop. cells. CC3: +; PAS: Glycogen to few ind. hpc 
14L-0940 3 Same as in 14L-0939 with increase amount of NL aggregates to ind. cell death. CC3: +; PAS: Glycogen at ind. hpc scattered to all zone 
Summary [2.13] CL cell loss with NL infiltration; few apop. cells; CC3: +/++; PAS: Scattered random hpc containing glycogen 
15 
14L-0943 1.5-2 CL cell loss, few scattered apop. with high NL between affected & unaffected area. CCL: +/++; PAS: Neg. 
14L-0944 1-2 
CL cell loss with high NL between affected/unaffected zone, with few apoptotic cells. CC3: +; PAS: Scattered glycogen at zone 1 with 
variable amount 
14L-0945 2 Same as in 14L-0943. PAS: No glycogen except few scattered individual hpc 
14L-0946 1.5-2 Evidence of a few apoptotic cells. PAS: No glycogen   
Summary [1.75] CL cell loss with a few scattered apoptotic cells and substantial NL infiltration; CC3: +; PAS: Neg. 
20 
14L-0949 1-1.5 
CL cell loss with numerous NL at zone 3. Scattered ind. glycogen randomly with variable density mainly zone 1 & 2. CC3: +; PAS: 
scattered glycogen randomly with variable amount 
14L-0950 1.5-2 
CN of inner 2-3 layers of CL with numerous NL infiltrations between affected and unaffected areas. CC3: +/++; PAS: Glycogen with 
variable amount only at some area of zone 1 
14L-0951 3 More extensive than 14L-0950. PAS: No glycogen 
14L-0952 1-3 Similar as in 14L-0951/52. CC3: +; PAS: No glycogen except scattered randomly ind. hpc with glycogen 
Summary [2] 
CN of innermost 2-3 CL hpc layers with few HD of remaining hpc at zone 2 between affected and unaffected areas; few 
apoptotic cells; CC3: +/++; PAS: Neg. except few scattered random ind. hpc 
24 
10L-2409 2-2.5 CN of CL, and moderate no of apoptosis at zone 3, moderate amount of NL. CC3: +/++; PAS: No glycogen at zone 3 
2 
10L-2410 2 CN of CL; few apop, high NL between affected and unaffected area. CC3: +; PAS: No glycogen at  affected areas 
10L-2411 2 Aggregation of NL to death cell, few scattered apoptosis at affected area. CC3: ++; PAS: Neg. at affected areas 
10L-2412 2-2.5 CN, HD of remaining cells, few scattered apoptotic body, some NL infiltration.  CC3: +; PAS: Neg. at affected areas 
10L-2413 2 CN of CL, moderate apoptosis, some NL with aggregate to ind. cell death. CC3: ++; PAS: Neg. at affected areas 
Summary [2.1] 
Similar to 20 hpd; CN, HD and occasional apoptosis of remaining hpc in affected areas; CC3: ++; PAS: No glycogen in affected 
areas of zone 3 
36 
14L-0955 2 
CN of innermost layer of zone 3 and few scattered apoptotic cells; few NL at affected areas. CC3: +; PAS: Diffuse glycogen outside 
affected areas 
5 
14L-0956 2 Similar to 14L-0955 
14L-0957 1-2 CN of 2-3 layers of inner CL, some apoptotic hpc at CL. CC3: +/++; PAS: Glycogen at unaffected area of zone 2 & 1 
14L-0958 1-2 
Inner 2-3 layers of CN at CL, some apoptotic hpc and moderate NL between affected and unaffected areas. CC3: +; PAS: Glycogen at 
unaffected area of zone 2 and 1  
Summary [1.5] 
CN of innermost 2-3 CL hpc layers with moderate NL infiltration and some apoptotic hpc; CC3: +; PAS: Diffuse glycogen 
outside affected areas 
 
Exp – Experiments performed by 2 - Craig Benson (2011) and 5 - Fazila Hamid (2013/2014).   
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Table 6.33. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in time-matched control and APAP treated fed C57BL/6J mice, using the delta Ct 
method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. The fold change values of APAP dosed C57BL/6J mice were 
also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. In CD-1 mice only (*15- relative to 10 h post 
saline; *20- relative to 24 h post saline).  
 
TNF-α 
Time 
(hpd) 
Control APAP p-value control  
vs APAP 
p-value vs APAP  
CD-1 Mean SD Mean SD Fold change SD 
1 3.90E-04 3.40E-04 7.30E-04 3.30E-04 1.87 0.62 NS NS 
*5 7.30E-04 5.60E-04 4.34E-03 8.45E-04 5.95 2.23 0.0065 NS 
10 3.70E-04 4.80E-04 8.10E-04 3.13E-04 2.19 1.18 NS 0.0229 
15 2.50E-04 7.80E-05 3.40E-04 2.80E-04 1.36 0.63 NS NS 
20 3.50E-04 2.12E-04 5.60E-04 1.12E-04 1.60 0.34 NS NS 
24 2.10E-04 1.70E-04 2.20E-04 6.80E-05 1.05 0.14 NS NS 
36 3.50E-04 1.23E-04 5.10E-04 2.74E-04 1.46 0.66 NS - 
IL-6 
Time 
(hpd) 
Control APAP p-value control vs 
APAP 
p-value vs APAP  
CD-1 Mean SD Mean SD Fold change SD 
1 2.68E-04 6.89E-05 1.38E-04 6.20E-05 0.52 0.06 NS 0.0052 
*5 3.80E-04 9.26E-05 7.55E-04 2.20E-04 1.99 0.84 NS 0.0309 
10 5.50E-04 8.33E-05 1.20E-03 6.36E-04 2.19 1.29 NS 0.0001 
15 3.55E-04 7.40E-05 1.68E-03 3.60E-04 4.73 1.38 0.0225 NS 
20 2.00E-04 1.03E-04 9.07E-04 2.30E-04 4.54 1.03 0.0095 0.004 
24 2.66E-04 4.85E-05 2.27E-03 6.08E-04 8.52 2.34 0.0030 NS 
36 3.18E-04 2.38E-04 2.33E-03 3.60E-04 7.31 2.05 0.0011 - 
IL-10 
Time 
(hpd) 
Control APAP p-value control vs 
APAP 
p-value vs APAP  
CD-1  Mean SD Mean SD Fold change SD 
1 2.78E-06 1.43E-06 1.10E-06 3.84E-07 0.39 0.14 NS NS 
3 1.16E-06 1.45E-07 2.06E-06 2.58E-07 1.78 0.44 NS - 
*5 2.54E-06 1.97E-06 3.29E-06 8.54E-07 1.29 0.36 NS 0.0005 
10 3.92E-06 1.30E-06 1.27E-05 6.14E-06 3.23 1.05 NS 0.0102 
15 6.78E-06 3.31E-06 5.09E-05 9.42E-06 7.51 2.14 0.0068 NS 
20 5.85E-06 9.70E-07 4.90E-05 7.00E-06 8.37 1.94 0.0056 NS 
24 2.72E-06 1.13E-06 2.90E-05 1.01E-05 10.60 2.24 0.0005 NS 
36 5.76E-06 1.50E-06 3.83E-05 4.78E-06 6.64 1.41 0.0017 - 
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Table 6.34. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in pooled liver samples of fed control C57BL/6J mice and in APAP treated fed 
C57BL/6J mice, using the delta Ct method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. The fold change values of APAP 
dosed C57BL/6J mice were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
 
TNF-α 
Time 
(hpd) 
Control APAP 
p-value control vs APAP 
p-value vs 
APAP CD-1 Mean SD Mean SD Fold change SD 
1 
3.71E-04 2.80E-04 
7.30E-04 3.30E-04 1.97 0.68 NS NS 
*5 4.34E-03 8.45E-04 11.7 4.75 0.0004 0.0292 
10 8.10E-04 3.13E-04 2.18 1.16 NS 0.0391 
15 3.40E-04 2.80E-04 0.92 0.63 NS NS 
20 5.60E-04 1.12E-04 1.51 0.30 NS NS 
24 2.20E-04 6.80E-05 0.59 0.11 NS NS 
36 5.10E-04 2.74E-04 1.37 0.59 NS - 
IL-6 
Time 
(hpd) 
Control APAP p-value vs 
APAP CD-1 Mean SD Mean SD Fold change SD p-value control vs APAP 
1 
3.23E-04 1.01E-04 
1.38E-04 6.20E-05 0.43 0.05 NS NS 
*5 7.55E-04 2.20E-04 2.33 1.45 NS 0.0204 
10 1.20E-03 6.36E-04 3.71 1.07 0.0112 0.0492 
15 1.68E-03 3.60E-04 5.20 2.08 0.0103 NS 
20 9.07E-04 2.30E-04 2.80 1.00 NS 0.0003 
24 2.27E-03 6.08E-04 7.02 1.87 0.0025 NS 
36 2.33E-03 3.60E-04 7.21 2.15 0.0009 - 
IL-10 
Time 
(hpd) 
Control APAP p-value vs 
APAP CD-1 Mean SD Mean SD Fold change SD p-value control vs APAP 
1 
4.05E-06 1.47E-06 
1.10E-06 3.84E-07 0.27 0.12 NS NS 
3 2.06E-06 2.58E-07 0.51 0.38 NS - 
*5 3.29E-06 8.54E-07 0.81 0.28 NS 0.0278 
10 1.27E-05 6.14E-06 3.14 0.89 NS 0.0302 
15 5.09E-05 9.42E-06 12.6 3.42 0.0001 NS 
20 4.90E-05 7.00E-06 12.1 4.09 0.0001 NS 
24 2.90E-05 1.01E-05 7.17 1.23 0.0005 NS 
36 3.83E-05 4.78E-06 9.47 3.64 0.0001 - 
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Table 6.35. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in time-matched control and APAP treated male C57BL/6J mice had been fasted for 16 
h prior to dosing using delta Ct method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. The fold change values of APAP 
dosed C57BL/6J mice were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. In CD-1 mice only (*15- 
relative to 10 h post saline; *20- relative to 24 h post saline). 
 
TNF-α 
Time 
(hpd) 
Control APAP p-value control vs 
APAP 
p-value fasted vs fed 
C57BL/6J 
p-value vs APAP 
CD-1 Mean SD Mean SD Fold change SD 
1 5.41E-04 1.75E-04 4.30E-04 2.30E-04 0.79 0.51 NS NS NS 
*5 3.73E-04 2.56E-04 5.40E-04 1.38E-04 1.45 0.89 NS 0.0083 NS 
10 7.21E-04 4.84E-04 1.14E-03 3.30E-04 1.58 1.29 NS NS 0.0300 
*15 1.23E-04 7.40E-05 2.60E-04 1.25E-04 2.11 0.90 NS NS 0.0006 
*20 1.97E-04 8.39E-05 8.20E-04 2.74E-04 4.16 1.41 0.0450 0.0323 NS 
24 1.59E-04 1.82E-04 1.52E-03 4.40E-04 9.56 2.75 0.0010 0.0001 0.0137 
36 1.73E-04 1.19E-04 1.36E-03 6.20E-04 7.86   3.26 0.0032 0.0015 - 
IL-6 
Time 
(hpd) 
Control APAP p-value control vs 
APAP 
p-value fasted vs fed 
C57BL/6J 
p-value vs APAP 
CD-1 Mean SD Mean SD Fold change SD 
1 2.30E-04 2.05E-04 2.49E-04 3.74E-05 1.08 0.7 NS NS NS 
*5 5.10E-04 1.77E-04 3.72E-04 2.74E-04 0.73 0.67 NS NS 0.0360 
10 4.44E-04 1.07E-04 4.56E-04 7.65E-05 1.03 0.32 NS NS NS 
*15 3.19E-04 8.47E-05 6.18E-04 7.37E-05 1.94 0.27 NS 0.0289 0.0151 
*20 5.41E-04 1.92E-04 1.50E-03 1.80E-04 2.77 1.18 NS NS NS 
24 2.86E-04 1.87E-04 1.01E-03 2.30E-04 3.53 1.78 0.0280 0.0329 NS 
36 2.42E-04 7.30E-05 1.17E-03 8.14E-05 4.83 0.53 0.0059 NS - 
IL-10 
Time 
(hpd) 
Control APAP p-value control vs 
APAP 
p-value fasted vs fed 
C57BL/6J 
p-value vs APAP 
CD-1 Mean SD Mean SD Fold change SD 
1 2.39E-06 9.00E-07 1.74E-06 1.28E-06 0.73 0.18 NS NS NS 
3 3.28E-06 1.15E-06 3.32E-06 1.74E-06 1.01 0.35 NS NS - 
*5 3.12E-06 1.50E-06 6.11E-06 1.05E-06 1.96 0.58 NS NS NS 
10 2.70E-06 7.00E-07 5.68E-06 2.92E-06 2.10 0.35 NS NS NS 
*15 3.90E-06 2.47E-06 9.98E-06 2.60E-06 2.56 1.13 NS 0.0044 NS 
*20 4.61E-06 7.41E-07 1.00E-05 8.48E-07 2.18 0.66 NS 0.0070 0.0056 
24 3.60E-06 1.70E-06 1.25E-05 2.28E-06 3.47 1.75 0.0410 0.0015 0.0063 
36 3.42E-06 7.98E-07 2.09E-05 5.14E-06 6.11 2.26 0.0012 NS - 
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Table 6.36. Hepatic cytokine transcription of TNF-α, IL-6 and IL-10 in pooled liver samples of fasted control C57BL/6J mice and in APAP treated fasted 
C57BL/6J mice, using the delta Ct method, 2
-ΔCt 
and also the comparative Ct value method, i.e. the fold change with p-value. The fold change values of APAP 
dosed C57BL/6J mice were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
 
TNF-α 
Time 
(hpd) 
Control APAP p-value control 
vs APAP 
p-value fasted vs 
fed C57BL/6J 
p-value vs 
APAP CD-1 Mean SD Mean SD Fold change SD 
1 
3.63E-04 1.96E-04 
4.30E-04 2.30E-04 1.19 0.76 NS NS NS 
*5 5.40E-04 1.38E-04 1.49 0.86 NS 0.0052 NS 
10 1.14E-03 3.30E-04 3.14 1.97 NS NS 0.0399 
15 2.60E-04 1.25E-04 0.72 0.64 NS NS 0.0003 
20 8.20E-04 2.74E-04 2.26 1.06 NS 0.0417 NS 
24 1.52E-03 4.40E-04 4.19 1.44 0.0462 0.0058 0.0381 
36 1.36E-03 6.20E-04 3.75 1.08 0.0370 0.0454 - 
IL-6 
Time 
(hpd) 
Control APAP p-value control 
vs APAP 
p-value fasted vs 
fed C57BL/6J 
p-value vs 
APAP CD-1 Mean SD Mean SD Fold change SD 
1 
3.35E-04 1.47E-04 
2.49E-04 3.74E-05 0.74 0.7 NS NS NS 
*5 3.72E-04 2.74E-04 1.11 0.67 NS NS 0.0337 
10 4.56E-04 7.65E-05 1.36 0.32 NS NS NS 
15 6.18E-04 7.37E-05 1.84 0.27 NS 0.0380 0.0208 
20 1.50E-03 1.80E-04 4.47 1.18 0.0409 NS NS 
24 1.01E-03 2.30E-04 3.01 1.39 0.0280 0.0183 NS 
36 1.17E-03 8.14E-05 3.49 0.53 0.0362 0.0170 - 
IL-10 
Time 
(hpd) 
Control APAP p-value control 
vs APAP 
p-value fasted vs 
fed C57BL/6J 
p-value vs 
APAP CD-1 Mean SD Mean SD Fold change SD 
1 
3.37E-06 1.24E-06 
1.74E-06 1.28E-06 0.52 0.13 NS NS NS 
3 3.32E-06 1.74E-06 0.99 0.3 NS NS NS 
*5 6.11E-06 1.05E-06 1.81 0.48 NS NS NS 
10 5.68E-06 2.92E-06 1.69 0.32 NS NS NS 
15 9.98E-06 2.60E-06 2.96 1.47 NS 0.0001 NS 
20 1.00E-05 8.48E-07 2.97 0.96 NS 0.0001 0.0490 
24 1.25E-05 2.28E-06 3.71 1.85 0.0252 NS NS 
36 2.09E-05 5.14E-06 6.20 2.12 0.0083 NS - 
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Table 6.37. Comparison of splenic TNF-α and IL-6 cytokine transcription in fed and fasted control and APAP treated C57BL/6J mice at 5 and 24 hpd using 
delta Ct value, 2
-ΔCt
 and the comparative Ct value, i.e. fold change as compared to time-matched control mice. The fold change values of APAP dosed 
C57BL/6J mice were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice.  
 
  
TNF-α 
Time 
(hpd) 
Fed Fasted 
p-value fed 
vs fasted 
C57BL/6J 
Mean Fold change 
(SD) 
p-value 
APAP  
5 vs 24 h 
p-value  
vs APAP 
CD-1 
Mean Fold change 
(SD) 
p-value  APAP  
5 vs 24 h 
p-value vs 
APAP CD-1 Control APAP Control APAP 
*5 8.4E-04 2.4E-03 2.86 (0.93) 
NS 
- 3.7E-03 5.4E-03 1.46 (0.73) 
0.0003 
- NS 
24 1.2E-03 2.2E-04 0.18 (0.19) NS 1.6E-04 1.5E-03 9.38 (2.96) NS 0.0075 
IL-6 
Time 
(hpd) 
Fed Fasted 
p-value fed vs 
fasted 
C57BL/6J 
Mean Fold change 
(SD) 
p-value  
APAP  
5 vs 24 h 
p-value  
vs APAP 
CD-1 
Mean Fold change 
(SD) 
p-value  APAP  
5 vs 24 h 
p-value  
vs APAP  
CD-1 Control APAP Control APAP 
*5 8.2E-05 6.5E-04 7.93 (2.13) 
0.0043 
- 3.4E-04 6.8E-04 1.99 (0.74) 
0.0067 
- 0.0087 
24 6.4E-05 6.4E-05 1.00 (0.52) 0.039 2.8E-05 2.4E-04 8.57 (3.02) 0.0013 0.0254 
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Table 6.38. Comparison of hepatic NF-kB transcription in fed and fasted control and APAP treated C57BL/6J mice in a 36 h period using delta Ct value, 2
-ΔCt
 
and the comparative Ct value, i.e. fold change as compared to time-matched control mice. The fold change values of APAP dosed C57BL/6J mice were 
also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. In CD-1 mice only (*15- relative to 10 h post saline; 
*20- relative to 24 h post saline). 
Fed 
Time 
(hpd) 
Control APAP p-value control vs APAP 
p-value vs  
APAP CD-1  
Mean SD Mean SD 
Fold 
change 
SD  
 
1 3.00E-04 7.00E-05 8.43E-05 7.63E-06 0.28 0.14 NS NS 
3 5.00E-04 4.52E-04 1.67E-04 9.44E-05 0.33 0.14 NS - 
*5 1.00E-04 2.80E-05 2.67E-04 1.19E-04 2.67 0.53 0.0490 NS 
10 2.00E-04 8.22E-05 1.13E-03 5.25E-04 5.66 1.77 0.0035 0.0030 
*15 4.00E-04 7.47E-05 2.77E-03 4.91E-04 6.92 1.54 0.0020 0.0052 
*20 6.00E-04 2.53E-04 2.11E-03 5.04E-04 3.52 1.33 0.0424 0.0001 
24 5.00E-04 1.17E-04 1.88E-03 7.15E-04 3.77 1.66 0.0280 0.0038 
36 6.00E-04 5.09E-05 2.83E-03 3.49E-04 4.71 0.97 0.0063 - 
Fasted  
Time 
(hpd) 
Control APAP 
p-value control 
vs APAP 
p-value fasted vs 
fed C57BL/6J 
p-value vs 
APAP CD-1  Mean SD Mean SD 
Fold 
change 
SD 
1 2.00E-04 1.40E-04 2.23E-04 6.13E-05 1.12 0.32 NS NS NS 
3 4.00E-04 3.62E-05 4.35E-04 5.43E-05 1.01 0.24 NS NS - 
*5 1.00E-04 8.65E-05 1.14E-04 2.97E-05 1.14 0.56 NS NS NS 
10 9.00E-05 5.00E-05 2.32E-04 1.82E-05 2.58 0.46 NS 0.0409 NS 
*15 1.40E-04 9.09E-05 5.85E-04 4.14E-05 4.18 0.56 0.0114 0.0253 NS 
*20 6.80E-04 1.26E-05 2.69E-03 4.30E-04 3.96 1.18 0.0203 NS NS 
24 6.70E-04 2.33E-04 2.21E-03 7.31E-04 4.81 1.88 0.0417 NS NS 
36 7.30E-04 1.88E-04 3.20E-03 1.03E-04 4.38 0.76 0.0084 NS - 
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Table 6.39. Comparison of hepatic NF-kB transcription in fed and fasted control and APAP treated C57BL/6J mice in a 36 h period using delta Ct value, 2
-ΔCt
 
and the comparative Ct value, i.e. fold change as compared to pooled liver samples of the control mice. The fold change values of APAP dosed C57BL/6J 
were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. 
Fed 
Time 
(hpd) 
Control APAP 
Fold change SD 
p-value control vs 
APAP  
p-value vs APAP CD-1  
Mean SD Mean SD 
1 
4.0E-04 1.35E-04 
8.43E-05 7.63E-06 0.21 0.14 NS NS 
3 1.67E-04 9.44E-05 0.42 0.11 NS NS 
*5 2.67E-04 1.19E-04 0.67 0.34 NS NS 
10 1.13E-03 5.25E-04 2.83 0.96 0.0303 0.0003 
15 2.77E-03 4.91E-04 6.93 1.54 0.0015 NS 
20 2.11E-03 5.04E-04 5.28 1.95 0.0075 0.0256 
24 1.88E-03 7.15E-04 4.70 2.06 0.0083 NS 
36 2.83E-03 3.49E-04 7.08 2.97 0.0097 - 
Fasted 
Time 
(hpd) 
Control APAP 
Fold change SD 
p-value control vs 
APAP 
p-value vs APAP 
CD-1  
p-value fasted 
vs fed 
C57BL/6J Mean SD Mean SD 
1 
3.5E-04 
 
1.0E-04 
 
2.23E-04 6.13E-05 0.64 0.25 NS NS NS 
3 4.35E-04 5.43E-05 1.25 0.59 NS NS NS 
*5 1.14E-04 2.97E-05 0.33 0.28 NS NS NS 
10 2.32E-04 1.82E-05 0.66 0.30 NS NS 0.0052 
15 5.85E-04 4.14E-05 1.68 0.44 NS NS 0.0036 
20 2.69E-03 4.30E-04 7.71 2.68 0.0011 NS NS 
24 2.21E-03 7.31E-04 6.33 3.55 0.0066 NS NS 
36 3.20E-03 1.03E-04 9.17 4.04 0.0058 - NS 
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Table 6.40. Comparison of hepatic cyclin-D1 transcription in fed and fasted control and APAP treated C57BL/6J mice in a 36 h period using delta Ct value,  
2
-ΔCt
 and the comparative Ct value, i.e. fold change as compared to time-matched control mice. The fold change values of APAP dosed C57BL/6J mice 
were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice; In CD-1 mice only (*15- relative to 10 h post 
saline; *20- relative to 24 h post saline). 
 
  
Fed 
Time 
(hpd) 
Control APAP 
p-value control 
vs APAP 
p-value vs 
APAP CD-1 Mean SD 
Fold 
change 
SD Mean SD Fold change SD 
1 1.60E-07 7.24E-08 0.36 0.13 4.27E-08 5.44E-09 0.27 0.07 NS NS 
3 9.60E-08 2.48E-08 3.45 2.94 8.99E-08 2.32E-08 0.94 0.14 NS - 
*5 2.50E-07 4.51E-08 1.36 1.19 3.94E-07 5.03E-08 1.57 0.09 NS 0.0064 
10 1.30E-07 5.40E-08 1.85 1.08 3.37E-07 6.26E-08 2.59 0.26 NS NS 
*15 9.54E-08 4.43E-08 1.26 0.22 8.58E-07 1.39E-07 8.99 1.95 0.0012 NS 
*20 8.21E-08 8.13E-08 1.14 0.77 4.91E-07 8.18E-08 5.98 0.64 0.0011 0.0017 
24 1.70E-07 5.33E-08 0.65 0.64 1.12E-06 3.03E-07 6.62 1.74 0.0093 0.0069 
36 1.48E-07 6.66E-08 1.24 0.70 7.97E-07 2.03E-07 5.37 1.53 0.0070 - 
Fasted 
Time 
(hpd) 
Control APAP p-value 
control vs 
APAP 
p-value fasted vs 
fed C57BL/6J 
p-value vs 
APAP CD-1  
Mean SD 
Fold 
change 
SD Mean SD 
Fold 
change 
SD 
1 5.7E-08 1.50E-08 0.36 0.13 3.10E-08 3.10E-09 0.54 0.21 NS NS NS 
3 3.31E-07 8.61E-08 3.45 2.94 1.09E-07 2.02E-08 0.33 0.23 NS NS - 
*5 3.40E-07 8.84E-08 1.36 1.19 6.18E-07 7.72E-08 1.82 0.83 NS NS NS 
10 2.40E-07 8.90E-08 1.85 1.08 1.96E-07 5.09E-08 0.82 0.25 NS 0.0155 NS 
*15 1.20E-07 3.12E-08 1.26 0.22 1.31E-07 7.51E-08 1.09 0.69 NS 0.0036 0.0070 
*20 9.38E-08 2.44E-08 1.14 0.77 1.93E-07 5.02E-08 2.06 0.25 NS 0.0445 0.0057 
24 1.10E-07 9.50E-08 0.65 0.64 3.50E-07 9.11E-08 3.18 0.98 0.0180 0.0301 0.0280 
36 1.83E-07 5.17E-08 1.24 0.70 8.37E-07 2.18E-07 4.58 1.69 0.0106 NS - 
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Table 6.41. Comparison of hepatic cyclin-D1 transcription in fed and fasted control and APAP treated C57BL/6J mice in a 36 h period using delta Ct value, 
2
-ΔCt
 and the comparative Ct value, i.e. fold change as compared to pooled liver samples of the control mice. The fold change values of APAP dosed 
C57BL/6J mice were also compared to APAP dosed CD-1 mice. *5- values of 5 h C57BL/6J was compared to 4 h CD-1 mice. hpd – hours post dosing; SD 
– standard deviation; NS not significant.  
 
Fed 
Time 
(hpd) 
Control APAP 
Fold change SD 
p-value control  
vs APAP  
p-value vs APAP CD-1 
Mean SD Mean SD 
1 
1.6E-07 
 
4.96E-08 
 
4.27E-08 5.44E-09 0.27 0.07 NS NS 
3 8.99E-08 2.32E-08 0.57 0.12 NS - 
*5 3.9E-07 5.03E-08 2.48 0.29 NS 0.0005 
10 3.4E-07 6.26E-08 2.12 0.19 NS 0.0073 
15 8.6E-07 1.39E-07 5.39 1.88 0.0093 NS 
20 4.9E-07 8.18E-08 3.09 0.60 0.0480 0.0001 
24 1.1E-06 3.03E-07 7.04 2.32 0.0069 NS 
36 8.0E-07 2.03E-07 5.01 1.30 0.0135 - 
 
Fasted 
Time 
(hpd) 
Control APAP 
Fold change SD 
p-value control vs 
APAP 
p-value vs 
APAP CD-1 
p-value fasted vs 
fed C57BL/6J Mean SD Mean SD 
1 
1.95E-07 
 
5.69E-08 
 
3.10E-08 3.1E-09 0.16 0.12 NS NS NS 
3 1.09E-07 2.02E-08 0.56 0.30 NS - NS 
*5 6.18E-07 7.72E-08 3.17 1.19 NS NS NS 
10 1.96E-07 5.09E-08 1.01 0.78 NS NS NS 
15 1.31E-07 7.51E-08 0.67 0.45 NS 0.0002 0.0066 
20 1.93E-07 5.02E-08 0.99 0.20 NS 0.0127 0.0211 
24 3.5E-07 9.11E-08 1.80 0.87 NS 0.0068 0.0061 
36 8.37E-07 2.18E-07 4.29 1.51 0.0079 - NS 
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Table 6.42. A summary comparison of the examined parameters for the assessment of APAP hepatotoxicity in fed and fasted C57BL/6J mice (5-36 hpd). 
Statistically significant differences were observed between the fasted and fed mice that had received APAP intraperitoneally. Hepatic or splenic mRNA levels 
were summarised based on fold change relative to pooled control animals. *P<0.005, <0.01 or <0.05. 
 
 Time (hours post APAP dosing) 
5 10 15 20 24 36 
Fed Fast Fed Fast Fed Fast Fed Fast Fed Fast Fed Fast 
Hepatic GSH 17.8 (9) 4.2 (0.7)* 31 (6.5) 13.7(6.9)* 38 (2.8) 22 (6.5)* 61.3 (11) 36.5 (16.5)* 69.8 (7.9) 29.9(3.8)* 75.5 (13) 72.4 (1.4) 
Hepatic ATP 5.0 (2.5) 3.27 (2.0) 14 (3.3) 3.5 (2.2)* 21 (3.5) 3.2 (1.6)* 29.4 (4.8) 2.5 (1.6)* 26.7 (5.4) - 29.5 (2.0) 4.48(2.3)* 
Fold change 
1- GSH 
2- ATP 
 
0.21 
0.18 
 
- 
- 
 
0.78 
0.50 
 
0.17 
0.25 
 
0.81 
0.75 
 
0.18 
0.16 
 
1.15 
0.97 
 
0.48 
0.10 
 
0.85 
1.00 
 
0.78 
- 
 
1.25 
1.21 
 
0.82 
0.16* 
Serum ALT 2056.8 
(214.5) 
2240.8 
(425) 
2066.6 
(79.6) 
1972.96 
(836) 
1964.1 
(246) 
3064.2 
(91.18)* 
2598.3 
(217.2) 
3886.1 
(501.1)* 
2709.5 
(231.7) 
3597 
(299.5)* 
1763.9 
(539) 
3518.3 
(805.5)* 
HE score 2.75 
(1.22) 
3.25 
(0.5) 
1.5  
(0.5) 
2.13  
(0.75) 
2.17 
(0.58) 
1.75 
(0.29) 
1.3  
(0.61) 
2.0 
(0.74)* 
1.15 
(0.47) 
2.1 
(0.14)* 
0.8 
 (0.13) 
1.5  
(0) 
TNF-α 
1- Liver 
2- Spleen 
3- Serum 
 
11.7(4.8) 
2.9(0.9) 
74.4(7) 
 
1.5(0.9)* 
1.5(0.7) 
124(24) 
 
2.2(1.2) 
- 
104(17) 
 
3.1(2.0) 
- 
122(18.9) 
 
0.9(0.6) 
- 
95(31.7) 
 
0.7(0.6) 
- 
144(27) 
 
1.5(0.3) 
- 
72 (10.3) 
 
2.3(1.1)* 
- 
212(5.3)* 
 
0.6(0.1) 
0.2(0.19) 
75.9(7.9) 
 
4.2(1.4)* 
9.38(3.0)* 
250(40)* 
 
1.4 (0.6) 
- 
56.3(0.9) 
 
3.8(1.1)* 
- 
227(22)* 
IL-6 
1- Liver 
2- Spleen 
3- Serum 
 
2.3(1.5) 
7.9(2.1) 
61.7(6) 
 
1.1(0.7) 
2.0(0.7)* 
56.3(12) 
 
3.7(1.1) 
- 
112(25) 
 
1.4(0.3) 
- 
40.3(35) 
 
5.2(2.1) 
- 
105(19) 
 
1.8(0.3)* 
- 
52(15.4)* 
 
2.8(1.0) 
- 
240(18) 
 
4.5(1.2) 
- 
103.2(23)* 
 
7.0(1.9) 
1.0(0.5) 
229(38) 
 
3.0(1.4)* 
8.6(3.0)* 
94(35.7)* 
 
7.2(2.2) 
- 
180(24) 
 
3.5(0.5)* 
- 
131 (51) 
Hepatic IL-10 0.8(0.3) 1.8(0.5) 3.1(0.9) 1.7(0.3) 12.6(3.4) 3.0(1.5)* 12.1(4.1) 3.0(1.0)* 7.2(1.2) 3.7(1.9) 9.5(3.6) 6.2(2.1) 
Hepatic NF-kB 0.7(0.5) 0.3(0.3) 2.8(1.0) 0.7(0.3)* 6.9(1.5) 1.7(0.4)* 5.3(2.0) 7.7(2.7) 4.7(2.1) 6.3(3.6)* 7.1(3.0) 9.2(4.0) 
Hepatic cyclin-D1 2.5(0.3) 3.2(1.2) 2.1(0.2) 1.0 (0.8)* 5.4(1.9) 0.7(0.5)* 3.1(0.6) 1.0 (0.2)* 7.0(2.3) 1.8(0.9)* 5.0(1.3) 4.3(1.5) 
IH PCNA (%) 
1- Overall 
2- Cyto 
 
2.1(1.8) 
0.2(0.1) 
 
1.2(0.3) 
0.1(0.1) 
 
5.5(1.2) 
1.4(0.4) 
 
2.8(2.3) 
0.2(0.2)* 
 
8.0(1.7) 
0.5(0.1) 
 
1.0(0.1)* 
0.3(0.1) 
 
19.5(0.8) 
0.8(0.3) 
 
6.0(2.4)* 
1.7(0.5)* 
 
23.2(2.0) 
1.1(0.2) 
 
13.0(6.6)* 
0.9(0.9) 
 
25(7.5) 
0.5(0.3) 
 
12.7(2.7)* 
0.1(0.1) 
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Table 6.43. A summary comparison of the examined parameters for the assessment of APAP hepatotoxicity in fed and fasted CD-1 and C57BL/6J mice at 
*5, 10 and 24 hpd. Statistically significant differences were observed between CD-1 and C57BL/6J mice that had received APAP intraperitoneally in either fed 
or fasted groups. Hepatic and/or splenic mRNA levels were summarised based on fold change relative to pooled control animals. *5- values of 5 h C57BL/6J 
was compared to 4 h CD-1 mice for measurement of hepatic and/or splenic TNF-α, IL-6, IL-10, NF-kB and cyclin-D1. *P<0.005, <0.01 or <0.05. 
 Time (hours post APAP dosing) 
*5 10 24 
Fed Fasted  Fed Fasted  Fed Fasted  
CD-1 C57BL/6J CD-1 C57BL/6 CD-1 C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J CD-1 C57BL/6J 
Hepatic GSH 4.95 (0.56) 17.8 (9) 4.47 (3.6) 4.2 (0.7) 40 (0.7) 31 (6.5) 5.28 (1.2) 13.7 (6.9) 45.5(10) 69.8 (7.9)* 50.6 (25) 29.9 (3.8) 
Hepatic ATP 10.5 (2.3) 5.0 (2.5)* 3.5 (4.9) - 18 (5.7) 14 (3.3) 3.4 (1.2) 3.5 (2.2) 35.4 (3.9) 26.7 (5.4) 8.1 (1.3) - 
Fold change 
1- GSH 
2- ATP 
 
0.14 
0.30 
 
0.21 
0.18 
 
0.09 
0.20 
 
- 
- 
 
1.96 
0.61 
 
0.78* 
0.50 
 
0.06 
0.25 
 
0.17 
0.25 
 
0.96 
1.07 
 
0.85 
1.00 
 
0.33 
0.49 
 
0.78 
- 
Serum ALT 2146.4 
(1012.3) 
2056.8 
(214.5)  
2048.6 
(461.7) 
2240.8 
(425) 
- 
2066.6 
(79.6) 
- 
1972.96 
(836) 
2654.5 
(334.5) 
2709.5 
(231.7) 
3603.8 
(508.8) 
3597 
(299.5) 
HE score 2.44 (1.25) 2.75 (1.22) 2.5 (1.41) 3.3 (0.5) 1 (0.89) 1.5 (0.5) 2.6 (0.42) 2.13 (0.8) 0 (0) 1.15(0.5)* 2.38(0.7) 2.1(0.14) 
TNF-α 
1- Liver 
2- Spleen 
3- Serum 
 
4.4(0.7) 
- 
62 (13.5) 
 
11.7(4.8)* 
2.9(0.9) 
74.4(7) 
 
2.3 (0.6) 
- 
101.2(40) 
 
1.5(0.9)* 
1.5(0.7) 
124(24) 
 
7.9 (2.7) 
4.4 (1.8) 
- 
 
2.2(1.2)* 
- 
104(17) 
 
6.8 (2.4) 
4.9 (2.0) 
- 
 
3.1(2.0)* 
- 
122(18.9) 
 
1.77(0.8)
1.2(0.6) 
95 (14) 
 
0.6(0.1) 
0.2(0.19) 
75.9(7.9) 
 
1.5 (0.5) 
3.2 (0.8) 
228 (54) 
 
4.2(1.4)* 
9.38(3.0)* 
250(40) 
IL-6 
1- Liver 
2- Spleen 
3- Serum 
 
6.0 (1.9) 
- 
54.3(10) 
 
2.3(1.5)* 
7.9(2.1) 
61.7(6) 
 
4.7 (1.7) 
- 
35.4(11) 
 
1.1(0.7) 
2.0(0.7) 
56.3(12) 
 
7.9 (0.8) 
1.9 (0.3) 
- 
 
3.7(1.1)* 
- 
112(25) 
 
2.2 (1.0) 
1.0 (0.6) 
- 
 
1.4(0.3) 
- 
40.3(35) 
 
7.6 (2.7) 
3.7(1.2) 
203(40) 
 
7.0(1.9) 
1.0(0.5)* 
229(38) 
 
7.4 (3.1) 
1.1 (0.4) 
96(35.2) 
 
3.0(1.4) 
8.6(3.0)* 
94(35.7) 
Hepatic IL-10 3.9 (1.5) 0.8(0.3)* 1.5 (1.2) 1.8(0.5) 9.0 (2.9) 3.1(0.9)* 1.8 (0.9) 1.7(0.3) 8.8 (1.3) 7.2(1.2) 5.2 (3.9) 3.7(1.9) 
Hepatic NF-kB 2.1 (0.4) 0.7(0.5) 2.1 (1.3) 0.3(0.3) 13.3(3.1) 2.8(1.0)* 1.5 (1.6) 0.7(0.3) 6.1 (1.1) 4.7(2.1) 4.7 (1.3) 6.3(3.6) 
Hepatic cyclin-D1 8.1 (1.3) 2.5(0.3)* 4.0 (1.8) 3.2(1.2) 8.7 (2.5) 2.1(0.2)* 4.2 (2.0) 1.0 (0.8)* 9.6 (1.1) 7.0(2.3) 6.0 (1.2) 1.8(0.9)* 
IH PCNA (%) 
1- Overall 
2- Cyto 
 
15.62 
1.02 
 
2.1(1.8)* 
0.2(0.1)* 
 
3.23 
1.46 
 
1.2(0.3) 
0.1(0.1) 
 
7.71 
0.27 
 
5.5(1.2) 
1.4(0.4)* 
 
2.98 
0.06 
 
2.8(2.3) 
0.2(0.2) 
 
15.02 
0.94 
 
23.2(2.0) 
1.1(0.2) 
 
8.36 
0.92 
 
13.0(6.6) 
0.9(0.9) 
  
 
